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Abstract 
 
Boron dipyrromethenes (BODIPYs) have attracted considerable attention due to their 
fluorescence properties, including high fluorescence quantum yields and absorption 
coefficients, good photochemical stability and narrow absorption and emission 
bandwidths. Because of these properties, they have found extensive use for in vivo 
imaging, analyte sensing, photodynamic therapy, solar cells and light harvesting arrays. 
This thesis is divided in two parts. Part one covers the synthesis of functionalised chiral 
BODIPYs whilst part two involves investigations into the synthesis and application of 
aminoBODIPY via metal catalysed amination reactions. 
Four approaches to the synthesis of novel chiral BODIPY dyes were investigated. The 
axially chiral BODIPY dye with C2-symmetry I was synthesised via Suzuki coupling of 
the corresponding 2,6-dibromoBODIPY with 2-methoxyphenyl boronic acid. The 
unsymmetrical axially chiral BODIPY II was synthesized via Suzuki coupling of the 
corresponding 2-bromoBODIPY with phenyl boronic acid. Unfortunately, attempted 
resolution of these chiral systems by analytical chiral HPLC was unsuccessful.  
 
                  
The new helically chiral BODIPYs IIIa-c were synthesised. Resolution of racemic 
helically chiral BODIPYs IIIa and IIIb was successfully accomplished by preparative 
chiral HPLC. 
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Electronic circular dichroism (ECD) spectra of both (M) and (P) isomers of IIIa and IIIb 
were measured by Prof. W. Herrebout (University of Antwerp). Comparison of the 
measured and computationally predicted ECD spectra allowed the absolute configuration 
of each of the enantiomeric samples of IIIa-b to be established. The CPL spectra of both 
(M) and (P) isomers of IIIa and IIIb were recorded by Prof. R. D. Peacock (University 
of Glasgow). The |glum| of IIIa at 637 nm is 0.0043 and IIIb at 675 nm is 0.0042, which 
are among the largest so far reported for a simple BODIPY fluorophore in solution. 
 
We designed and synthesized the mono-strapped BODIPY V scaffold via sequential 
regioselective functionalisation of the unsymmetrical BODIPY IV. Resolution of 
N,N,F,O-BODIPY V by analytical chiral HPLC gave two peaks confirming that single 
enantiomers of this compound should be accessible. 
 
The 8-anisyl-substituted BODIPY VI was synthesized using a standard synthetic route, 
regioselective iodination with ICl then gave the 2-iodo-substituted BODIPY VII. We 
unexpectedly found that copper catalysed nucleophilic substitution of the 2-iodoBODIPY 
VII produced the 3-amino BODIPYs VIIIa-n in good yield. The reactions occurred 
successfully for a range of primary and secondary alkyl and aryl amines and even with 
benzamide, albeit in low yield. 
 
 
2-aminoBODIPYs Xa-e have been prepared successfully via Buchwald–Hartwig 
amination of the 2-iodoBODIPY IX (fully blocked). The presence of the nitrogen group 
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in the 2-position gives a broadened red-shifted absorption maximum and quenched 
fluorescence. 
 
This palladium catalysed amination was used to prepare the 2-nitroaniline-substituted 
BODIPY XI. Reduction of the nitro group by hydrogenation gave the novel fluorescence-
quenched 2-aminoaniline-substituted BODIPY XII. Reaction of this compound with 
triphosgene gave the corresponding benzimidazolone-substituted BODIPY XIII. The 
bright yellow fluorescence of the triphosgene reaction product XIII can be easily 
visualized by the naked eye. The detection limit for phosgene was determined to be 160 
nM in solution at room temperature. 
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Chapter 1: Introduction 
  
1.1. General introduction to fluorescence 
  
Luminescence is the emission of ultraviolet, visible or infrared photons from any 
substance, which occurs from an electronically excited state.1–3 There are various types 
of luminescence, i.e. photoluminescence, radioluminescence, chemiluminescence, 
electroluminescence, and thermoluminescence, which are classified according to the 
mode of excitation.1–3 Photoluminescence is the emission of the light from a material after 
absorption of photons. Photoluminescence is formally divided into two types: 
phosphorescence and fluorescence, which are determined by the nature of the excited 
state. 
The phenomenon of fluorescence was introduced in the middle of the nineteenth century 
by the British scientist Sir George Gabriel Stokes.2 Fluorescence is defined as the 
radiative emission of a photon by a substance from the first excited singlet state (S1) to 
the ground singlet state (S0), which can be schematically explained by the Jablonski 
energy level diagram (Figure 1.1).  
 
Figure 1.1: Jablonski energy level diagram.1 
As shown in the Jablonski diagram bold horizontal lines correspond to the electronic 
states and above these the thin horizontal lines represent vibrational sublevels. Normally, 
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electrons are in the ground state (S0). When incoming light with appropriate energy 
interacts with an electron in the molecule the photon may be absorbed, causing the 
electron to jump to an excited state (S1 or S2) and this process is very fast (10
-15 second). 
The electron then loses energy due to the vibration of the molecule. This process is called 
internal conversion and the electron falls to the lowest electronic level (S1). Finally the 
electron may return to one of the vibrational sub-levels of the ground state (S0) by 
releasing light. Fluorescence is characterised by its emission spectrum, quantum yield 
and lifetime.  
Quantum yield (ФF) is a measure of the efficiency of a fluorescent system. It is the ratio 
of the total number of emitted photons over the total number of absorbed photons.1 The 
quantum yield (ФF) is expressed as a number or a percentage, with the maximum being 1 
or 100%. It is common to measure the fluorescence quantum yield by comparison to a 
reference compound whose quantum yield has been accurately determined by direct 
measurement. In this case, the quantum yield of the sample is calculated according to 
Equation 1.1.  
Φsample= Φreference (Fsample (1-10-Areference)ɳ2sample / Freference (1-10-Asample)ɳ2reference).4,5 
Equation 1.1 
 
Here, Φ is the fluorescence quantum yield for the sample or reference, A is the absorption 
intensity at the excitation wavelength, F is the fluorescence area and ɳ is the solvent 
refractive index. 
The fluorescence lifetime is also important, it is a measure of the time that a fluorophore 
remains in its excited state (S1) before returning to the ground state (S0).
1,2 
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1.2. General introduction to fluorophores 
  
Over the past few decades, fluorescent compounds have continued to attract the attention 
of researchers due to their spectral and physicochemical properties.6 The term fluorophore 
refers to a fluorescent molecule that can re-emit light upon light excitation. There are two 
different classes: intrinsic (that occur naturally) and extrinsic (typically synthetic) and 
each has its own properties.2 
There are many organic dyes in common use including rhodamine,7 fluorescein,8 alexa,9 
ethidium,10 cyanine,11 and BODIPYs (Figure 1.2). Fluorescein is an example of a 
fluorescent dye which has been used as a fluorescent tracer for many applications. 
Fluorescein isothiocyanate is a reactive derivative of fluorescein dye which is commonly 
used to tag a target nucleophile. 
 
 
Figure 1.2: Structures of organic fluorescent dyes. 
Rhodamine is another example of a fluorescent dye which can be used as a tracer dye 
within water to determine the direction and rate of flow and transport. There are many 
different Rhodamine derivatives such as Rhodamine B and Rhodamine 6G. 
  Chapter 1                                                                                                    Introduction 
 
 
4 
 
 
1.3. Borondipyrromethene Difluoride (BODIPY) 
 
1.3.1. Background and structure 
 
4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene 1.1 (abbreviated to BODIPY), shown below, 
is the central heterocyclic core of a large family of fluorescent compounds.12 In 1968, 
Treibs and Kreuzer synthesized the first BODIPY dye.9 However, this discovery was not 
used until the 1990s when Boyer and co-workers realized that BODIPY dyes could be 
used as possible fluorescent probes. 
 
Scheme 1.1 shows the numbering of a dipyrromethane 1.2, a dipyrrin 1.3 and a boron 
dipyrrin 1.1.13 The numbering of a BODIPY core is different from that of a dipyrrin and 
a dipyrromethane.12,13 The 8-position in the BODIPY core is often referred to as the meso 
site.6,13 
 
Scheme 1.1: Structure and numbering of a dipyrromethane 1.2, a dipyrrin 1.3 and a boron dipyrrin 1.1.6 
In recent years, the number of published data on the synthesis and properties of BODIPYs 
has been increasing rapidly (Figure 1.3). According to the Web of Science Citation report, 
6105 articles have been published on BODIPY as a topic since 1989.  
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Published Items in Each Year 
 
Citations in Each Year 
 
Figure 1.3: Web of Science citation report of the number of publications and citations resulting from 
searching “BODIPY” as the topic. 
Also, in reviewing the literature, a number of reviews on BODIPY dyes have been 
published because of the fast increase in their popularity over the last few years. For 
instance, in 2007, Loudet and Burgess12 reviewed the synthesis and spectroscopic 
properties of different types of BODIPY dyes and their derivatives.  
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In 2008, Ziessel6 and co-workers discussed the chemistry and photophysical properties 
of BODIPY dyes. In 2011, Boyle and co-workers14 reported a review on using BODIPYs 
as fluorescent components of novel light active materials. Awuah and You,15 in 2012, 
provided an overview BODIPY dyes as photosensitizers for photodynamic therapy of 
cancer. Boens, Leen and Dehaen16 described the synthesis of different BODIPYs as 
fluorescent indicators. In 2014, Shen17 published a review on structural modification 
strategies for synthesis of long wavelength absorbing BODIPY dyes. In 2015, 
Ravikanth18 discussed the synthesis, properties and applications of halogenated BODIPY 
dyes containing halogens at the pyrrole carbons of the BODIPY core. 
1.3.2. General properties of BODIPY 
  
Boron dipyrromethenes 1.1 tend to absorb light in the visible range, and are often 
characterised by sharp absorption and emission spectra with high molar extinction 
coefficient, high quantum yields of fluorescence and narrow absorption and emission 
bandwidths.12 Also, they are soluble in most organic solvents and mostly insensitive to 
the solvent polarity and pH of their environment. They are stable under physiological 
conditions, display low toxicity, high photostability and resistance to chemical 
degradation.12 The photophysical properties of the BODIPYs can be affected by 
introducing different substituents at the various positions of the BODIPY core as shown 
in Figure 1.4. The symmetrical alkylated BODIPYs 1.4 and 1.5 have not been reported.12 
The fluorescence quantum yields for 1.6, 1.7, 1.8 and 1.9 were reported in the literature 
and could be used as a reference to which other BODIPYs can be compared.12 Also, the 
unsymmetrically substituted BODIPYs 1.9 and 1.10 have been synthesised. Comparing 
compounds 1.6 and 1.7 with compound 1.8, alkylation at the 2,6-position generally leads 
to red-shift of absorption and emission maxima but lower quantum yield.12 
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Figure 1.4: Different alkyl substitution on the core BODIPY dye.12 
The presence of the aryl group at the meso-position of the 1,7-substituted BODIPY 1.13 
leads to a slightly lower fluorescence quantum yield and red-shift of absorption and 
emission maxima compared to BODIPY 1.7.12 However, the fluorescence quantum yield 
of BODIPYs 1.11 and 1.12 are appreciably less than BODIPY 1.6. Such differences are 
usually referred to the presence of 1,7-substituents which prevent free rotation of the aryl 
group, thus reducing loss of energy from the excited states through non-radiative 
processes.12  
  
 
   
 EtOH, Φf = 0.81 
λmax abs 507 nm 
λmax emiss 520 nm 
 
EtOH, Φf = 0.56 
λmax abs 528 nm 
λmax emiss 535 nm 
 
EtOH, Φf = 0.70 
λmax abs 599 nm 
λmax emiss 509 nm 
 
EtOH, Φf = 0.40 
λmax abs 510 nm 
λmax emiss 520 nm 
 
EtOH, Φf = 0.80 
λmax abs 505 nm 
λmax emiss 516 nm 
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Figure 1.5: Different alkyl and aryl substitution at the pyrrole carbons of the BODIPY 
core.12,17,19 
Polyphenylated BODIPYs 1.14-1.17 have been synthesised.17–21 Arylation at the pyrrole 
carbons of the BODIPY core leads to red-shifted absorption and emission maxima and 
increased quantum yield for these compounds (compare 1.14 with 1.7, and 1.16 with 1.8) 
as seen in Figure 1.5.  
MeOH, Φf = 0.65 
λmax abs 508 nm 
λmax emiss 598 nm 
 
MeOH, Φf = 0.19 
λmax abs 508 nm 
λmax emiss 521 nm 
 
 
MeOH, Φf =0.06 
λmax abs 501 nm 
λmax emiss 517 nm 
 
THF, Φf = 0.31 
λmax abs 561 nm 
λmax emiss 597 nm 
 
THF, Φf = 0.92 
λmax abs 571 nm 
λmax emiss 601 
nm 
 
 
THF, Φf = 0.2 
λmax abs 573 nm 
λmax emiss 613 nm 
 
THF, Φf = 0.96 
λmax abs 576 nm 
λmax emiss 608 nm 
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Moreover, it has found that the replacement of the fluorine atoms with aryl or alkyne 
groups such as BODIPY 1.19 and 1.20 produced only minor changes in the absorption 
and emission maxima as compared to parent BODIPY 1.18 (Figure 1.6).12  
 
 
Figure 1.6: Example of the replacement of the two fluorine atom with aryl or alkyne group.12  
Addition of alkoxy groups to the boron centre has also been reported in the literature.22,23 
For example, the replacement of the fluorine atoms in the BODIPY 1.21 with various 
alcohols produced O-BODIPYs 1.22-1.24 and the presence of alkoxy group cause little 
change to the photophysics (Figure 1.7).22,23 
 
 
Figure 1.7: Example of the replacement of the two fluorine atoms with alkoxy groups.23 
  
CH2Cl2, Φ = 0.83 
λmax abs 517 nm 
λmax emiss 538 nm 
 
 
 
CH2Cl2, Φ = 0.91 
λmax abs 513 nm 
λmax emiss 548 nm 
 
 
 
CH2Cl2, Φ = 0.95 
λmax abs 516 nm 
λmax emiss 537 nm 
 
 
 
CH2Cl2, Φ = 0.57 
λmax abs 504 nm 
 
 
CH2Cl2, Φ = 0.52 
λmax abs 505 nm 
 
 
CH2Cl2, Φ = 0.55 
λmax abs 505 nm 
 
 
CH2Cl2, Φ = 0.65 
λmax abs 506 nm 
 
 
  Chapter 1                                                                                                    Introduction 
 
 
10 
 
Conversion of the 3,5-di(methoxyphenyl)BODIPYs 1.25 and 1.26 into the corresponding 
O-chelated derivative 1.27 and 1.28 leads to a significant increase in quantum yield of 
fluorescence and red shifted absorption and emission maxima. This is probably due to 
structure rigidification and a decrease in the dihedral angle between the aryl ring and the 
BODIPY core.17  
 
 
Figure 1.8: Examples of O-chelated BODIPYs.17 
1.3.3. General synthetic routes to BODIPY dyes 
 
As mentioned earlier, Treibs and Kreuzer synthesised the first BODIPY in 1968.24 The 
reaction between acetic anhydride and 2,4-dimethyl pyrrole in the presence of boron 
trifluoride diethyl etherate (BF3.OEt2) gave a mixture of highly fluorescent compounds 
1.29 and 1.30 (Scheme 1.2). 
THF, Φf = 0.41 
λmax abs 630 nm 
λmax emiss 654 nm 
 
THF, Φf = 0.07 
λmax abs 550 nm 
λmax emiss 597 nm 
 
THF, Φf = 0.99 
λmax abs 626 nm 
λmax emiss 645nm 
 
THF, Φf = 0.77 
λmax abs 550 nm 
λmax emiss 583 nm 
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Scheme 1.2: Synthesis of the first BODIPYs 1.29 and 1.30 by Triebs et al.24 
BODIPY derivatives can be synthesized by using various different synthetic methods, 
and the most obvious approaches are well known from porphyrin research. Synthetic 
approaches to the BODIPY core usually start from the condensation of a simple pyrrole 
with a highly electrophilic carbonyl compound, such as an acyl chloride, acid anhydride 
or aldehyde. However, the instability of the intermediate (unsubstituted dipyrromethene), 
which can undergo porphyrin formation or polymerization leads to the use of a 2-
substituted pyrrole in most of the routes. Burgess12 describes the synthesis of BODIPY 
dyes using three major routes: from pyrrole and aldehyde, from pyrrole and acid chloride, 
and from pyrrole and ketopyrrole. 
1.3.3.1.   From aldehyde 
   
A straightforward approach to simple symmetrical BODIPY compounds is the acid 
catalysed condensation of an aldehyde 1.31 with two molecules of a pyrrole to afford a 
dipyrromethane 1.32.16 To avoid a polymerization in this reaction the pyrrole is used as 
the solvent25 while the reaction with substituted pyrrole does not require excess pyrrole 
and occurs in normal organic solvent. The dipyrromethane 1.32 is oxidized immediately 
after preparation to generate the corresponding dipyrromethene 1.33 which is less stable. 
Subjecting the dipyrromethene 1.33 to a base, such as triethylamine (Et3N) or 
diisopropylethylamine (i-Pr2NEt), and boron trifluoride diethyl etherate (BF3.OEt2) 
generates the symmetric BODIPY dyes 1.34, as shown in Scheme 1.3. 
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Scheme 1.3: General synthetic route to the symmetrical BODIPY from aldehyde.  
Numerous BODIPY dyes have been synthesized from readily available pyrroles by using 
this synthetic method, which allows variation of the substituents on both the pyrrole (R2) 
and meso (R1) carbon atoms. Moreover, it has been found that substituents on the pyrrole, 
specifically on the 1-and 7- positions of the BODIPY, restrict rotation of an aromatic 
group attached at the meso-position. The resulting orthogonal geometry results in a 
reduction of the electronic coupling between the 8-substituent and the dye.16 Many 
researchers have performed this method in a one-pot process without isolation of the 
intermediates. For example, Vicente26 synthesised BODIPY 1.35 from the reaction 
between substituted pyrrole and aldehydes.  
 
Scheme 1.4: Synthesis of BODIPY 1.35. Reagent and conditions; a) TFA and CH2Cl2; b) DDQ; c) 
NEt3, BF3.OEt2, 84%.26  
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1.3.3.2.   From carboxylic acid 
  
A more efficient route for the synthesis of symmetrical BODIPY cores is by acid-
catalysed condensation of pyrroles with an acylium equivalent 1.36 such as an acid 
chloride, anhydride or an orthoester (Scheme 1.5).16 Often, the acylpyrrole intermediate 
1.37 is not isolated, because it reacts with an excess of the pyrrole under acidic conditions 
to form a dipyrromethene 1.38. Treatment of the dipyrromethene intermediate 1.38 with 
base, and boron trifluoride diethyl etherate (BF3.OEt2) affords the symmetric BODIPY 
dye 1.39, as shown in Scheme 1.5.  
 
Scheme 1.5: General synthetic route to symmetrical BODIPYs by from acylation of pyrrole 
followed by condensation and complexation. 
The advantage of this approach is that it does not require an oxidation step, and the 
formation of the BODIPY can be performed in a one-pot without isolation of the 
dipyrromethane. The disadvantage of this method is in the reaction conversion which is 
not always complete and this leads to a challenging purification. An example is the 
synthesis of BODIPYs 1.41a-d in one-pot from 2,4-dimethyl-3-ethylpyrrole and acid 
chlorides 1.40a-d (Scheme 1.6).27 
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Scheme 1.6: Synthesis of BODIPY 1.41a-d from acyl chlorides. Reagent and conditions; a) CH2Cl2, r.t., 
72 h; b) NEt3, BF3.OEt2, r.t., 24 h. 
1.3.3.3.   From a ketopyrrole 
 
Unsymmetrical BODIPY compounds, unsubstituted or substituted at the 8-position 
cannot be prepared by using the two previous methods. They can be formed via 
condensation of a ketopyrrole with a second pyrrole in the presence of a Lewis acid 
followed by complexation in the presence of BF3.OEt2 and base to give unsymmetrical 
BODIPYs 1.42 (Scheme 1.7). 
Scheme 1.7: Synthesis of unsymmetrical BODIPY 1.42 from ketopyrrole. 
This method is advantageous because no oxidation step is required. Also, in this method 
symmetrical or unsymmetrical BODIPYs can be prepared in one-pot without isolation of 
the unstable dipyrromethene hydrochloride salt intermediate which can be difficult. 
Although BODIPYs are prepared in one-pot with no isolation, this approach does require 
isolation of the ketopyrrole intermediate in order to synthesise the unsymmetrical 
BODIPY.  
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For instance, Duportail28 applied this method in the synthesis of symmetrical BODIPY 
1.45. The ketopyrrole 1.43 was synthesised by the reaction of 4-iodobenzoyl chloride 
with the magnesium salt of 2,4-dimethylpyrrole (formed by deprotonation with 
MeMgBr). Then, condensation of ketopyrrole 1.43 with another equivalent of 2,4-
dimethylpyrrole in the presence of POCl3 gave dipyrromethene 1.44. Finally, 
complexation the dipyrromethene with BF3.OEt2 in the presence of triethylamine 
produced the symmetrical BODIPY 1.45 (Scheme 1.8). 
 
Scheme 1.8: Synthesis of symmetrical BODIPY 1.45. Conditions and reagents; a) MeMgBr, Et2O, 35 °C, 
30 min, 81%; b) 2,4-dimethylpyrrole, POCl3, CH2Cl2/pentane, 0 °C, r.t., 24 h, 46 %; c) BF3.OEt2, NEt3, 
toluene, 80 °C, 30 min, 80 %.16 
A similar approach was used by Chang29 in order to synthesise unsymmetrical BODIPY 
1.46. In this case, BODIPY 1.46 was synthesised in a one-pot reaction without isolation 
of the dipyrromethene intermediate by condensation of 2-formylpyrrole with 2,4-
dimethylpyrrole in the presence of POCl3, followed by BF2 chelation leading to BODIPY 
1.46 (Scheme 1.9). 
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Scheme 1.9: Synthesis of unsymmetrical BODIPY 1.46. Conditions and reagents; a) 2,4-dimethylpyrrole, 
POCl3, CH2Cl2, -5 °C, 3 h, r.t., 3 h; b) BF3.OEt2, NEt3, r.t., 3 h, 51 %.29 
1.4. Some applications of functionalized BODIPYs 
 
Design and development of near-infrared (NIR) BODIPY dyes has gained considerable 
research interest over the past decade because of rapid developments in various optical 
imaging and bioanalytical techniques, such as nucleic acid detection, in vivo imaging, 
DNA sequencing, gel electrophoresis, vascular mapping and tissue perfusion.30 
There are a number of commercially available BODIPY scaffolds which can be 
connected to proteins, peptides, oligonucleotides, lipids, polystyrene microspheres and 
dextran (Table 1.1). By standard chemical reactions succinimidyl esters of BODIPY acids 
and carboxylic acids can be converted into fluorescent amides, acid halides, or esters. 
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Table 1.1: Examples of commercially available BODIPY dyes. 
Dye name Chemical structure 
Absorption  
max (nm) 
Emission  
max (nm) 
BODIPY 
630/650 (Life 
Technologies 
Inc.) 
 
625 640 
BODIPY 
650/665 (Life 
Technologies 
Inc.) 
 
646 660 
BODIPY FL-
X 
(ThermoFisher 
Scientific)  
501 510 
BODIPY 
665/676 
(ThermoFisher 
Scientific) 
 
605 676 
BODIPY TR-
X 
(ThermoFisher 
Scientific) 
 
591 620 
Owing to their favourable characteristics, BODIPY dyes can act as an important 
component in many different applications. Figure 1.9 shows some applications of 
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functionalised BODIPYs in which R1, R7, R3 and R
6 may extend the delocalisation and/or 
carry other functional groups.   
 
Figure 1.9: Applications of BODIPY Dyes.31–34 
BODIPY dyes have been used in a photodynamic therapy (PDT) which is a potential 
treatment for cancer and other localized diseases that uses a photosensitizer agent, a 
visible or near-visible light and oxygen as elements in its mechanism of action. 
For example, O’Shea and his group35 have disclosed a new class of potential 
photodynamic therapy agent, the BF2-chelated azadipyrromethenes 1.47 and synthesised 
a sequence of a supramolecular photonic therapeutic agent (SPTA) analogues 1.48-1.50 
with pH-responsive amine receptors. They described a new method for achieving 
photodynamic therapy selectivity based upon the reversible off/on switching of the main 
therapeutic property (generation of singlet oxygen) of a SPTA (Figure 1.11).35  
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Figure 1.10: Structure of aza BODIPYs.35 
 
Figure 1.11: “Design and function of an SPTA. Blue circle, substrate-specific receptor. Red 
rectangle, photosensitizer. Black cross, substrate”.35 (Adapted from S. O. McDonnell, M. J. Hall, L. T. 
Allen, A. Byrne, W. M. Gallagher, and D. F. O’Shea, J. Am. Chem. Soc. 2005, 127, 16360-16361). 
BODIPY dyes have also been developed as a sensitizer in dye-sensitized solar cell 
(DSSC) systems which are a new type of low cost photovoltaic (solar) cell that absorbs 
visible light to produce electricity. The DSSC device consists of glass sheet (transparent 
conducting indium tin oxide (ITO) or fluorine doped tin oxide (FTO)), a semiconducting 
electrode (n-type TiO2, p-type NiO), a dye sensitizer (which is able to harvest light and 
transfer electrons), redox mediator (I–/I3
– or CoII/CoIII complexes) and a counter electrode 
(carbon or Pt) (Figure 1.12). 
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Figure 1.12: “Schematic diagram of the energy flow in a DSSC”.36 (Adapted from S. S. P. 
Singh, and T. Gayathri, Eur. J. Org. Chem. 2014, 4689-4707) 
The first BODIPY photosensitizers 1.51 and 1.52 for DSSCs were reported by Fukuzumi 
and his group.36 The percentage power conversion efficiency (η) of these compounds is 
0.16% and 0.13% respectively.  
 
Figure 1.13: Structure of sensitizers 1.51 and 1.52. 
Kubo et al.37 have designed and synthesised sensitizers 1.53-1.55 (Figure 1.14) which 
involve thienyl-cyanoacrylic acid units and reported their efficiency in a DSSC setup. The 
cell based on BODIPY 1.55 has a good conversion efficiency (6.06%) which is the 
highest value for BODIPY-based DSSCs has been reported up to date .37   
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Figure 1.14: Structure of sensitizer 1.53, 1.54 and 1.55.37 
BODIPY dyes have been widely used to target biological molecules such as amino acids, 
nucleotides, DNAs, RNAs, lipids and proteins.38–40 There are many examples in the 
literature of the synthesis of BODIPYs dyes containing different reactive groups for 
protein labelling.41 A succinimidyl ester is one of the most commonly used groups for 
conjugation of BODIPYs to amino acids (specifically lysines). A BODIPY-succinimidyl 
ester can react with amino groups in the protein producing an amide bond and releasing 
N-hydroxysuccinimide as shown in Figure 1.15a.41 
Also, several BODIPY compounds containing an isothiocyanate group have been 
reported in the literature. The nucleophilic reaction between the amino group of an amino 
acid (specifically lysines) and the isothiocyanate group of an BODIPY leads to formation 
of a thiourea linkage as seen in Figure 1.15b.41  
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Figure 1.15: General mechanisms of amine labelling with succinimidyl ester and isothiocyanate 
functionalised BODIPYs.41 (Adapted from L. C. D. D. L. Rezende, S. Emery and F. Emery, Orbital Elec. 
J. Chem, 2013, 5, 62–83.).  
The reactivity of iodoacetamide and maleimide toward sulfhydryl groups of amino acid 
residues (specifically cysteine) has also been described in the literature.41 Figure 1.16a 
and b illustrate the mechanism of sulfhydryl labeling with iodoacetamide and maleimide 
BODIPY derivatives.   
 
 
Figure 1.16: General mechanism of sulfhydryl labelling with iodoacetamide and malemaide 
functionalised BODIPY derivatives.41 (Adapted from L. C. D. D. L. Rezende, S. Emery and F. Emery, 
Orbital Elec. J. Chem, 2013, 5, 62–83.). 
  
  Chapter 1                                                                                                    Introduction 
 
 
23 
 
1.5. Goals and objectives 
  
This project aimed to synthesize functionalized BODIPY dyes. The first part of the 
research focuses on the synthesis of novel chiral BODIPY dyes in which chirality is 
intimately associated with the BODIPY core in order to maximise the likelihood of 
enantioselective modification of the optical properties in response to the two enantiomeric 
forms of a chiral analyte. Ultimately, this approach might be used in the development of 
high throughput screening of enantiomeric excess and the use of this methodology may 
be applied, for example, in the development of novel chiral catalysts and the optimisation 
of reaction conditions.  
In the second part, investigation into the synthesis and application of amino-substituted 
BODIPYs via metal catalysed amination reactions are described as a new strategy 
towards fluorescence-quenched BODIPY dyes. Such fluorescence-quenched systems are 
highly useful for many different applications in which fluorescence ˈswitch onˈ can be 
achieved in response to an analyte.
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Chapter 2: Synthesis of chiral BODIPY dyes 
 
2.1. Introduction 
 
Chiral compounds can exist as two non-superimposable mirror image forms which are 
termed enantiomers. In general, enantiomers have the same physical properties like 
refractive index, UV, solubility, IR, NMR, X-ray diffraction pattern and density. 
However, the two enantiomers are not identical in chiroptical properties such as optical 
rotatory dispersion, optical rotation and circular dichroism.42,43 
Each enantiomer often shows very different pharmacological, physiological, 
pharmacokinetic and pharmacodynamic properties.42 For instance, there were a number 
of adverse effects when using racemic dopa for the treatment of Parkinson’s disease such 
as nausea and anorexia. It was subsequently found that the drug must be marketed as a 
single enantiomer (L)-dopa because (D)-dopa is ineffective and quite toxic.44 
  
 
Molecular chirality can be divided into four types: central, axial, planar and helical.42,43 
Examples of the four different types of chiral molecules are shown in Figure 2.1. In all 
cases the two mirror images of the molecules cannot be superimposed. The first type and 
the most common is central chirality which usually created by an atom with four different 
groups. Axial chirality is a stereoisomerism resulting from the nonplanar arrangement of 
four substituents about an axis. This kind of chirality can be observed in atropisomeric 
biaryl compounds such as BINAP and BINOL due to restricted rotation between the aryl-
aryl single bond. Planar chirality is a stereoisomerism resulting from the arrangement of 
out of plane substituents with respect to the plane. Helical chirality is a special type of 
axial chirality in which the molecules twist (like a cork-screw) and can therefore be right 
handed or left handed.   
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Figure 2.1: examples of the four different types of chiral molecules a) central, b) axial, c) planar, d) 
helical.42,43 
 
A variety of methods are used for determination of enantiomeric composition.45 
Chromatography techniques have been used for many years for quantification of ee and 
for enantiomer separations. For instance, chiral high-performance liquid chromatography 
(HPLC), capillary electrophoresis (CE) and chiral gas chromatography (GC) are used to 
attempt high-throughput screening (HTS) of ee values.45,46 These methods have produced 
the most accurate measurements. However, a major limitation of these methods is the 
long elution times and the sequential nature of the method when used for multiple 
analyses.   
Alternative methods for determining ee are the use of liquid crystals (LCs) via visual 
detection and by spectroscopic measurements. A major disadvantage of these methods is 
that they require derivatization of analytes or substrates. Another approach to the 
determination of ee is the use of enzymes and antibodies which feature high selectivity 
and inherent chirality.45 However, these techniques suffer from a lack of generality. 
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Recently, researchers have turned to optical methods which are more accurate, precise, 
and user-friendly. The use of fluorescent molecular sensors for the measurement of the 
enantiomeric excess of chiral chemical compounds has several advantages. For example, 
measurement can be made rapidly thus avoiding time consuming chromatography. Also, 
optical methods offer the possibility of real-time measurement, amenability to 
automation, inexpensive instrumentation, virtually no waste and low-cost reagents.47 
Therefore, these sensors have been used for (HTS) to determine a compound’s stability 
to racemization under different conditions and to rapidly detect the enantioselectivity of 
chemical reaction products.45  
There are several important features must be present in sensor molecules such as:- 
1. Suitable groups that will bind reversibly with the target species, for in-
stance;acidic/basic groups, hydrogen bonding groups or polar groups.47 
2. A signal must be formed by the host-guest interaction.47  
3. The signal transduction and groups conferring recognition must be organized in an 
interactive conformation, so binding with a target species results in signal genera-
tion.47 
Enantiomeric fluorescent sensors give different responses by reaction or interaction with 
chiral molecules (Figure 2.2).48 One enantiomer of a given chiral selector molecule can 
interact with a chiral analyte containing a fluorescent group, thus forming distereomeric 
complexes of different structure and stability (Figure 2.2a). Moreover, fluorescent 
compounds can be used to produce an enantioselective response in the presence of both 
non-fluorescent and fluorescent analytes (Figure 2.2b).48 Consequently, there are many 
fluorophores that have been used for this purpose such as cyclodextrin, cyclic urea, 
binaphthol, calixarene and crown ethers. Most commonly chirality is introduced into 
these compounds as atropisomerism using biphenyls, cumulenes and allenes. 
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Figure 2.2: Two different schemes for inducing an enantioselective fluorescence response.48
 
Boron dipyrromethenes (BODIPYs) have found extensive use in imaging and sensing 
due to their fluorescence properties. Few different chiral BODIPYs have been 
synthesized and their structure, electrochemical and spectroscopic properties have been 
investigated.49–54 However, there is one report of the use of chiral BODIPY species for 
enantioselective applications.54 The binaphthol BODIPY derivative 2.1 is optically active 
and shows chiral discrimination towards the enantiomers of α-methylbenzylamine by 
display of different fluorescence quenching rates of the BODIPY fluorescence.54 
 
It was found that specific changes of the BODIPY fluorescence signal were generated by 
the interaction between the α-methylbenzylamine quencher and the 1,1’-binaphthalene 
receptor. A decrease of the intensity of the fluorescence band was detected by addition of 
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(R) - and (S)-1-phenylethylamine respectively. The efficiency of the quenching process 
for (S) - and (R)-1-phenylethylamine (PEA) were examined. The equation for static 
quenching was used to analyze the experimental data.54 
 
Figure 2.3: Plots for the quenching of 2.1 with R-PEA and S-PEA in acetonitrile.54 
Figure 2.3 shows the corresponding plots for the quenching of 2.1 with (R)- and (S)-1-
phenylethylamine. The different slopes indicate the suitability of 2.1 as a chirally 
discriminating sensor for optically active amines. The steeper slope for quenching of 2.1 
with (S)-PEA in acetonitrile, based on a higher association constant (KS = 226 M
-1) for 
(S)-PEA–2.1 as compared to (R)-PEA–2.1 (KS = 161 M-1), suggests that association of 
the S-PEA and 2.1 is more effective. The ratio of KS(R-S)/KS(R-R) = 1.40 is relatively 
high for amine complexes of a simple binaphthol receptor unit and obviously 
demonstrates the potential of 2.1 as an enantioselective sensor molecule.54 
In this project, we aimed to synthesise functionalised BODIPYs in which chirality is 
intimately associated with the BODIPY core in order to maximise the likelihood of 
enantioselective modification of the optical properties in response to the two enantiomeric 
forms of a chiral analyte. Therefore, this chapter is discussed several approaches to the 
synthesis of chiral BODIPY dyes.  
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2.2. Axially chiral BODIPYs 
 
More recent attention has focused on the synthesis of axially chiral BODIPY dyes.49–52 
For instance, Akkaya explored a new chiral system based on rotationally hindered di-
BODIPY core.50 They synthesised rac-BODIPY 2.2 and separated the enantiomers by 
HPLC using a chiral stationary phase (Chiralcel-OD column) (Figure 2.4).50 As shown in 
Figure 2.5 the circular dichroism spectrum has been used to establish successful 
separation of the two enantiomers 2.2a and 2.2b). 
 
 
Figure 2.4: HPLC separation of BODIPY 2.2 to 2.2a (20.3 min) and 2.2 b (33.4 min).50 
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Figure 2.5: Circular dichroism spectra of rac-BODIPY 2.2 and the two enantiomers.50 
 
In 2014, Hall51 reported the synthesis, resolution and determination of the absolute 
configuration of axially chiral BODIPY 2.3 as shown in Figure 2.6 and 2.7.51 
 
 
Figure 2.6: HPLC separation of BODIPY 2.3 to the two enantiomers.51  
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Figure 2.7: ECD spectra of 2.3-(+) and 2.3-(-).51 
2.2.1.   Synthesis of axially chiral BODIPY dyes with C2-symmetry 
  
Due to restricted rotation around the pyrrole-aryl bonds, the BODIPY 2.6 was expected 
to be chiral (see later). A synthetic route to 2,6-bis(2-methoxyphenyl)BODIPY 2.6 is 
shown in Scheme 2.1. 
 
 
Scheme 2.1: Synthetic approach to the synthesis of 2,6-bis(2-methoxyphenyl)BODIPY 2.6.  
Synthesis of symmetrical BODIPYs can be accomplished by starting with different acyl 
chlorides or aryl aldehydes both of which are commercially available. Using a literature 
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procedure,55 the one-pot condensation of benzoyl chloride with two equivalents of 2,4-
dimethyl pyrrole was used to synthesise the symmetrical BODIPY 2.4. Initially, 2,4-
dimethylpyrrole and benzoyl chloride were stirred at room temperature, followed by BF2 
chelation by treatment with boron trifluoride diethyl etherate (BF3.OEt2) in the presence 
of N,N-diisopropylethylamine (i-PrNEt2) to produce the symmetrical BODIPY 2.4 
(Scheme 2.2).  
 
Scheme 2.2: Synthesis of 8-phenyl BODIPY 2.4. Conditions and reagents: a) DCM, 16 h, r.t; b) 
BF3.OEt2, i-Pr2NEt, 0 ̊C, 1 h, 40%. 
It is perhaps not surprising that the most common method for the synthesis of halogenated 
BODIPY dyes relies on direct electrophilic halogenation. Using a literature56 procedure, 
the 2,6-dibromoBODIPY 2.5 was prepared by reaction of the 8-phenylBODIPY 2.4 with 
Br2 (Scheme 2.3). Purification using column chromatography gave the desired 2,6-
dibromoBODIPY 2.5 in high yield (90%). Crystals of 2,6-dibromoBODIPY 2.5 were 
obtained by slow evaporation from a mixture of ethyl acetate and petrol (1:3). The crystal 
structure shown in figure 2.8 was obtained through single crystal X-ray crystallography.  
 
 
Scheme 2.3: Synthesis of 8-phenylBODIPY 2.5. Conditions and reagents: a) Br2, DCM, r.t., 3 h, 90%. 
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Figure 2.8: Molecular structure of 2,6-dibromoBODIPY 2.5. Hydrogen atoms have been omitted for 
clarity. 
 
The synthesis of halogenated BODIPYs has been reported as a useful reaction which can 
be followed by various transition metal catalysed cross-coupling reactions or nucleophilic 
substitution. 2,6-Bis(2-methoxyphenyl) BODIPY 2.6 was synthesized via a Suzuki 
coupling reaction. 2,6-DibromoBODIPY 2.5 was reacted with  2-
methoxybenzeneboronic acid in the presence of Pd(OAc)2 and  H-KITPHOS 2.7
57 in 
toluene to form BODIPY 2.6 in 25%. 
 
Scheme 2.4: Synthesis of 2,6-bis(2-methoxyphenyl) BODIPY 2.6. Conditions and reagents: a) H-
KITPHOS 2.7 (12 mol %), Pd(OAc)2 (5 mol %), K3PO4 (4 eq), toluene, reflux, 20 h, 25%. 
 
In this reaction we expected to form a diastereomeric mixture of the syn-2.6 and anti-2.6 
isomers of 2,6-bis(2-methoxyphenyl) BODIPY but this was not evident from the 1H NMR 
spectrum of the product. 19F NMR spectroscopy is a useful tool to distinguish between 
the two isomers because it can distinguish different fluorine chemical environments. 
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In general, the 19F NMR spectrum shows four peaks (1:1:1:1 quartet) for symmetrical F2-
BODIPY dyes, resulting from the coupling of the two identical fluorine atoms with the 
single boron (I = 3/2) nucleus. For instance, the 19F NMR spectrum for phenyl-BODIPY 
2.4, recorded in CDCl3, is reported to consist of four peaks, clearly indicating that the 
fluorine atoms reside in identical environments (Figure 2.9). 
 
Figure 2.9: 19F NMR spectrum reported for phenyl-BODIPY 2.4 in CDCl3. 
 
In 2008, Benniston published a paper58 in which they synthesised the symmetric quinone 
substituted BODIPY 2.9 for detection of reactive oxygen species (ROS) and monitoring 
lipid oxidation in living cells (Scheme 2.5).58 
 
Scheme 2.5: Synthesis of 8-quinone BODIPY 2.8. Conditions and reagents: a) TFA, DCM, r.t., 24 h. b) 
DDQ, 24h. c) BF3.OEt2, i-Pr2NEt, r.t., 6 h, 50%. d) H2 (4 atm), Pd/C (10 mol%), DCM/MeOH,. (d) THF, 
DDQ, r.t., 82%.58 
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The 19F NMR spectrum for the symmetrical BODIPY 2.9 consists of 16 peaks due to the 
two different fluorine atoms coupling to each other and also coupling to the boron atom, 
indicating that the fluorines are diastereotopic. (Figure 2.10).58 
 
Figure 2.10: 19F NMR spectrum reported for BODIPY 2.9 in CDCl3.58 
 
Benniston reported the same phenomenon in BODIPY 2.11. Even though BODIPY 2.11 
contains hydrogens at the 1 and 7 positions, free rotation of the 8-phenanthrene 
substituent appears to be restricted as indicated by the double quartet in the 19F NMR 
spectrum of BODIPY 2.11 (Scheme 2.6).59  
 
Scheme 2.6: Synthesis of 8-phenanthrene substituted BODIPY 2.11. Conditions and reagents: a) TFA, 
r.t., 90 h, 54%. b) DDQ, DCM, 90 min. c) BF3.OEt2, i-Pr2NEt, r.t., 20 h, 55%.59  
Therefore, in the case of BODIPY 2.6, due to restricted rotation around the pyrrole-aryl 
bond, the anti diastereoisomer was expected to be chiral. The 19F NMR spectrum for the 
  Chapter 2                                                                                   Results and Discussion  
 
 
36 
 
2,6-bis(2-methoxyphenyl) BODIPY 2.6 showed 20 peaks and corresponds to a 
diastereomeric mixture (50 : 50 ratio) of the syn-2.6 and anti-2.6 isomers (Figure 2.11). 
 
Figure 2.11: 19F NMR spectrum for the mixture of isomers of 2,6-bis-(2-methoxyphenyl)BODIPY 2.6. 
In order to measure the barrier to rotation for the 2-methoxyphenyl group a variable 
temperature (VT) 19F NMR experiment was performed using toluene-d8 from 298 
to 373 K (Figure 2.12). However, no sign of coalescence or broadening of the peaks 
was observed which indicates that restricted rotation of the 2-
methoxyphenyl/BODIPY bond, even at high temperature results in the two fluorine 
atoms being inequivalent. This restriction is caused by a combination of the steric 
bulk of the 2-methoxy groups together with the 1,3,5,7 methyl groups. 
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Figure 2.12: 19F VT NMR spectra of the mixture of isomers of 2,6-bis-(2-methoxyphenyl)BODIPY 2.6, 
in d8-toluene. 
2.2.1.1.   Chiral resolution 
  
Chiral resolution, also called chiral separation, is a process used to separate the two 
enantiomers of a racemic compound. There are a several different methods by which 
enantiomers can be separated such as creation of diastereomers by reaction of the 
enantiomers with an enantiomerically pure chiral compound; the resulting 
diastereoisomers can be purified for example by standard column chromatography or by 
crystallization (common for diastereoisomeric salts). Chiral column chromatography is 
frequently used as an analytical tool to measure the ratio of enantiomers but can also be 
used preparatively. 
 
2.2.1.2.   Chiral HPLC separation 
 
In direct chiral chromatographic separation the two enantiomers are placed in a chiral 
environment. As a matter of principle, chiral selectors are employed in the stationary 
phase and/or the mobile phase, which produce diastereomeric interactions with the 
enantiomeric analytes which consequently elute at different rates. The enantiomer which 
interacts less strongly with the stationary phase will elute more quickly.  
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Unfortunately, attempts to separate 2.6 syn and the two enantiomers of 2.6 anti by chiral 
HPLC were not successful as shown in Figure 2.13. 
 
Figure 2.13: Attempted HPLC separation of the stereoisomers of BODIPY 2.6. Daicel Chiralpk 
OB column (25 cm x 0.46 cm) hexane:isopropanol (80:20); 0.5 mL min-1.  
  Chapter 2                                                                                   Results and Discussion  
 
 
39 
 
2.2.1.3.   Photophysical data for 2,6-bis(2-methoxyphenyl) BODIPY 2.6 
 
The UV and fluorescence spectra of BODIPYs 2.4-2.6 were measured in CHCl3 at room 
temperature (Table 2.1). Rhodamine 6G was used as the reference compound for 
determination of fluorescence quantum yields (rhodamine 6G Φf= 0.95, λex= 479 or 496 
nm, in ethanol). 
Table 2.1. Photophysical data of the BODIPYs 2.4-6 in CHCl3. 
 
BODIPY λabs (max)/nm ε/104 M-1cm-1 λem (max)/nm Φf (λex) 
2.4 502 3.74 511 0.57(479) 
2.5 530 5.67 543 0.46(496) 
2.6 578 7.15 591 0.98(496) 
 
Figure 2.14 shows the absorption and emission spectra of parent BODIPY 2.4 and of 2,6-
dibromoBODIPY 2.5 and BODIPY 2.6. As Table 2.1 illustrates all of these BODIPY 
dyes showed strong absorption bands. In comparison to the parent BODIPY 2.4, the 
presence of bromine atoms (heavy atoms) at the 2 and 6 positions of the BODIPY core 
leads to a 28 nm (1052 cm-1) red-shift of the absorption maximum and a 32 nm (1153 cm-
1) red-shift of the emission maximum. Also, the presence of the 2-methoxyphenyl group 
in the position 2 and 6 leads to red-shift by 76 nm (2619 cm-1) of the absorption and red-
shift by 80 nm (2649 cm-1) of the emission maximum. 
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Figure 2.14: Absorption spectrum (solid lines) in terms of the molar absorption coefficient (ε) 
and normalised fluorescence spectrum (dashed lines) for 2.4 (—), 2.5 (—), and 2.6 (—) in 
CHCl3. 
Due to the formation of 1:1 diastereoisomeric mixture, and the failure of attempted isomer 
separation by chiral HPLC, this BODIPY was not pursued further.  
 
2.2.2.   Synthesis of unsymmetrical axially chiral BODIPY dyes 
 
In order to avoid the diastereoisomer separation problem we decided to synthesise a 1 and 
7 substituted BODIPY with an 8-quinoline group at the meso position (8 position). The 
restricted rotation between 8-quinoline and the substituents in positions 1 and 7 leads to 
the potential for atropisomerism as long as the BODIPY is unsymmetrically substituted. 
A functionalized axially chiral BODIPY such as 2.15 might interact enantioselectively 
with a chiral analyte. The two enantiomers of the chiral 8-quinolinyl substituted BODIPY 
2.15 might even be resolved by crystallization of diastereoisomeric salts formed using an 
enantiopure chiral acid, or simply by chiral HPLC. 
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Functionalization at the meso position can be achieved simply by acid catalyzed 
condensation of a pyrrole with a suitably substituted acyl chloride or aryl aldehyde. The 
first step in the synthesis of BODIPY 2.15 is acid catalysed condensation of 2,4-
dimethylpyrrole with quinoline-8-carbonyl chloride 2.12 which is not commercially 
available. In general, acyl chlorides are prepared by treating the corresponding carboxylic 
acid with thionyl chloride, phosphorus pentachloride, or phosphorus trichloride. By using 
the literature procedure,60 quinolinecarboxylic acid was treated with 6 equivalents of 
thionyl chloride at room temperature for 2 days, followed by the addition of hexane to 
induce precipitation of the hydrochloride salt of the quinoline-8-carbonyl chloride 2.12 
(Scheme 2.7). The crude product was used immediately due to its expected sensitivity 
towards hydrolysis.  
 
Scheme 2.7: Synthesis of the quinoline-8-carbonyl chloride 2.12. Conditions and reagents: a) SOCl2 (12 
eq), r.t., 48 h.   
 
BODIPY 2.13 was synthesised using a non-oxidative method via condensation of 2,4-
dimethylpyrrole with quinoline-8-carbonyl chloride 2.12 in presence of i-PrNEt2 in 
DCM.53 The presumed dipyrromethene intermediate was converted directly to the 
BODIPY 2.13 without isolation by treatment with i-Pr2NEt and boron trifluoride etherate 
(BF3.OEt2) (Scheme 2.8).
 
   
 
Scheme 2.8: Synthesis of the BODIPY 2.13. Conditions and reagents: a) 2,4-dimethylpyrrole (2 eq), 
DCM, r.t., 24 h. b) i-Pr2NEt (6.8 eq), BF3.OEt2 (7.7 eq), 0 ̊C, 1 h, 85%.   
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The 19F NMR spectrum of 2.13 BODIPY showed 16 peaks which are typical of this class 
of BODIPY (Figure 2.15). Based on restricted rotation of the 8-quinoline ring in the 
meso-position (or 8-position) the two fluorine atoms are non-identical and therefore 
couple to each other and also to the boron atom. 
 
Figure 2.15: 19F NMR spectrum of BODIPY 2.13 (282 MHz, CDCl3). 
 
Desymmetrization of the BODIPY 2.13 is required in order to form an axially chiral 
system. We decided to desymmetrise 2.13 by bromination of one of the two pyrrole units 
of the BODIPY. Mono-halogenation of BODIPY is challenging to achieve without any 
double halogenation. Jia-Hai reported a method61 for the mono- and di-bromonation of 
BODIPY using CuBr2 as the brominating agent. Using this procedure,
61 the novel 2-
bromoBODIPY 2.14 was synthesized in 60% yield via electrophilic substitution of 
BODIPY 2.13 with CuBr2, potassium carbonate in acetonitrile under oxygen atmosphere 
(1 atm, balloon) at room temperature for 24 h (Scheme 2.9). This 2-bromoBODIPY 2.14 
allows further functionalization by coupling reactions such as Heck and Suzuki. 
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Scheme 2.9: Synthesis of the 2-bromo BODIPY 2.14. Conditions and reagents: a) CuBr2 (1.5 eq), K2CO3 
(3 eq), MeCN, r.t., 24 h, 60%. 
 
Suzuki coupling of the 2-bromoBODIPY 2.14 with phenylboronic acid gave the 
unsymmetrical axially chiral BODIPY 2.15 in good yield (86%) (Scheme 2.10).  
    
 
Scheme 2.10: Synthesis of the 2-phenyl BODIPY 2.15. Conditions and reagents: a) phenylboronic acid 
(3 eq), Pd(PPh3)4 (5 mol %), THF, toluene, water, 80 ̊C, 24 h, 86%.   
Although, in principle, the quinoline 2.15 might be resolved by fractional crystallisation 
of diastereoisomeric salts using an enantiopure chiral acid, this would be difficult on a 
small scale. For this reason we decided to resolve the two enantiomers using analytical 
chiral HPLC. Unfortunately, attempts to separate the enantiomers of BODIPY 2.15 in 
this way were unsuccessful. Figure 2.16 shows the best separation which was achieved. 
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Figure 2.16: Attempted HPLC resolution of BODIPY 2.15. Daicel Chiralpk OB column (25 cm x 0.46 
cm), hexane:isopropanol (80:20) 0.5 mL min-1. 
2.2.2.1.   Photophysical data of the 2-phenyl BODIPY 2.15. 
 
The UV and fluorescence spectra of BODIPYs 2.13-2.15 were measured in CHCl3 at 
room temperature (Table 2.2). Rhodamine 6G was used as the reference compound for 
determination of fluorescence quantum yields (rhodamine 6G Φf= 0.95, λex= 479 or 496 
nm, in ethanol). 
Table 2.2. Photophysical data of the BODIPYs 2.13-15. 
 
BODIPY λabs (max)/nm ε/104 M-1cm-1 λem (max)/nm Φf (λex) 
2.13 506 6.03 517 0.75(479) 
2.14 518 9.68 532 0.83(496) 
2.15 518 7.06 531 0.86(496) 
 
Figure 2.17 shows the absorption and emission spectra of parent quinoline-substituted 
BODIPY 2.13 and of the 2-bromoBODIPY 2.14 and 2-phenyl BODIPY 2.15. As Table 
2.2 illustrates all of these BODIPY dyes showed strong absorption bands. In comparison 
to the parent BODIPY 2.14, the presence of bromine atom (heavy atom) at the 2 position 
of the BODIPY core leads to a 12 nm (457 cm-1) red-shift of the absorption maximum 
and a 15 nm  
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(510 cm-1) red-shift of the emission maximum. However, there was no significant further 
red-shift of the absorption and emission maximum in the presence of the phenyl group in 
the position 2 of the core BODIPY.  
 
Figure 2.17: Absorption spectrum (solid lines) in terms of the molar absorption coefficient (ε) 
and normalised fluorescence spectrum (deshed lines) for 2.13 (—), 2.14 (—), and 2.15 (—) in 
CHCl3.  
Although the axially chiral BODIPY 2.15 was successfully prepared in 2 steps from 
BODIPY 2.13, attempts to resolve BODIPY 2.15 into its separate enantiomers by chiral 
HPLC have so far been unsuccessful. It is possible that resolution of this quinoline 
derivative might be possible by fractional crystallisation of distereisomeric salts formed 
by treatment with an enantiopure chiral acid but this would require a larger quantity of 
the BODIPY than was available from our initial synthesis. 
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2.3. Helically chiral BODIPY 
 
2.3.1.   Approach to synthesis of functionalized Aza BODIPY dyes 
 
Exchange of the meso-carbon atom of BODIPY dyes for a nitrogen atom generates a sub-
class of BODIPY called aza-BODIPY. The first aza dipyrromethene chromophore was 
synthesized in the 1940s,62–64 but the aza-BODIPY species was not reported until 1994.65 
Interest in the aza-BODIPY species has increased due to their photophysical properties; 
in particular it has been found that inclusion of the meso-nitrogen produces a large red 
shift of the absorption and emission bands in the 650-850 nm range, with high molar 
extinction coefficient, and moderate to high fluorescence quantum yields.6,16,35,60,66–72 
O’Shea reported the conversion of tetraarylazadipyrromethenes 2.16 into BF2 chelates 
2.17 and application for photodynamic therapy (Scheme 2.11).35,66 
 
 
Scheme 2.11: Synthesis of the aza-BODIPY dyes 2.17. Conditions and reagents: a) BF3.OEt2, i-Pr2NEt, 
DCM, 16 h, r.t. 
 
O’Shea subsequently reported a new class of aza-BODIPY 2.19, in which the cyclisation 
of the two oxygen atoms of the aryl substituents of the BODIPY 2.18 onto the boron atom 
renders the molecule chiral (Scheme 2.12).72 
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Scheme 2.12. Synthesis of Near-IR fluorophores 2.19. Conditions and reagents: a) BBr3, DCM, 0-25 ̊C, 
12 h.72 
Symmetrical aza-BODIPY derivatives 2.21 were synthesized by using the synthetic route 
in Scheme 2.13. We aimed in this project to synthesise a functionalized aza-BODIPY and 
then study potential uses of these chiral dyes.  
 
Scheme 2.13: General synthetic approach to the synthesis of an aza-bodipy dye.72 
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Before attempting the synthesis of more highly functionalized N,N,O,O-aza-BODIPYs 
we started with the synthesis of the known72 N,N,O,O-aza-BODIPY compounds 2.25a, b 
to gain familiarity with the synthetic route (Scheme 2.14) and the properties of the key 
N,N,O,O-aza-BODIPY core. 
Scheme 2.14: Four steps for the synthesis of N,N,O,O-aza-BODIPY 2.25a-b. 
Initially, by using a literature procedure the aldol condensation between 2’-
hydroxyacetophenone and aldehyde was carried out by treatment with sodium hydroxide 
(Scheme 2.15). The expected chalcone derivatives 2.22a, b were formed in good 
yield.73,74 The 1H NMR spectrum of the product showed the appearance of the signals 
corresponding to the two protons on the alkene (2.22a, 7.92 and 7.66 ppm; 2.22b, 7.91 
and 7.57) and the coupling constant between these protons (2.22a, 15.5 Hz; 2.22b, 15.4 
Hz) indicated that the configuration of the double bond was E. 
 
Scheme 2.15: Synthesis of chalcone derivatives 2.22.73,74 Conditions and reagents: a) NaOH, MeOH, 48 
h, r.t., (2.22a, 52%; 2.22b, 54%).  
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Michael addition to form compound 2.23a,b was accomplished by treatment of chalcone 
derivatives 2.22a,b with nitromethane and diethylamine (Scheme 2.16).72 The 1H NMR 
spectrum of the crude product mixture showed disappearance of the signals 
corresponding to the two vinylic hydrogens and appearance of a signal corresponding to 
the CH2 which is α to the NO2 (2.23a, Ar = Ph, 3.64 – 3.39 ppm). The crude products 
were recrystallized from methanol to give 2.23a and 2.23b in good yields 55 and 80% 
respectively. 
 
Scheme 2.16: Synthesis of compounds 2.23.72 Conditions and reagents: a) MeNO2 (4 eq), Et2NH, MeOH, 
17 h, reflux, (2.23a, 55%; 2.23b, 80%).72 
 
Tetraarylazadipyrromethenes 2.24a, b were synthesized by treating diaryl-γ-nitro ketones 
2.23a,b with excess of ammonium acetate in cumene under reflux for 3 hours.72 The 
products 2.24a, b were isolated by trituration with cold methanol in low yield (2.24a, 
11% and 2.24b, 20%) as blue solids.72 The 1H NMR spectrum of the pure product showed 
appearance of the signal corresponding to the CH on the position 3 (2.24a, Ar = Ph, 7.28 
ppm; 2.24b, Ar = 4-MeOC6H4, 7.78ppm). 
 
Scheme 2.17: Synthesis of tetraarylazadipyrromethenes 2.24. Conditions and reagents: a) NH4OAc (35 
eq), cumene, 3 h, reflux, (2.24a, 11%; 2.24b, 20%).72 
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The aza-BODIPY compounds 2.25a, b were synthesized by treatment of compounds 
2.24a, b with i-Pr2NEt and BF3.Et2O in toluene (Scheme 2.18).
72 The target compounds 
2.25a and 2.25b were formed by BF2 chelation and intramolecular phenolic oxygen 
fluorine displacement in good yields (82 and 73% respectively). 
  
 
Scheme 2.18: Synthesis of aza-BODIPY compounds 2.25.35 Conditions and reagents: a) i-Pr2NEt (14 eq), 
BF3.OEt2 (10 eq), toluene, 2 h, reflux, (2.25a, 82%; 2.25b, 73%). 
 
The preparation of aza-BODIPY 2.25a, b succeeded in a good yield. However, these 
compounds have no functional groups which could interact with a chiral molecule. 
Therefore, we decided to prepare a more highly functionalized aza-BODIPY 2.26 for 
potential applications to enantioselective sensing. The two enantiomers of the chiral aza-
BODIPY 2.26 might be resolved by simply by chiral HPLC. 
 
We envisioned that aza-BODIPY 2.26 could be obtained starting from the commercially 
available 2-hydroxy-5-methyl-3-nitroacetophenone and benzaldehyde. Aldol 
condensation of these two compounds in ethanol gave 1-(2-hydroxy-5-methyl-
3nitrophenyl)-3-phenylpropenone 2.27 in 89% yield (Scheme 2.19).  
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Scheme 2.19: Synthesis of chalcone derivative 2.27. Conditions and reagents: a) KOH (3 eq), EtOH, r.t., 
24 h, 89%. 
Michael addition reaction of the resulting chalcone 2.27 with nitromethane in 
diethylamine and methanol successfully produced the γ-nitroketone 2.28 in a good yield 
73% (Scheme 2.20). 
 
Scheme 2.20: synthesis of compound 2.26. Conditions and reagents: a) Et2NH (4 eq), MeNO2 (4 eq), 
MeOH, reflux, 17 h; b) r.t., HCl (2M), 73%. 
 
The most challenging step in the synthesis of aza-BODIPYs is preparation of the aza-
dipyrrin. We attempted to synthesise 2.29 following O’Shea’s conditions72 by treatment 
of compound 2.28 with ammonium acetate in cumene under reflux for 3 hours. 
Unfortunately, the dark crude product was insoluble in a range of organic solvents. 1H 
NMR spectrum in D2O indicated a very complex mixture of compounds. 
 
 
Scheme 2.21: synthesis of compound 2.29. Conditions and reagents: a) NH4OAc (35 eq), cumene, 3 h, 
reflux. 
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We then examined Gray’s conditions71 to make 2.29 by performing the reaction in 1-
butanol as a solvent under reflux for 24 h, nevertheless, similar insoluble dark crude 
material was observed with a highly complex 1H NMR spectrum. A possible explanation 
for this might be the presence of two NO2 groups in the Michael addition product 2.28. A 
mechanism for the formation of aza-dipyrrins from nitromethane was proposed by 
O’Shea in 2012.70 As Scheme 2.22 shows, the start of the reaction to form aza-dipyrrin 
involves the formation of enamine intermediate 2.32 from Michael addition product 2.30 
and ammonia, followed by nucleophilic addition to produce intermediate 2.33. Three 
potential routes then lead from 2.33 to the aza-dipyrrin 2.36. 
 
Scheme 2.22: Three different proposed routes for the synthesis of aza-dipyrrins.70 
Since the formation of aza-dipyrrin 2.29 was unsuccessful by using the Michael addition 
product 2.28, we decided to hydrogenate the NO2 group of the 2-hydroxy-5-methyl-3-
nitroacetophenone followed by protection of the resulting NH2 group to prevent any 
complication during the formation of the aza-dipyrrin.  
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Following a literature procedure,75 the nitro group of 2-hydroxy-5-methyl-3-
nitroacetophenone was reduced to 2-hydroxy-5-methyl-3-aminoacetophenone 2.39 using 
SnCl2.2H2O in absolute ethanol. Purification using column chromatography gave the 
desired compound 2.39 in good yield (75%) (Scheme 2.23). 
 
Scheme 2.23: Synthesis of compound 2.39. Conditions and reagents: a) SnCl2.2H2O (5 eq), EtOH, 4 h, 
reflux, 75%. 
Treatment of the reduced compound 2.39 with di-tert-butyl dicarbonate (Boc) and 
triethylamine in DCM produced the protected compound 2.40 in low yield 30% (Scheme 
2.24).   
 
Scheme 2.24: Synthesis of protected compound 2.40. Conditions and reagents: a) Di-tert-butyl 
dicarbonate (1.1 eq), NEt3 (1.1 eq), DCM, r.t., 48 h, 30%. 
Unfortunately, the aldol condensation reaction of compound 2.40 with benzaldehyde 
failed to form the expected chalcone derivative 2.41 (Scheme 2.25). 
 
Scheme 2.25: Attempt to synthesis of chalcone 2.41. Conditions and reagents: a) KOH (3 eq), EtOH, r.t., 
24 h. 
  Chapter 2                                                                                   Results and Discussion  
 
 
54 
 
The known aza-BODIPY compounds 2.25a, b were synthesized successfully, 
nevertheless, all attempts for synthesis of the functionalized aza-BODIPY 2.26 proved 
unsuccessful. There are some disadvantages in the synthesis of aza-BODIPYs. For 
instance, the yield of formation of the aza-dipyrrins 2.24a, b is very low. It has been 
reported that aza-BODIPYs can only be synthesized from heavily substituted pyrroles, 
such as ring annelated pyrroles or 2,4-diarylpyrroles.16 Also, there are few 2-
hydroxyacetophenone derivatives which are commercially available thus limiting the 
ease with which structural variation can be accomplished. Therefore, we decided to 
exchange of the central nitrogen atom of the aza-BODIPYs with a C atom (C-meso) to 
form the corresponding helically chiral N,N,O,O-BODIPYs. 
2.3.2.   Synthesis of helically chiral N,N,O,O-BODIPY dyes. 
 
Burgess76 reported the synthesis and investigation of the N,N,O,O-BODIPY structure. 
This compound is helically chiral due to the chelation to boron which prevents rotation 
of the aryl rings about the pyrrole rings. The two enantiomers of this compound were not 
resolved, nonetheless, the reported HPLC analysis of the rac 2.42 on a Pirkle column 
showed two peaks which indicates that separation is possible. In general, this ring system 
gives a red-shifted and sharper fluorescence emission than the ordinary BODIPY.   
 
In 2008, Kung successfully synthesised and characterized a water soluble O-chelated 
BODIPY 2.43, for targeting β-amyloid plaques.77 In addition, Kubo prepared O-chelated 
BODIPY 2.44 which can work as a light-harvesting sensitizer in polymeric solar cells.78  
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A considerable number of O-chelated BODIPYs have been reported in the literature.77,79–
84 However, there is no report of the use of O-chelated BODIPY species for 
enantioselective applications or use as chiroptical dyes. Interestingly, the separation of 
the two enantiomers and information about the chiral properties of these molecules (O-
chelated BODIPY) has not been reported. Therefore, we aimed to synthesise O-chelated 
BODIPY derivatives followed by resolution of these racemic helically chiral BODIPYs 
to give single enantiomers, and then study the chiral properties of these molecules in their 
excited state.   
In general, only one synthetic approach to O-chelated BODIPYs has been investigated 
(Scheme 2.26).77–83 Suzuki coupling of (2-methoxyphenyl)boronic acid with 2-bromo-N-
Boc pyrrole followed by Boc deprotection gives the 2-arylpyrrole 2.46. Then, 
condensation of an aryl chloride with pyrrole 2.46 affords the dipyrromethene 2.47. 
Subjecting the dipyrromethene 2.47 to base and boron trifluoride etherate affords the 
BODIPY complex 2.48. Finally, double demethylation of BODIPY 2.48 affords O-
chelated BODIPY 2.49 (Scheme 2.26). Therefore, our first approach toward the synthesis 
of O-chelated BODIPYs followed this route. 
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Scheme 2.26: General synthetic approach to the synthesis of O-chelated BODIPYs 2.49. 
 
The commercially available pyrrole was reacted with 1,3-dibromo-5,5-
dimethylhydantoin 2.50 in the presence of  azoisobutyronitrile (AIBN) in THF at -78 ̊C 
to give brominated pyrrole, followed by Boc-protection by using triethylamine, di-tert-
butyl dicarbonate and a catalytic amount of 4-dimethylaminopyridine84 to give a 70:30 
ratio of the N-Boc-2-bromopyrrole 2.51 as major product together with a minor amount 
of N–Boc-3-bromopyrrole 2.52 which were not separable by column chromatography. 
 
Scheme 2.27: Synthesis of N-Boc-2-bromopyrrole 2.51. Conditions and reagents: a) DBDMH (1 eq), 
THF, AIBN (2 mol %), -78 ̊C, 2 h; b) Et3N (0.8 eq), Di-tert-butyl dicarbonate (2.8 eq), DMAP (2 mol%), 
r.t., 16 h (2.51, 65%; 2.52, 20%). 
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Figure 2.18: 1H NMR spectrum of a mixture of N-Boc-2-bromopyrrole 2.51 and 2.52. 
Tert-butyl 2-(2-methoxyphenyl)-1H-pyrrole-1-carboxylate 2.45 was synthesized via 
Suzuki coupling reaction. Initially, a mixture of N-Boc-2 and 3-bromopyrrole 2.51 and 
2.52 were reacted with 2-methoxybenzeneboronic acid in the presence of Pd(PPh3)4 and 
Na2CO3 in methanol. The crude product was purified using column chromatography to 
give 2.45 as a light grey solid in good yield (73%). 
 
Scheme 2.28: Synthesis of tert-butyl 2-(2-methoxyphenyl)-1H-pyrrole-1-carboxylate 2.45. Conditions 
and reagents: a) 2-methoxyphenylboronic acid (1 eq), Pd(PPh3)4  (5 mol%), Na2CO3 (2 eq),  toluene, 
MeOH, 80 ̊C, 20 h, 73%. 
Deprotection of the N-Boc group to give the pyrrole 2.46 was accomplished by treatment 
with sodium methoxide in a mixture of methanol and THF at room temperature for 6 h.85 
The crude product was purified using column chromatography to give 2.46 as a light 
green solid in 50% yield.  
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Scheme 2.29: Synthesis of 2-(2-methoxyphenyl)-1H-pyrrole 2.46. Conditions and reagents: a) NaOMe (3 
eq), THF, MeOH, r.t., 20 h, 50%. 
Our initial attempt to form symmetrical BODIPY 2.49 was via condensation of pyrrole 
2.46 with 4-methylbenzoyl chloride to give dipyrromethene 2.47 (Scheme 2.30). The 
crude product was purified using column chromatography to give 2.47 as a grey solid in 
20% yield. 
 
Scheme 2.30: Synthesis of symmetrical dipyrromethene 2.47. Conditions and reagents: a) 4-
methylbenzoyl chloride (1 eq), DCE, 85 ̊C, 3 h, 20%. 
 
The dipyrromethene 2.47 was synthesized successfully. However, there are some 
disadvantages in this synthetic route. For instance, the difficulties in the purification and 
handling of 2-bromopyrrole 2.51. In addition, the yield of the Boc deprotection reaction 
and formation of dipyrromethene is very low. Therefore, we developed an alternative 
synthetic route. This new approach involves the synthesis of the symmetrical 
dipyrromethane 2.54 followed by double bromination reaction and DDQ oxidation to 
give a 1,9-dibromodipyrromethene followed by formation of the symmetrical 3,5-
dibromoBODIPY 2.56. Suzuki coupling with ortho-methoxyphenyl boronic acid to give 
BODIPY 2.48.  Finally, demethylation of the aryl ether with BBr3 should result in the 
replacement of the B-F bonds with B-O bonds to give BODIPY 2.49 (Scheme 2.31).
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Scheme 2.31: General synthetic approach to the synthesis of O-chelated chiral BODIPYs. 
 
Condensation of p-tolualdehyde 2.53a with pyrrole in the presence of catalytic BF3.OEt2 
proceeded to give the corresponding dipyrromethane86 2.54a (Scheme 2.32). The reaction 
mixture was stirred for 30 min at room temperature, resulting in complete disappearance 
of the aldehyde by TLC. The 1H NMR spectrum of the crude reaction mixture showed 
the appearance of the signal corresponding to the CH at the meso position as a singlet at 
5.47 ppm. 
 
Scheme 2.32: Synthesis of symmetrical dipyrromethane 2.54a. Conditions and reagents: a) p-
tolualdehyde 2.53a (1 eq), pyrrole (25 eq), BF3.OEt2 (10 mol%), r.t., 30 min., 69%. 
1,9-dibromo-5-(4-methylphenyl)dipyrromethene 2.55a was synthesized as reported in 
the literature87 via the selective addition of an electrophilic brominating agent to the 1 and 
9 positions of compound 2.54a followed by oxidation. Thus, compound 2.54a was treated 
with of N-bromosuccinimide at -78 ̊C for 1 h. Then, the crude product was oxidized with 
1 equivalent of DDQ at room temperature for 10 min. The dipyrromethene 2.55a was 
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isolated in 80% yield by flash column chromatography. Then, BF2 chelation by treatment 
1,9-dibromodipyrromethene 2.55a with boron trifluoride diethyl etherate (BF3.OEt2) in 
the presence of N,N-diisopropylethylamine87 (i-Pr2NEt) gave the fluorescent BF2 
complex 2.56a in a good yield (Scheme 2.33). 
  
 
Scheme 2.33: Synthesis of symmetrical 3,5-dibromoBODIPY 2.56a. Conditions and reagents: a) NBS (2 
eq), THF, -78 ̊C, 1 h; b) DDQ (1 eq), THF, 10 min., r.t., 80%; c) i-Pr2NEt (7 eq), BF3.OEt2 (7 eq), r.t., 31 
h, 86 %. 
  
Crystals of compound 2.56a were obtained by slow evaporation from a mixture of 
chloroform and hexane (1:3). The crystal structure shown in Figure 2.19 was obtained 
through single crystal X-ray crystallography. 
 
Figure 2.19: Molecular structure of 3,5-dibromoBODIPY 2.56a, confirming the bromination reaction 
occurred at positions 3 and 5. Hydrogen atoms have been omitted for clarity.   
Suzuki coupling to form compound 2.48a was accomplished using conditions reported 
by Hao for related compounds.56 The 3,5-dibromo-BODIPY 2.56a was treated with 3 
equivalents of 2-methoxybenzeneboronic acid in toluene in the presence of Pd(PPh3)4 as 
catalyst and Na2CO3, under reflux for 4 h (Scheme 2.34). The crude material was purified 
using column chromatography. The diarylated BODIPY 2.48a was generated in high 
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yield (98%). The signal for the 6 protons of the two methoxy groups was observed as a 
singlet at 3.70 ppm in the 1H NMR spectrum. 
 
Scheme 2.34: Synthesis of symmetrical compound 2.48a. Conditions and reagents: a) 2-
methoxybenzeneboronic acid (3 eq), Pd(PPh3)4 (5 mol%), Na2CO3 (4 eq), toluene, 4 h, reflux, 98%. 
 
Following Kung’s procedure,77 double demethylation of the aryl ether 2.48a was 
accomplished by treatment with 10 equivalents of BBr3. The crude product was purified 
using column chromatography to give 2.49a as a dark red solid. The 1H NMR spectrum 
of this novel compound showed loss of the signal corresponding to the two methoxy 
groups.  
 
 
Scheme 2.35: Synthesis of N,N,O,O-BODIPY 2.49a. Conditions and reagents: BBr3 (10 eq), 
CH2Cl2, r.t., 5 h, 96%. 
 
Crystals of 2.49a were obtained by slow evaporation from a mixture of chloroform and 
hexane (1:3). The X-ray crystal structure reveals significant twisting of the N,N,O,O-
BODIPY 2.49a; the twist angle between the planes defined by the two pyrrolic rings is 
9.8̊. The O-B-O angle is 107.91̊, but the N1-B-O2 and N2-B-O1 angles are 115.06 and 
115.11̊, respectively. However, the N-B-N angle is 105.53̊ which is pinched inward. 
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Figure 2.20: Two views of one molecule in the molecular structure of N,N,O,O-BODIPY 2.49a showing 
the helical chirality of the molecule. Hydrogen atoms have been omitted for clarity.   
The preparation of N,N,O,O-BODIPY 2.49a succeeded in a good yield. However, this 
compound has no functional group which could interact with a chiral molecule. 
Substitution at the pyrrolic positions is more difficult than functionalization at the meso 
position which can be achieved simply by acid catalysed condensation of pyrrole with 
suitably substituted acyl chlorides or aryl aldehydes.  
 
We decided to attach a 2-pyridyl group at the meso-position by using an activated 2-
picolinic acid derivative or pyridine 2-carboxaldehyde to form N,N,O,O-BODIPY 2.49b. 
The two enantiomers of the chiral 2-pyridyl substituted BODIPY 2.49b might be resolved 
by crystallization of diastereoisomeric salts formed using an enantiopure chiral acid, or 
simply by chiral HPLC. 
 
Following the success in preparing helically chiral N,N,O,O-BODIPY 2.49a through our 
developed synthetic route, we decided to apply a similar approach to form N,N,O,O-
BODIPY 2.49b.  
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Condensation of picolinaldehyde 2.53b with pyrrole proceeded to give the corresponding 
dipyrromethane 2.54b in a good yield (62%) (Scheme 2.36).  
 
Scheme 2.36: Synthesis of symmetrical dipyrromethane 2.54b. Conditions and reagents: a) 
Picolinaldehyde 2.53b (1 eq), pyrrole (25 eq), BF3.OEt2 (10 mol%), r.t., 24 h., 62%. 
As scheme 2.37 illustrates, 3,5-dibromo-8-(2-pyridyl)BODIPY 2.56b was synthesized 
via the regioselective bromination at the 1 and 9 positions of dipyrromethane 2.54b with 
N-bromosuccinimide to give 1,9-dibromo-5-(2-pyridyl)dipyrromethane 2.55b in 76% 
yield. Then, the pure product was oxidized with DDQ at room temperature for an hour 
and this was followed by BF2 chelation with N,N-diisopropylethylamine (i-Pr2NEt) and 
boron trifluoride diethyl etherate (BF3.OEt2) to produce symmetrical 3,5-
dibromoBODIPY 2.56b. 
 
 
Scheme 2.37: Synthesis of symmetrical 3,5 dibromoBODIPY 2.56b. Conditions and reagents: a) NBS (2 
eq), THF, -78 ̊C, 1 h, 76%; b) DDQ (1 eq), toluene, 1 h, r.t; c) i-Pr2NEt (7 eq), BF3.OEt2 (7 eq), r.t., 31 h, 
50%. 
 3,5-Bis(2-methoxyphenyl) BODIPY 2.48b was synthesized via Suzuki coupling 
reaction. Initially, 3,5-dibromo BODIPY 2.56b was treated with  2-
methoxybenzeneboronic acid in the presence of Pd(PPh3)4, and Na2CO3 in water and 
toluene under reflux for 26 h. This resulted in unreacted 3,5-dibromo BODIPY 2.56b and 
2-methoxybenzeneboronic acid. Therefore, a different catalyst and reaction conditions 
were used. 2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl (S-Phos) was added to 
Pd(OAc)2 in toluene at room temperature for 30 min. Three equivalents of 2-
methoxybenzeneboronic acid, 3,5-dibromo BODIPY 2.56b and four equivalents K3PO4 
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were added (Scheme 2.38). The reaction mixture was refluxed for 4 h, resulting in 
complete disappearance of the 3,5-dibromo BODIPY 2.56b. The pink crude product was 
purified by column chromatography to give the product 2.48b as pink solid in 81% 
(Scheme 2.38). 
 
Scheme 2.38: Synthesis of symmetrical compound 2.48b. Conditions and reagents: a) 2-
methoxybenzeneboronic acid (3 eq), SPhos (12.5 mol%), Pd(OAc)2 (5 mol%), K3PO4 (4 eq), toluene, 4 h, 
reflux, 81%. 
  
Finally, double demethylation of the aryl ether 2.48b was accomplished by treatment with 
excess of BBr3 (Scheme 2.39). The crude product was purified using column 
chromatography to give 2.49b as a dark red solid in 60% yield. 
  
 
Scheme 2.39: Synthesis of N,N,O,O-BODIPY 2.49b. Conditions and reagents: BBr3 (10 eq), 
CH2Cl2, r.t., 5 h, 60%. 
The final symmetrical N,N,O,O-BODIPY which was considered incorporates a lipophilic 
long-chain alkoxy substituent on the meso-aryl group (2.49c). Such a compound might 
be of use, for example, for selective incorporation into lipid layers or micelles. 
Condensation of 4-octyloxybenzaldehyde 2.53c with pyrrole in presence of 
BF3.OEt2proceeded to give the corresponding dipyrromethane 2.54c in high yield (89%) 
(Scheme 2.40).  
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Scheme 2.40: Synthesis of symmetrical dipyrromethane 2.54c. Conditions and reagents: a) 4-
Octyloxybenzaldehyde 2.53c (1 eq), pyrrole (25 eq), BF3.OEt2 (10 mol%), r.t., 24 h., 62%. 
  
3,5-DibromoBODIPY 2.56c was then synthesised in one-pot with no isolation of the 
intermediates. Dipyrromethane 2.45c was treated with N-bromosuccinimide for 1 h, 
followed by oxidation with DDQ and then BF2 chelation with boron trifluoride diethyl 
etherate (BF3.OEt2) in the presence of N,N-diisopropylethylamine (i-Pr2NEt). 
Purification using column chromatography gave 3,5-dibromoBODIPY 2.56c in 61% 
yield (Scheme 2.41).  
The next task was Suzuki coupling reaction of the 3,5-dibromoBODIPY 2.56c with 2-
methoxybenzeneboronic acid. Buchwald88 has reported the use of the palladacycle 3.54 
in conjunction with the bulky, electron rich XPhos ligand for highly efficient Suzuki 
coupling reaction. The catalyst is activated via dissociation of chloride and reductive 
elimination of the carbocycle to produce the monoligated Pd(0)XPhos active catalyst.  
 
This catalyst was applied to the Suzuki coupling of dibromoBODIPY 2.56c. The crude 
material was purified using column chromatography to generate BODIPY 2.48c as a pink 
solid in 60%. Finally, double demethylation of the aryl ether 2.48c was accomplished by 
treatment with 12 equivalents of BBr3. The crude product was purified using column 
chromatography to give N,N,O,O-BODIPY 2.49c as a dark red solid (Scheme 2.41). 
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Scheme 2.41: Synthesis of N,N,O,O-BODIPY 2.49c. Conditions and reagents: a) NBS (2.4 eq), 
THF, -78 ̊C, 1 h; b) DDQ (1 eq), 1 h, r.t; c) i-Pr2NEt (6 eq), BF3.OEt2 (8 eq), DCM, r.t., 3 h, 61%; d) 2-
methoxybenzeneboronic acid (3 eq), LPd(XPhos)Cl 3.54 (5 mol%), K3PO4 (2 eq), THF-water, 6 h, reflux, 
60%; e) BBr3 (10 eq), CH2Cl2, 0 ̊C  to r.t., 5 h, 67%. 
In order to shorten the synthetic route, we examined different conditions to make 
N,N,O,O-BODIPY 2.49c by performing the Suzuki reaction using 2-
hydroxybenzeneboronic acid instaed of 2-methoxybenzeneboronic acid (Scheme 2.42). 
We hoped that the Suzuki coupling between 3,5-dibromoBODIPY 2.56c and 2-
hydroxybenzeneboronic acid might lead directly to the formation of the strapped 
BODIPY 2.49c. This might happen by nucleophilic substitution of the two fluorine atoms 
with 2-hydroxyphenyl groups to form the chelated BODIPY 2.49c with loss of HF.  
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Scheme 2.42: Attempted synthesis of N,N,O,O-BODIPY 2.49c.a) 2-methoxybenzeneboronic acid (3 eq), 
LPd(XPhos)Cl 3.54 (5 mol%), K3PO4 (2 eq), THF-water, 6 h, reflux. 
 
TLC analysis of the reaction indicated a mixture of the required product 2.49c and a new 
material. Purification using column chromatography gave the desired strapped BODIPY 
2.49c as a minor product together with a major amount of a new purple product which 
was not completely purified. Attempts to further purify this material by crystallisation 
were not successful, probably as a result of the presence of a long alkyl chain. The 1H 
NMR spectrum of this slightly impure purple compound showed 16 peaks corresponding 
to the aromatic protons which have different chemical shifts compared to the BODIPY 
2.49c (Figure 2.21). It is possible that the reaction between 3,5-dibromoBODIPY 2.56c 
and 2-hydroxybenzeneboronic acid produced the C,O-coordinated BODIPY 2.49d 
(Scheme 2.43). A similar reaction has been observed by Rebecca Clarke (Dr Hall’s 
research group, Newcastle University) and in that case the product was confirmed by X-
ray crystallography.  
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Figure 2.21: 1H NMR spectra of N,N,O,O-BODIPY 2.49c and BODIPY 2.49d. 
 
Scheme 2.43: Synthesis of N,N,O,O-BODIPY 2.49c and possible co-product N,N,O,C-BODIPY 2.49d.a) 
2-methoxybenzeneboronic acid (3 eq), LPd(XPhos)Cl 3.54 (5 mol%), K3PO4 (2 eq), THF-water, 6 h, 
reflux. 
 
The formation of C,O-coordinated BODIPY 2.49d might occur via the mechanisms 
shown in (Scheme 2.44). In general, 3,5-halogenated BODIPY compounds are very 
reactive toward a nucleophilic substitution reaction. Therefore, the first step is mono-
nucleophilic substitution between the dibromo BODIPY 2.56c and 2-
hydroxybenzeneboronic acid. In fact a second nucleophilic substitution reaction is usually 
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more difficult because the lone-pair of electrons of the 3-alkoxy group are delocalized 
into the aromatic π electron system which strongly reduces its electrophilicity.  
The second step is Suzuki coupling reaction between mono-bromo BODIPY and the 
excess of 2-hydroxybenzeneboronic acid in presence of LPd(XPhos)Cl 3.54 and K3PO4. 
Finally, replacement of the BF2 with the tethered boronic acid is consistent with the 
literature.80 The last step is cyclisation with loss of water. Future work will investigate 
the optimised conditions for the synthesis of this type of N,N,C,O-BODIPY type. 
 
 
Scheme 2.44: Proposed mechanism of formation N,N,O,C-BODIPY 2.49d. 
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2.3.2.2.   Photophysical properties of helically chiral N,N,O,O-BODIPYs 
  
2.3.2.2.1.   UV Absorption and Fluorescence of the helically chiral N,N,O,O-
BODIPYs 
  
In reviewing the literature, the photophysical properties of helically chiral N,N,O,O-
BODIPYs have been reported in detail.77–83 All of the reported N,N,O,O-BODIPY 
derivatives show good to high fluorescence quantum yield and a red shift of the 
absorption and emission maxima in comparison to the corresponding N,N-BODIPY 
systems. A possible explanation for this might be due to the chelation of the bottom aryl 
rings which rigidifies the system and extends the conjugation. For comparison the 
photophysical properties for the novel parent BODIPY 2.48a were measured (Table 2.3). 
As Figure 2.22 shows, the absorption and emission spectra are sharp and narrow bands.  
 
Figure 2.22: Absorption spectrum (solid line) in terms of the molar absorption coefficient (ε) and 
normalised fluorescence spectrum (hashed line) for BODIPY 2.48a, recorded in CHCl3 at room 
temperature, with an excitation wavelength of 500 nm. 
The novel N,N,O,O-BODIPYs 2.49a, 2.49b and 2.49c, are red coloured and appear to be 
highly fluorescent under UV at 365 nm. The photophysical data, including absorption and 
fluorescence maxima, were collected for all three N,N,O,O-BODIPYs (Table 2.3). 
Mg[TPP] in toluene was used as the standard for measuring Φf. The absorption and 
emission spectra of N,N,O,O-BODIPYs 2.49a, 2.49b and 2.49c are represented in Figure 
2.23. 
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Table 2.3: Absorption and fluorescence data for compounds 2.48a and 2.49a-c.a 
No 8-Aryl group 
λmax(abs)/
nm 
λmax(em) 
[λex]/nm 
ε/104 M-1 
cm-1 
Φfb/ 
CHCl3 
Φf/ 
CH3CN 
2.48a 4-MeC6H4 545 588[490] 3.84 0.65 - 
2.49a 4-MeC6H4 622 637[565] 4.00 0.56 0.52 
2.49b 2-pyridyl 643 675[565] 2.82 0.26 0.28 
2.49c 4-OctOC6H4 619 636[565] 6.34 0.48 - 
a All values measured in CHCl3. b Relative to Mg[TPP] (Φf= 0.15 , 565 nm, toluene).89 
 
Figure 2.23: Absorption spectrum (solid lines) in terms of the molar absorption coefficient (ε) and 
normalised fluorescence spectrum (hashed lines) for 2.49a (—), 2.49b (—), and 2.49c (—) in CHCl3. 
As Table 2.3 illustrates the low-energy maxima (λabs) of 2.49a, 2.49b and 2.49c are 622 
nm, 643 and 619 nm respectively and all of these BODIPY dyes showed strong absorption 
bands. In comparison to the BODIPY 2.48a, the chelation of the bottom aryl rings onto 
the BODIPY 2.49a leads to red-shifts of both the absorption and emission maxima. The 
most significant shifts can be seen in the 2-pyridyl-substituted compound 2.49b for which 
the absorption maximum is red shifted by 98 nm (2796 cm-1) and the emission maximum 
by 87 nm (2192 cm-1).  
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The helically chiral N,N,O,O-BODIPY 2.49a was used as an example of this system for 
meausuring the excited-singlet state lifetime (τ). The excited-singlet state lifetime (τ) of 
BODIPY 2.49a in 2-methyltetrahydrofuran (MTHF) at room temperature is 10 ns. It is 
interesting to note that the replacement of the two fluorine atoms with oxygen leads to a 
significant increase in the τ compared to BODIPYs 2.57-2.60.90,91 Moreover, strapping 
results in an unsually long lifetime for a BODIPY. The τ of 2.49a was recorded by 
Patrycja Stachelek (Prof. A Harriman’s group, Newcastle University). 
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We decided to examine chiral HPLC as a method for resolution of the helically chiral 
BODIPY’s 2.49a and 2.49b. Separation of 2.49a by chiral HPLC using a Daicel Chiralcel 
OD-H column (25 cm × 0.46 cm); hexane:isopropanol (80:20) as the eluent gave two 
peaks in a 1:1 ratio confirming that 2.49a was racemic (Figure 2.24). 
 
Figure 2.24: Chiral HPLC trace of 2.49a. Daicel Chiralcel OD-H column (25 cm x 0.46 cm); hexane:iso-
propanol (80:20); 0.5 mL min-1    
 
Analysis of the helically chiral BODIPY 2.49b under the same conditions gave similar 
HPLC trace. These results illustrated that the helically chiral BODIPYs were separable 
by chiral HPLC. 
 
Figure 2.25: Chiral HPLC trace of 2.49b. Daicel Chiralcel OD-H column (25 cm x 0.46 cm); hexane:iso-
propanol (80:20); 0.5 mL min-1. 
We succeeded in the separation of small amounts of the two enantiomers of BODIPYs 
2.49a and 2.49b which were then used to examine their chiroptical properties.  
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2.3.2.3.   Chiroptical properties of the helically chiral N,N,O,O-BODIPYs 
 
The term chiroptical/chiroptic refers to optical techniques which use absorption, emission 
or refraction of anisotropic radiation for exploration of chiral substances.92 There are 
several chiroptical techniques which can differentiate between the two enantiomers such 
as optical rotatory dispersion (ORD), circular dichroism (CD) and circular polarization 
of luminescence (CPL).92–94 
 
2.3.2.3.1.   Electronic Circular Dichroism (ECD) of the helically chiral N,N,O,O-
BODIPYs. 
Circular Dichroism (CD) is a spectroscopic technique which measures differences in the 
absorption of left and right handed circularly polarised light by a molecule which contains 
one or more chiral chromophores.94 
After the resolution of 2.49a and 2.49b by chiral HPLC, the absorption spectra of the two 
enantiomers of 2.49a and 2.49b were recorded as shown in Figure 2.26. Then the two 
enantiomers of 2.49a and 2.49b were submitted to Electronic Circular Dichroism (ECD). 
Electronic circular dichroism (ECD) spectra of both (M) and (P) isomers of 2.49a and 
2.49b were measured by Prof. W. Herrebout (University of Antwerp).  
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Figure 2.26: a) CD spectra of (P)-2.49a red (A) and (M)-2.49a cyan (B) after baseline correction; b) CD 
spectra of (P)-2.49b red (A) and (M)-2.49b cyan (B) after baseline correction; c) Absorbance spectra of 
(M)-2.49a red (A) and (P)-2.49a cyan (B) [hexane]; d) Absorbance spectra of (M)-2.49b red (A) and (P)-
2.49b cyan (B) [CHCl3] after baseline correction. 
 
Electronic circular dichroism (ECD) spectra were measured of both (M) and (P) isomers 
of 2.49a and 2.49b in hexane or chloroform as appropriate at 20 ̊C for ~5.5 to 6 minutes, 
by using an Applied Photophysics Ltd. Chirascan-plus spectrometer. In each case mirror 
image ECD spectra were obtained from the corresponding enantiomers and showed that 
(M) and (P) isomers of 2.49a and 2.49b are enantiomers. Also, the major peaks of the 
electronic circular dichroism (ECD) spectra aligned well with those of the absorption 
spectra (Figure 2.27). 
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Figure 2.27: Normalised ECD (red and blue) and UV−vis absorption spectra (black): (2.49a) (M)-2.49a 
(red) and (P)-2.49a (blue) [hexane], (2.49b) (M)- 2.49b (red) and (P)- 2.49b (blue) [CHCl3]. 
 
Boltzmann weighted ECD spectra, for samples (P)-2.49(a-b) were calculated (Figure 
2.28) to determine the absolute configuration to the resolved enantiomers of 2.49a-b. The 
agreement between experimental and calculated ECD allowed the absolute configuration 
of each of the enantiomeric samples of 2.49a-b to be established. Calculation were 
performed by Prof. W. Herrebout (University of Antwerp). 
 
Figure 2.28: Calculated ECD spectra of (P)-2.49a and (P)-2.49b.  
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2.3.2.3.2.   Circular Polarization of Luminescence (CPL) of the helically chiral 
N,N,O,O-BODIPYs 
 
Circularly polarized luminescence (CPL) is a spectroscopic technique which measures 
differences in the emission of left and right handed circularly polarised radiation by chiral 
luminescent systems.92,93 The magnitude of CPL is measured by the luminescence 
dissymmetry factor glum = 2(IL − IR)/(IL + IR), where IL and IR the luminescence intensities 
of left and right circularly polarized components, respectively.92,93 
In recent years, the interest in CPL has grown due to its use as a valuable source of 
information on the geometry of the excited state and also its application in the 
development and improvement of numerous photonic tools, such as display devices 
including optical storage and processing system, 3D optical displays, spintronics-based 
devices, CPL lasers, security tags, biological probes and signatures and enantioselective 
CPL sensors.95 
The circularly polarized luminescence (CPL) of helically chiral N,N,O,O-BODIPY 
systems has not been reported. The CPL spectra of both (M) and (P) isomers of 2.49a and 
2.49b were recorded by Prof. R. D. Peacock (University of Glasgow). The CPL was 
performed by using a home built instrument constructed around a Fluoromax 2. The CPL 
spectra were recorded of both (M) and (P) isomers of 2.49a and 2.49b in MeCN and 
excited at 540 nm. As is evident from Figure 2.29, it can be seen that both (M) and (P) 
isomers of 2.49a and 2.49b show mirror-image CPL and also show maxima matching the 
maximum visible emission of the N,N,O,O-BODIPYs. The spectra are an average of five 
scans. As is common for reports of the CPL spectra of most transition-metal and chiral 
organic chromophores, the solid line in the CPL plot is drawn to show the luminescence 
spectral line shape (Figure 2.29). The |glum| of 2.49a at 637 nm is 0.0043 and for 2.49b at 
675 nm is 0.0042, which is in the range of most CPL compounds from 10-5 to 10-2.96–98 
The |glum| values for these compounds include the largest so far reported for a simple 
BODIPY fluorophore in solution.  
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Figure 2.29: Normalised CPL spectra (red and blue) and normalised fluorescence spectra (black) shown 
(MeCN, excitation 540 nm): (2.49a) (M)-2.49a (red) and (P)- 2.49a (blue), (2.49b) (M)- 2.49b (red) and 
(P)- 2.49b (blue). 
 
We have successfully synthesised helically chiral N,N,O,O-BODIPY 2.49a-b and 
measured their absorption, emission, molar absorption coefficient and quantum yield ɸF. 
We also succeeded in the separation of the two enantiomers of BODIPYs 2.49a and 2.49b 
by chiral HPLC and recorded the ECD and CPL spectra. Next we turned our attention to 
the synthesis of a new helically chiral N,N,N,N-BODIPY 2.63. 
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2.3.3.   Approaches to helically chiral N,N,N,N-BODIPY dyes. 
  
Up to now, the synthesis of helically chiral N,N,N,N-BODIPYs has not been reported. 
Formation of the N-B chelated product might cause significant effects on the position of 
the absorption and emission maxima. Therefore, we decided to synthesise the helically 
chiral N,N,N,N-BODIPY 2.63 as an example of this novel system. Also, we aimed to 
study the photophysical properties of this new system in order to understand the effect of 
N-N chelation on the BODIPY core. 
We have designed a synthetic route for N,N,N,N-BODIPYs as shown in Scheme 2.45. 
Suzuki coupling of a 3,5-dibromoBODIPY 2.56a with 2-nitrophenylboronic acid, 
followed by hydrogenation and then fluorine replacement affords N-chelated BODIPYs. 
The two enantiomers of the helical chiral N,N,N,N-BODIPYs might be resolved by chiral 
HPLC in the same way as the corresponding N,N,O,O-chelated system. 
  
 
Scheme 2.45: General synthetic approach for the synthesis of helically chiral N,N,N,N-BODIPYs. 
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Suzuki coupling reaction to form compound 2.61 was accomplished by treatment of 3.5-
dibromo-BODIPY 2.56a with 3 equivalents of 2-nitrobenzeneboronic acid in THF and 
water in the presence of the cyclometalated catalyst precursor LPd(XPhos)Cl 3.54 
(Scheme 2.46). The crude material was purified using column chromatography to 
generate BODIPY 2.61 as a dark orange solid in 75%.  
 
Scheme 2.46: Synthesis of symmetrical compound 2.61. Conditions and reagents: a) 2-
nitrobenzeneboronic acid (3 eq), LPd(XPhos)Cl 3.54 (5 mol%), K3PO4 (4 eq), THF-water, 6 h, reflux, 
75%. 
 
Hydrogenation of the nitroaryl-BODIPY 2.61 by using Pd/C and H2 in DCM and MeOH 
for 2 h at room temperature produced the BODIPY 2.62 as a dark purple solid in high 
yield (80%) (Scheme 2.47). 
 
Scheme 2.47: Synthesis of BODIPY 2.62. Conditions and reagents: a) H2 (1 atm), 10% Pd/C, MeOH-
CH2Cl2, r.t., 2 h (80%). 
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Our initial attempt to effect the replacement of the two fluorine atoms to give helically 
chiral N,N,N,N-BODIPY 2.63 involved treating BODIPY 2.62 with Cs2CO3 in 1,4-
dioxane at 95 ̊C under nitrogen for 16 h (Scheme 2.48). After 4 hours, TLC of the reaction 
mixture indicated formation of a new compound together with starting material. After a 
further 12 h, however, the resulting mixture showed several spots on the TLC. The 1H 
and 11B NMR spectra of the crude product were complicated with no sign of the desired 
product. Unfortunately due to time constraints the synthesis of helically chiral N,N,N,N-
BODIPY 2.63 was not completed. It is possible that the use of i-Pr2NEt or even with 
BF3.OEt2might be more successful.  
 
Scheme 2.48: Attempted synthesis of N,N,N,N-BODIPY 2.63. Conditions and reagents: BODIPY 2.62 
(0.100 mmol), Cs2CO3 (5 eq), 1,4-dioxane (2 mL), 95  ̊C, 16 h. 
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2.3.4.   Synthesis of half strapped N,N,O,F-BODIPY dyes 
 
The previous section 2.3.2 has provided interesting results concerning the formation and 
separation of N,N,O,O-BODIPY derivatives. Next, we turned our attention to prepare 
`half strapped` N,N,O,F-BODIPYs which might be expected to have an emission 
wavelength less red-shifted a the previous N,N,O,O-BODIPYs. So far, very little attention 
has been paid to the synthesis of mono-strapped BODIPYs.80,99–101 
An early example of this type of BODIPY was reported by Nabeshima80 in 2009 when 
the free ligand 2.64 was treated with arylboronic acids to afford the half strapped 
BODIPYs 2.65a-c (Scheme 2.49).  
 
Scheme 2.49: Synthesis of N,N,O,C-BODIPY 2.65a-c.80 
 
Kovtun60 reported a new method for synthesis of this type of BODIPY by treating 3-
acetaldehyde BODIPY 2.66 with boron trifluoride diethyl etherate (BF3.OEt2) in toluene 
under reflux (Scheme 2.50). BODIPY 2.67 is presumably formed by trapping of the 
corresponding enol. The increase in conjugation, and the loss of HF may help to make 
the strapping favourable. 
 
Scheme 2.50: Synthesis of N,N,O,F-BODIPY 2.67. 
 
Our target molecule was the N,N,O,F-BODIPY 2.74 which could not be prepared by 
following Kovtun’s approach60, nor using Nabeshima’s approach80. The proposed 
synthetic route for N,N,O,F-BODIPYs is shown in Scheme 2.51. 
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Scheme 2.51: General synthetic approach or the synthesis of N,N,O,F-BODIPYs 2.74. 
In 2013, Min Ji described an efficient solvent free procedure for preparing 2-acylpyrroles 
by using zinc oxide (ZnO) as an inexpensive and nontoxic Lewis acid catalyst.102 
Following this procedure, Friedel-Crafts acylation of pyrrole with p-toluoyl chloride or 
acetyl chloride in the presence of ZnO gave the ketone 2.67a-b in 55 and 53% yield 
respectively (scheme 2.52). 
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Scheme 2.52: Synthesis of 2-ketopyrrole 2.68a-b. Conditions and reagents; a) ZnO (25 mol%), r.t., 5 
min., 2.68a 55% and 2.68b 53%. 
The next step was the BF2 chelation of ketopyrrole 2.68a-b. The condensation of the 
ketopyrrole 2.68a-b with 3-ethyl-2,4-dimethylpyrrole in the presence of borontrifluoride 
diethyl etherate (BF3.OEt2) and Hünig’s base (i-Pr2NEt) produced the unsymmetrical 
BODIPYs 2.69a-b (Scheme 2.53). This method has been reported in the synthesis of 
other BODIPY’s previously.103    
 
Scheme 2.53: Synthesis of unsymmetrical BODIPY 2.69a-b. Conditions and reagents; a) 3-ethyl-2,4-
dimethylpyrrole (1.1 eq), BF3.OEt2 (0.1 mol%), CH2Cl2, r.t., 1 h; b) BF3.OEt2 (8 eq), i-Pr2NEt (1.1 eq), 
r.t., 16 h, 2.69a 66% and 2.69b 55%. 
The regioselective iodination of the BODIPY 2.69a will occur at the 2 position (as 
discussed in chapter 3).56 The BODIPYs 2.69a-b were treated with NIS in DCM for 16 
h. The crude products were purified using column chromatography to give 2.70a-b in 
good yield of 60 and 85% respectively (Scheme 2.54). 
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Scheme 2.54: Synthesis of 2-iodoBODIPY 2.70a-b. Conditions and reagents; a) NIS (1.7 eq), CH2Cl2, 
r.t., 16 h, 2.70a 60% and 2.70b 85%. 
The unsymmetrical BODIPY 2.71 was synthesised via palladium catalysed Suzuki cross 
coupling. In the first attempt, 2-iodoBODIPY 2.70a was treated with phenylboronic acid 
(1.3 equivalents) in presence Pd(PPh3)4 ( 10 mol %) and Na2CO3 (2 equivalents) in toluene 
under reflux for 4 h to afford BODIPY 2.71 in low yield (25%). In the second attempt we 
used the highly efficient cyclometalated precatalyst Pd(Xphos)Cl88 3.54 and K3PO4 in 
THF and water under reflux for 16 h (Scheme 2.55). The crude product was purified using 
column chromatography to give 2.71 as red solid in high yield (83%) (Scheme 2.55). 
 
Scheme 2.55: Synthesis of unsymmetrical BODIPY 2.71. Conditions and reagents; a) Phenylboronic acid 
(2 eq), LPd(XPhos)Cl 3.54 (2 mol%), K3PO4 (2 eq), THF-water, 16 h, reflux, 83%. 
 
The structure of unsymmetrical BODIPY 2.71 was confirmed unambiguously by X-ray 
structure determination after crystal growth through slow diffusion of petroleum ether 
into a solution of the BODIPY in DCM (Figure 2.30). 
 
Figure 2.30: Molecular structure of BODIPY 2.71. Hydrogen atoms have been omitted for clarity. 
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To the unsymmetrical BODIPY 2.71 another regioselective iodination with NIS in DCM 
was completed, affording 3-iodoBODIPY 2.72 as a dark red solid in 78% yield (Scheme 
2.56).  
 
Scheme 2.56: Synthesis of 3-iodoBODIPY 2.72. Conditions and reagents; a) NIS (1.3 equivalents), 
CH2Cl2, r.t., 16 h, 78%. 
1H NMR spectrum was used to determine that the reaction had been completed 
regioselectively. The 1H NMR spectrum of the product showed the disappearance of one 
signal at 7.8 ppm which corresponds to the proton at the 3 position and the proton at the 
1 position was shifted upfield upon incorporation of iodine.  
 
Figure 2.31: 1H NMR spectra of 3-iodoBODIPY 2.72 and BODIPY 2.71. 
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It was hoped that the second Suzuki coupling between the 3-iodoBODIPY 2.72 and 2-
hydroxybenzeneboronic acid would lead to the formation of the half strapped BODIPY 
2.74. This might happen by nucleophilic substitution of one fluorine atom by the 2-
hydroxyphenyl group with loss of HF. However, the resulting product from the second 
Suzuki coupling was actually the unstrapped BODIPY 2.73 as seen in Scheme 2.57.  
 
Scheme 2.57: Synthesis of unsymmetrical BODIPY 2.73. Conditions and reagents; a) 2-
Hydroxyphenylboronic acid (2 eq), LPd(XPhos)Cl 3.54 (2 mol%), K3PO4 (2 eq), THF-water, 16 h, reflux, 
25%. 
This was confirmed by 11B NMR which shows a triplet peak at 0.58, this indicates that 
the core boron atom is still coupled to two fluorine atoms (Figure 2.32). 
 
Figure 2.32: 11B NMR spectrum of BODIPY 2.73 (96 MHz, CDCl3). 
What was surprising is that the 19F NMR spectrum (Figure 2.33) shows two double 
quartet peaks. As explained earlier in this chapter, this pattern results from the fluorine 
atoms coupling to the boron atom and also coupling to each other. This implies that the 
two fluorine atoms are in different environments. The two different environment may be 
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formed because of steric hindrance around the BODIPY structure leading to restricted 
rotation around the pyrrole-phenol bond. Alternatively, it may be that a hydrogen-bond 
exists between the phenol OH group and one of the fluorine atoms, again restricting 
rotation.  
 
Figure 2.33: 19F NMR spectrum of BODIPY 2.73 (282MHz, CDCl3). 
In order to prepare the half strapped BODIPY we followed Kovtun’s method, as they 
formed a mono-strapped 3-enol BODIPY derivative using BF3.OEt2 in toluene. We first 
attempted the reaction on a very small scale in an NMR tube, following the progress by 
11B and 19F NMR. The BODIPY 2.73 was dissolved in CDCl3 and then once BF3.OEt2 
was added the solution colour changed from orange to a deep red colour. The crude 11B 
NMR and 19F NMR spectra indicated the formation of the product, however, it appeared 
to decompose over time, and this may be due to the generation of HF. Therefore, in the 
second attempt we decided to add a base to prevent such acidic conditions from forming. 
The BODIPY 2.73 was treated with i-Pr2NEt and then BF3.OEt2 in DCM (Scheme 2.58). 
The reaction was followed by TLC until disappearance of all the starting material. The 
crude product was purified using column chromatography to afford the strapped BODIPY 
2.74 in 50% yield. 
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Scheme 2.58: Synthesis of half strapped BODIPY 2.74. Conditions and reagents; a) i-Pr2NEt (1 eq), 
BF3.OEt2 (1 eq), DCM, 10 min, reflux, 50%. 
 
The 11B NMR spectrum of the half strapped BODIPY 2.74 shows a doublet peak, this 
indicates that the core boron atom is coupled to one fluorine atom (Figure 2.34). 
 
Figure 2.34: 11B NMR spectrum of BODIPY 2.74 (160 MHz, CDCl3). 
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2.3.4.1.   Chiral HPLC Separation 
 
Chiral HPLC separation of the two enantiomers of N,N,F,O-BODIPY 2.74 was 
investigated. HPLC of BODIPY 2.74 using a Daicel Chiralcel OD-H column (25 cm × 
0.46 cm); hexane:isopropanol (80:20) as the eluent successfully produced two well 
resolved peaks as shown in Figure 2.35.  
 
Figure 2.35: Chiral HPLC trace of 2.74. Daicel Chiralcel OD-H column (25 cm x 0.46 cm); hexane:iso-
propanol (80:20); 0.5 mL min-1. 
 
The chiral N,N,F,O-BODIPY 2.74 has been successfully synthesised through the use of 
our designed route. Unfortunately, due to time constraints and lack of material further 
spectroscopic analysis has not yet been performed. 
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2.3.4.2.   Photophysical data of parent BODIPY 2.69a and BODIPY 2.73 
 
The UV and fluorescence spectra were measured for BODIPY 2.69a and 2.73 in CHCl3 
at room temperature (Table 2.4). Rhodamine 6G was used as the reference compound for 
determination of fluorescence quantum yields (rhodamine 6G Φf= 0.95, λex= 479 or 496 
nm, in ethanol). 
Table 2.4: Photophysical data of the selected BODIPYs in CHCl3. 
 
BODIPY λabs (max)/nm ε/104 M-1cm-1 λem (max)/nm Φf (λex) 
2.69a 502 4.59 515 0.55(479) 
2.73 530 5.04 567 0.56(496) 
 
 
Figure 2.36: Absorption spectrum (solid lines) in terms of the molar absorption coefficient (ε) 
and normalised fluorescence spectrum (hashed lines) for 2.69a (—), and 2.73 (—) in CHCl3.  
Figure 2.36 shows the absorption and emission spectra of parent BODIPY 2.69a and of 
BODIPY 2.73. As Table 2.4 illustrates both of these BODIPY dyes showed strong 
absorption bands. In comparison to the parent BODIPY 2.69a, the presence of aromatic 
rings in both the 3- and 2-positions of the BODIPY core leads to a 28 nm (1053 cm-1) 
red-shift of the absorption maximum and a 52 nm (1781 cm-1) red-shift of the emission 
maximum. Future effort will involve synthesis of the N,N,F,O-BODIPY 2.74 on a larger 
scale, to measure the absorption and emission spectra and also to separate the two 
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enantiomers. Overall, these encouraging results indicate that the synthesis of activated 
chiral N,N,F,O-BODIPYs is worth investigated in the future.   
  Chapter 2                                                                                   Results and Discussion  
 
 
93 
 
2.4.   Conclusion 
 
The BODIPY system has come a long way from its initial discovery, and is now well 
established as a useful fluorophore. Many synthetic approaches and structural variations 
have been reported in literature. However, there are few reports of the use of chiral 
BODIPY species for enantioselective applications. During this research to synthesise 
functionalised chiral BODIPYs for enantioselective sensing we have disclosed a range of 
novel chiral systems.  
The 2,6-bis(2-methoxyphenyl) BODIPY 2.6 was synthesized via Suzuki coupling 
reaction, by coupling of the corresponding 2,6-dibromo BODIPY with 2-methoxyphenyl 
boronic acid. 19F NMR of the product indicated that a 1:1 mixture of diastereoisomers 
was formed, presumably corresponding to compounds in which the methoxy groups are 
either syn- or anti- to each other. 
The axially chiral quinoline-BODIPY 2.15 has been successfully synthesised from 
readily available starting materials by regioselective monobromination at the 2-position 
of the BODIPY core. Suzuki coupling reaction gave the axially chiral quinoline-BODIPY 
2.15. However, all attempts separate the enantiomeric BODIPYs were unsuccessful. 
The known aza-BODIPY compounds 2.25a, b were synthesized successfully, 
nevertheless, attempts to synthesise more heavily functionalized aza-BODIPY 2.26 
proved unsuccessful. 
Helically chiral N,N,O,O-BODIPYs 2.49a-c were synthesised using modular approach. 
These compounds showed very desirable spectral properties, such as high molar 
absorption coefficients and good quantum yields of fluorescence. The two enantiomers 
of 2.49a and 2.49 were separated by chiral HPLC. The ECD spectra of the two 
enantiomers of BODIPYs 2.49a and 2.49b were recorded and in combination with 
computational modelling allowed the absolute configuration of each of the enantiomeric 
samples of 2.49a-b to be established. Moreover, CPL spectra of each of the enantiomeric 
samples of 2.49a-b were recorded. 
We attempted to synthesise helically chiral N,N,N,N-BODIPY 2.63, however, due to time 
constraints successful conditions for the final boron chelation step have yet to be 
identified. 
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Finally, the mono-strapped BODIPY scaffold 2.74 was synthesised and was analysed by 
1H, 11B, 19F NMR, all of which confirmed the correct product. Separation of N,N,F,O-
BODIPY 2.74 by analytical chiral HPLC gave two peaks confirming that 2.74 was 
racemic. This indicated that the N,N,F,O-BODIPY 2.74 is separable by chiral HPLC.
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Chapter 3: Synthesis of aminoBODIPYs via metal catalyzed amination 
 
3.1. Introduction 
 
It is perhaps not surprising that many electrophilic substitution reactions into the 
BODIPY core have been reported including halogenation,56 sulfonation,12 and nitration.12 
The synthesis of halogenated BODIPYs has been reported as a useful reaction which can 
be followed by various transition metal catalysed cross-coupling reactions or by 
nucleophilic substitution. The most common approach to introduce amine substituents on 
the BODIPY core is nucleophilic substitution (SNAr) of a BODIPY carrying a good 
leaving group (e.g. methoxy, halogen, or methylthio).6,104 A nucleophilic substitution 
(SNAr) of a BODIPY can only occur in the 1, 3 ,5, 7 and 8 (meso) positions due to the 
electronic requirements of SNAr.
104,105 As shown in Figure 3.1, a nucleophile can attack 
these positions to form an intermediate anion in which the negative charge may be 
delocalized on to one of the nitrogen atoms of the core BODIPY.105 This may explain 
why there are few reports of 2-amino-substituted BODIPYs.  
     
 
Figure 3.1: Nucleophilic substitution (SNAr) at each portion of a BODIPY core. 
 
Likewise, an unusual example of SNAr, oxidative nucleophilic hydrogen substitution by 
amines, occurs in the electron poor 3,5-positions of unhalogenated BODIPYs 3.1 in the 
presence of a suitable oxidizing agent (permanganate, CAN, DDQ, or O2). This approach 
is limited to primary and secondary alkyl amines (Scheme 3.1).106 
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Scheme 3.1: Direct oxidative hydrogen substitution on a BODIPY dye 3.1. 
 
The 2-amino group has been introduced by nitration followed by reduction. The 
electrophilic substitution of BODIPY 3.3 with HNO3 in Ac2O produced the 2-
nitroBODIPY 3.4 together with a minor amount of the 3-nitroBODIPY 3.5. However, 
this approach is limited to the parent 2-NH2 substituent (Scheme 3.2).
107  
 
Scheme 3.2: Synthesis of 2-amino BODIPY 3.6. a) HNO3, Ac2O, 0 ̊C, b) H2, Pd/C. 
Introduction of 2-NH2 has also been reported by palladium-catalysed coupling of a 2-
bromoBODIPY 3.8 with benzophenone imine followed by hydrolysis of the resulting 2-
iminoBODIPY 3.9. This approach is also structurally limited and uses a rather high 
palladium loading (5 – 40 mol %) (Scheme 3.3).108 
Scheme 3.3: Synthesis of 2-aminoBODIPY 3.10. Conditions; (a) benzophenone imine (1.5 eq), Cs2CO3 
(2.0 eq), Xantphos (40 mol%), Pd2dba3 CHCl3 (20 mol%), dioxane, 100  ̊C, 2 h, (b) HCl (1 M), THF, 
60 ̊C, 1 h. 
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Introduction of an amino group onto the BODIPY core causes significant effects on the 
position of the absorption and emission maxima, and it quenches the fluorescence 
quantum yield because of intramolecular charge transfer or photoelectron transfer.109 This 
electron donation can be reduced by co-ordination of the nitrogen lone pair to a Lewis or 
Brønsted acid, leading to restoration of the BODIPY fluorescence (switch on sensors).110 
We envisaged that 2-aminoBODIPYs might be synthesised by metal catalysed amination 
of the corresponding 2-halogeno derivatives (Scheme 3.4).  
 
 
Scheme 3.4: General scheme for metal catalysed amination. 
 
This chapter describes the results of our investigation into metal catalysed amination of 
2-halogeno BODIPYs.  
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3.2. Copper catalysed amination of aryl halides 
 
The Ullmann condensation is a reaction between an aryl halide and an amine, thioether 
or phenol in the presence of a copper catalyst and base to synthesise the corresponding 
aryl amine, thioether or ether compounds 3.11, respectively (Scheme 3.5).111–113 In 1904, 
Fritz Ullmann reported the first copper mediated aromatic nucleophilic substitution 
reaction. The original method for the coupling reaction requires the use of stoichiometric 
amounts of copper salts and high reaction temperatures. 
 
 
Scheme 3.5: Cu(I) or Cu(II) salts, base, ligand, solvent, 100-300  ̊C. 
 
3.2.1. Proposed mechanistic hypotheses for Ullmann condensation reaction 
  
The exact nature (oxidation state) of the Cu-intermediate remains under debate. 111–113 
There are four different proposed mechanisms for the Ullmann condensation reaction, 
which can be classified into two main categories: those in which the oxidation state of 
copper remains constant and those in which the oxidation state changes throughout the 
mechanistic cycle. The four different strategies are shown in Scheme 3.6:111–113 
(1) Oxidative addition of aryl halide to Cu(I) resulting in an intermediate Cu(III) species 
(Scheme 3.6, a). 
(2) Formation of aryl radical intermediates via halide atom transfer (Scheme 3.6, d).  
(3) Formation of aryl radical intermediates via single electron transfer (Scheme 3.6, b). 
(4) σ-bond metathesis through a four-centre intermediate (Scheme 3.6, e). 
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Scheme 3.6: Four mechanisms pathway for Ullmann condensation. 
 
A considerable amount of literature has been published on copper catalyzed amination of 
halogenobenzene derivatives. However, there is little published data on the amination of 
3-halogeno-5-membered heteroaromatic compounds.114–120 
For instance, in 2001, Buchwald and his co-workers115 developed an inexpensive copper 
catalyst system for the amination of aryl halides by using diamine ligand, a weak base 
and non-polar solvent. For example, they synthesised N-thiophen-3-yl benzamide 3.12 
by using copper iodide and 1,2 diaminocyclohexane as ligand in the presence of K3PO4 
in dioxane at 110 ̊C (Scheme 3.7). 
 
Scheme 3.7: Synthesis of N-thiophen-3-yl benzamide 3.12. Conditions and reagents; 3-bromothiophene 
(1.00 mmol), benzamide (1.20 mmol), CuI (10 mol%), 1,2-diaminocyclohexane (10 mol%), K3PO4 (2.0 
mmol), dioxane, 110  ̊C, 15 h, 96%.115 
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In 2002, Padwa and Grawford117 applied Buchwald amidation conditions to 2 and 3-
substituted bromofurans and bromothiophenes by using N,N-dimethylethylenediamine as 
a ligand (Scheme 3.8). 
 
 
Scheme 3.8: General scheme for copper catalysed amidation of 2- and 3-bromothiophene. Conditions and 
reagents; CuI (1 mol%), N,N-dimethylethylenediamine (10 mol%), K3PO4 (4 eq), dioxane, 110  ̊C (97-
81%).
117 
In addition, Twieg (2005) found that N,N-dimethylethanolamine (deanol) is a useful 
solvent and ligand for copper catalyzed amination (Scheme 3.9).114  
 
 
Scheme 3.9: N,N-dimethylethanolamine, Cu metal (10 mol%), K3PO4.H2O (2 eq) 60-75 C̊, 10-24 h.114 
 
Surprisingly, there is no report of copper catalysed amination of 2 and 6 halogeno 
BODIPYs. A general synthetic route to 2-aminoBODIPY is shown in Scheme 3.10. 
 
Scheme 3.10: A general synthetic route to 2-aminoBODIPY. 
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3.3. Synthesis of an 8-arylBODIPY 3.16 
Using a literature procedure, the 8-arylBODIPY 3.16 was synthesized through a 
condensation of anisaldehyde and pyrrole in the presence of boron trifluoride-etherate 
(BF3.OEt2) as catalyst to form dipyrromethane 3.15,
121 followed by oxidation with 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) to the corresponding dipyrromethene and 
then the BF2 chelation by treatment with boron trifluoride diethyl etherate (BF3.OEt2) in 
the presence of N,N-diisopropylethylamine (i-Pr2NEt) (Scheme 3.11). 
 
Scheme 3.11: Synthesis of 8-arylBODIPY 3.16. Conditions and reagents; a) BF3.OEt2, r.t., 4 h (87%), b) 
DDQ, CH2Cl2, 0 °C, 30 min, BF3.OEt2, i-Pr2NEt, r.t., 2 h (77%); 
 
3.4. Synthesis of the 2-iodoBODIPY 3.17 
Halogenated BODIPYs can be synthesized by using three different synthetic strategies: 
by using a suitably halogenated pyrrole, by halogenation of a dipyrromethane precursor 
or by electrophilic substitution onto the pre-formed BODIPY.6,18 Several reports have 
shown that it is possible to introduce halogens on to the BODIPY core regioselectively.18 
Indeed, the halogenation of BODIPYs should be controlled by electronic and steric 
factors.122 According to Burgess (2007) the 1 and 7 positions of an 8-arylBODIPY are 
sterically hindered, because of the bulky aryl group at the 8-position, and also due to the 
large size of the halogen atom (Figure 3.2).12,122 In addition to being less sterically 
hindered, the 2 and 6 positions of the BODIPY are the most susceptible to electrophilic 
attack due to having the lower positive charge. 108 
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Figure 3.2: Electrophilic attack on unsubstituted 8-aryl BODIPY. 
Regioselective iodination122 of BODIPY 3.16 with ICl produced the 2-iodo-substituted 
BODIPY 3.17 together with a minor amount of the 2,6-diiodide 3.18 which were 
separable by column chromatography (Scheme 3.12). 
 
Scheme 3.12: Synthesis of 2-iodoBODIPY 3.17. Conditions and reagents; (a) ICl, CH2Cl2–MeOH, r.t., 2 
h (3.17, 65%; 3.18, 15%). 
The regioselectivity of the halogenation was confirmed by X-ray structure, after crystal 
growth through slow diffusion of hexane into a solution of the BODIPY in chloroform, 
which confirmed that the iodide was introduced on to position 2 then 6 regioselectively 
(Figure 3.3).    
  
Figure 3.3: Molecular structure of BODIPY 3.17 and 3.18, confirming the regioselectivity of the 
halogenation. Hydrogen atoms have been omitted for clarity.  
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3.5. Attempted synthesis of 2-amino BODIPY via Copper catalysed amination 
In the first attempt we followed Twieg’s procedure,114 1.5 equivalents of hexylamine 
were added to the 2-iodoBODIPY 3.17, in the presence of Cu (5 mol%), CuI (5 mol%) 
and 2 equivalents of K3PO4 in N,N-dimethylethanolamine at 80  ̊C for 48 h. We were 
delighted to observe that amination had occurred, but in only 16% yield. In the 1H NMR 
spectrum, we were expecting to observe the same or slight shifting for the two signals of 
the CH in positions 3 and 5 at 8.0 and 7.8 ppm. However, the 1H NMR spectrum of the 
product showed the disappearance of one signal at 8.0 ppm (Figure 3.4). Surprisingly, it 
was found that the amination had occurred in the 3-position (Scheme 3.13). 
 
Scheme 3.13: Cu/CuI catalysed amination of BODIPY 3.17. Conditions and reagents; (a) N-hexylamine 
(1.5 eq), Cu metal (5 mol%), CuI (5 mol%), K3PO4 (2.0 eq), N,N-dimethylethanolamine, 80 ̊C, 48 h, 16%.  
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Figure 3.4: 1H NMR spectra of 2-iodoBODIPY 3.17 and BODIPY 3.19a. 
The regioselectivity of amination of the 2-iodoBODIPY 3.17 was confirmed by X-ray 
structure determination, after crystal growth through slow diffusion of  petroleum ether 
into a solution of the BODIPY in DCM, which confirmed that the hexylamine was 
introduced on to position 3 (Figure 3.5). 
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Figure 3.5: Molecular structure of 3-hexylaminoBODIPY 3.19a, confirming the amination reaction 
occurred at position 3. Hydrogen atoms have been omitted for clarity.   
3.5.1. Screening of ligand 
  
Many different ligands have been reported for copper catalysed amination reactions such 
as ligands L1, L2, L3 and L4 (Figure 3.6).  
 
 
Figure 3.6: Ligands screened in the amination of BODIPY.  
In 2006 Buchwald reported that the use of the diketone ligand L1 allows the amination 
reaction of aryl halides with aliphatic amines to occur under mild conditions. The catalyst 
is formed easily in situ by combining ligand L1 with CuI (Scheme 3.14).123  
 
Scheme 3.14: Buchwald amination using L1.123 Conditions and reagents; 5 mol% CuI, 20 mol% L1, 
Cs2CO3 (2 eq), DMF, r.t., 98%. 
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In 2009, Ding studied the use of 2-pyridinyl β-ketone ligand L2 in the CuI-catalyzed 
amination and found that good yields were obtained by using a weak base and non-polar 
solvent at room temperature (Scheme 3.15).124 
 
Scheme 3.15: Ding amination using L2.
124
 Conditions and reagents; 10 mol% CuI, 20 mol% L2, Cs2CO3 
(2 eq), DMF, Ar, r.t., 97%. 
 
Diamine ligands such as N,N’-dimethyl ethylenediamine L3, ethylenediamine and 1,10-
phenanthroline L4 are also useful in Cu-catalyzed C-N bond formation.125,126 In order to 
optimise the yield of synthesis 3-aminoBODIPY 3.19 we screened a series of bidentate 
ligands L1-L4 as shown in Table 3.1. The choice of catalyst and ligand loading, base and 
solvent were taken from Buchwald’s report123 using L1. The choice of 80 ̊C was based 
on a first temperature screening reaction using L3 which showed that no reaction was 
observed with hexylamine at 25 or 50 ̊C. Also, it was established that no reaction at room 
temperature occurred with hexylamine for any of these ligands. 
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Table 3.1: Ligand variation in the amination of BODIPY 3.17. 
 
Entry R Ligand Product Isolated yield 
1 CH3(CH2)5 L1 3.19a 30 
2 CH3(CH2)5 L2 3.19a 20 
3 CH3(CH2)5 L3 3.19a 35 
4 CH3(CH2)5 L4 3.19a 60 
5 4-MeC6H4 L1 3.19b 6 
6 4-MeC6H4 L2 3.19b 70 
7 4-MeC6H4 L3 3.19b 30 
8 4-MeC6H4 L4 3.19b 84 
9 PhCO L1 3.19c 6 
10 PhCO L2 3.19c 11 
11 PhCO L3 3.19c 10 
12 PhCO L4 3.19c 15 
Conditions and reagents: BODIPY 3.17 (0.25 mmol), amine or amide (0.47 mmol), CuI (5 mol%), ligand 
(20 mol%), Cs2CO3 (0.47 mmol), DMF (0.8 mL), 80 ̊C, 24 h. 
The catalytic activity of the chosen ligands was evaluated by reaction of the 2-
iodoBODIPY 3.17 with n-hexylamine, p-toluidine and benzamide at 80 ̊C to give the 
corresponding 3-substituted BODIPY 3.19a, 3.19b and 3.19c respectively. From Table 
3.1 it is clear that the ligand L4 (1,10-phenanthroline) gives the highest yield regardless 
of the nature of the nucleophile. Good yields were obtained in the case of n-hexylamine 
(60%) and p-toluidine (80%) and also the reaction was successful even in the case of the 
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much more weakly nucleophilic benzamide (15%). The ketopyridine L2 and 
dimethylethylenediamine L3 also successfully promoted the copper-catalysed amination 
reaction with moderate yields (20-70%). Interestingly, diketone (L1) showed much lower 
efficiency, although it contains a bidentate chelating centre.  
3.5.2. Scope of the amination of the 2-iodoBODIPY 3.16  
 
Subsequently, to explore the scope of the copper catalyzed nucleophilic substitution 
reaction, 5 mol% CuI, 20 mol% L4 in DMF with Cs2CO3 as the base at 80 
◦C for 2 h were 
used as the general conditions in the reaction of the 2-iodoBODIPY 3.17 with a range of 
different amines (Table 3.2). 
Different primary alkyl amines including n-hexylamine, benzylamine, 2-thiophenyl ethyl 
amine and cyclohexylamine were reacted successfully in good yield (entries 1 and 4-6). 
Also, good yields were obtained with secondary alkyl amines such as morpholine and 
pyrrolidine (entries 7 and 8). High yields were achieved for electron rich primary anilines 
including 4-methylphenyl amine and 4-methoxyphenyl amine (entries 2 and 10). 
However, slightly lower yields were obtained in the case of the less nucleophilic electron 
deficient anilines (entries 11-13) and the yields were slightly lower with the more 
sterically hindered 2-methoxy substituted aniline (entry 9) and a secondary aniline 
methylphenylamine (entry 14). One interesting finding was that in many cases the 3-
aminoBODIPY 3.19 was accompanied by formation of a small amount of the 
corresponding 3-amino-6-iodoBODIPY 3.22 (Table 3.2). The structure of 3-hexylamino-
6-iodoBODIPY 3.22a was confirmed unambiguously by X-ray structure determination 
(Figure 3.7). 
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Figure 3.7: molecular structure of 3-hexylamino-6-iodoBODIPY 3.22a. Hydrogen atoms have 
been omitted for clarity. 
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Table 3.2: Scope of the amination of the 2-iodoBODIPY 3.17. 
Entry R1 R2 Product 
Isolated yield  
3.19 3.22 
1 CH3(CH2)5 H 3.19a/3.22a 60 5 
2 4-MeC6H4 H 3.19b/3.22b 84 5 
3 PhCO  H 3.19c 15 - 
4 PhCH2 H 3.19d 64 - 
5 2-ThiophenylCH2CH2 H 3.19e 65 - 
6 Cyclohexyl H 3.19f/3.22f 78 4 
7 O(CH2CH2)2 3.19g 85 - 
8 CH2CH2CH2CH2 3.19h/3.22h 87 4 
9 2-MeOC6H4 H 3.19i 60 - 
10 4-MeOC6H4 H 3.19j/3.22j 78 6 
11 4-ClC6H4 H 3.19k/3.22k 66 13 
12 4-NCC6H4 H 3.19l/3.22l 77 15 
13 2-Pyridyl H 3.19m/3.22m 60 14 
14 Ph Me 3.19n 40 - 
Conditions and reagents: BODIPY 3.17 (0.25 mmol), amine or amide (0.47 mmol), CuI (5 mol%), ligand 
L4 (20 mol%), Cs2CO3 (0.47 mmol), DMF (0.8 mL), 80 ̊C, 24 h.  The second entry refers to the yield of 
6-iodo by-product 3.22, where isolated. 
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3.6. Synthesis of the 2-bromoBODIPY 3.23  
Using a literature procedure,56 the 2-bromoBODIPY 3.23 was prepared by reaction of the 
8-(4-methoxyphenyl)BODIPY 3.16 with NBS in DCM at room temperature for 90 min 
(Scheme 3.16). Purification using column chromatography gave the desired 2-
bromoBODIPY 3.23 in high yield (73%).  
 
Scheme 3.16: Synthesis of 2-bromoBODIPY 3.23. Conditions and reagents; (a) NBS, CH2Cl2, r.t., 90 
min. (73%). 
The copper catalysed nucleophilic amination was attempted by applying the same 
reaction conditions, using phenanthroline (L4), to the reaction of the 2-bromoBODIPY 
3.23 with pyrrolidine to give the 3-(pyrrolidin-1-yl)BODIPY 3.19h in 80% yield, together 
with the corresponding 6-bromo-3-(pyrrolidin-1yl)BODIPY 3.24 in 5% yield (scheme 
3.17). 
 
Scheme 3.17: synthesis of 3-(pyrrolidin-1-yl)BODIPY 3.19h and 6-bromo-3-(pyrrolidin-1yl)BODIPY 
3.24. Conditions and reagents; pyrrolidine (2.0 eq), CuI (5 mol%), 1,10-phenanthroline L4 (20 mol%), 
Cs2CO3 (2.0 eq), DMF, 80 ̊C, 24 h. 
The structure of the 3-pyrrolidinyl product 3.19h was confirmed by X-ray structure 
determination (Figure 3.8). 
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Figure 3.8: molecular structure of 3-(pyrrolidin-1-yl)BODIPY 3.19h. Hydrogen atoms have been omitted 
for clarity. 
The high yields of amination regardless of the nature of the halogen support a 
straightforward nucleophilic substitution mechanism. 
3.7. Attempted synthesis of a 3,5-diaminoBODIPY 
The synthesis of a 3,5-diaminoBODIPY via copper catalysed double amination of the 
2,6-diiodoBODIPY 3.18 was attempted. Attempts using both a primary aniline and 
pyrrolidine were unsuccessful (Table 3.3). In both cases the unreacted diiodoBODIP 3.18 
was recovered under these reaction conditions and there was no sign of any singly 
aminated product, which may be due to the higher degree of steric hindrance in this 
reaction in comparison to the successful reaction using 2-iodoBODIPY.  
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Table 3.3: All attempts carried out for synthesis of a 3,5-diaminoBODIPY. 
 
Entry R1 R2 Product 
1 4-MeOC6H4  H No product 
2 CH2CH2CH2CH2 No product 
Conditions and reagents: BODIPY 3.18 (0.25 mmol), amine (0.47 mmol), CuI (5 mol%), 1,10-
phenanthroline L4 (20 mol%), Cs2CO3 (0.47 mmol), DMF (0.8 mL), 80 ̊C, 24 h. 
3.8. Mechanism of reaction 
In order to explore the reaction mechanism, we have tried to determine the role of each 
component in the amination reaction. The reaction between 2-iodoBODIPY 3.17 and 
pyrrolidine was repeated using the same reaction conditions with omission of each 
component in turn. As shown in Table 3.4, in the absence of cooper iodide no reaction 
occurred between 2-iodoBODIPY 3.17 and pyrrolidine. When the ligand was omitted 
then the amination product 3.19h was formed in 50% yield together with 3% of the 2-
iodo-5-(pyrrolidin-1yl)BODIPY 3.22h. Also, in the absence of added base (Cs2CO3) the 
product 3.19h was formed in low yield together with the by-product 3.22h (14% and 10% 
respectively). Therefore, copper is essential for the amination to occur and the base and 
ligand improve the reaction conversion. 
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Table 3.4: Investigation of the role of each component in the amination reaction. 
 
Starting material CuI L4 Cs2CO3 Outcome 
3.17 
X X  Starting material 
X   Starting material 
  X 3.19h (15%) 3.22h (10%) 
 X  3.19h (50%) 3.22h (3%) 
Conditions and reagents: BODIPY 3.17 (0.25 mmol), amine (0.47 mmol), CuI (5 mol%), 1,10-
phenanthroline L4 (20 mol%), Cs2CO3 (0.47 mmol), DMF (0.8 mL), 80 ̊C, 24 h. 
Since iodoBODIPY compounds are known to act as initiators for photooxidation,127 the 
reaction between the 2-iodoBODIPY 3.17 and 4-cyanoaniline was repeated with careful 
exclusion of light and also with a 5-cycle freeze-pump-thaw sequence to degas the 
solution. This did not significantly change the yields of the products (3.17l and 3.22l) and 
so it is unlikely that the reaction is photoinitiated or requires the presence of dioxygen. 
We considered three different mechanisms for this copper catalysed nucleophilic 
substitution reaction.  
A first possibility involves a base-catalysed halogen dance128 (BCHD). Based-catalyzed 
halogen dance (BCHD) reactions, also referred to as halogen-dance (HD), halogen 
migration or halogen scrambling were first found by chance in 1953.129 The base 
catalysed halogen dance (BCHD) reaction represents a base induced reaction of a 
haloaromatic compound in which a halogen atom moves to a new position in the product. 
Halogen dance reactions are an excellent synthetic tool which empower functionalization 
of positions which are otherwise difficult to address. There is a large volume of published 
studies describing the mechanism of BCHD reactions. Figure 3.9 describes the general 
equation of the halogen dance reaction. 
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Figure 3.9: the general mechanism of the halogen dance reaction. 
In the case of 2-iodoBODIPY 3.17, the first step of a halogen dance would be formation 
of an anion by deprotonation of 2-iodoBODIPY 3.17 in the 5-position. The resulting 
anion 3.17a can abstract iodine from the 2-iodoBODIPY 3.17 to give 2,5-diiodoBODIPY 
3.25  and the newly formed anion 3.26. These two species can react again to form anion 
3.27 followed by protonation to give 3-iodoBODIPY 3.28. After amination of 3-
iodoBODIPY 3.28, 3-aminoBODIPY 3.19 can obtained as shown in Scheme 3.18.  
In principle the deprotonation and subsequent halogen migration could occur on any of 
the BODIPY positions; only when the halogen reaches the 3-position can it be displaced 
by the nucleophile, leading to the observed product.  
 
  Chapter 3                                                                                   Results and Discussion  
 
 
116 
 
 
Scheme 3.18: Possible mechanistic pathway involving base catalysed halogen dance of BODIPY. 
According to the proposed halogen dance mechanism (Scheme 3.18), deprotonation of 
the unhalogenated compound 3.16 followed by abstraction of iodine from the 2,6-diiodide 
3.18 would be expected to allow both compounds to enter into the halogen dance 
manifold. In order to establish whether the reaction between 2-iodoBODIPY and amines 
occurs by a halogen dance mechanism, the unhalogenated BODIPY 3.16 was treated with 
the 2,6-diiodide 3.18 and pyrrolidine under the same reaction conditions, however, no 
aminated product was observed and the unreacted starting materials were isolated 
(Scheme 3.19). 
This observation, together with the high yield obtained even with the 2-bromoBODIPY 
3.23, suggest that a halogen dance mechanism is not involved.  
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Scheme 3.19: Attempted copper catalysed amination of a 1:1 mixture of the BODIPY 3.16 and the 2,6-
diiodide 3.18 with pyrrolidine; Conditions and reagents; pyrrolidine (2 eq), CuI (5 mol%), 1,10-
phenanthroline L4 (20 mol%), Cs2CO3 (2 eq), DMF, 80 ̊C, 24 h. 
A second possibility is that the loss of iodine from C-2 is a reductive process, linked to 
oxidation of the copper (I) catalyst130 [e.g. via a copper (I)/copper (III) cycle or single 
electron transfers involving copper (II)] (Scheme 3.20). Such a mechanism would provide 
the oxidant required for the known direct nucleophilic hydrogen displacement by the 
amine106 and could explain formation of the iodinated by-product 3.22 by direct 
nucleophilic hydrogen displacement reaction at the 5-postion of the iodoBODIPY 3.17. 
The unreactivity of the 2,6-diiodide 3.18 is hard to explain by this mechanism, since it 
might be expected to be just as good an oxidant for the copper as the monoiodoBODIPY 
3.17. 
 
Scheme 3.20: Possible mechanistic pathway involving a copper redox cycle. 
Scheme 3.21 shows a third mechanistic possibility which involves initial nucleophilic 
attack at C-3. The necessity for copper catalysis (Table 3.4) suggests that the nucleophile 
might be an amido copper species such as 3.29.131 The resulting anion 3.30 might be 
copper-bound, corresponding to an amidocupration, but may be delocalised over the 
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BODIPY π-system. In order to produce the product, iodide must be lost and this requires 
protonation at C-2 to give 3.31 followed by base-mediated elimination of HI. This 
mechanism does not account for the formation of the 5-amino-2-iodoBODIPY by-
product 3.22.  
 
Scheme 3.21: Possible mechanistic pathway initiated by nucleophilic attack at 3-position. 
Observation of the 2-iodo-5-aminoBODIPY by-product 3.22 suggests initial attack might 
occur at the 5-postion of the iodoBODIPY 3.17 rather than at the 3-position (Scheme 
3.22). 
 
Scheme 3.22: Possible mechanistic pathway initiated by nucleophilic attack at 5-position. 
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Formation of the by-product 3.22 is an oxidative process requiring the formal loss of 
hydride from iodoBODIPY 3.17 and thus the yield of 3.22 might be expected to be 
increased in the presence of oxygen, which is not observed. Direct oxidative nucleophilic 
hydrogen substitution by amines occurs in the 3-position of unhalogenated 8-
arylBODIPYs but requires a stoichiometric oxidant (DDQ, CAN, permanganate, or O2) 
and is reported to be successful for primary and secondary alkyl amines but to fail in the 
case of anilines (Scheme 3.23).106 
 
Scheme 3.23: Direct oxidative nucleophilic hydrogen substitution by amines.
106 
In order to investigate the position of the nucleophilic attack the unsymmetrical BODIPY 
3.34 was synthesised via zinc oxide mediated Friedel-Crafts acylation of pyrrole followed 
by reaction of the resulting ketone 2.68b with 2,4-dimethylpyrrole in the presence of 
boron trifluoride-etherate (Scheme 3.24). Iodination with NIS was moderately 
regioselective in favour of substitution on the more electron rich, methylated, ring to give 
a mixture of mono-iodoBODIPYs 3.35 and 3.36 in a ratio of 6:1 respectively. The 2-
iodoBODIPY 3.35, in which the 5-position is blocked by a methyl group, did not react 
under the amination conditions. This observation suggest that initial nucleophilic attack 
actually occurs at C-5 of the 2-iodoBODIPY, however it was also found that the reaction 
between 2-iodoBODIPY 3.36, in which the 5-position is free, and pyrrolidine did not 
form any amination product under the amination conditions. A possible explanation for 
these results may be the presence of the electron donating methyl groups in C1 and C3 of 
the BODIPYs is sufficient to disfavour nucleophilic attack by the amine. It is noteworthy 
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that the direct oxidative hydrogen displacement was reported only on BODIPYs lacking 
any substituent except at the 8-position. 106 
 
Scheme 3.24: Conditions and reagents; a) ZnO, r.t., 5 min (55%); b) 2,4-dimethylpyrrole, BF3.OEt2, i-
Pr2NEt, CH2Cl2, r.t., 24 h (84%); c) NIS, CH2Cl2, r.t., 21 h (3.35, 13%; 3.36, 74%); d) pyrrolidine (2 eq), 
CuI (5 mol%), 1,10-phenanthroline L4 (20 mol%), Cs2CO3 (2 eq), DMF, 80 ̊C, 24 h. 
3.9. Synthesis of 6-deuterio-2-iodoBODIPY 
Due to the failure of the reactions between pyrrolidine and BODIPY 3.35 or 3.36 we 
decided to synthesise isotopically labeled compounds to investigate the position of the 
nucleophilic attack. The synthesis of isotopically labelled compounds is very important 
for detailed mechanistic studies of many chemical reactions. The most common stable 
isotopes used in research include 13C, 18O, 2H (Deuterium or D) and 15N. A radical 
mediated halogen deuterium exchange is one of the most common methods for 
deuteration, and the mechanism of the reaction is described in Figure 3.10. 
 
Figure 3.10: The proposed reaction mechanism of the halogen-deuterium exchange.36 
Radical-mediated deuteration of the diiodoBODIPY 3.18 was attempted using tributyltin 
deuteride in deuterobenzene (Table 3.5, entry 1). The reaction mixture was degassed by 
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a 5-cycle freeze-pump-thaw sequence and also with careful exclusion of light before 
heating but no dehalogenated product 3.39 was observed. Mutsumi (2011) has reported132 
the use of THF-d8 as the deuterium source in presence of tributyltin hydride (Bu3SnH) 
for high yielding deuterium-halogen exchange in aromatic iodides (Scheme 3.25).  
 
 
Scheme 3.25: THF-d8 mediated radical deuteration.
132
 Conditions and reagents; Bu3SnH (1.2 
eq), V-65 (0.2 eq), THF-d8, 2 h, reflux, 62%. 
In the second attempt we followed the Mutsumi procedure,132 by treating diiodo BODIPY 
3.18 with Bu3SnH and AIBN as the initiator in THF-d8 as the D source at 66 ̊C for 18 h, 
However, no product was observed in the 1H NMR spectrum of the crude material as all 
starting material was recovered. Finally, we used Bu3SnD instate of Bu3SnH; again no 
product 3.39 was observed in the 1H NMR spectrum of the crude material and the starting 
material was still present.  
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Table 3.5: All attempts carried out for synthesis of 6-deuterio-2-iodoBODIPY 3.39 
 
Attempts Reaction conditions Product 
1 
BODIPY 3.18 (0.18 mmol), (C4H9)3SnD (0.22 mmol), AIBN 
(0.018 mmol), benzene-d6, 80 ̊C, 18 h 
 No reaction 
2 
BODIPY 3.18 (0.4 mmol), (C4H9)3SnH (0.47 mmol), AIBN 
(0.079 mmol), THF-d8, 66 C̊, 18 h 
No reaction 
3 
BODIPY 3.18 (0.4 mmol), (C4H9)3SnD (0.47 mmol), AIBN 
(0.079 mmol), THF-d8, 66 C̊, 18h 
No reaction 
 
May (2001), has reported a convenient method for the deuteration of compound 3.40 by 
using 10% Pd/C, Et3N and deuterium gas in ethyl acetate to form compound 3.41 in an 
excellent yield (96%).133 
 
Scheme 3.26: Synthesis of deuterated phenoxyketophosphonate 3.41. Conditions and reagents; 
D2, Pd/C, EtOAc, r.t., 2 h, 96%. 
Following this literature procedure, the deuteration of 2,6-diiodoBODIPY 3.18 was carried 
out by using Pd/C and D2 (1 atm, balloon) in DCM and MeOH for 5 h at room temperature 
(Scheme 3.27). The 6-deuterio-2-iodoBODIPY 3.39 was formed in 60% yield together 
with 17% of the 2,6-dideuteriated BODIPY 3.42  which were separable by column 
chromatography. 
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Scheme 3.27: Synthesis of deuterioBODIPY 3.39. Conditions and reagents; D2 (1 atm), Pd/C, CH2Cl2-
MeOH, r.t., 5 h (3.39, 60%; 3.42, 17%). 
The 6-deuterio-2-iodoBODIPY 3.39 was reacted with pyrrolidine in the presence of CuI, 
L4 and Cs2CO3 in DMF at 80 ̊C for 24 h to give a 70:30 ratio of the 3-amino-6-
deuterioBODIPY 3.43 together with the regioisomeric 3-amino-2-deuterioBODIPY 3.44 
(Scheme 3.28).  
 
 
Scheme 3.28: Synthesis of 3-amino-6-deuterioBODIPY 3.43. Conditions and reagents; pyrrolidine (2.0 
rq), CuI (5 mol%), 1,10-phenanthroline L4 (20 mol%), Cs2CO3 (2.0 rq), DMF, 80 ̊C, 24 h (95%; 
3.43:3.44 = 70:30). 
The ratio of regioisomeric mono-duterated aminoBODIPYs 3.43 and 3.44 was measured 
by 1H NMR integration of the 2-H signal at δ 6.06 ppm (0.7 H) which indicates 30% 
deuteration at the 2-position (Figure 3.11). Likewise, integration of the resonance at δ 
6.79 ppm (1.3 H for 5-H and 5ʹ-H) indicates 70% deuteration at the 5-position. 
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Figure 3.11: 1H NMR spectrum of a mixture of amino-6-deuterioBODIPY 3.43 and 3.44 (500 MHz, 
CDCl3). 
 
Formation of 3-amino-6-deuterioBODIPY 3.43 as the major product is consistent with 
the straightforward nucleophilic substitution mechanism involving attack at C-3 (as 
shown in Scheme 3.21), but the presence of the regioisomeric 2-deuteriated product 3.44 
indicates a minor pathway involving nucleophilic attack by the amine at C-5 in the 
iodoBODIPY 3.39. The unequal ratio of products 3.43:3.44 rules out any mechanisms 
involving prior dehalogenation to produce the unsubstituted BODIPY 3.45 in situ 
(Scheme 3.29).  
 
 
Scheme 3.29: Possible mechanistic pathway involving prior dehalogenation of BODIPY 3.39. 
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Although synthesis of 3-aminoBODIPYs was successful, due to the failure to form 2-
aminoBODIPYs via copper catalysed amination, we decided to attempt the synthesis of 
2-aminoBODIPYs by using palladium catalysed Buchwald-Hartwig amination. 
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3.10. Palladium catalysed amination of aryl halides  
Buchwald-Hartwig cross coupling is a reaction between aryl halides or 
trifluoromethanesulfonates and amines in the presence of a palladium catalyst and base 
to synthesise the corresponding aryl amines. In 1983, Migita and co-workers reported the 
first palladium catalysed formation of aryl C-N bonds.134 
 
Scheme 3.30: First palladium catalysed amination. Conditions and reagents: a) PhBr (1 eq), Bu3SnNEt2 
(1.5 eq), PdCl2(o-tolyl3P)2 (0.01 eq), toluene, 100 ̊C, 3 h. 
In 1995, Buchwald developed a new catalytic procedure based on Migita’s amination 
method.135 The main disadvantage of these early methods is that both methods used a 
stoichiometric amount of heat and moisture sensitive tributyltin amides as coupling 
reagent. In 1995, Hartwig136 and Buchwald137 concurrently discovered that the amination 
can occur by replacing a toxic aminotin species with the free amine if one uses a strong 
hindered base such as sodium tert-butoxide, which formed the corresponding sodium 
amide in situ by deprotonating the palladium-coordinated amine.  
 
 Scheme 3.31: General equation for formation of arylamines by using Pd catalyst. 
As shown in Figure 3.12 the initial step in catalytic cycle of Buchwald reaction is 
generating the LnPd(0) catalyst in situ which can readily undergo an oxidative addition 
into the carbon-halogen bond of the aryl halide substrate to give an ArPdXL complex.41 
The amine nucleophile then coordinates to Pd(II) and is subsequently deprotonated by the 
base. The final step in the Buchwald catalytic cycle is reductive elimination, forming the 
amino aryl product and regenerating the active catalyst.138   
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Figure 3.12: Buchwald-Hartwig Amination Reaction Mechanism.
138
 
As mentioned previously (section 3.1), Hiroto108 and his group prepared 2-amino-8-
mesityl BODIPY 3.10 via palladium-catalysed imination of 2-bromoBODIPY 3.8 with 
benzophenone imine to form an imino BODIPY followed by hydrolysis with aqueous 
HCl.108 
 
We modified Hiroto’s procedure108 by using an amine instead of benzophenone imine in 
order to produce 2-aminoBODIPYs. We attempted to synthesise 2-aminoBODIPY 3.46 
following Hiroto’s conditions, 1.5 equivalents of p-toluidine were added to the 2-
iodoBODIPY 3.17 in the presence of Xantphos, Pd2(dba)3-CHCl3 and Cs2CO3 in 1,4-
dioxane at 95 ̊C for 16 h (Scheme 3.32). TLC analyses of the reaction indicated a complex 
mixture of products, including unreacted starting material. There was no sign of the 
desired 2-aminoBODIPY in the 1H NMR spectrum of the crude material. 
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Scheme 3.32: Attempted amination of 2-iodoBODIPY 3.17. Conditions and reagents: a) Pd2(dba)3.CHCl3 
(20 mol%), Xantphos (40 mol%), Cs2CO3 (1.7 equivalents), 1,4-dioxane, 95 ̊C, 16 h. 
Due to the failure of the reaction between p-toludine and 3,5-unsubstituted BODIPY 3.17, 
we decided to synthesise a BODIPY 3.50 in which the 1, 3, 5 and 7 positions are blocked 
by substitutions, followed by iodination and then amination. Two different routes to 
synthesis of 2-iodoBODIPY 3.50 were investigated as shown in Scheme 3.33. 
 
Scheme 3.33: Synthetic approaches to the synthesis of 2-iodoBODIPY 3.50. 
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3.11. Synthesis of a 2-iodoBODIPY 3.50 
The initial step in the synthesis of fully blocked BODIPY 3.50 was the synthesis of 2-
ketopyrrole 3.47. Following a literature procedure,51 deprotonation of 2,4-
dimethylpyrrole by MeMgBr as a base followed by selective C-2 acylation with p-toluoyl 
chloride produced the 2-ketopyrrole 3.47 in 40% yield (Scheme 3.34). 
 
Scheme 3.34: Synthesis of 2-ketopyrrole 3.47. Conditions and reagents; a) THF, MeMgCl (1.1 eq), 
reflux, 1 h. b) p-toluoyl chloride (1.3 eq), r.t., 24 h, 40%. 
In order to increase the reaction yield and reduce the reaction time we followed the Min 
Ji procedure for Friedel-Crafts acylation of 2,4-dimethylpyrrole with p-toluoyl chloride 
in the presence of ZnO to produce 2-acylpyrrole 3.47 in an improved yield of 55% 
(Scheme 3.35). 
 
Scheme 3.35: Synthesis of 2-ketopyrrole 3.47. Conditions and reagents; a) ZnO (25 mol%), r.t., 5 h, 
55%. 
The next step, electrophilic iodination of 2-ketopyrrole 3.47 was be anticipated to be 
straightforward as just one reactive site is available to be iodinated. 3-Iodo-2-ketopyrrole 
3.48 was synthesised in excellent yield by treating 2-ketopyrrole 3.47 with N-
iodosuccinimide in DCM (Scheme 3.36).  
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Scheme 3.36: Synthesis of 3-iodo-2-ketopyrrole 3.48. Conditions and reagents; a) NIS (1.1 eq), DCM, 
r.t., 2 h, 98%. 
Condensation of the 3-iodo-2-ketopyrrole 3.48 with 3-ethyl-2,4-dimethylpyrrole in the 
presence of borontrifluoride etherate as catalyst to form the intermediate dipyrromethene 
was followed by in situ conversion to the BODIPY 3.50 by further treatment with 
borontrifluoride etherate and Hünig’s base. Purification using column chromatography 
gave the desired 2-iodoBODIPY 3.50 in 50%, together with the dehalogenated BODIPY 
3.49 in 30% (Scheme 3.37). 
 
Scheme 3.37: Synthesis of 2-iodoBODIPY 3.50. Conditions and reagents; a) 3-ethyl-2,4-
dimethylpyrrole, BF3.OEt2, DCM, r.t., 2 h; b) BF3.OEt2, i-Pr2NEt, CH2Cl2, r.t., 4 h, (3.50, 50%, 3.49, 
30%). 
The synthesis of 2-iodoBODIPY 3.50 was successful, however, due to difficulties in the 
separation of the product 3.50 and the deiodinated BODIPY 3.49 which have a very close 
Rf values on TLC we decided to synthesise 2-iodoBODIPY 3.50 by using a modified 
route. The second route involved the synthesis of the unhalogenated BODIPY 3.49 
followed by electrophilic iodination with N-iodosuccinimide to give the iodoBODIPY 
3.50. 
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BODIPY 3.49 was prepared according to a previous procedure139 by BF3 mediated 
condensation of the ketopyrrole 3.47 and dimethylethylpyrrole followed by further 
treatment with borontrifluoride etherate and Hünig’s base (Scheme 3.38). 
 
Scheme 3.38: Synthesis of BODIPY 3.49. Conditions and reagents; a) 3-ethyl-2,4-dimethylpyrrole, 
BF3.OEt2, DCM, r.t., 2 h; b) BF3.OEt2, i-Pr2NEt, CH2Cl2, r.t., 4 h, 86%. 
Using a literature procedure,140 the 2-iodoBODIPY 3.50 was then prepared by reaction 
of the BODIPY 3.49 with NIS in DCM at room temperature for 4 h (Scheme 3.39). 
Purification by column chromatography gave the desired 2-iodoBODIPY 3.50 in high 
yield (80%). 
 
Scheme 3.39: Synthesis of 2-iodoBODIPY 3.50. Conditions and reagents; a) NIS (1.1 eq), DCM, r.t., 4 h, 
80%. 
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3.12. Synthesis of 2 aminoBODIPYs via Palladium catalysed amination 
Our initial attempt to form a 2-aminoBODIPY from the 2-iodoBODIPY 3.50 was by 
modifying Hiroto’s and Shinokubo’s procedure108 (as detailed previously). Much to our 
delight we indeed observed formation of the 2-aminoBODIPY 3.51 upon stirring the fully 
blocked BODIPY 3.50 with 4-methoxyaniline in the presence of Xantphos, Pd2dba3-
CHCl3 and Cs2CO3 in 1,4-dioxane at 95 ̊C for 16 h, however, the yield was moderate 
(36%) (Scheme 3.40). This model system was then optimized with respect to the 
influence of different ligands L5-L8, Pd sources, bases and temperature.  
 
Scheme 3.40: Amination of 2-iodoBODIPY 3.50. Conditions and reagents; Pd2dba3.CHCl3 (20 mol%), 
Xantphos (1.1 mol per mol Pd), Cs2CO3 (1.7 eq), 1,4-dioxane, 95 ̊C, 16 h, 36%. 
3.12.1   Screening of the ligand 
 
In general, the key features of Buchwald amination cross coupling mechanism are; the 
activation of the catalyst, oxidative addition, transmetalation and reductive elimination. 
The role of the ligands in Pd-catalysed C-N cross coupling reactions are summarized in 
Table 3.6.141  
Table 3.6: the catalytically active species in Buchwald amination reactions 
Step of catalytic 
cycle 
Roles of ligands 
Preactivation 
Generation of LnPd(0)catalyst and protection of Pd(0) from 
deactivation 
Oxidative 
addition 
Promotion of oxidation addition is essential for less reactive 
substrates 
Reductive 
elimination  
Required to remove the product from the coordination shell of 
Pd 
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As Table 3.6 illustrates, the catalytically active species in Buchwald amination reactions 
is the LnPd(0) species, with Pd in the zero oxidation state.141 Most catalysts will require 
activation to form LnPd(0) species in solution before entering the catalytic cycle. 
Therefore, Pd-catalysed C-N cross-coupling is controlled by ligand design. To date there 
have been a huge number of ligands used for Buchwald amination reactions such as 
diphosphines and biphenylmonophosphine ligands.  
Buchwald reported that the combination of BINAP as a ligand and Pd2(dba)3 in the 
presence of NaOtBu as a base formed an efficient catalyst system for the cross-coupling 
of amines with aryl bromides (Scheme 3.41).142  
 
 
Scheme 3.41: General scheme for amination using BINAP as ligand.
142 
 
Buchwald has developed a range of bulky dialkyl biarylmonophosphines for palladium 
catalysed coupling reactions, including amination.143–145 The particular features of these 
ligands, typified by XPhos (L7) and SPhos (L8), are: the electron-rich nature promotes 
oxidative addition of challenging substrates, such as aryl chlorides; the large steric bulk 
of the ligands accelerates reductive elimination and also promotes formation of the 
monoligated. L1Pd(0) species; and a weak interaction between the metal and the second 
ring of the biaryl unit stabilises the low-coordinate metal species.   
 
 
Figure 3.13: Ligands screened in the Buchwald amination of BODIPY 3.50. 
We started with the ligand screening of L5-L8 (Figure 3.13) using 4-methoxyaniline. 
Figure 3.14 shows the results of the amination of the 2-iodoBODIPY 3.50. The choice of 
solvent, base, temperature (110 ̊C), Pd source and its loading were taken from Hiroto’s 
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and Shinokubo’s report using XantPhos L5 as ligand. As mentioned earlier, Pd2(dba)3 
together with XantPhos formed 2-aminoBODIPY 3.51 in a moderate yield of 36% 
(Figure 3.14). While using rac-BINAP L6 as ligand reduced the yield of the product 3.50 
to 5% (Figure 3.14). The use of the biphenyl derivatives with bulky alkyl groups at 
phosphorus, XPhos L7 and SPhos L8, produced much improved product yields (71% and 
80% respectively) (Figure 3.14). We further optimized the reaction condition by varying 
the Pd source. 
 
 
Figure 3.14: Ligand effects in the palladium-catalysed amination of 2-iodoBODIPY 3.50. Conditions and 
reagents: BODIPY 3.50 (0.23 mmol), 4-MeOC6H4NH2 (1.01 mmol), Pd2(dba)3 (10 mol%), ligand L5-L8 
(1.1 mol per mol Pd), Cs2CO3 (0.35 mmol), 1,4-dioxane (2 mL), 95  ̊C, 16 h. 
3.12.2   Screening of Pd source 
 
In general, the activation of catalysts takes place as impulsive coordination 
transformations using either Pd(OAc)2 or Pd2(dba)3 as the palladium source.
146 This 
activation can either be through a reduction step if the palladium source is in the +2 
oxidation state, such as Pd(OAc)2 or through ligand dissociation if the palladium source 
is already in the zero oxidation state, such as Pd2(dba)3.  
In recent years, there has been an increasing interest in the development of a new series 
of Pd(I) and Pd (II) precatalysts147,148 which are stable and which release monoligated 
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Pd(0) by simple procedures. In 2008, Buchwald and his group149 developed a new class 
of Pd precatalysts such as 3.52 that are useful for Suzuki cross coupling of aryl chlorides.  
 
However, it is obtained in several steps. Moreover, the activation of this precatalyst with 
weak bases is slow and occurs only at high temperatures. Buchwald148 subsequently 
developed precatalyst (XPhosPdCl) 3.53, its activation with weak base occurs at room 
temperature and it is easily synthesised in one pot reaction as shown in Scheme 3.42. This 
precatalyst is useful for the fast and efficient Suzuki coupling reaction of unstable boronic 
acids. 
  
Scheme 3.42: Synthesis of Precatalyst 3.53, Conditions and reagents: a) Pd(OAc)2, toluene, 60 ̊C, b) 
LiCl, acetone, r.t., then XPhos, r.t., 83%.148 
However, this type of precatalyst (3.53) cannot be generated with larger ligands such as 
BrettPhos and tBuXphos. Moreover, these precatalysts are not stable in solution for long 
periods of time. In 2013, Buchwald designed and synthesised the μ-OMs dimer88 
(LPdOMs) (3.54) from commercially available 2-aminobiphenyl and treated this with 
different ligands to afford the corresponding precatalysts.88 
 
Figure 3.15: Pd sources screened in the Buchwald amination of BODIPY 3.50. 
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As shown in Figure 3.16, the yield of the 2-aminoBODIPY 3.50 dropped to 19% from 
80% due to changing the Pd source from Pd2(dba)3 to Pd(OAc)2. However, the use of the 
μ-OMs dimer (LPdOMs)2 3.54 produced an excellent yield of the 2-aminoBODIPY 3.50 
(96%). Therefore, the combination of μ-OMs dimer (LPdOMs)2 3.54 (10 mol%) and 
SPhos L8 in presence of Cs2CO3 in dioxane at 95 ̊C was optimal. 
 
 
Figure 3.16: Pd source effects in the palladium-catalysed amination of 2-iodoBODIPY 3.50. Conditions 
and reagents: BODIPY 3.50 (0.23 mmol), 4-MeOC6H4NH2 (1.01 mmol), Pd source (10 mol%), SPhos L8 
(1.1 mol per mol Pd), Cs2CO3 (0.35 mmol), 1,4-dioxane (2 mL), 95  ̊C, 16 h. 
It was then shown (Table 3.7) that a reduction of the palladium loading from 10 mol% 
down to 1.2 mol% resulted in a slight drop in yield (from 96% to 81%, entries 1–4) but 
further reduction to 0.5 mol% and 0.1 mol% was unsuccessful (entries 5,6). 
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Table 3.7: Pd source loading effects in the palladium-catalysed amination of 2-iodoBODIPY 3.50. 
 
Entry %Pd Yield% 
1 10 96 
2 5 94 
3 2.5 92 
4 1.2 81 
5 0.5 10 
6 0.1 No reaction 
Conditions and reagents: BODIPY 3.50 (0.23 mmol), 4-MeOC6H4NH2 (1.01 mmol), (LPdOMs)2 3.54 
(10-0.1mol%), SPhos L8 (1.1 mol per mol Pd), Cs2CO3 (0.35 mmol), 1,4-dioxane (2 mL), 95  ̊C, 16 h. 
 
3.12.4   Screening of base and temperature  
We further optimized the reaction conditions by varying base and temperature. On 
examining the effect of changing the base to K3PO4 a decrease in the yield was observed, 
to 60% compared to the 82% on using Cs2CO3. However, on employing KF the reaction 
did not proceed (Table 3.8).  
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Table 3.8: Base effects in the palladium-catalyzed amination of 2-iodoBODIPY 3.50. 
 
Entry Base Yield% 
1 Cs2CO3 80 
2 K3PO4 60 
3 KF No reaction 
Conditions and reagents: BODIPY 3.50 (0.23 mmol), 4-MeOC6H4NH2 (1.01 mmol), (LPdOMs)2 3.54 
(1.2mol%), SPhos L8 (1.1 mol per mol Pd), base (0.35 mmol), 1,4-dioxane (2 mL), 95  ̊C, 16 h. 
The effect of the reaction temperature on the yield of the 2-aminoBODIPY 3.51 was 
studied in the temperature range 20 to 95 ̊C. Figure 3.17 shows that the percentage yield 
of the 2-aminoBODIPY 3.50 decreased with decrease in the reaction temperature from 
95 to 20 ̊C. 
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Figure 3.17: Reaction temperature effects in the palladium-catalyzed amination of 2-iodoBODIPY. 
Conditions and reagents: BODIPY 3.50 (0.203 mmol), 4-MeOC6H4NH2 (1.01 mmol), (LPdOMs)2  3.54 (1.2 
mol%), SPhos L8 (1.1 mol per mol Pd), Cs2CO3 (0.345 mmol), 1,4-dioxane (2 mL), 20-95  ̊C, 16 h. 
 
Overall, after screening of different ligand, Pd sources, bases and reaction temperatures, 
the combination of SPhos L8 as a ligand, μ-OMs dimer (LPdOMs)2 3.54 (1.2 mol%), 
Cs2CO3 as a base and 1,4-dioxane as a solvent at 95 ̊C for 16 h was an efficient system for 
the Buchwald amination of the 2-iodoBODIPY 3.50. These conditions were applied to the 
reaction of the 2-iodoBODIPY 3.50 with a range of amines (Figure 3.18). 
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3.12.5.   Scope of the amination of the 2-iodoBODIPY 3.49  
 
Having established the optimized reaction conditions, the scope of the Buchwald-
coupling was then explored by using a series of different amines. As shown in Figure 
3.18, the aniline with electron donating substituents afforded the desired products (3.51 
and 3.57) in excellent yield. Also, good yields were obtained even with anilines with 
electron withdrawing substituents (3.55, 3.56) and the sterically hindering substituents 
(3.57). However in the case of a primary alkylamine (n-hexylamine), the yield obtained 
was low (3.58), and attempts to use secondary alkyl amines (pyrrolidine and morpholine) 
were unsuccessful. 
 
 
Figure 3.18: Amination of 2-iodoBODIPY 3.50. Conditions and reagents: BODIPY 3.50 (0.23 
mmol), amine (1.01 mmol), (LPdOMs)2  3.54 (1.2 mol%), SPhos L8 (1.1 mol per mol Pd), Cs2CO3 (0.345 
mmol), 1,4-dioxane (2 mL), 95  ̊C, 16 h. 
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3.13. Spectroscopic properties 
3.13.1.   Photophysical properties of the 3-aminoBODIPYs 
 
One of the features of BODIPY compounds is that structural modifications may be easily 
made, which affords additional opportunities to vary their optical properties. In reviewing 
the literature, most simple BODIPY derivatives display a strong absorption band at 530 
(± 20 nm) and weaker absorption bands (around 350 nm) with sharp and narrow bands in 
the absorption spectra. However, the absorption maxima of substituted BODIPY’s are 
strongly affected by the electronic nature of the substituents.104  
Moreover, the intensity of fluorescence of substituted BODIPYs can be affected by a 
wide variety of processes.150-151 For instance, photoinduced electron transfer (PeT) often 
results in fluorescence quenching due to an attached electron donor substituent,12 an 
example is shown below (Figure 3.19).  
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Figure 3.19: Electron Transfer: energy level diagram.
12 
In general, when the BODIPY acts as the electron acceptor, the HOMO of the BODIPY 
should be lower than the HOMO of the donor (such as an amine group) so that an electron 
from the donor can be transferred to the BODIPY and fill its singly occupied HOMO 
resulting in fluorescence quenching and a weakly fluorescent or nonfluorescent 
BODIPY.16  
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However, coordination of the electron donor group to the analyte may stabilise and lower 
its HOMO energy below that of the BODIPY HOMO and thus electron transfer is reduced 
and fluorescence is turned on.16  
Figure 3.20 illustrates a specific example in which the 8-substituted bodipy 3.59152 is used 
as photoinduced electron transfer (PET) fluorescence sensor for Zn2+. The lone pair of 
the electrons on the amine quenches the fluorescence of the excited state in the free 
BODIPY 3.59. However, addition of zinc ions disrupts the PeT quenching due to 
coordination of the lone pair with the metal.152   
 
Figure 3.20: An example of a BODIPY-based Zn2+ switch, which works by fluorescent quenching via a 
photoinduced electron transfer.
152 
A decrease in fluorescence is often observed in the presence of heavy atom substituents 
on a BODIPY core (e.g. I, Br) because heavy atoms increase the possibility of intersystem 
crossing.153 
The installation of electron-donating groups on BODIPY leads to an increase in the molar 
absorption coefficient and red-shift of the absorption and fluorescence spectrum and 
reduced quantum yield. Also, introduction of electro-donating groups generally leads to 
broad spectra. The presence of lone pairs of electrons on the nitrogen or oxygen atoms 
does not change the π-π* nature of the transitions of the parent BODIPY, but they may be 
involved directly in π bonding with the BODIPY system. The photophysical properties 
  Chapter 3                                                                                   Results and Discussion  
 
 
144 
 
of 3-amino-substituted BODIPYs have previously been reported in detail.56,107,108,122,154–
168 
The photophysical properties of non-aminated BODIPY 3.16 and 3-aminoBODIPY 
derivatives were measured in THF at room temperature (Table 3.9). Rhodamine 6G was 
used as the reference compound, for determination of fluorescence quantum yields 
(rhodamine 6G Φf= 0.95, λex= 470-510 nm, in ethanol).169 
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Table 3.9: Absorption and fluorescence data for compounds 3.16, 3.19a-n in THF. 
 
 
BODIPY R1 R2 
λabs (max) 
/nm 
ε/104 M-1 
cm-1 
λem (max) 
/nm 
Φf (λex) 
3.16 - 494 4.59 508 0.075(479) 
3.19a CH3(CH2)5 H 493 3.51 525 0.026(484) 
3.22a CH3(CH2)5 H 508 2.09 524  0.058(484) 
3.19b 4-MeC6H4 H 500 4.34 — — 
3.19c PhCO  H 522 4.69 534 0.050(492) 
3.19d PhCH2 H 498 3.43 525 0.030(484) 
3.19e 2-ThiophenylCH2CH2 H 496 3.09 528 0.033(485) 
3.19f Cyclohexyl H 496 3.56 525 0.015(484) 
3.19g O(CH2CH2)2 484 3.23 — — 
3.19h CH2CH2CH2CH2 476 4.15 540 0.005(490) 
3.19i 2-MeOC6H4 H 500 3.07 — — 
3.19j 4-MeOC6H4 H 501 1.99 — — 
3.19k 4-ClC6H4 H 508 4.53 565 0.007(475) 
3.19l 4-NCC6H4 H 533 5.34 557 0.015(500) 
3.19m 2-Pyridyl H 527 3.44 549 0.022(497) 
3.19n Ph Me 500 1.95 — — 
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The absorption and fluorescence data for non-aminated BODIPY 3.16 and 3-
aminoBODIPYs 3.19 are summarized in Table 3.9. Figure 3.21 shows the absorption and 
emission spectra of non-aminated BODIPY 3.16 and of 3-aminoBODIPY 3.19a (R= n-
Hex) and 3.19I (R= 4-CNC6H4), with the remaining absorption spectra for 3.19b-h and 
3.19j-n are given in the appendix. 
As Table 3.9 illustrates the majority of these BODIPY dyes showed strong absorption 
bands. In comparison to the parent BODIPY 3.16, the presence of an amino group at the 
3 position of the BODIPY core leads to an up to 40 nm (1481 cm-1) red-shift of the 
absorption maximum and an up to 57 nm (1986 cm-1) red-shift of the emission maximum.  
Consistent with the literature, all of the 3-aminoBODIPY derivatives show low 
fluorescent quantum yield, and some are non-fluorescent. A possible explanation for this 
might be attributed to photoinduced electron transfer (PeT) which often results in 
fluorescence quenching due to the electron donating effect of the amine group. 
 
 
Figure 3.21: Absorption spectrum (soild lines) in terms of the molar absorption coefficient (ε) and 
normalised fluorescence spectrum (dashed lines) for 3.16 (—), 3.19a (—), and 3.19I (—) in THF.  
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3.13.2.   Photophysical properties of the 2-aminoBODIPYs 
 
In reviewing the literature, the photophysical properties of 2-aminoBODIPYs have not 
been reported in detail. Therefore, in order to understand the effect of incorporating the 
NH group in the 2-positon on the BODIPY fluorophore, the photophysical properties for 
the novel parent BODIPY 3.49 was measured. As Figure 3.22 shows, the absorption and 
emission spectra are sharp and narrow band.  
  
Figure 3.22:  The absorption spectrum (solid line) in terms of the molar absorption coefficient (ε) and the 
normalised fluorescence spectrum (dashed line) of the parent BODIPY 3.49, recorded in THF at room 
temperature, with an excitation wavelength of 487 nm. 
 
The absorption and emission data for the 2-aminoBODIPY compounds and the parent 
unsubstituted compound 3.49 are summarized in Table 3.10.  
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Table 3.10: Photophysical data of the 2-aminoBODIPYs. 
 
BODIPY R 
λabs 
(max)/nm 
ε/104 M-1 
cm-1 
λem 
(max)/nm 
Φf (λex) 
3.49 - 512 9.30 523 0.97(487) 
3.51 4-MeOC6H4 523 1.83 - - 
3.55 4-ClC6H4 524 2.51 - - 
3.56 4-NCC6H4 520 3.60 - - 
3.57 2-MeC6H4 523 2.91 - - 
3.58 CH3(CH2)5 524 2.39 - - 
 
The absorption spectra of 2-aminoBODIPYs 3.51 and 3.55-3.58 are represented in Figure 
3.23. The majority of these BODIPY dyes showed strong absorption bands. In 
comparison to the parent BODIPY 3.49, the presence of an amino group at the 2-position 
of the BODIPY core leads to very broad peaks, an up to 12 nm (447 cm-1) red-shift of the 
absorption maximum and the molar absorption coefficients are lower, but still typical of 
BODIPY compounds (Figure 3.23). 
 
Figure 3.23: The absorption spectrum in terms of the molar absorption coefficient (ε) of the 2-
aminoBODIPY 3.51 and 3.55-3.58, recorded in THF at room temperature.  
The novel 2-aminoBODIPY 3.51 and 3.55-8, are dark purple coloured and appear to be 
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fluorescence quantum yields of 2-aminoBODIPYs 3.51 and 3.55-8 in tetrahydrofuran and 
toluene, however, the fluorescence of 2-aminoBODIPYs 3.51 and 3.55-8 is essentially 
completely quenched. As discussed earlier, all of the 3-aminoBODIPYs show low 
fluorescent quantum yield, however incorporation of the amino group in the 2-position 
has an even stronger deleterious effect on the fluorescence properties of the molecules. 
The electron releasing capacity of the amino group at the 2-position appears to be strong 
enough to prompt a charge transfer state, which generally quenches the fluorescence 
emission.  
 
3.13.2.1.   Absorption data for 2-aminoBODIPY 3.51 (R= 4-MeOC6H4) in different 
solvents 
The absorption spectra of 2-aminoBODIPY 3.51 in other solvents (Figure 3.24) are very 
similar to that in THF which all show two main absorption bands: (1) in the visible 
wavelength region, the 0-0 band of a strong S0-S1 transition with a maximum ranging 
from 520 to 525 nm (Table 3.11) and shoulder on the high-energy side, which is attributed 
to the 0-1 vibrational band of the same transition. The wavelengths of these absorption 
maxima (Table 3.11) are very similar to those of 3-aminoBODIPY 
derivatives.56,107,108,122,154–168 As mentioned earlier, the absorption spectra are dependent 
on solvent polarity; the maximum being red-shifted (by ∼5 nm) when the solvent is 
changed from acetonitrile (520 nm) to toluene (525 nm). (2) Additionally, a weaker, broad 
absorption band is found in the UV at about 464 nm, the position of which is not 
appreciably affected by solvent polarity.   
This band is also attributed to the S0-S1 transition but involving a vibronic state of higher 
energy than that in the shoulder described above. 
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Table 3.11: Absorption spectral data of compound 3.51 in different solvents 
 
 
 
 
Figure 3.24: Absorption spectrum in terms of the molar absorption coefficient (ε) for 2-aminoBODIPY 
3.51 in different solvents. 
In addition to these features, a pronounced low-energy ˈtailˈ is evident and appears to be 
more significant as the solvent polarity is increased. This might be due to a charge transfer 
state. To try to help confirm the validity of this analysis, the absorption spectrum was 
fitted to a series of Gaussian components (peak fitting was performed by Prof. A. 
Harriman, Newcastle University). Figure 3.25 shows the experimental and fitted spectra 
for the 2-(4-methoxyaniline)-BODIPY 3.51 in toluene and acetonitrile. The experimental 
data is well reproduced by a combination of components (Figure 3.25):  
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Figure 3.25: Peak fitting of absorption spectra for 2-aminoBODIPY 3.51 in toluene 
(top) and MeCN (bottom). 
(1) A broad, low energy band (Peak 1) attributed to charge transfer. This band moves 
to higher energy as the solvent polarizability increases (νmax  = 18,855 cm-1 in 
toluene, 19,156 cm-1 in MeCN). The relatively small shift in energy observed 
between solvents of significantly different polarizability suggests that the ground 
state is already rather polar and that excitation does not lead to a dramatic change 
in polarity. A calculation (DFT at the B3LYP/6-31 G (d) level, appling the 
polarizable continuum model with solvent = toluene) indicated a ground state 
dipole moment of 4.6 D. The solvent reorganisation energy (λCT) can be calculated 
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from the full width at half maximum (FWHM) of the band, according to Equation 
3.1.170 
λCT  = (FWHM)2/[16 ln2KBT]             Equation 3.1.170 
KB= Boltzmann’s constant = 0.6950 cm-1K-1 
The FWHM of the charge-transfer band (Peak 1) in toluene is 3086.6 cm-1, 
corresponding to λCT = 4,218 cm-1 (at 293 K). In acetonitrile, the FWHM is 3613.9 
cm-1, which corresponds to λCT = 5,783 cm-1. This solvent dependence of the 
reorganisation energy is as expected for a charge-transfer transition.  
(2) A sharper band (Peak 2) corresponding to the S0-S1 transition of the BODIPY 
(π→π*). This is also blue shifted on moving from toluene (νmax = 19,055 cm-1) to 
MeCN (νmax = 19,215 cm-1) but considerably less so than the CT band, as expected 
of a transition which does not lead to significant charge redistribution. Likewise, 
The FWHM of this band is less solvent dependent (906.2 cm-1 in toluene, 952.0 
cm-1 in MeCN) as expected.  
(3) Peak 3, corresponding to the shoulder of the the S0-S1 BODIPY transition, and 
attributed to the 0-1 vibrational band. In toluene, this band is centred at 20,368 
cm-1. This is 1,314 cm-1 higher in energy than the main 0-0 band and presumably 
corresponds to a low energy torsional mode. 
(4) Peak 4, corresponding to a higher energy vibrational band. In toluene this band is 
centred at 21,691 cm-1. This is 2,636 cm-1 higher in energy than the main 0-0 band 
and may correspond to the N-H stretch of the amine.  
The remaining three Gaussians (Peaks 5-7) centred at higher energies, included to fit 
the model closely to the experimental data, are not interpreted.  
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3.13.2.2.   Crystal structure determination of 3.57 
 
Further structural confirmation of 2-aminoBODIPY was performed through X-ray 
crystallography. A crystal of the 2-methylaniline-derived 3.57 was grown by slow 
evaporation of a solution in hexane/DCM. The orientation of the 2-methylphenyl moiety 
is rotated out of the dipyrrolyl plane with a dihedral angle (C10, C8, C24 and C25) of 
82.7̊ (2) for compound 3.57. In addition, the crystal structure confirmed that the amine 
group and the BODIPY core are not coplanar, the calculated twist angle between the 
aniline and the BODIPY core (dihedral angle C12, N3, C2 and C3) is 75.3̊ (2).   
 
Figure 3.26: molecular structure of 2-aminoBODIPY 3.57. Hydrogen atoms have been omitted for 
clarity.   
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3.13.2.3.   Electrochemical properties of the 2-aminoBODIPYs 3.51 and 3.58 
 
In general, the unsubstituted BODIPY is electron deficient and the electrochemical 
properties display one reversible reduction, one irreversible reduction and a poorly 
defined oxidation wave.171,172 However, introducing different groups on the BODIPY 
core can significantly influnce the electrochemical properties.171,172 The 2-
aminoBODIPYs 3.51 and 3.58 were subject to cyclic voltammetry (CV) in order to 
investigate the electrochemical properties of the system (Figure 3.27). The measurements 
were made in acetonitrile by using a graphite (carbon) and platinum electrodes. 1.0 M 
Tetrabutylammonium hexafluorophosphate (TBA. PF6) was used as the background 
electrolyte and ferrocene was used as an external standard. Cyclic voltammetric analysis 
of the BODIPY dye 3.51 showed several oxidation waves (Figure 3.27), the first is 
reversible (E1/2 = 0.33 V) which is too low to be related to the oxidation of the BODIPY 
unit. This is most probably related to the oxidation of the amine group for the 4-
methoxyaniline derivative 3.51. Following this initial oxidation, a further two irreversible 
oxidations occur (Ep = 0.56 and 0.92 V) which may also be due to oxidation of the amine. 
A final irreversible oxidation occurs at Ep = 1.26 V and is probably due to one electron 
oxidation of the BODIPY. 
The oxidation behaviour of the alkylamine derivative 3.58 is broadly similar (Figure 3.27) 
with a reversible oxidation at E1/2 = 0.26 V, one irreversible oxidation at Ep = 0.61 V 
associated with the amine and an irreversible oxidation at Ep = 0.97 V. 
At a negative voltage one redox peak is observed for each of the BODIPYs 3.51 and 3.58, 
showing one fully reversible one electron reduction (E1/2 = -1.48 and -1.55 V 
respectively). The cyclic voltammograms of 3.51 and 3.58 were recorded by Patrycja 
Stachelek (Prof. A Harriman’s group, Newcastle University). 
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Figure 3.27: Cyclic voltammetry: oxidation waves (V˃O) and reduction waves (V<O) of the 2-
aminoBODIPYs 3.51 (top) and 3.58 (bottom) in acetonitrile and 1.0 M tetrabutylammonium hex-
afluorophosphate (TBA PF6) as electrolyte at room temperature and referenced to the potential of 
ferrocene/ferrocenium couple. Scan rate 0.2 vs-1.  
For the 4-methoxyaniline derivative 3.51, the reversible one electron reduction of 
the BODIPY occurs ar -1.48 V. The fitted absorption spectrum (in MeCN) indi-
cates an energy for the BODIPY π→π* transition of 19,215 cm-1 = 2.38 eV. On this 
basis, the BODIPY oxidation potential would be expected to occur at approxi-
mately 2.38-1.48 = + 0.9 V. This value does correspond to the oxidation peak seen 
for the alkylamino-derivative 3.58 but not to the value (+1.26 V) ascribed to BOD-
IPY oxidation in the arylamino derivative 3.51. It may be that the multiple initial 
oxidation events associated with the arylamine sufficiently perturb the system such 
that the final oxidation cannot be regarded as a simple BODIPY oxidation.  
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3.13.2.4.    Quantum chemical calculations of 2-aminoBODIPYs 
 
In order to shed light on the interesting absorption features of the 2-aminoBODIPY 3.51, 
we explored their structures by using density functional theory (DFT) at the B3LYP/6-
31G(d) level, applying the polarizable continuum model (IEFPCM, with solvent = THF) 
to account for solvent effects (calculation were performed by Dr Julian Knight). Figure 
3.28 shows the the HOMO and LUMO orbitals and energies for the 2-unsubstituted 
BODIPY 3.49 and the 2- aminoBODIPYs 3.51 and 3.61 (as a model for alkylamine 
substitution). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.28: HOMO and LUMO molecular orbitals and energies (eV) for 3.49, 3.51, and the 2-
NHMe model BODIPY 3.61. 
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As expected for 1,3-dimethylated systems, the amine (NHR) and the BODIPY core 
are not coplanar, the calculated dihedral angle between the aryl carbon–amino ni-
trogen bond and the C2-C3 bond of the BODIPY pyrrole was < CNCC = 103.6̊ 
and 105.7̊ for compounds 3.51 (4-MeOC6H4NH-BODIPY) and 3.61 (MeNH-
BODIPY) respectively. Such twisting reduces conjugation between the nitrogen 
and the BODIPY and consequently the nitrogen in the alkyl amine derivative 3.61 
is significantly pyramidalized (the sum of bond angles at the nitrogen is 336.4̊). 
Inspection of the orbitals (Figure 3.28) indicates that the 2-amino substituent has a 
minimal effect on the energy and topology of the LUMO whereas the HOMO is 
substantially delocalised onto the substituent and raised in energy. The destabili-
zation of the HOMO relative to the LUMO is expected to result in a red-shift in 
the absorption spectrum, which is in qualitative agreement with the experimental 
observations. 
Overall, the structural, spectral, electrochemical and quantum chemical behaviour 
of these 2-amino BODIPYs is consistent with a significant charge transfer state 
which completely quenches the fluorescence.  
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3.14. Conclusion  
3-AminoBODIPYs have been synthesised successfully via a rather unusual copper 
catalysed vicarious nucleophilic substitution of the 2-iodoBODIPY. This approach also 
succeeded with less nucleophilic nitrogen nucleophiles such as anilines and an amide in 
many cases in high yields. Nevertheless, this approach does not produce any singly or 
doubly aminated product when using a 2,6-diiodoBODIPY. This observation allows 
straightforward separation of this by-product of the preceding iodination reaction after 
the amination.  
In addition, 2-aminoBODIPYs derivatives have been prepared successfully via 
Buchwald–Hartwig amination of the 2-iodoBODIPY (fully blocked). Aniline 
nucleophiles were highly reactive under the Pd catalysed amination conditions, and 
primary amine (hexyl amine) readily participated in the Pd amination. However, 
secondary amines failed to substitute the 2-iodoBODIPY under the given conditions. The 
absorption and emission spectra for 2 and 3-aminoBODIPY were measured. The presence 
of the nitrogen group in both positions gives a broadened red-shifted absorption 
maximum and the fluorescence of the 3-aminoBODIPYs is low and sometimes quenched, 
while the fluorescence of the 2-aminoBODIPY is quenched.  
Quenched fluorophores have often been used for sensing of a wide variety of analytes 
including heavy metals, oxygen and NO, and can also be used as pH sensors. In the next 
chapter, the use of a 2-aminoBODIPY as switch on sensor is discussed.
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Chapter 4: Application of 2-aminoBODIPY derivatives 
4.1.   Introduction 
Due to the great flexibility of BODIPY synthesis there is an extensive range of 
applications in biomolecular labels, drug delivery agents, cation sensors, laser dyes, 
electroluminescent films and fluorescent switches.6,12,152,173–182 
In recent years, there has been an increasing interest in the development of BODIPY 
derivatives for the detection of heavy metal ions due to their biological importance and 
potential for environmental harm. Several examples of BODIPY derivatives are known 
in which the fluorescence is ‘switched off or on’ or does not change on coordination.12 
Particularly, the possibility to introduce nitrogen nuclophiles at the BODIPY core can be 
of interest as substitution at these positions directly influences the spectral properties of 
the dye. Surprisingly, there are no reports of BODIPY-based phosgene sensors, nor of the 
use 2-aminoBODIPYs for heavy metal ion sensing.  
In previous chapters we have explored a new approach towards the synthesis of 2-
aminoBODIPYs. In this chapter the synthesis of a reactive novel 2-aminoBODIPY and 
its applications will be reported.  
 
4.2.   Synthesis of a functionalised 2-aminoBODIPY 
  
In designing a potential metal-ion sensor based on the 2-aminoBODIPY architecture, 
simple incorporation of an amino aryl substituent with additional substitution suitable for 
chelation to a metal was envisaged.   
In the first attempt to synthesise such a functionalised 2-aminoBODIPY, 1.5 equivalents 
of 2-aminophenol were added to the 2-iodoBODIPY 3.50, in the presence of SPhos L8, 
μ-OMs dimer 3.54 (LPdOMs)2 (1.2 mol%) and Cs2CO3 in 1,4-dioxane at 95 ̊C for 16 h 
(scheme 4.1) which gave a new spot on TLC. Purification using column chromatography 
gave 64% of a purple product. 
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Scheme 4.1: Attempt to synthesise 2-aminoBODIPY 4.1. Conditions and reagents: BODIPY 3.50 (0.20 
mmol), amine (1.01 mmol), (LPdOMs)2 3.54 (1.2 mol%), SPhos L8 (1.1 mol per mol Pd), Cs2CO3 (0.35 
mmol), 1,4-dioxane (2 mL), 95  ̊C, 16 h. 
The 1H NMR spectrum of this purple compound showed the appearance of four additional 
aromatic protons, however, the 11B NMR spectrum had changed from a quartet as seen 
in all 2-aminoBODIPY derivatives to a singlet at 5.1 ppm and there were no signals in 
the 19 F NMR spectrum. This indicates that the two fluorine atoms in a BODIPY were 
substituted with 2-aminophenol to produce the N,O-coordinated BODIPY 4.2 (Scheme 
4.2). 
 
Figure 4.1: 11B NMR spectrum of BODIPY 4.2. 
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Scheme 4.2: Synthesis of N,O-coordinated BODIPY 4.2. Conditions and reagents: BODIPY 3.50 (0.23 
mmol), amine (1.01 mmol), (LPdOMs)2 3.54 (1.2 mol%), SPhos L8 (1.1 mol per mol Pd), Cs2CO3 (0.35 
mmol), 1,4-dioxane (2 mL), 95  ̊C, 16 h, 64%. 
 
The replacement of the fluorine atoms to give BODIPY 4.2 was confirmed by X-ray 
structure determination, after crystal growth through slow diffusion of petroleum ether 
into a solution of the BODIPY in DCM (Figure 4.2).  
 
Figure 4.2: molecular structure of BODIPY 4.2, confirming substitution of fluorine by 2-aminophenol. 
Hydrogen atoms have been omitted for clarity.  
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In reviewing the literature, there is no published data on BODIPY dyes in which the 
fluorine atoms have been substituted with 2-aminophenol. On the other hand, the fluorine 
atom in a BODIPY has been substituted with other groups including alcohols.28,183–193 
Several examples of the substitution of the fluorine atoms at the boron centre have been 
reported to give alkoxy or aryloxy BODIPY derivatives (O-BODIPY) under very harsh 
conditions.28,183–193 Unsurprisingly, the boron-halogen bond strengths decrease in the 
order F ˃ Cl ˃ Br ˃ I .193 Thus, B-Cl bonds are much more labile than B-F. However, it 
was reported that the yields of formation of O-BODIPY compounds are often low. For 
instance, in 2007 Bonnet reported that refluxing BODIPY 4.3 with various alcohols in 
the presence of AlCl3 led to a mixture of monosubstituted 4.4 and disubstituted product 
4.5 (Scheme 4.3). 
 
 
Scheme 4.3: Replacement of fluorine by oxygen nucleophiles. Conditions and reagents: a) BODIPY 4.3, 
DCM, AlCl3 (1.5 eq), reflux, 5 min, b) ROH, r.t. 
 
In one recent publication the authors investigated three different methods for the synthesis 
of alkoxy BODIPY derivatives (O-BODIPY) as shown in Scheme 4.4.187 Method A 
involves addition of NaOMe in refluxing MeOH, method B employs refluxing 
dichloromethane in presence of AlCl3 followed by addition of MeOH as nucleophile, and 
method C uses trimethylsilyltrifluoromethanesulfonate (TMSOTf) for activation of the 
BODIPY in refluxing toluene followed by adding MeOH. The yields achieved depend on 
the structure of the BODIPYs.187 
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Scheme 4.4: Synthesis of BODIPYs 4.7. Conditions and reagents: method A: MeONa, MeOH, reflux, 12 
h. Method B: a) AlCl3, DCM, reflux, 15 min. b) MeOH, reflux, 15-30 min. Method C: a) TMSOTf, 
toluene, reflux, 30 min. b) MeOH, DIPEA, r.t., 1 h. 
 
The absorption spectrum of N,O-BODIPY 4.2 is represented in Figure 4.3. The low-
energy maximum (λabs) of N,O-BODIPY 4.2 is 528 nm which is assigned to the S0-S1 (π-
π*) electronic transition associated with the BODIPY core and has a high molar 
absorption coefficient (ε) (34,745 M−1cm−1). N,O-BODIPY 4.2 is non-fluorescent which 
might be due to either the replacement of the two fluorine atoms with nitrogen and oxygen 
atoms or due to the presence of the iodine atom (heavy atom). Future work will investigate 
the optimised conditions for the synthesis of this type of N,O-BODIPY.  
 
Figure 4.3: The absorption spectrum in terms of the molar absorption coefficient (ε) of the N-O-BODIPY 
4.2, recorded in tetrahydrofuran at room temperature.   
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Despite the successful incorporation of primary amines and anilines in the previous 
chapter, preparation 2-(ortho-aminophenol)BODIPY 4.1 by using ortho-aminophenol 
was shown to be unsuccessful under our conditions. We then decided to examine other 
anilines to synthesise a functionalized 2-aminoBODIPY. Therefore, the palladium 
catalysed nucleophilic amination was attempted by applying our reaction conditions, 
using SPhos L8, μ-OMs dimer (LPdOMs)2 3.54 to the reaction of the 2-iodoBODIPY 
3.50 with ortho-nitroaniline to give the 2-((2-nitrophenyl)amino)-BODIPY 4.8  as a dark 
orange solid in 67% yield (Scheme 4.5). 
 
Scheme 4.5: Synthesis of BODIPY 4.8. Conditions and reagents: BODIPY 3.50 (0.20 mmol), amine 
(1.01 mmol), (LPdOMs)2 3.54 (1.2 mol%), SPhos L8 (1.1 mol per mol Pd), Cs2CO3 (0.35 mmol), 1,4-
dioxane (2 mL), 95  ̊C, 16 h. 
Hydrogenation of 2-nitroaniline BODIPY 4.8 by using Pd/C and H2 in DCM and MeOH 
for 2 h at room temperature gave the 2-aminoanilineBODIPY 4.9 as a dark purple solid 
in high yield (96%) (Scheme 4.6). 
 
Scheme 4.6: Synthesis of 2-aminoBODIPY 4.9. Conditions and reagents: a) H2 (1 atm), 10% Pd/C, 
MeOH-CH2Cl2, r.t., 2 h (95%). 
  
  Chapter 4                                                                                   Results and Discussion 
 
 
165 
 
The absorption spectrum of 2-aminoBODIPY 4.9 is represented in Figure 4.4. The low-
energy maximum (λabs) of 2-aminoBODIPY 4.9 is 524 nm and is assigned to the S0-S1 
(π-π*) electronic transition associated with the BODIPY core. The high molar absorption 
coefficient (ε) is 29,894 M−1cm−1. 
 
 
Figure 4.4: The absorption spectrum in terms of the molar absorption coefficient (ε) of the 2-
aminoBODIPY 4.9, recorded in tetrahydrofuran at room temperature. 
The novel 2-aminoBODIPY 4.9, is dark purple coloured and appears to be non 
fluorescent during column chromatography. We attempted to measure the fluorescence 
quantum yield of 2-aminoBODIPY 4.9 in tetrahydrofuran, however, the fluorescence is 
strongly quenched.  
 
The key features of the novel 2-aminoBODIPY 4.9 are that it is nonfluorescent and 
contains two adjacent reactive functional groups, one of which is an NH group attached 
directly to the BODIPY core. This novel compound 4.9 might be used for many different 
applications such as for sensing phosgene, heavy metals and pH. 
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 4.3.   2-AminoBODIPY 4.9 for rapid visual detection of phosgene 
Phosgene (COCl2) is a colourless, suffocating gas. This highly toxic
194 compound was 
responsible for about 85% of the 100,000 deaths caused by chemical weapons during 
World War I. Exposure to phosgene can cause severe damage to lungs and respiratory 
tract, the lethal dose for humans is 2 ppm. Phosgene is an important industrial chemical, 
with several million tons produced globally each year. The main commercial use of 
phosgene is in the synthesis of other chemicals such as pesticides, herbicides, medicines, 
plastics and dyes.195 It is perhaps surprising that there are few reports of the use of 
fluorescence-based sensors for phosgene. 
In 2007, Zhang and Rudkevich designed a new system of phosgene sensors based on 
fluorescent resonance energy transfer (FRET).196 It includes a selective reaction between 
fluorescent donor and an acceptor fluorophore and phosgene as shown in Figure 4.5.  
 
Figure 4.5: A fluorescent resonance energy transfer based approach to the detection of 
phosgene.
196 
For instance, coumarin 4.10 and coumarin 4.11 rapidly react with phosgene and form 
urea 4.12 which leads to changes in fluorescence emission spectra (limit of detection 
5×10-5 M) (Scheme 4.7).196 
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Scheme 4.7: A reaction between coumarins 4.10 and 4.11 and phosgene with the formation of urea 
4.12.
196 
 
In 2012, Han reported a highly sensitive chemodosimeter for rapid detection of phosgene 
(limit of detection 50 nM).197 A deep-coloured and highly fluorescent species was formed 
by treatment of N-(rhodamine B)-deoxylactam-ethylenediamine 4.13 (dRB-EDA, 
colourless) with phosgene (Scheme 4.8)197 
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Scheme 4.8: chromo-fluorogenic detection of phosgene with dRB-EDA.
197 
 
In 2012, Kundu and Hwang reported rational design of unimolecular fluorescent 
phosgene sensors.198 The cyclisation of an hydroxycinnamic acid (nonfluorescent) with 
phosgene gave a fluorescent coumarin (limit of detection 1 nM) (Scheme 4.9).198 
 
Scheme 4.9: Chemical reaction of 2,4-dihydroxy cinnamic acid 4.16 with phosgene to produce coumarin 
4.17.
198 
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Interestingly, there are no reports of a BODIPY-based phosgene sensor. As we explained 
in the previous chapter, the presence of an amino group at the 2-position quenches the 
fluorescence emission of BODIPY 4.9 by resonance energy transfer, however, the 
nucleophilic attack of a 2-aminoBODIPY 4.9 on phosgene would decrease the electron-
donor ability of the substituent and thus reduce fluorescence-quenching, potentily leading 
to fluorescence ‘switch-on’. 
In order to explore this possibility, the 2-aminoaniline-drived BODIPY 4.9 was reacted 
with triphosgene in the presence of triethylamine to give the corresponding 
benzimidazolone-substituted BODIPY 4.18 in excellent yield (98%) (Scheme 4.10). 
 
Scheme 4.10: Synthesis of the benzimidazolone BODIPY 4.18. Conditions and reagents: a) 
(Cl3CO)2CO, Et3N, CH2Cl2, r.t., 10 min (98%). 
 
The 19F NMR spectrum of BODIPY 4.18  consists of 16 peaks due to the two 
different fluorine atoms coupling to each other and also coupling to the boron atom 
(Figure 4.6) as explained in chapter 2. Inequivalence of the two fluorine atoms 
implies restricted rotation of the imidazolone substituent around the C2-N bond. 
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Figure 4.6: 19F NMR spectrum of the benzimidazolone BODIPY 4.18, in CDCl3. 
In order to measure the barrier to rotation for the benzimidazole group a variable 
temperature (VT) 19F NMR experiment was performed using d8-toluene from 298 
to 373 K (Figure 4.7). However, no sign of coalescence or broadening of the peaks 
was observed which indicates that restricted rotation of the 
benzimidazole/BODIPY bond, even at high temperature results in the two fluorine 
atoms being inequivalent. 
 
Figure 4.7: 19F VT NMR spectra of the benzimidazolone BODIPY 4.18, in d8-toluene. 
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We also studied variable temperature 1H NMR spectra in order to confirm the previous 
result. The VT study was again performed in d8-toluene (from 298 to 373 K) (Figure 4.8). 
As we expected there was no coalescence or broadening of the peaks and hence rotation 
around the benzimidazole/BODIPY bond is restricted. This restriction is caused by the 
steric bulk of the benzimidazole ring in conjunction with the methyl groups at C1 and C3 
of the BODIPY.  
 
Figure 4.8: 1H VT NMR spectra of the benzimidazolone BODIPY 4.18, in d8-toluene. 
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The 2-aminoaniline BODIPY 4.9 is dark purple and nonfluorescent, and instantly turned 
orange and strongly fluorescent in dichloromethane (DCM) upon addition of triphosgene. 
The low-energy maximum (λabs) of beznimidazolone 4.18 is 515 nm and is assigned to 
the S0-S1 (π-π*) electronic transition associated with the BODIPY core. The molar 
absorption coefficient (ε) is 64,024 M−1cm−1. Figure 4.9 shows the normalised absorption 
and emission spectra of the bezimidazolone 4.18 and the parent BODIPY 3.49.
 
Figure 4.9: Absorption spectrum (solid lines) in terms of the molar absorption coefficient (ε) and 
normalised fluorescence spectrum (dashed lines) for 3.49 (—) and 4.18 (—) in THF.  
As Figure 4.9 illustrates the benzimidazolone-substituted BODIPY 4.18 showed strong 
absorption bands. In comparison to the parent BODIPY 3.49, the presence of 
benzimidazolone-substituent in the 2 position of the BODIPY core leads to a very small 
red-shift (3 nm, 114 cm-1) of the absorption maximum and a 23 nm (585 cm-1) red-shift 
of the emission maximum.  
In addition to fluorescence spectroscopy, the response of 2-aminoaniline BODIPY 4.9 to 
triphosgene can be easily visualized even with the naked eye (Figure 4.10). The bright 
yellow fluorescence intensity was clearly observed within few seconds after the addition 
of triphosgene. 
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Figure 4.10: The ‘‘naked eye’’ detection of triphosgene. Optical images inset: solution of the 
BODIPY 4.9 (50 µM in CH2Cl2 containing 3% Et3N) before (left) and after (right) addition of tri-
phosgene (25 µM). A visible light illumination; B illumination with hand-held lamp at 365 nm. 
Limit of Dectection (LoD) is the term used to describe the lowest amount or concentration 
of a substance that can be reliably distinguished from the absence of that substance (a 
blank value).199 In order to determine the detection limit, we have recorded the 
fluorescence emission of 2-aminoaniline BODIPY 4.9 on treatment with varying 
concentrations of triphosgene in acetonitrile. Figure 4.11 displays that the fluorescence 
emission intensity at 534 nm increased as a function of phosgene concentration. In this 
case, the Limit of Dectection for phosgene was calculated according to Equation 4.1.199  
3sB/m         Equation 4.1 
Where sB is the standard deviation of the blank measurement (dye solution in the absence 
of analyte) and m is the slope of the calibration curve.199 
On the basis of the fluorescence titration (Figure 4.11, inset) the Limit of Detection for 
phosgene was found to be 160 nM. 
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Figure 4.11: Fluorescence emission spectra of the 2-aminoaniline 4.9 (0.01 mg mL-1, 21 μM) in 
the presence of triphosgene (3.4, 2.7, 2.4, 2.0, 1.6, 1.2, 0.7, 0.4, 0.1 µM from the top to the bot-
tom) in MeCN containing 3% Et3N. Graphical inset: fluorescence emission intensity at 534 nm vs 
triphosgene concentration (λex = 490 nm). 
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4.4.   Synthesis of 2-aminoBODIPYs for heavy metal sensing 
Recently, researchers have shown an increased interest in the design and synthesis of 
BODIPY derivatives for the recognition of metal ions with high selectivity and sensitivity 
because these ions play essential roles in many biological system or have potential to be 
toxic. Figure 4.12 shows several examples of polydentate nitrogen based BODIPY 
derivatives,174,200–203 these compounds act as molecular switches for a different metal 
cation by producing kinetically stable complexes. They work on the basis of internal 
charge transfer (ICT) or photoinduced electron transfer (PET) processes. In the absence 
of metal, both types of BODIPY derivatives show reduced fluorescence due to the 
efficient quenching process (ICT or PET) in the excited state. There are no published 
reports of applying metal coordination chemistry to a functionalized 2-aminoBODIPY. 
Herein we report the synthesis of suitably functionalised 2-aminoBODIPYs and also the 
attempts to study their complexation properties towards different metal ions. 
 
Figure 4.12: Several examples of polydentate nitrogen based BODIPY derivatives.
174,200–203 
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In addition, Schiff base ligands have been reported to form complexes with several metal 
ions, such as Mg2+, Al3+, Co2+, Ni2+, Mn2+, Fe2+, Ag+, Cd2+, Zn2+, Hg2+, Pb2+ and Cu2+. 
For example, Kim developed a turn on fluorescence method with high selectivity to 
quantify the presence of Al3+ by using a simple salicylimine based chemosensor (Scheme 
4.11).204  
 
 
Scheme 4.11: Chemical structures of the receptor o-phenolsalicylimine and a 1:1 complex of o-
phenolsalicylimine and Al3+ in CH3OH:H2O.
204
 
Zhu reported two salen based ligands 4.21 and 4.22 which act as fluorescent sensors for 
rapid detection of Mg2+ (Figure 4.13).205 
 
 
 
Figure 4.13: Chemical structure of two coumarin salen-based Mg2+ sensors.
205 
Schiff bases combined with a BODIPY have been published as on/off type for optical 
sensing of Cu2+ over other common cations (Scheme 4.12).206 
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Scheme 4.12: An example of synthesis of a Schiff base combined with BODIPY 4.25.
206 
Conditions and reagents: a) NH2NH2.H2O, 10% Pd/C. b) EtOH, 6 h, reflux. 
Following this literature precedent, we chose to synthesise an ortho-hydroxy aromatic 
Schiff base, commonly used as a chelator.205 Azomethine-BODIPY 4.26 was prepared 
successfully by the condensation of the primary amine 4.9 and salicylaldehyde (Scheme 
4.13). Purification using column chromatography gave the desired azomethine-BODIPY 
4.26 in high yield (73%).  
 
 
Scheme 4.13: Synthesis of the azomethine-BODIPY 4.26. Conditions and reagents: a) salicylaldehyde (1 
equivalent), AcOH, EtOH, 78 ̊C, 20 h (73%). 
 
The azomethine-BODIPY 4.26 was a dark red colour and nonfluorescent and the solid 
product was allowed to dry in air overnight. Surprisingly, an orange and fluorescent 
compound was formed. Figure 4.14 illustrates the 1H NMR spectrum for azomethine-
BODIPY 4.26 immediately after being columned and after being dried in air overnight, 
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which indicated disappearance of the singlet peak at 8.7 ppm corresponding to the CHN 
group (Figure 4.14). 
 
Figure 4.14: 1H NMR spectra of azomethine-BODIPY 4.26 immediately after column chromatography 
(top) and after drying in air (bottom). 
A possible explanation for this might be that nucleophilic attack by the secondary amine 
NH tends to cause ring closure to give a dihydrobenzimidazole 4.26b which then 
undergoes oxidation by air to form a benzimidazole 4.27. 
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Scheme 4.14: proposed mechanism for synthesis of the BODIPY 4.27. Conditions and reagents: 
air, CHCl3, r.t., overnight (89%). 
As shown in the above scheme, the proximal phenol may assist in the cyclisation step by 
protonating the imine nitrogen. 
This result seem to be consistent with other research207 which found that the preparation 
of the 3-benzimidazole dipyrromethane 4.29 was successfully achieved simply by 
treating 1,9-diformyl dipyrromethane 4.28 in methanol with o-phenylene diamine in the 
presence of a catalytic amount of TFA. The authors offered no explanation for the 
oxidative transformation of the formyl groups to ester and benzimidazole simply on 
treatment under acidic conditions. The BODIPY 4.30 was formed by subsequent 
oxidation with DDQ and then BF2 chelation (Scheme 4.15). 3-Benzimidazole BODIPY 
4.30 shows good selectivity toward Hg(II) in vitro and in vivo.207 
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Scheme 4.15: Synthesis of the 3-benzimidazole BODIPYs 4.30. Conditions and reagents: a) 
MeOH, TFA. b) DCM, DDQ, TEA and BF3.OEt2. 
BODIPY 4.26 was synthesised successfully in good yield, however, it was not stable in 
air. Therefore, in the second attempt of synthesis of a polydentate nitrogen based 
BODIPY we decided to choose bis(pyridin-2-ylmethyl)amine, commonly known as di-
(2-picolyl)amine (DPA), as a chelator. 
Regioselective alkylation of BODIPY 4.9 with 3 equivalents of 2-chloromethyl pyridine 
hydrochloride produced the double alkylated BODIPY 4.31 together with a minor amount 
of the mono alkylated BODIPY 4.30 which were separable by column chromatography 
(Scheme 4.16). Immediately it was observed that the compounds are a dark purple colour 
and not fluorescent, in line with spectroscopic results for the other 2-aminoBODIPYs.  
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 Scheme 4.16: Synthesis of the BODIPYs 4.31 and 4.32. Conditions and reagents: a) 2-chlorome-
thyl pyridine hydrochloride, MeCN, K2HPO4, reflux, overnight (4.31 69% and 4.32 17%). 
The absorption spectrum of dialkylated BODIPY 4.31 is represented in Figure 4.15. The 
low-energy maximum (λabs) occurs at 526 nm and is assigned to the S0-S1 (π-π*) 
electronic transition associated with the BODIPY core. The molar absorption coefficient 
(ε) is 20,574 M−1cm−1. The BODIPY 4.31 is slightly fluorescent in THF solution with a 
maximum (λem = 522 nm) located at 526 nm and a low quantum yield Φf of 0.002.  
  
  Chapter 4                                                                                   Results and Discussion 
 
 
182 
 
 
Figure 4.15: Absorption spectrum (solid lines) in terms of the molar absorption coefficient (ε) and 
normalised fluorescence spectrum (dashed lines) for 4.31 in THF at room temperature (λex= 485nm). 
 
4.5.   Binding properties  
 
Firstly, using visual examination, we checked for colour changes of BODIPY 4.31 under 
both naked eye and UV light, with the addition of the various metal ions (Ca2+, Cu2+, 
Fe2+, Fe3+, Li+, Hg2+, Mg2+, Mn2+, Ni2+, Pb2+, Na+, Sn+2, Zn2+). We established that an 
obvious colour change (from pink to yellow or orange) of the BODIPY 4.31 solution 
occurs in the presence of Cu(II) and Fe(II) respectively (Figure 4.16). Nonetheless, the 
change of colour due to the presence of Fe(II) was not as obvious as that for Cu(II), which 
shows that BODIPY 4.31 might act as a sensor for copper ions.  
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                          Fe2+        Fe3+         Mg+2       Mn2+    Ni2+     Hg2+    Pd2+    Cu2+    Sn2+      Na+      Zn2+     Ca2+     Li+      BODIPY 
 
 
Figure 4.16: Photographs of solutions of 4.31 in HEPES-CH3CN upon addition of various metal ions. 
Upper row: optical image and the lower row fluorescence observed upon excitation at 365 nm. 
  
This result encouraged us to further investigate the selectivity of BODIPY 4.31 for Cu(II) 
using different spectrophotometric techniques. The emission spectra of BODIPY 4.31 in 
the presence of different metal ions (Ca2+, Cu2+, Fe2+, Fe3+, Li+, Hg2+, Mg2+, Mn2+, Ni2+, 
Pb2+, Na+, Sn2+, Zn2+) were measured under simulated physiological conditions (HEPES-
water/CH3CN 9:1 ), (20 mM HEPES buffer pH 7.2). A stock solution of BODIPY 4.31 
(1.68 x 10-4 mM) in acetonitrile was prepared and used to prepare the sample solution for 
the binding experiment. The fluorescence emission was recorded 120 seconds after 
adding each metal ion. There was a slight increase in the  fluorescence emission of 
BODIPY 4.31 upon addition of excess of various metal ions (Ca2+, Fe2+, Mn2+, Ni2+) 
(Figure 4.17). However, under the same conditions, the largest increase in fluorescence 
intensity of BODIPY 4.31 was formed in the presence of Cu2+ (Figure 4.17).   
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Figure 4.17: Selectivity of BODIPY 4.31 toward Cu2+ and other metal ions: fluorescence intensity of the 
BODIPY 4.31 (0.21 μM in HEPES-CH3CN pH 7.2) after treatment with metal ions (25 eq). 
Future effort will involve competitive binding experiments by addition of excess amounts 
of different metal ions in the presence of a small amount of Cu(II), to investigate whether 
the sensor can specifically detect copper ions even in the presence of excess amount of 
other metal ions. We will also study the binding and detection of copper ions by titration 
measurements of BODIPY 4.31 using spectrophotometric assays. 
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4.6.   Conclusion  
A new type of N,O-BODIPY 4.2 has been formed accidentally by treating 2-
iodoBODIPY 3.50 with 2-aminophenol in the presence of SPhos L8, μ-OMs dimer 
(LPdOMs)2 3.54 and Cs2CO3. In the future, the optimised conditions for the synthesis of 
this type of N,O-BODIPY will be investigated.  
The reactive novel 2-aminoBODIPY 4.9 was synthesized in good yield (95%) from the 
corresponding BODIPY 4.8. Reaction of this compound with triphosgene gave the 
corresponding benzimidazolone-substituted BODIPY 4.18 in excellent yield (98%). The 
bright yellow fluorescence of the triphosgene reaction product 4.18 can be easily 
visualized by the naked eye. The detection limit for phosgene is 160 nM in solution at 
room temperature. 
Moreover, the synthesis of polydentate nitrogen based BODIPY 4.31 has been achieved 
in excellent yields via the reduction of the BODIPY 4.8, and subsequent alkylation of the 
diaminoBODIPY 4.9. This route could be an excellent route to a library of new 
polydentate nitrogen based-BODIPY derivatives. The novel BODIPY 4.31 showed 
promise as a sensor for Cu2+ ions.  Future work will test these complexes for use in 
diagnostic imaging and therapy.
  Chapter 5                                                                                                       Summary 
 
 
186 
 
Chapter 5: Summary 
 
5.1   General summary  
 
This study covers the synthesis of chiral and amino-substituted BODIPIY dyes. 
The first aim of this project was to investigate synthetic approaches to chiral BODIPYs. 
Ultimately, these routes might be applicable to the synthesis of functionalised BODIPYs 
capable of interacting or coupling with non-fluorescent chiral analytes for use in 
enantioselective applications. Towards this end, four approaches to the synthesis of novel 
chiral BODIPY dyes were investigated. 
The C2-symmetric axially chiral 2,6-bis(2-methoxyphenyl) BODIPY 2.6 was 
synthesized via Suzuki coupling of the corresponding 2,6-dibromo BODIPY with 2-
methoxyphenyl boronic acid. 19F NMR revealed that this compound had been produced 
as a 50:50 mixture of diastereoisomers (corresponding to the methoxy groups being syn 
and anti across the BODIPY plane). Variable temperature 19F NMR indicated that these 
isomers did not interconvert up to 373 k, as expected due to steric hindrance to rotation 
around the BODIPY C2-aryl bond. Unfortunately, the stereoisomers could not be 
separated by chiral HPLC.  The unsymmetrical axially chiral quinoline-BODIPY 2.15 
was synthesized via Suzuki coupling of the corresponding 2-bromoBODIPY with phenyl 
boronic acid. Although some separation of the enantiomeric form of this BODIPY could 
be seen by chiral HPLC the resolution was not sufficient to allow isolation of pure 
individual enantiomers. 
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The known helically chiral aza-BODIPY compounds 2.25a, b were synthesized 
successfully following the literature route. Unfortunately, all attempts to synthesise more 
heavily functionalized aza-BODIPY 2.26, which carries amino groups which might 
interact with a chiral analyte, were unsuccessful. 2-Hydroxy-5-methyl-3-
nitroacetophenone was converted to the corresponding chalcone by reaction with 
benzaldehyde, and then subsequently converted to the γ-nitroketone by conjugate 
addition of nitromethane. Further transformation to the azaBODIPY was not successful, 
perhaps due to interference by the second nitro group on the aromatic ring.  
 
A new synthetic route was developed to N,N,O,O-BODIPY’s 2.49a-c. Preparation of the 
3,5-dibromoBODIPY’s 2.56a-c enabled late stage introduction of 2-methoxyphenyl 
groups by Suzuki coupling and then demethylation using BBr3 to form the helically chiral 
N,N,O,O-BODIPYs in good yield. In comparison to the corresponding N,N,F,F-
BODIPYs the N,N,O,O-systems displayed significantly red-shifted absorption and 
emission maxima and retained high extinction coefficients and fluorescence quantium 
yields. Both the p-tolyl (2.49a) and pyridyl-substituted systems (2.49b) were resolved by 
chiral HPLC. The enantiomeric forms of each BODIPY (2.49a and b) displayed mirror 
image ECD spectra and the configuration of the enantiomers was assigned on the basis 
of the agreement between the experimental and calculated ECD (calculations and 
measurement were made in the group of W. Herrebout, University of Antwerp). 
The resolved enantiomers of 2.49a,b also displayed circularly polarised luminescence 
(CPL) with luminescence dissymmetry factor |glum| of 0.0043 (637 nm) and 0.0042 (675 
nm) respectively (measured by Prof. R. D. Peacock, University of Glasgow).  
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Extension of our synthetic approach to N,N,O,O-BODIPYs in order to synthesise the 
corresponding N,N,N,N-BODIPY 2.63 was investigated. Suzuki coupling of the 3,5-
dibromoBODIPY 2.56a with 2-nitrobenzeneboronic acid followed by palladium 
catalysed hydrogenation gave the diamine 2.62. Unfortunatly, due to time constraints, 
conversion of this compound into the N,N,N,N-BODIPY 2.63 was not accomplished. 
 
The final novel helically chiral BODIPY to be synthesised was the ‘half-strapped’ 
N,N,O,F system 2.74 which was synthesised by stepwise elaboration of the 
unsymmetrical BODIPY 2.69a using a sequence of regioselective halogenation and 
Suzuki coupling reactions. 
  
 
Analytical chiral HPLC of the BODIPY 2.74 indicated that it should be possible to 
separate the enantiomers of this compound for further study. 
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The second aim of this research was to investigate the synthesis of amino-BODIPYs via 
metal catalysed amination reactions for use as a new strategy towards fluorescence-
quenched BODIPY dyes. Attempted copper catalysed amination of the 2-iodoBODIPY 
3.17 was found unexpectedly to produce the corresponding 3-aminoBODIPY 3.19 by a 
rather unusal vicarious nucleophilic substitution. The product distribution from reaction 
of a 6-deutero-2-iodoBODIPY indicated that this reaction takes place by initial 
nucleophilic attack at either C3 or C5, with attack at C3 predominating. Using this 
reaction, a range of new 3-aminoBODIPYs was synthesised and the reaction was shown 
to be successful with less nucleophilic nitrogen nucleophiles such as anilines and even an 
amide, in many cases in good yield.  
In agreement with reports in the literature, the presence of the amine in the 3-position of 
the BODIPY leads to a broadened red-shifted absorption maximum and the fluorescence 
is weak and sometimes quenched.  
 
A series of fluorescence-quenched 2-aminoBODIPY dyes was synthesised via palladium 
catalysed Buchwald–Hartwig amination of the corresponding 2-iodoBODIPY 3.49 (fully 
blocked) with anilines and a primary amine. Secondary amines were found not to react 
with 2-iodoBODIPY 3.50 under the given conditions.  
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The presence of the 2-amino group leads to broadened absorption bands and small red-
shift of the absorption maximum. These compounds were found to be non-emissive which 
may be due to quenching via charge transfer from the electron rich amino substituent. 
Cyclic voltammetry indicated a very facile oxidation process, presumably associated with 
the amine and much lower in energy than the typical BODIPY oxidation.The modular 
synthesis of these quenched fluorophores allows them to be used for a wide-range of 
applications.  
An attempt to convert the 2-iodoBODIPY 3.50 into a more highly functionalised 2-amino 
derivative by palladium catalysed reaction with 2-aminophenol produced instead the 
novel N,N,N,O-BODIPY 4.2. It is likely that this transformation does not require 
palladium catalysis, and is simply base-mediated however, due to time constraints, the 
optimised conditions for the synthesis of this type of BODIPY have yet to be identified. 
The structure of this species was confirmed by x-ray crystallography and it was observed 
to be non-emissive. 
 
 
The 2-aminoBODIPY 4.9, incorporating an ortho-phenylenediamine substituent, was 
suceessfully prepared by palladium catalysed amination of the 2-iodoBODIPY 3.50 with 
2-nitroaniline followed by hydrogenation of the nitro group. Compound 4.9 was found to 
be non-emissive, as expected, but reacts rapidly with triphosgene to form the strongly 
fluorescent benzimidazolone derivative 4.18. Fluorescence titration of the 
aminoBODIPY 4.9 revealed a limit of detection of 160 nM for phosgene. The bright 
yellow fluorescence of the triphosgene reaction product 4.18 can be easily visualized by 
the naked eye. 
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The regioselective alkylation of the 2-aminoBODIPY 4.9 with 2-chloromethyl pyridine 
hydrochloride gave doubly alkylated BODIPY 4.31 together with a minor amount of the 
mono alkylated BODIPY 4.32. The novel BODIPY 4.31 showed promise as a sensor for 
Cu2+ ions. Further work needs to be done to establish whether the BODIPY 4.31 can 
specifically detect copper ions.  
 
 
  
  Chapter 6                                                                                    Experimental section 
 
 
192 
 
Chapter 6: Experimental Section 
 
6.1. Materials and Methods 
 
All chemicals were purchased from commercial suppliers (Sigma Aldrich, Apollo, 
Fluorochem and Alfa Aesar) and used without further purification except where 
indicated. All manipulations involving air-sensitive materials were carried out using 
standard Schlenk line techniques under an atmosphere of nitrogen in flame-dried 
glassware. Where necessary, solvents were dried prior to use.   
Chloroform (CHCl3), dichloromethane (CH2Cl2) and triethylamine (NEt3) were distilled 
from calcium hydride (CaH2); methanol (MeOH) and ethanol (EtOH) from magnesium; 
1,4-dioxane, diethyl ether (Et2O) and tetrahydrofuran (THF) from Na/benzophenone; 
toluene from sodium; and acetonitrile (MeCN) from K2CO3, under an atmosphere of 
nitrogen. Dimethyl formamide (DMF) was dried over activated 4 Å molecular sieves and 
stored under nitrogen.  
IR spectra were recorded on a Varian 800 FT-IR Scimitar Series infrared spectrometer.  
1H, 13C{1H}, 19F{1H} and 11B{1H}NMR spectra were recorded on a JEOL ECS 400 or a 
Bruker Avance 300 or a Jeol Lambda 500 or a Bruker Avance 700 MHz instrument. All 
1H NMR were referenced relative to CDCl3 (δH = 7.26, δC = 77.16). Data for 1H NMR 
spectra are reported as follows: chemical shifts measured in ppm from internal 
tetramethylsilane on the δ scale, integration, multiplicity (br = broad, s = singlet, d = 
doublet, t = triplet, q = quartet, p = pentet and m = multiplet). 13C NMR chemical shifts 
are reported in ppm from tetramethylsilane on the δ scale, using solvent resonance as the 
internal standard [deuterated chloroform (CDCl3) at 77.16 ppm]. The 
11B NMR chemical 
shift is referenced to BF3.Et2O (δ = 0ppm) and the 19F NMR chemical shift is given 
relative to CFCl3 (δ = 0 ppm). 
 
Mass spectrometry analysis was performed using a Micromass LCT premier Mass 
Spectrometer in Electrospray (ES) mode. Thin layer chromatography was performed on 
EM reagent 0.25 mm silica gel 60F plates. Visualisation was accomplished with UV light 
and aqueous potassium permanganate (VII) solution. UV-vis and fluorescence spectra 
were recorded at 20 °C on a Shimadzu UV-1800 and Hitachi F2500 machines 
respectively. Relative fluorescence quantum yields (Φf) were determined using dilute 
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solutions with an absorbance below 0.1 at the excitation wavelength and using 
Rhodamine 6G (Φf = 0.95) or Rhodamine B (Φf = 0.65) in ethanol or MgTPP in toluene 
(Φf = 0.15) as standard. Flash column chromatography was perfomed on Fluorochem 
LC3025 (40-63 μm) silica gel. 
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4,4-Difluoro-1,3,5,7-tetramethyl-8-phenyl-4-bora-3a,4a-diaza-s-indacene 2.4. 
 
 
Benzoyl chloride (1.48 g, 10.5 mmol) was dissolved in dry CH2Cl2 (75 mL) and 2,4-
dimethylpyrrole (2.00 g, 21.0 mmol) was added and the mixture was stirred at room tem-
perature for 13 h. The mixture was then cooled to 0 ̊C and N,N-diisopropylethylamine 
(9.20 g, 71.4 mmol) and BF3.OEt2 (11.5 g, 80.9 mmol) were added and stirred for an 
additional 1 h. The reaction mixture was poured into water (100 mL). The organic layer 
was dried (MgSO4) and the solvent was removed under reduced pressure. The product 
was purified using column chromatography (petroleum ether:CH2Cl2 1:1) to give the title 
compound 2.4 as a green solid (1.00 g, 30%), mp 175-176 ̊C (lit.1 176-177 ̊C). Rf = 0.43 
(petroleum ether:CH2Cl2 1:1). 
 1H NMR (400 MHz, CDCl3) δ 7.49 – 7.46 (m, 3H), 7.29 
– 7.25 (m, 2H), 5.97 (s, 2H, pyrrole-H), 2.54 (s, 6H), 1.36 (s, 6H).13C NMR (101 MHz, 
CDCl3) δ 154.70, 142.45, 141.03, 134.27, 130.72, 128.42, 128.22, 127.21, 120.50, 13.78, 
13.51.11B NMR (96 MHz, CDCl3) δ -0.79 (t, JB-F = 33.1 Hz). 19F NMR (282 MHz, CDCl3) 
δ -146.33 (q, JF-B = 33.1 Hz). IR (neat): υmax/cm-1: 2991, 1979, 1684, 1586, 1540, 1506, 
1400, 1298, 1151, 969, 721. HRMS-ES Calcd for C19H19N2
11B19F2 + H
+: 325.1688, 
found: 325.1685. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.55 
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2,6-Dibromo-4,4-difluoro-1,3,5,7-tetramethyl-8-phenyl-4-bora-3a,4a-diaza-s-
indacene 2.5. 
 
 
4,4-Difluoro-1,3,5,7-tetramethyl-8-phenyl-4-bora-3a,4a-diaza-s-indacene 2.4 (0.34 g, 
1.06 mmol) was dissolved in dry CH2Cl2 (60 mL). Br2 (0.67 g, 4.24 mmol) in dry CH2Cl2 
(15 mL) was added dropwise to the mixture over 1 h. The mixture was stirred at room 
temperature for an additional 2 h. The mixture was washed with an aqueous solution of 
sodium thiosulfate (50 mL), and extracted by CH2Cl2 (100 mL). The organic layer was 
dried (MgSO4), filtered and the solvent removed under reduced pressure. The product 
was purified using column chromatography (petroleum ether:ethyl acetate 7:1) to give 
the title compound 2.5 as a red solid (0.15 g, 90%), mp 230-232 ̊C (lit.2 mp 229-231 ̊C). 
Rf = 0.75 (petroleum ether:ethyl acetate 7:1).  
1H NMR (300 MHz, CDCl3) δ 7.57-7.53 
(m, 3H), 7.32 – 7.24 (m, 2H), 2.65 (s, 6H), 1.40 (s, 6H).13C NMR (101 MHz, CDCl3) δ 
154.03, 142.18, 140.73, 134.45, 130.48, 129.63, 129.58, 127.83, 111.87, 13.79, 13.76. 
11B NMR (96 MHz, CDCl3) δ 0.50 (t, JB-F = 32.2 Hz). 19F NMR (282 MHz, CDCl3) δ -
146.02 (q, JF-B = 32.2 Hz). IR (neat): υmax/cm-1: 3666, 2981, 1527, 1463, 1349, 1171, 
1071, 721. HRMS-ES Calcd for C19H17N2
11B79Br81Br19F2 + H
+: 482.9877, found: 
482.9861. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.56 
  
  Chapter 6                                                                                    Experimental section 
 
 
196 
 
4,4-Difluoro-2,6-bis(2-methoxyphenyl)-1,3,5,7-tetramethyl-8-phenyl-4-bora-3a,4a-
diaza-s-indacene 2.6. 
 
 
2,6-Dibromo-4,4-difluoro-1,3,5,7-tetramethyl-8-phenyl-4-bora-3a,4a-diaza-s-indacene 
2.5 (0.10 g, 0.21 mmol) was dissolved in dry toluene (5 mL). Then 2-methoxyphenyl-
boronic acid (0.10 g, 0.63 mmol), 11-dicyclohexylphosphino-12-phenyl-9,10-dihydro-
9,10-ethenoanthracene (Kitphos) (0.12 g, 0.03 mmol, 12.5 mol%), Pd(OCOCH3)2 (2.00 
mg, 0.01 mmol, 5 mol%), and K3PO4 (0.18 g, 0.83 mmol) were added. The mixture was 
heated under reflux for 20 h and then allowed to cool to room temperature.  The solution 
was diluted with CH2Cl2 (50 mL) and washed with water (40 mL). The organic layer was 
dried (MgSO4) and the solvent was removed under reduced pressure. The purple crude 
product was purified by column chromatography (petroleum ether:ethyl acetate 7:1) to 
give the title compound 2.6 as a pink solid (0.04 g, 36%), mp 268-272  ̊C, Rf = 0.25 (pe-
troleum ether:ethyl acetate 7:1). 1H NMR (300 MHz, CDCl3) δ 7.47 – 7.35 (m, 3H), 7.35 
– 7.28 (m, 2H), 7.28 – 7.19 (m, 2H), 7.02 – 6.94 (m, 2H), 6.58-6.91 (m, 4H), 3.69 (s, 6H), 
2.37 (s, 6H), 1.15 (s, 6H).13C NMR (101 MHz, CDCl3) δ 157.47, 154.99, 141.44, 135.71, 
132.25, 131.30, 130.03,129.12, 129.02, 128.87, 128.40, 128.29, 122.52, 120.39, 110.91, 
55.40, 13.53, 12.91.11B NMR (128 MHz, CDCl3) δ 0.06 (apparent t, J = 32.7 Hz).19F 
NMR (471 MHz, CDCl3) δ -145.35 (dq, JF-F = 109.96, JF-B= 32.5 Hz), -145.93 (q, JF-B = 
31.5), -146.54 (dq, JF-F = 109.92, JF-B= 32.8 Hz). IR (neat): υmax/cm-1: 3735, 2970, 2360, 
1717, 1532, 1463, 1245, 1174, 1006, 722. HRMS-ES Calcd for C33H31N2
11BO2F2 + H
+: 
537.2525, found: 537.2512. 
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Quinoline-8-carbonyl chloride hydrochloride 2.12. 
 
 
2-Quinoline carboxylic acid (0.20 g, 1.15 mmol) was dissolved in SOCl2 (0.88 g, 7.39 
mmol) and the mixture was stirred at room temperature under N2 for 48 h. Hexane (5 mL) 
was added to the solution, a precipitate was formed and the solvent was removed using a 
cannula. The precipitate was dried under vacuum to give the title compound 2.12 as a tan 
solid (0.22 g). The product was used without further purification. 
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4,4-Difluoro-8-(quinolin-8-yl)-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene 
2.13. 
 
 
Quinoline-8-carbonyl chloride hydrochloride 2.12 (0.20 g, 0.88 mmol) was dissolved in 
a mixture of dry CH2Cl2 (75 mL) and N,N-diisopropylethylamine (0.11 g, 0.88 mmol). 
2,4-Dimethylpyrrole (0.17 g, 1.75 mmol) was added and the mixture was stirred at room 
temperature for 24 h. The mixture was then cooled to 0 ̊C and N,N-diisopropylethylamine 
(0.77 g, 5.96 mmol) and BF3.OEt2 (0.96 g, 6.75 mmol) were added and stirred for an 
additional 2 h. The reaction mixture was poured into water (10 mL). The organic layer 
was dried (MgSO4) and the solvent was removed under reduced pressure. The product 
was purified using column chromatography (CH2Cl2) to give the title compound 2.13 as 
an orange solid (1.00 g, 30%), mp 276-277 ̊C. Rf = 0.32 (CH2Cl2). 1H NMR (400 MHz, 
CDCl3) δ 8.89 (dd, J = 4.2, 1.8 Hz, 1H), 8.20 (dd, J = 8.3, 1.8 Hz, 1H), 7.95 (dd, J = 6.3, 
3.4 Hz, 1H), 7.70-7.60 (m, 2H), 7.43 (dd, J = 8.3, 4.2 Hz, 1H), 5.91 (s, 2H), 2.56 (s, 6H), 
0.99 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 155.03, 151.20, 146.74, 142.26, 140.28, 
136.11, 134.69, 132.18, 129.61, 129.38, 128.38, 126.74, 121.77, 121.02, 14.66, 13.98 
.11B NMR (128 MHz, CDCl3) δ -0.05 (t, JB-F = 32.2 Hz). 19F NMR (282 MHz, CDCl3) δ 
-145.26 (dq, JF-F = 108.9, JFB = 32.2 Hz), -147.02 (dq, JF-F = 108.9, JFB = 33.2 Hz). IR 
(neat): υmax/cm-1: 2991, 2918, 2360, 1535, 1497, 1296, 1154, 966. 745. HRMS-ES Calcd 
for C22H20N3
11B19F2 + Na
+: 398.1616, found: 398.1607. 
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2-Bromo-4,4-difluoro-8-(quinolin-8-yl)-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-
indacene 2.14. 
 
 
4,4-Difluoro-8-(quinolin-8-yl)-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene 2.13 
(0.10 g, 0.27 mmol) was dissolved in dry acetonitrile (45 mL). CuBr2 (0.11 g, 0.79 mmol) 
and K2CO3 were added and the mixture was stirred at room temperature for an additional 
2 h. The solvent was removed under reduced pressure. The residue was dissolved in ethyl 
acetate (20 mL) and washed with water (30 mL).  The organic layer was dried (MgSO4), 
filtered and the solvent removed under reduced pressure. The product was purified using 
column chromatography (petroleum ether:ethyl acetate 5:1) to give the title compound 
2.14 as an orange solid (0.16 g, 60%), mp 248-249 ̊C. Rf = 0.29 (petroleum ether:ethyl 
acetate 5:1).  1H NMR (400 MHz, CDCl3) δ 8.89 (dd, J = 4.1, 1.7 Hz, 1H), 8.22 (dd, J = 
8.3, 1.7 Hz, 1H), 7.98 (dd, J = 7.9, 1.7 Hz, 1H), 7.71 – 7.58 (m, 2H), 7.45 (dd, J = 8.3, 
4.2 Hz, 1H), 5.97 (s, 1H), 2.60 (s, 3H), 2.58 (s, 3H), 1.00 (s, 3H), 0.99 (s, 3H). 11B NMR 
(96 MHz, CDCl3) δ 0.81 (t, JB-F = 31.9 Hz). 19F NMR (282 MHz, CDCl3)) δ -145.18 (dq, 
JF-F = 108.9, JF-B = 31.9), -145.18 (dq, JF-F = 108.9, JF-B = 31.9 Hz).  IR (neat): υmax/cm-1: 
2970, 2922, 2360, 1733, 1538, 1461, 1302, 1161, 969, 805, 744. HRMS-ES Calcd for 
C22H19N3
11B81Br19F2 + Na
+: 478.0701, found: 478.0707. 
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4,4-Difluoro-8-(quinolin-8-yl)-2-phenyl-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-
indacene 2.15. 
 
 
2-Bromo-4,4-difluoro-8-(quinolin-8-yl)-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-inda-
cene 2.14 (0.10 g, 0.22 mmol) was dissolved in dry toluene (3 mL) and THF (3 mL). 
Then phenylboronic acid (0.09 g, 0.73 mmol), Pd(PPh3)4 (0.01 g, 0.01 mmol, 5 mol%), 
and aqueous Na2CO3 (1 M, 1.0 mL, 1.0 mmol) were added. The mixture was heated under 
reflux for 24 h and then allowed to cool to room temperature. The solution was diluted 
with CH2Cl2 (60 mL) and washed with brine (30 mL). The organic layer was dried 
(MgSO4) and the solvent was removed under pressure. The orange crude product was 
purified by column chromatography (petroleum ether:CH2Cl2 1:1) to give the title com-
pound 2.15 as an orange solid (0.06 g, 86%), mp 190-192 ᵒC, Rf = 0.37 (petroleum 
ether:CH2Cl2, 1:1). 
1H NMR (300 MHz, CDCl3) δ 8.85 (dd, J = 4.2, 1.8 Hz, 1H), 8.14 
(dd, J = 8.3, 1.7 Hz, 1H), 7.89 (dd, J = 7.2, 2.5 Hz, 1H), 7.69 – 7.53 (m, 2H), 7.37 (dd, J 
= 8.3, 4.2 Hz, 1H), 7.30 – 7.13 (m, 4H), 7.07 – 6.99 (m, 1H), 5.87 (s, 1H), 2.52 (s, 3H), 
2.46 (s, 3H), 0.93 (s, 3H), 0.88 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 155.18, 153.75, 
151.09, 147.14, 142.19, 140.65, 138.33, 135.78, 135.26, 134.02, 133.44, 132.56, 131.90, 
130.15, 129.66, 129.08, 128.43, 128.08, 126.80, 126.56, 121.60, 121.00, 14.46, 13.74, 
13.20, 11.96. 11B NMR (96 MHz, CDCl3) δ 0.81 (apparent t, JB-F = 32.5 Hz).19F NMR 
(376 MHz, CDCl3) δ -145.30 (dq, JF-F = 110.0, JF-B = 33.6 Hz), -146.91 (dq, JF-F = 110.0, 
JF-B = 32.2 Hz).  IR (neat): υmax/cm-1: 2969, 2360, 1538, 1494, 1302, 1162, 980, 744. 
HRMS-ES Calcd for C28H24N3
11BF2 + Na
+: 474.1929, found: 474.1929. 
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1-(2-Hydroxyphenyl)-3-phenylpropenone 2.22a. 
 
 
An aqueous solution of NaOH (60%, 30.0 g, 750 mmol in 50 mL of water) was added to 
a solution of 2'-hydroxyacetophenone (1.85 g, 13.6 mmol) in MeOH (50 mL). The result-
ing yellow solution was cooled to room temperature and benzaldehyde (1.75 g, 16.5 
mmol) was added. The mixture was stirred at room temperature for 48 h. The solution 
was poured into a mixture of water (30 mL) and ice. Conc. HCl (80 mL) was added until 
the pH was adjusted to 2. The solution was extracted with chloroform (124 mL) and the 
organic extract was washed with saturated aqueous NaHCO3 (2 x 80 mL). The organic 
extract was dried (Na2SO4) and the solvent was removed under reduce pressure. The 
crude product was recrystallized from EtOH to give the title compound 2.22a as a yellow 
solid (1.60 g, 52%), mp 85-87 ᵒC (lit.3 81-83 ᵒC ). 1H NMR (400 MHz, CDCl3) δ 12.83 
(s, 1H), 7.92 (d, J = 15.4 Hz, 1H), 7.93 (dd, J = 8.2, 1.8 Hz, 1H), 7.66 (d, J = 15.5 Hz, 
1H), 7.68 – 7.65 (m, 2H), 7.50 (ddd, J = 8.6, 7.2, 1.6 Hz, 1H), 7.46 – 7.41 (m, 3H), 7.03 
(dd, J = 8.4, 1.0 Hz, 1H), 6.95 (ddd, J = 8.2, 7.3, 1.1 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ 193.83, 163.70, 145.59, 136.54, 134.66, 131.06, 129.77, 129.15, 128.78, 
120.16, 120.10, 118.98, 118.74. IR (neat): υmax/cm-1: 3051, 2879, 1638, 1570, 1485, 1437, 
1340, 1202, 1152, 976, 729. HRMS-ES Calcd for C15H12O2 + H
+: 225.0916, found: 
225.0907.  
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.73 
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1-(2-Hydroxyphenyl)-3-(4-methoxyphenyl)propanone 2.22b. 
 
 
 
An aqueous solution of potassium hydroxide (21.0 g, 374 mmol in 30 mL of water) was 
added to a solution of 2'-hydroxyacetophenone (16.4 g, 120 mmol) in ethanol (300 mL). 
The resulting yellow solution was cooled to room temperature and 4-
methoxybenzaldehyde (16.4 g, 120 mmol) was added. The mixture was stirred at room 
temperature for 24 h. The solution was poured into a mixture of water (1500 mL) and ice. 
Conc.HCl was added until the pH was adjusted to 2. The resulting orange precipitate was 
filtered and washed with water. The crude product was recrystallized from EtOH to give 
the title compound 2.22b as a yellow solid (15.0 g, 54%), mp 93-95 ̊C (lit.4 93-94 ̊C). 1H 
NMR (400 MHz, CDCl3) δ 12.97 (s, 1H), 7.91 (d, J = 15.5 Hz, 1H), 7.93 (d, J = 7.8 Hz, 
1H), 7.66 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 15.5 Hz, 1H), 7.54 – 7.48 (m, 1H), 7.04 (d, J 
= 8.2Hz, 1H), 7.01 – 6.95 (m, 3H), 3.89 (s, 3H).13C NMR (75 MHz, CDCl3) δ 193.64, 
163.61, 162.12, 145.22, 135.94, 130.43, 129.53, 127.49, 120.26, 118.59, 117.87, 114.26, 
114.00, 55.34. IR (neat): υmax/cm-1: 2840, 2754, 1635, 1607, 1558, 1492, 1423, 1202, 984, 
757. HRMS-ES calcd for C16H14O3 + H
+: 255.1021, found: 255.1012. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.72 
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1-(2-Hydroxyphenyl)-4-nitro-3-phenylbutan-1-one 2.23a. 
 
 
 
1-(2-Hydroxyphenyl)-3-phenylpropenone 2.22a (4.00 g, 17.8 mmol) was dissolved in 
methanol (40 mL). Then diethylamine (1.90 g, 70.3 mmol) and nitromethane (1.07 g, 
70.3 mmol) were added. The mixture was heated under reflux for 17 h and then allowed 
to cool to room temperature. 2M HCl was added until the pH was adjusted to 4 and 
CH2Cl2 (100 mL) was added. The organic layer was dried (Na2SO4) and the solvent was 
removed under reduced pressure. The green crude product was recrystallized from 
methanol to give the title compound 2.23a as a white crystals (2.50 g, 55%), mp 78-80 ̊C 
(lit.4 76-77 ̊C). 1H NMR (300 MHz, CDCl3) δ 11.99 (s, 1H), 7.74 (dd, J = 8.1, 1.6 Hz, 
1H), 7.50 (ddd, J = 8.6, 7.2, 1.6 Hz, 1H), 7.41 – 7.28 (m, 5H), 7.00 (dd, J = 8.5, 1.0 Hz, 
1H), 6.92 (ddd, J = 8.2, 7.2, 1.1 Hz, 1H), 4.84 (dd, J = 12.5, 6.9 Hz, 1H), 4.71 (dd, J = 
12.5, 7.7 Hz, 1H), 4.30 – 4.18 (m, 1H), 3.64 – 3.39 (m, 2H).13C NMR (75 MHz, CDCl3) 
δ 202.72, 162.59, 138.83, 136.76, 129.57, 129.11, 127.97, 127.39, 119.08, 118.73, 79.52, 
41.16, 39.26. IR (neat): υmax/cm-1: 3297, 3032, 2282, 1643, 1550, 1292, 1160, 702. 
HRMS-ES Calcd for C16H15NO4 + Na
+: 308.0899, found: 308.0898. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.72 
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1-(2-Hydroxyphenyl)-3-(4-methoxyphenyl)-4-nitrobutan-1-one 2.23b. 
 
 
 
1-(2-Hydroxyphenyl)-3-(4-methoxyphenyl)propanone 2.22b (15.0 g, 58.9 mmol) was 
dissolved in methanol (500 mL). Then diethylamine (20.2 g, 276 mmol) and nitromethane 
(16.8 g, 275 mmol) were added. The mixture was heated under reflux for 17 h. 2M HCl 
was added until the pH was adjusted to 4 and CH2Cl2 (100 mL) was added. The organic 
layer was dried (Na2SO4) and the solvent was removed under reduced pressure. The green 
crude product was recrystallized from methanol to give the title 2.23b as a white crystals 
(15.0 g, 80%), mp 88-89 ̊C (lit.4 84-86 ̊C). 1H NMR (300 MHz, CDCl3) δ 12.01 (s, 1H), 
7.73 (d, J = 8.1 Hz, 1H), 7.50 (t, J = 7.2 Hz, 1H), 7.21 (d, J = 8.7 Hz, 2H), 6.99 (d, J = 
8.4 Hz, 1H), 6.92 (t, J = 6.2 Hz, 1H), 6.88 (d, J = 8.6 Hz, 2H), 4.80 (dd, J = 12.4, 6.9 Hz, 
1H), 4.66 (dd, J = 12.4, 7.8 Hz, 1H), 4.20 (apparent p, J = 7.1 Hz, 1H), 3.80 (s, 3H), 3.57 
– 3.38 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 202.81, 162.64, 162.56, 136.67, 130.56, 
129.69, 128.56, 119.45, 118.81, 114.85, 79.88, 55.36, 41.30, 38.53. IR (neat): υmax/cm-1: 
2981, 2404, 1646, 1615, 1581, 1549, 1512, 1244, 1157, 972, 723. HRMS-ES Calcd for 
C17H17NO5 + Na
+: 338.1004, found: 338.1013. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.72 
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[5-(2-Hydroxyphenyl)-3-phenyl-1H-pyrrol-2-yl]-[5-(2-hydroxyphenyl)-3-
phenylpyrrol-2-ylidene]amine 2.24a. 
 
 
 
1-(2-Hydroxyphenyl)-4-nitro-3-phenylbutan-1-one 2.23a (1.50 g, 5.90 mmol) and am-
monium acetate (16.0 g, 205 mmol) were heated under reflux in cumene (3 mL) for 3 h. 
The resulting dark blue mixture was cooled to room temperature, diluted with CH2Cl2 (80 
mL) and the organic solution was then washed with water (4 x 120 mL). The organic 
layer was dried (Na2SO4) and the solvent was removed under reduced pressure. The re-
sulting solid was triturated with cold methanol (25 mL) and filtered to give the title com-
pound as a dark blue solid 2.24a (0.11 g, 11%), mp >260 ̊C (lit.4 mp >230 ̊C). 1H NMR 
(400 MHz, CHCl3) δ 8.02 – 7.96 (m, 4H), 7.80 – 7.75 (m, 2H), 7.43 – 7.33 (m, 6H), 7.27 
– 7.21 (m, 7H), 7.01 – 6.95 (m, 4H). Due to insolubility a 13C NMR spectrum was not 
obtained. IR (neat): υmax/cm-1: 3418, 3061, 1953, 1602, 1535, 1479, 1290, 1135, 909, 741. 
HRMS-ES Calcd for C32H23N3O2 + Na
+: 504.1688, found: 504.1694.  
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.72 
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[5-(2-Hydroxyphenyl)-3-(4-methoxyphenyl)-1H-pyrrol-2-yl]-[5-(2-hydroxyphenyl)-
3-(4-methoxyphenyl)-pyrrol-2-ylidene]amine 2.24b. 
 
 
  
1-(2-Hydroxyphenyl)-4-nitro-3-phenylbutan-1-one 2.24b (2.00 g, 6.34 mmol) and am-
monium acetate (16.0 g, 205 mmol) were heated under reflux in cumene (3 mL) for 3 h. 
The resulting dark blue mixture was cooled to room temperature, diluted with CH2Cl2 (60 
mL) and the organic solution was then washed with water (4 x 120 mL). The organic 
layer was dried (Na2SO4) and the solvent was removed under reduced pressure. The re-
sulting solid was triturated with cold methanol (25 mL) and filtered to the title compound 
as a dark blue solid 2.24b (0.7g, 20%), mp > 260 ̊C (lit.4 > 240 ̊C ). 1H NMR (300 MHz, 
CDCl3, OH and NH signals not observed) δ 8.02 – 7.95 (m, 4H), 7.78 (dd, J = 8.3, 1.6 
Hz, 2H), 7.24 (d, J = 7.5 Hz, 2H), 7.21 (s, 2H), 7.01 (d, J = 2.0 Hz, 2H), 6.99 – 6.94 (m, 
7H), 3.91 (s, 6H).13C NMR spectrum was not obtained for the product due to insolubility. 
IR (neat): υmax/cm-1: 3575, 3432, 2981, 2891, 1606, 1505, 1285, 965, 748. HRMS-ES 
Calcd for C34H27N3O4 + H
+: 542.2080, found: 542.2078. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.72 
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Boron chelated [5-(2-hydroxyphenyl)-3-phenyl-1H-pyrrol-2-yl]-[5-(2-
hydroxyphenyl)-3-phenylpyrrol-2ylidene]amine 2.25a. 
 
 
 
[5-(2-Hydroxyphenyl)-3-phenyl-1H-pyrrol-2-yl]-[5-(2-hydroxyphenyl)-3-phenylpyrrol-
2-ylidene]amine 2.24a (0.10 g, 0.20 mmol) was dissolved in toluene (20 mL). Diisopro-
pylethylamine (0.27 g, 2.01 mmol) and BF3.Et2O (0.41 g, 2.90 mmol) were then added. 
The solution was heated under reflux for 2 h. The solution was cooled to room tempera-
ture and washed with water (3 × 120 mL). The organic layer was dried (Na2SO4) and the 
solvent was removed under reduce pressure. The crude product was purified by column 
chromatography with (petroleum ether:ethyl acetate 2:1) to give the title compound 2.25a 
as a brown solid (0.08 g, 82%), mp 261-263 ̊C (lit.4 mp >230 ̊C).  Rf = 0.67 (petroleum 
ether:ethyl acetate 2:1). 1H NMR (300 MHz, CDCl3) δ 8.21 – 8.14 (m, 4H), 7.90 (dd, J = 
7.8, 1.6 Hz, 2H), 7.55 – 7.40 (m, 8H), 7.27 (s, 2H), 7.15 (td, J = 7.5, 1.1 Hz, 2H), 7.05 
(dd, J = 8.2, 1.1 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 156.04, 149.88, 144.93, 142.22, 
133.27, 132.45, 129.20, 129.01, 128.65, 126.52, 120.84, 120.23, 118.93, 113.28. IR 
(neat): υmax/cm-1: 2961, 2927, 1728, 1607, 1487, 1427, 1136, 1099, 749.  HRMS-ES 
Calcd for C32H20BN3O2 + H
+: 490.1727, found: 490.1727.  
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.72 
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Boron chelated [5-(2-hydroxyphenyl)-3-(4-methoxyphenyl)-1H-pyrrol-2-yl]-[5-(2-
hydroxyphenyl)-3-(4-methoxyphenyl)-pyrrol-2-ylidene]amine 2.25b. 
 
 
 
[5-(2-Hydroxyphenyl)-3-(4-methoxyphenyl)-1H-pyrrol-2-yl]-[5-(2-hydroxyphenyl)-3-
(4-methoxyphenyl)-pyrrol-2-ylidene]amine 2.24b (0.16g, 0.30 mmol) was dissolved in 
toluene (60 mL). Diisopropylethylamine (0.54g, 4.17 mmol) and BF3.Et2O (0.42 g, 2.98 
mmol) were then added. The solution was heated under reflux for 2 h. The solution was 
cooled to room temperature and washed with water (3 × 120 mL). The organic layer was 
dried (Na2SO4) and the solvent was removed under reduced pressure. The crude product 
was purified by column chromatography (petroleum ether:ethyl acetate 2:1) to give the 
title compound 2.25b as a purple solid (0.12 g, 73%), mp 264-266 ̊C (lit.4 mp >230 ̊C ). 
Rf = 0.52 (petroleum ether:ethyl acetate 2:1). 
1H NMR (300 MHz, CDCl3) δ 8.15-8.20 
(m, 4H), 7.87-7.91 (m, 2H), 7.41 (t, J = 7.0 Hz, 2H), 7.17 – 7.08 (m, 4H), 7.03 (m, 6H), 
3.92 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 160.81, 156.09, 149.67, 144.75, 142.03, 
133.19, 130.62, 126.66, 125.40, 120.92, 120.27, 119.07, 114.36, 111.66, 55.53. IR (neat): 
υmax/cm-1: 2961, 2840, 1603, 1482, 1454, 1235, 1135, 1021, 748. HRMS-ES Calcd for 
C34H24BN3O4 + Na
+: 572.1758, found: 572.1779. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.72 
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1-(2-Hydroxy-3-nitro-5-methylphenyl)-3-phenylpropenone 2.27. 
 
  
An aqueous solution of potassium hydroxide (0.89 g, 15.4 mmol in 1.3 mL of water) was 
added to a solution of 2-hydroxy-5-methyl-3-nitroacetophenone (1.0 g, 5.12 mmol) in 
ethanol (60 mL). The resulting orange solution was cooled to room temperature and 
benzaldehyde (0.54 g, 5.12 mmol) was added. The mixture was stirred at room 
temperature for 24 h. The solution was poured into a mixture of water (20 mL) and ice. 
Conc. HCl was added until the pH was adjusted to 2. The resulting yellow precipitate was 
filtered and washed with water. The crude product was recrystallized from MeOH to give 
the title compound 2.27 as a yellow solid (1.30 g, 89%), mp 162-165 ̊C. 1H NMR (400 
MHz, CDCl3) δ 13.07 (s, 1H), 8.04 (d, J = 2.1 Hz, 1H), 7.94 (s, 1H), 7.91 (d, J = 15.5 Hz, 
1H), 7.68-7.66 (m, 2H), 7.57 (d, J = 15.5 Hz, 1H), 7.47-7.44 (m, 3H), 2.42 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 192.31, 154.53, 146.83, 136.70, 134.32, 131.47, 131.12, 
129.22, 128.99, 128.45, 124.90, 121.33, 20.47. IR (neat): υmax/cm-1: 3410, 3359, 2981, 
2889, 2360, 1684, 1560, 1267, 1029, 716. HRMS-ES calcd for C16H13NO4 + H
+: 
284.0923, found: 284.0912. 
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1-(2-Hydroxy-5-methyl-3-nitrophenyl)-4-nitro-3-phenylbutan-1-one 2.28. 
 
 
 
1-(2-Hydroxy-3-nitro-5-methylphenyl)-3-phenylpropenone 2.27 (0.50 g, 1.76 mmol) was 
dissolved in dry methanol (10 mL). Diethylamine (0.52 g, 7.06 mmol) and nitromethane 
(0.43 g, 7.06 mmol) were then added. The mixture was heated under reflux for 17 h and 
then allowed to cool to room temperature. 2M HCl was added until the pH was adjusted 
to 4 and CH2Cl2 (100 mL) were added. The organic layer was dried (Na2SO4) and the 
solvent was removed under reduced pressure. The brown crude product was purified by 
column chromatography (petroleum ether:CH2Cl2 1:4) to give the title compound 2.28 as 
a tan solid (0.45 g, 74%), mp 150-152 ̊C. 1H NMR (400 MHz, CDCl3) δ 12.09 (s, 1H), 
8.03 (s, 1H), 7.80 (s, 1H), 7.39 – 7.20 (m, 5H), 4.72 – 4.65 (m, 2H), 4.27 – 4.15 (m, 1H), 
3.64 – 3.45 (m, 2H), 2.35 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 199.26, 153.38, 138.67, 
137.78, 136.06, 130.99, 129.30, 129.23, 128.14, 127.54, 125.30, 79.62, 44.67, 39.28, 
20.34. IR (neat): υmax/cm-1: 3072, 2931, 1655, 1584, 1550, 1530, 1466, 1353, 1272, 1162, 
702. HRMS-ES Calcd for C17H16N2O6 + Na
+: 367.0906, found: 367.0912. 
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3-Amino-2-hydroxy-5-methylacetophenone 2.39. 
 
 
2-Hydroxy-5-methyl-3-nitroacetophenone (0.50 g, 2.56 mmol) was dissolved in dry 
ethanol (30 mL). Tin chloride dihydrate (2.89 g, 12.8 mmol) was added. The mixture was 
heated under reflux for 3 h and then allowed to cool to room temperature. 2M NaHCO3 
was added until the pH was adjusted to 7 and ethyl acetate (100 mL) was added. The 
organic layer was dried (MgSO4) and the solvent was removed under reduced pressure. 
The brown crude product was purified by column chromatography (CH2Cl2) to give the 
title compound 2.39 as a yellow solid (0.32 g, 75%), mp 52-54 ̊C (lit.5 mp 55-57 ̊C ). 1H 
NMR (400 MHz, CDCl3) δ 12.28 (s, 1H), 6.92 (s, 1H), 6.72 (s, 1H), 3.85 (s, 2H), 2.58 (s, 
3H), 2.23 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 205.13, 148.51, 136.14, 128.02, 121.38, 
119.47, 118.77, 26.89, 20.93. IR (neat): υmax/cm-1: 3453, 3369, 2919, 1607, 1471, 1372, 
1314, 1280, 1222, 1186, 1151, 1017, 781. HRMS-ES Calcd for C9H11NO2 + H
+: 
166.0868, found: 166.0861. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.208 
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3-N-Boc-amino-2-hydroxy-5-methylacetophenone 2.40. 
 
 
3-Amino-2-hydroxy-5-methylacetophenone 2.39 (0.20 g, 1.21 mmol) was dissolved in 
dry CH2Cl2 (8 mL). Triethylamine (0.13 g, 1.34 mmol) was added. Di-tert-butyl dicar-
bonate (0.29 g, 1.34 mmol) in CH2Cl2 (3 mL) was added to the mixture dropwise over 10 
min and the mixture was stirred at room temperature for 48 h. The solution was poured 
into water (10 mL). The aqueous layer was extracted with dichloromethane (2 × 30 mL). 
The combined organic layers were dried (MgSO4) and the solvent was removed under 
reduced pressure. The crude product was purified by column chromatography (petroleum 
ether:CH2Cl2 1:4) to give the title compound 2.40 as a white solid (0.096 g, 30%), mp 
107-108 ̊C. Rf = 0.52 (petroleum ether:CH2Cl2 1:4). 1H NMR (400 MHz, CDCl3) δ 7.75 
(s, 1H), 7.53 (s, 1H), 2.68 (s, 3H), 2.40 (s, 3H), 1.65 (s, 9H).13C NMR (101 MHz, CDCl3) 
δ 194.29, 148.85, 147.56, 134.53, 128.39, 124.78, 120.28, 119.56, 86.80, 30.96, 28.01, 
21.56. IR (neat): υmax/cm-1: 2978, 2935, 1750, 1686, 1472, 1368, 1275, 1146, 1116, 762. 
HRMS-ES Calcd for C14H19NO4 + Na
+: 288.1212, found: 288.1216.   
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N-tert-Butoxycarbonyl-2-bromopyrrole 2.51 and N-tert-butoxycarbonyl-3-
bromopyrrole 2.52. 
 
  
Pyrrole (45 g, 67.2 mmol) was dissolved in dry THF (180 mL) and the flask was 
evacuated and purged with nitrogen. Then, the mixture was cooled to -78 ̊C and 
azoisobutyronitrile (AIBN) (0.1 g, 0.001 mmol) was added and the mixture stirred for 5 
min. 1,3-Dibromo-5,5-dimethylhydantoin was added over 20 min. via a solids addition 
funnel and the mixture was stirred for 10 min. The light green mixture was allowed to 
warm to room temperature and stirred for an additional 2 h. The solution was filtered by 
suction into a dry 250 mL three neck round bottom flask. Triethylamine (2.71 g, 26.9 
mmol) and di-tert-butyl dicarbonate (20.4 g, 93.9 mmol) and 4-dimethylaminopyridine 
(0.1 g, 0.012 mmol) were added and the mixture was stirred for 8 h at room temperature. 
The solvent was removed under reduced pressure. The crude product was dissolved in 
hexane (100 mL) and washed with water (3 × 100 mL). The organic layer was dried 
(NaSO4) and the solvent removed under reduced pressure. The crude product was purified 
by column chromatography (petroleum ether) to give a 70:30 mixture of the 2-bromo and 
3-bromo BOC-pyrrole 2.51 and 2.52 respectively as a colorless oil (14.1 g, 85.5%, ratio 
determined by 1H NMR). For the mixture: 1H NMR (400 MHz, CDCl3) δ 7.29 (dd, J = 
3.6, 2.0 Hz, 1H, 2.51), 7.23 – 7.20 (m, 1H, 2.52), 6.27 (dd, J = 3.1, 2.3 Hz, 1H, 2.51), 
6.22 (s, 1H, 2.52), 6.21 – 6.18 (m, 1H, 2.52), 6.13 (t, J = 3.8 Hz, 1H, 2.51), 1.63 (s, 9H, 
2.52), 1.59 (s, 9H, 2.51). HRMS-ES Calcd for C9H12N
79BrO2 + H
+: 246.0130, found: 
246.0120. 
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N-tert-Butoxycarbonyl-2-(2-methoxyphenyl)pyrrole 2.45. 
 
 
 
N-tert-Butoxycarbonyl-2-bromopyrrole 2.51 (1.50 g, 6.10 mmol) was dissolved in dry 
toluene (20 mL) and THF (5 mL). 2-Methoxyphenylboronic acid (1.39 g, 9.15 mmol), 
Pd(PPh3)4 (0.35 g, 0.31 mmol, 5 mol%), and aqueous Na2CO3 (2 M, 6.1 mL, 12.2 mmol) 
were then added. The mixture was heated under reflux for 24 h and then allowed to cool 
to room temperature. The solution was diluted with CH2Cl2 (60 mL) and washed with 
brine (30 mL). The organic layer was dried (MgSO4) and the solvent was removed under 
reduced pressure. The orange crude product was purified by column chromatography (pe-
troleum ether:ethyl acetate 9:1) to give the title compound 2.45 as a colorless oil (1.2 g, 
73%), Rf = 0.45 (petroleum ether:ethyl acetate 9:1).
 1H NMR (400 MHz, CDCl3) δ 7.46 
(dd, J = 3.3, 1.8 Hz, 1H), 7.42 – 7.35 (m, 2H), 7.05 (td, J = 7.4, 1.0 Hz, 1H), 6.94 (d, J = 
8.2 Hz, 1H), 6.33 (t, J = 3.3 Hz, 1H), 6.24 (dd, J = 3.2, 1.8 Hz, 1H), 3.81 (s, 3H), 1.42 (s, 
9H).13C NMR (101 MHz, CDCl3) δ 157.54, 149.63, 131.39, 130.42, 129.17, 124.40, 
122.00, 120.42, 114.02, 110.55, 110.09, 82.88, 55.37, 27.69. IR (neat): υmax/cm-1: 2978, 
2937, 2838, 1734, 1599, 1464, 1313, 1241, 1146, 1114, 1024, 752. HRMS-ES Calcd for 
C16H19NO3 + H
+: 274.1443, found: 274.1444. 
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2-(2-Methoxyphenyl)-1H-Pyrrole 2.46. 
 
 
N-tert-Butoxycarbonyl-2-(2-methoxyphenyl)pyrrole 2.45 (1.24 g, 4.54 mmol) was dis-
solved in mixture of dry  THF (15 mL) and dry methanol (4 mL). Sodium methoxide 
(0.73 g, 13.6 mmol) was added and the mixture stirred at room temperature for 6 h. The 
solvent was removed under reduced pressure and the residue dissolved in ether (30 mL) 
and washed with water (2 × 20 mL). The organic layer was dried (MgSO4) and the solvent 
removed under reduced pressure. The crude product was purified by column chromatog-
raphy (petroleum ether:ethyl acetate 10:1) to give the title compound 2.46 as a light green 
solid (0.39 g, 50%), mp 65-66 ̊C (lit.6 mp 66-67). Rf = 0.51 (petroleum ether:ethyl acetate 
10:1). 1H NMR (400 MHz, CDCl3) δ 9.88 (s, 1H), 7.74 (dd, J = 7.7, 1.7 Hz, 1H), 7.28 – 
7.17 (m, 1H), 7.06 (t, J = 7.0 Hz, 1H), 7.02 (t, J = 8.7 Hz, 1H), 6.97 – 6.89 (m, 1H), 6.71 
(s, 1H), 6.41 – 6.34 (m, 1H), 3.97 (s, 3H).13C NMR (101 MHz, CDCl3) δ 154.86, 130.00, 
126.85, 126.75, 121.59, 121.25, 117.98, 111.80, 109.00, 106.29, 55.79. IR (neat): 
υmax/cm-1: 3445, 2935, 1490, 1232, 1110, 1019, 755, 722. HRMS-ES Calcd for C11H11NO 
+ H+: 174.0919, found: 174.0916 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.209 
  
  Chapter 6                                                                                    Experimental section 
 
 
216 
 
1,9-Di(2-methoxyphenyl)-5-(4-methylphenyl)dipyrromethene 2.47.  
 
 
 
4-Methylbenzoyl chloride (0.55 g, 3.57 mmol) and 2-(2-methoxyphenyl)-1H-pyrrole 
2.46 (0.31 g, 1.78 mmol) were dissolved in 1,2-dichloroethane (DCE) (6 mL). The mix-
ture was heated under reflux for 5 h and then allowed to cool to room temperature. The 
solution was diluted with CH2Cl2 (60 mL) and washed with water (2×50 mL). The organic 
layer was dried (MgSO4) and the solvent was removed under reduced pressure. The pur-
ple crude product was purified by column chromatography (CH2Cl2:ethyl acetate 9:1) to 
give the title compound 2.47 as a dark purple solid (0.33 g, 20%), mp 127-129 ᵒC, Rf = 
0.35 (CH2Cl2:ethyl acetate 9:1). 
1H NMR (300 MHz, CDCl3) δ 13.65 (s, 1H), 7.67 (d, J 
= 7.2 Hz, 2H), 7.30 (d, J = 8.2 Hz, 2H), 7.25 – 7.19 (m, 4H), 6.93 (t, J = 7.2 Hz, 2H), 
6.84 (d, J = 8.4 Hz, 2H), 6.74 (d, J = 4.5 Hz, 2H), 6.40 (d, J = 4.7 Hz, 2H), 3.69 (s, 6H), 
2.33 (s, 3H). IR (neat): υmax/cm-1: 3258, 2963, 2360, 1736, 1609, 1551, 1507, 1480, 1449, 
1315, 1261, 1172, 1014, 968, 734. HRMS-ES Calcd for C30H26N2O2 + H
+: 447.2073, 
found: 447.2072. 
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2,2'-((4-Methylphenyl)methylene)bis(1H-pyrrole) 2.54a. 
 
 
 
4-Methylbenzaldehyde (1.60 ml, 1.73 g, 13.6 mmol) was added to pyrrole (24.0 mL, 346 
mmol) and the mixture was stirred at room temperature for 25 min. BF3.Et2O (0.14 g, 
1.40 mmol) was added to the mixture and stirred for 30 min. The solvent was removed 
under reduced pressure and the resulting material was partitioned between CH2Cl2 (50 
mL) and NaOH (200 mL). The organic extract was dried (MgSO4) and the solvent was 
removed under reduced pressure. The brown oil crude product was purified by column 
chromatography (petroleum ether:ethyl acetate:Et3N 9:1:0.1) to give the title compound 
2.54a as a tan solid (2.2 g, 69%), mp 108-110 ̊C (lit.7 110-111 ̊C). Rf = 0.23 (petroleum 
ether:ethyl acetate:Et3N 9:1:0.1). 
1H NMR (300 MHz, CDCl3) δ 7.94 (bs, 2H, NH), 7.17-
7.11 (m, 4H), 6.67-6.74 (m, 2H), 6.18 (q, J=2.8 Hz, 2H), 5.92-5,97 (m, 2H), 5.47 (s, 1H), 
2.35 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 139.15, 136.68, 132.80, 129.43, 128.37, 
117.21, 108.48, 107.18, 43.66, 21.15. IR (neat): υmax/cm-1: 3655, 3342, 2980, 2981, 1682, 
1553, 1513, 1111, 717. HRMS-ES Calcd for C16H16N2 + H
+: 237.1392, found: 237.1397. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.86 
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1,9-Dibromo-5-(4-methylphenyl)dipyrrin 2.55a. 
 
 
2,2'-((4-Methylphenyl)methylene)bis(1H-pyrrole) 2.54a (1.00 g, 4.24 mmol) was dis-
solved in dry THF (100 mL) and cooled to -78 ᵒC. N-Bromosuccinimide (1.52 g, 8.54 
mmol) was added to the mixture in two portions over 1 h. DDQ (0.98 g, 4.3 mmol) in 
THF (10 mL) was added to the mixture dropwise over 10 min. The reaction mixture was 
warmed to room temperature and the solvent was removed under reduced pressure. The 
orange crude product was purified by column chromatography (CH2Cl2) to give the title 
compound 2.55a as an light brown solid (1.33 g, 80%), mp 112-114 ̊C. Rf  = 0.92 
(CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ  12.47 (s, 1H), 7.26 (d, J = 8.5 Hz, 2H), 7.17 (d, 
J = 8.5 Hz, 2H), 6.44 (d, J = 4.2 Hz, 2H), 6.26 (d, J = 4.2 Hz, 2H), 2.37 (s, 3H, CH3). IR 
(neat): υmax/cm-1: 3130, 2980, 1717, 1573, 1595, 1414, 1308, 1246, 1111, 1041, 778. 
HRMS-ES Calcd for C16H12N2Br2 + H
+: 390.9445, found: 390.9454. 
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3,5-Dibromo-4,4-difluoro-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-indacene 2.56a. 
 
 
N,N-Diisopropylethylamine (2.14 g, 16.6 mmol) and BF3.Et2O (3.14 g, 22.1 mmol) were 
added to a solution of 1,9-dibromo-5-(4-methylphenyl)dipyrrin 2.55a (1.08 g, 2.76 mmol) 
in dry CH2Cl2 (20 mL) and the mixture was stirred at room temperature for 2 h.  The 
mixture was then washed with 0.1 M NaOH (50 mL) and water (100 mL). The aqueous 
layer was extracted with dichloromethane (2 × 150 mL). The combined organic layers 
were dried (MgSO4) and the solvent was removed under reduced pressure. The orange 
crude product was purified by column chromatography (CH2Cl2:petroleum ether 1:1) to 
give the title compound 2.56a as an orange solid (1.05 g, 86%), mp 208-210 ̊C (lit.8 mp 
210-211 ̊C). Rf = 0.30 (petroleum ether:CH2Cl2 1:1). 1H NMR (300 MHz, CDCl3) δ 7.37 
(d, J = 7.9 Hz, 2 H), 7.31 (d, J = 7.8 Hz, 2H), 6.80 (d, J = 4.3 Hz, 2H), 6.52 (d, J = 4.3 
Hz, 2H), 2.45 (s, 3H).13C NMR (101 MHz, CDCl3) δ 143.68, 141.67, 135.57, 132.32, 
131.78, 130.57, 129.67, 129.41, 122.66, 21.59. 11B NMR (128 MHz, CDCl3) δ -0.36 (t, 
JB-F = 28.5 Hz). 
19F NMR (282 MHz, CDCl3) δ -146.80 (q, JF-B =28.5 Hz). IR (neat): 
υmax/cm-1: 3139, 2446, 1530, 1446, 1381, 1312, 1093, 1063, 736. HRMS-ES Calcd for 
C16H11N2
11B79Br81Br19F2 + Na
+: 462.9227, found: 462.9222. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.87 
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4,4-Difluoro-3,5-di(2-methoxyphenyl)-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-
indacene 2.48a. 
 
 
3,5-Dibromo-4,4-difluoro-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-indacene 2.56a 
(0.10 g, 0.23 mmol) was dissolved in dry toluene (5 mL). 2-Methoxyphenylboronic acid 
(0.08 g, 0.54 mmol), Pd(PPh3)4 (13.0 mg, 0.01 mmol, 5 mol%), and aqueous Na2CO3 (1 
M, 1.0 mL, 1.0 mmol) were then added. The mixture was heated under reflux for 4 h and 
then allowed to cool to room temperature. The solution was diluted with CH2Cl2 (60 mL) 
and washed with brine (30 mL). The organic layer was dried (MgSO4) and the solvent 
was removed under reduced pressure. The pink crude product was purified by column 
chromatography (petroleum ether:ethyl acetate 4:1) to give the title compound 2.48a as a 
pink solid (0.11 g, 98%), mp 190-192 ̊C, Rf = 0.37 (petroleum ether:ethyl acetate 4:1). 1H 
NMR (300 MHz, CDCl3) δ 7.65 (d, J = 7.6 Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 7.30 – 7.21 
(m, 4H), 6.92 (apparent t, J = 7.6 Hz, 2H), 6.84 (d, J = 8.4 Hz, 2H), 6.80 (d, J = 4.8 Hz, 
2H), 6.51 (d, J = 4.8 Hz, 2H), 3.70 (s, 6H), 2.41 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 
157.60, 155.11, 143.88, 140.32, 135.54, 132.03, 131.98,131.83, 130.70, 130.59, 129.71, 
128.99, 122.18, 120.31, 111.03, 55.89, 21.56. 11B NMR (128 MHz, CDCl3) δ  0.14 (t, JB-
F = 31.0 Hz). 
19F NMR (376 MHz, CDCl3) δ -135.22 (q, JF-B = 31.0 Hz). IR (neat): 
υmax/cm-1: 3325, 2360, 1635, 1589, 1423, 1249, 1217. HRMS-ES Calcd for 
C30H25BN2O2F2 + H
+: 495.2055, found: 495.2055.  
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B,O-Chelated BODIPY 2.49a. 
 
 
4,4-Difluoro-3,5-di(2-methoxyphenyl)-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-inda-
cene 2.48a (0.11 g, 0.22 mmol) was dissolved in dry dichloromethane (7 mL) and the 
solution was cooled to 0 ᵒC. BBr3 (0.57 g, 2.27 mmol) was added dropwise and the mix-
ture was stirred at room temperature for 5 h. The reaction was quenched with ice (30 g) 
and the solution was extracted with ethyl acetate (2 x 30 mL). The combined organic 
extracts were washed with saturated aqueous NH4Cl (30 mL), dried (MgSO4) and the 
solvent was removed under reduced pressure. The crude product was purified by column 
chromatography (petroleum ether:ethyl acetate 4:1) to give the title compound 2.49a as a 
dark red solid (0.11 g, 96% yield), mp 190-192 ̊C, Rf = 0.56 (petroleum ether:ethyl acetate 
4:1). 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 7.7 Hz, 2H), 7.65 (d, J = 7.5 Hz, 2H), 
7.28-7.36 (m, 4H), 7.09 (d, J = 4.0 Hz, 2H), 7.04 (t, J = 7.5 Hz, 2H), 6.95 (d, J = 8.3 Hz, 
2H), 6.89 (d, J = 4.0 Hz, 2H), 2.48 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 154.18, 149.67, 
141.12, 139.06, 134.23, 132.09, 130.96, 130.63, 130.12, 129.49, 125.74, 120.42, 119.75, 
119.72, 116.34, 21.52.11B NMR (128 MHz, CDCl3) δ -1.84 (s). IR (neat): υmax/cm-1: 3273, 
2920, 2851, 1682, 1426, 1171, 1042, 762. HRMS-ES Calcd for C28H19BN2O2 + H
+: 
427.1618, found: 427.1612. 
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2,2'-((2-Pyridyl)methylene)bis(1H-pyrrole) 2.54b. 
 
Pyridine-2-carboxaldehyde (4.28 g, 40.0 mmol) was added to pyrrole (53.6 g, 800 mmol) 
and the mixture was stirred at room temperature for 24 h. The excess pyrrole was removed 
by distillation (60 ᵒ C) to give the crude product as a crimson oil. The product was purified 
by column chromatography (petroleum ether:ethyl acetate 7:3) to give the title compound 
2.54b as a sand-coloured solid (5.56 g, 62%), mp 117-119 ̊C (lit.9 115-116 ̊C). Rf = 0.55 
(petroleum ether:ethyl acetate 7:3). 1H NMR (300 MHz, CDCl3) δ 8.87 (br.s, 2H), 8.60 
(br d, J = 5.1 Hz, 1H), 7.69 (br t, J = 7.6 Hz, 1H), 7.28 (d, J = 7.8 Hz, 1H), 7.19-7.25 (m, 
1H), 6.71-6.76 (m, 2H), 6.12–6.17 (m, 2H), 5.93-5.97 (m, 2H) 5.54 (s, 1H). 13C NMR (75 
MHz, CDCl3) δ 161.27, 149.38, 137.19, 131.71, 123.25, 122.01, 117.50, 108.19, 106.55, 
45.41. IR (neat): υmax/cm-1: 3432, 3103, 2984, 2861, 1593, 1437, 1262, 1029, 722. 
HRMS-ES Calcd for C14H13N3 + H
+: 224.1188, found: 224.1182. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.210 
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1,9-Dibromo-5-(2-pyridyl)dipyrromethane 2.55b.  
 
2,2'-((2-Pyridyl)methylene)bis(1H-pyrrole) 2.54b (0.50 g, 2.20 mmol) was dissolved in 
dry THF (35 mL) and cooled to -78 ᵒC. N-Bromosuccinimide (0.79 g, 4.50 mmol) was 
added to the mixture in two portions over 1 h. The reaction mixture was warmed to room 
temperature and the solvent was removed under reduced pressure. The brown crude prod-
uct was purified by column chromatography (CH2Cl2) to give the title compound 2.55b 
as a yellow solid (0.60 g, 76%), mp 117-120 ̊C, Rf = 0.87 (CH2Cl2). 1H NMR (300 MHz, 
CDCl3) δ 8.90 (br. s, 2H), 8.51 (d, J= 4.6 Hz, 1H), 7.62 (td, J = 7.7, 1.8 Hz, 1H), 7.23 – 
7.10 (m, 2H), 6.02-5.92 (m, 2H), 5.78 (t, J = 3.0 Hz, 2H), 5.30 (s, 1H). 13C NMR (101 
MHz, CDCl3) 159.92, 149.32, 137.84, 132.46, 123.44, 122.56, 110.39, 108.67, 97.74, 
45.25. IR (neat): υmax/cm-1: 3343, 3059, 2950, 2689, 1571, 1474, 1005, 818. HRMS-ES 
Calcd for C14H11N3
79Br81Br + H +: 381.9377, found: 381.9368  
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3,5-Dibromo-4,4-difluoro-8-(2-pyridyl)-4-bora-3a,4a-diaza-s-indacene 2.56b. 
 
1,9-Dibromo-5-(2-pyridyl)dipyrromethane 2.55b (1.00 g, 2.62 mmol) was dissolved in 
dry toluene (20 mL) followed by the addition of a solution of DDQ (0.60 g, 2.62 mmol) 
in dry toluene (20 mL). The mixture was stirred at room temperature for 1h. Diisopro-
pylethylamine (2.35 g, 18.2 mmol) and BF3.Et2O (2.35 g, 18.2 mmol) were added, and 
the mixture was stirred for an additional 1 h. The reaction mixture was washed with 0.1 
M NaOH (2 × 100 mL) and the aqueous layer was extracted with toluene (2 × 60 mL). 
The combined organic extracts were dried (MgSO4) and the solvent was removed under 
reduced pressure to give the crude product as a purple solid. The product was purified by 
column chromatography (petroleum ether:ethyl acetate 2:3) to give the title compound 
2.56b as a dark purple solid (0.55 g, 50%), mp 217-220 ̊C, Rf = 0.47 (petroleum 
ether:ethyl acetate 2:3). 1H NMR (300 MHz, CDCl3) δ 8.80 (d, J = 7.8 Hz, 1H), 7.90 (td, 
J = 7.7, 1.7 Hz, 1H), 7.65-7.50 (m, 2H), 6.92 (d, J = 4.9 Hz, 2H), 6.56 (d, J = 4.3 Hz, 2H). 
13C NMR (75 MHz, CDCl3) δ 151.33, 150.36, 139.78, 136.72, 135.38, 133.49, 132.01, 
126.38, 125.10, 123.14. 11B NMR (128 MHz, CDCl3) δ -0.35 (t, JB-F= 27.8 Hz). 19F NMR 
(282 MHz, CDCl3) δ -146.75 (q, JF-B= 27.8 Hz). IR (neat): υmax/cm-1: 3139, 2927, 1725, 
1540, 1381, 1307, 1249, 1077, 713. HRMS-ES Calcd for C14H8N3
79Br81Br11BF2 + H
+: 
427.9204, found: 427.9210. 
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4,4-Difluoro-3,5-bis(2-methoxyphenyl)-8-(2-pyridyl)-4-bora-3a,4a-diaza-s-indacene 
2.48b. 
 
3,5-Dibromo-4,4-difluoro-8-(2-pyridyl)-4-bora-3a,4a-diaza-s-indacene 2.56b (0.13 g, 
0.31 mmol) was dissolved in dry toluene (5 mL). 2-Methoxyphenylboronic acid (0.11 g, 
0.72 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (SPhos) (15.6 mg, 0.04 
mmol, 12.5 mol%), Pd(OAc)2 (3.40 mg, 0.02 mmol, 5 mol%), and K3PO4 (0.26 g, 1.29 
mmol) were then added. The mixture was heated under reflux for 4 h and then allowed to 
cool to room temperature. The solution was diluted with CH2Cl2 (60 mL) and washed 
with brine (30 mL). The organic layer was dried (MgSO4) and the solvent was removed 
under reduced pressure. The pink crude product was purified by column chromatography 
(petroleum ether:ethyl acetate 4:1) to give the title compound 2.48b as a purple solid (0.40 
g, 81 %), mp 210-212 ̊C, Rf = 0.37 (petroleum ether:ethyl acetate 4:1).  1H NMR (300 
MHz, CDCl3) δ 8.76 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H), 7.81 (td, J = 7.7, 1.8 Hz, 1H), 7.67 
(d, J = 7.5 Hz, 2H), 7.62 (dt, J = 7.8, 1.1 Hz, 1H), 7.41 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 
7.30-7.22 (m, 2H), 6.92 (td, J = 7.6, 1.0 Hz, 2H), 6.86 (s, 2H), 6.83 (d, J = 4.0 Hz, 2H), 
6.55 (d, J = 4.0 Hz, 2H), 3.69 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 157.60, 156.02, 
153.46, 149.97, 136.27, 131.91, 131.46, 130.64, 129.51, 128.59, 126.22, 124.25, 122.75, 
122.03, 120.26, 111.05, 55.83. 11B NMR (160 MHz, CDCl3) δ 1.07 (t, JB-F = 30.8 Hz). 
19F NMR (282 MHz, CDCl3) δ -135.02 (q, JF-B= 30.8 Hz). IR (neat): υmax/cm-1: 3625, 
2839, 2364, 2338, 2163, 1988, 1553, 1469, 1248, 1137, 1072, 754. HRMS-ES Calcd for 
C28H22
11BN3O2
19F2 + H
+: 482.1851, found: 482.1855.  
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B,O-Chelated BODIPY 2.49b. 
 
 
4,4-Difluoro-3,5-bis(2-methoxyphenyl)-8-(2-pyridyl)-4-bora-3a,4a-diaza-s-indacene 
2.48b (0.05 g, 0.11 mmol) was dissolved in dry dichloromethane (7 mL) and the solution 
was cooled to 0 ᵒC. BBr3 (0.38 g, 1.52 mmol) was added dropwise and the mixture was 
stirred at room temperature for 5 h. The reaction was quenched with ice (30 g) and the 
solution was extracted with ethyl acetate (2 x 30 mL). The combined organic extracts 
were washed with saturated aqueous NH4Cl (30 mL), dried (MgSO4) and the solvent was 
removed under reduced pressure. The crude product was purified using column 
chromatography (petroleum ether:ethyl acetate 2:3) to give the title compound 2.49b as 
a dark red solid (0.026 mg, 60%) mp 240-241 ̊C, Rf = 0.56 (petroleum ether:ethyl acetate 
2:3).1H NMR (500 MHz, CDCl3) δ 8.89 (br d, J = 4.7 Hz, 1H), 7.92 (td, J = 7.6, 1.5 Hz, 
1H), 7.86 (d, J = 7.8 Hz, 1H), 7.81 (dd, J = 7.7, 1.5 Hz, 2H), 7.53 – 7.48 (m, 1H), 7.39 – 
7.34 (m, 2H), 7.27 (d, J = 4.4 Hz, 2H), 7.08 (t, J = 7.3 Hz, 2H), 6.99 (d, J = 8.2 Hz, 2H), 
6.96 (d, J = 4.4 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 154.39, 152.91, 150.60, 150.52, 
136.75, 135.35, 134.52, 132.46, 130.27, 126.45, 126.01, 124.64, 120.57, 119.86, 119.67, 
116.93. 11B NMR (96 MHz, CDCl3) δ -0.83 (s). IR (neat): υmax/cm-1: 3432, 2963, 2855, 
2360, 1716, 1593, 1569, 1499, 1437, 1260, 1087, 1029, 758. HRMS-ES Calcd for 
C26H16
11BN3O2 + H
+: 414.1414, found: 414.1434. 
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2,2'-((4-(Octyloxy)phenyl)methylene)bis(1H-pyrrole) 2.54c. 
 
 
4-Octyloxybenzaldehyde (0.50 g, 2.13 mmol) was added to pyrrole (3.57 g, 53.3 mmol) 
and the mixture was stirred at room temperature for 25 min. BF3.Et2O (0.03 g, 0.21 mmol) 
was added to the mixture and stirred for 30 min. The solvent was removed under reduced 
pressure and the resulting material was partitioned between CH2Cl2 (50 mL) and NaOH 
(200 mL). The organic extract was dried (MgSO4) and the solvent was removed under 
reduced pressure. The dark green oil crude product was purified by column chromatog-
raphy (petroleum ether:CH2Cl2 3:2) to give the title compound 2.54c as a tan solid (0.46 
g, 62%); mp 79-80 ̊C (lit.10 mp 78-80 ᵒC). Rf = 0.35 (petroleum ether:CH2Cl2 3:2). 1H 
NMR (300 MHz, CDCl3) δ 7.84 (s, 2H), 7.05 (d, J = 8.6 Hz, 2H), 6.77 (d, J = 8.6 Hz, 
2H), 6.62 (dd, J = 4.0, 2.6 Hz, 2H), 6.08 (dd, J = 5.8, 2.6 Hz, 2H), 5.85 (s, 2H), 5.36 (s, 
1H), 3.86 (t, J = 6.5 Hz, 2H), 1.77 – 1.63 (m, 2H), 1.43 – 1.14 (m, 10H), 0.81 (t, J = 5.7 
Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 158.14, 134.06, 133.03, 129.41, 117.19, 114.61, 
108.39, 107.12, 68.13, 43.17, 31.91, 29.46, 29.34, 26.15, 22.75, 14.21. IR (neat): υmax/cm-
1: 3339, 2923, 2854, 1608, 1553, 1509, 1249, 1023, 721. HRMS-ES Calcd for C23H30N2O
 
+ Na+: 373.2256, found: 373.2249. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.211 
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3,5-Dibromo-4,4-difluoro-8-(4-(octyloxy)phenyl)-4-bora-3a,4a-diaza-s-indacene 
2.56c.  
 
 
2,2'-((4-(Octyloxy)phenyl)methylene)bis(1H-pyrrole) 2.54c (0.38 g, 1.09 mmol) was 
dissolved in dry THF (24 mL) and cooled to -78 ᵒC. N-Bromosuccinimide (0.47 g, 2.64 
mmol) was added to the mixture in two portions over 1 h. DDQ (0.27 g, 1.21 mmol) was 
added to the mixture and stirred for 1h. The reaction mixture was warmed to room 
temperature and the solvent was removed under reduced pressure. The orange crude 
product was dissolved in dry CH2Cl2 (24 mL) and neutralized with N,N-
diisopropylethylamine (0.75 g, 6.59 mmol) and treated with BF3.Et2O (1.12 g, 8.72 
mmol). The mixture was stirred at room temperature for 3 h and washed with 0.1 M 
NaOH (50 mL) and water (100 mL). The aqueous layer was extracted with 
dichloromethane (2 × 150 mL). The combined organic layers were dried (MgSO4) and 
the solvent was removed under reduced pressure. The orange crude product was purified 
using column chromatography (petroleum ether:ethyl acetate 10: 1) to give the title 
compound 2.56c as an orange solid (0.37 g, 61%), mp 116-117 ̊C. 1H NMR (300 MHz, 
CDCl3) δ 7.36 (d, J = 8.8 Hz, 2H), 6.94 (d, J = 8.8 Hz, 2H), 6.76 (d, J = 4.3 Hz, 2H), 6.46 
(d, J = 4.3 Hz, 2H), 3.97 (t, J = 6.5 Hz, 2H), 1.82 – 1.70 (m, 2H), 1.45 – 1.16 (m, 10H), 
0.82 (t, J = 6.8 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 161.82, 143.51, 135.44, 132.31, 
131.79, 131.55, 124.59, 122.44, 114.67, 68.42, 31.82, 29.34, 29.24, 29.14, 26.04, 22.67, 
14.12. 19F NMR (282 MHz, CDCl3) δ -146.67 (q, JF-B =28.4 Hz). 11B NMR (96 MHz, 
CDCl3) δ 0.60 (t, JB-F = 28.4 Hz). IR (neat): υmax/cm-1: 3048, 2924, 2854, 1602, 1571, 
1538, 1505, 1380, 1251, 1176, 1096, 738. HRMS-ES Calcd for C23H25
11B19F2
79 
Br81BrN2O
 + Na+: 577.0272, found: 577.0285. 
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3,5-Bis(2-methoxyphenyl)-4,4-difluoro-8-(4-(octyloxy)phenyl)-4-bora-3a,4a-diaza-
s-indacene 2.48c. 
 
 
3,5-Dibromo-4,4-difluoro-8-(4-(octyloxy)phenyl)-3a,4a-diaza-s-indacene 2.56c (0.20 g, 
0.36 mmol), 2-methoxyphenylboronic acid (0.22 g, 1.44 mmol), K3PO4 (0.33 g, 1.44 
mmol) and chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-
amino-1,1'-biphenyl)]palladium(II) (LPd(XPhos)Cl) 3.54 (0.01 g, 0.014 mmol, 5 mol%) 
were dissolved in THF (6 mL) and water (3 mL ). The mixture was heated under reflux 
for 6 h and then allowed to cool to room temperature. The solution was diluted with 
CH2Cl2 (60 mL) and washed with brine (30 mL). The organic layer was dried (MgSO4) 
and the solvent was removed under reduced pressure. The pink crude product was purified 
by column chromatography (petroleum ether:CH2Cl2 2:1) to give the title compound 
2.48c as a pink solid (0.10 g, 45%), mp 110-111 ᵒC. 1H NMR (300 MHz, CDCl3) δ 7.65 
(d, J = 8.8 Hz, 2H), 7.49 (d, J = 8.7 Hz, 2H), 7.30 – 7.21 (m, 2H), 6.96 (d, J = 8.9 Hz, 
2H), 6.90 (dd, J = 7.5, 1.0 Hz, 2H), 6.84 (d, J = 7.5 Hz, 2H), 6.82 (s, 2H), 6.52 (d, J = 4.1 
Hz, 2H), 3.99 (t, J = 6.5 Hz, 2H), 3.70 (s, 6H), 1.78 (p, J = 6.8 Hz, 2H), 1.37 – 1.18 (m, 
10H), 0.86 – 0.80 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 159.87, 156.49, 153.68, 134.41, 
131.22, 130.89, 129.40, 128.53, 125.77, 122.66, 121.16, 120.90, 119.19, 113.17, 109.96, 
67.24, 54.79, 30.81, 28.35, 28.22, 25.06, 21.66, 13.10. 11B NMR (96 MHz, CDCl3) δ 1.04 
(t, JB-F = 31.6 Hz). 
19F NMR (282 MHz, CDCl3) δ -135.24 (q, JF-B = 31.6 Hz). IR (neat): 
υmax/cm-1: 3027, 2924, 2854, 1602, 1573, 1544, 1506, 1246, 1137, 1070, 797. HRMS-ES 
Calcd for C37H39
11B19F2N2O3
 + Na+: 631.2919, found: 631.2897. 
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B,O-Chelated BODIPY 2.49c. 
 
 
3,5-Bis(2-methoxyphenyl)-4,4-difluoro-8-(4-(octyloxy)phenyl)-4-bora-3a,4a-diaza-s-
indacene 2.48c (0.04 g, 0.07 mmol) was dissolved in dry dichloromethane (2 mL) and the 
solution was cooled to 0 ᵒC. BBr3 (0.85 mL, 0.85 mmol) was added dropwise and the 
mixture was stirred at room temperature for 5 h. The reaction was quenched with ice (30 
g) and the solution was extracted with CH2Cl2 (2 x 30 mL). The combined organic 
extracts were washed with saturated aqueous NH4Cl (30 mL), dried (MgSO4) and the 
solvent was removed under reduced pressure. The crude product was purified using 
column chromatography (petroleum ether:CH2Cl2 2:1) to give the title compound 2.49c 
as a dark green solid (0.02 g, 67% yield), mp 120-121 ᵒC. 1H NMR (300 MHz, CDCl3) δ 
7.70 (dd, J = 7.7, 1.6 Hz, 2H), 7.64 (d, J = 8.7 Hz, 2H), 7.29 – 7.21 (m, 2H), 7.03 (d, J = 
4.3 Hz, 2H), 7.01 – 6.94 (m, 4H), 6.88 (dd, J = 8.3, 0.8 Hz, 2H), 6.83 (d, J = 4.3 Hz, 2H), 
3.99 (t, J = 6.5 Hz, 2H), 1.84 – 1.71 (m, 2H), 1.30-1.17 (m, 10H), 0.83 (t, J = 6.8 Hz, 
3H).11B NMR (96 MHz, CDCl3) δ -0.94 (s). IR (neat): υmax/cm-1: 3043, 2917, 2847, 1432, 
1309, 1202, 1108, 1021, 997, 908. HRMS-ES Calcd for C35H33
11BN2O3
 + Na+: 563.2482, 
found: 563.2475. 
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4,4-Difluoro-8-(4-methylphenyl)- 3,5-bis(2-nitrophenyl)-4-bora-3a,4a-diaza-s-
indacene 2.61. 
 
  
3,5-Dibromo-4,4-difluoro-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-indacene 2.56a 
(0.20 g, 0.45 mmol), 2-nitrophenylboronic acid (0.38 g, 2.27 mmol), K3PO4 (0.42 g, 1.82 
mmol) and chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-
amino-1,1'-biphenyl)]palladium(II) (LPd(XPhos)Cl) 3.54 (0.02 g, 0.03 mmol, 6 mol%) 
were dissolved in THF (6 mL) and water (3 mL ). The mixture was heated under reflux 
for 24 h and then allowed to cool to room temperature. The solution was diluted with 
CH2Cl2 (60 mL) and washed with brine (30 mL). The organic layer was dried (MgSO4) 
and the solvent was removed under reduced pressure. The orange crude product was 
purified by column chromatography (petroleum ether:CH2Cl2 1:1) to give the title 
compound 2.61 as an orange solid (0.18 g, 75%), mp 275-277 ᵒC, 1H NMR (300 MHz, 
CDCl3) δ 8.00 (d, J = 7.9 Hz, 2H), 7.58 – 7.42 (m, 8H), 7.30 (d, J = 7.2 Hz, 2H), 6.92 (d, 
J = 3.6 Hz, 2H), 6.37 (d, J = 3.8 Hz, 2H), 2.43 (s, 3H). 13C NMR (176 MHz, CDCl3) δ 
153.65, 148.18, 146.76, 141.18, 135.61, 132.65, 132.28, 131.18, 131.06, 130.79, 130.06, 
129.17, 127.90, 124.40, 119.93, 21.51. 11B NMR (96 MHz, CDCl3) δ 0.49 (t, JB-F = 30.4 
Hz). IR (neat): υmax/cm-1: 2981, 2927, 2360, 1528, 1502, 1452, 1250, 1136, 1101, 1035, 
748. HRMS-ES Calcd for C28H19
11B19F2N4O4
 + H+: 525.1546, found: 525.1544. 
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3,5-Bis(2-aminophenyl)-4,4-difluoro-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-
indacene 2.62. 
 
  
4,4-Difluoro-8-(4-methylphenyl)-3,5-bis(2-nitrophenyl)-4-bora-3a,4a-diaza-s-indacene 
2.61 (0.10 g, 0.19 mmol) was dissolved in CH2Cl2 (2 mL) and MeOH ( 2 mL). 10% Pd/C 
(0.10 g) was added. The mixture was stirred under nitrogen for 15 min and the nitrogen 
line was replaced with a hydrogen-filled balloon. The mixture was stirred at room 
temperature for 1 h and then filtered through Celite, washing with CH2Cl2 (30 mL). The 
solvent was removed under reduced pressure. The crude product was purified by column 
chromatography (CH2Cl2) to give the title compound 2.62 as dark purple solid (0.07 g, 
80%). Rf = 0.25 (CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.45 (d, J = 8.0 Hz, 2H), 7.28-
2.30 (m, 4H), 7.08 (td, J = 8.0, 1.5 Hz, 2H), 6.90 (d, J = 4.1 Hz, 2H), 6.72 (t, J = 7.1 Hz, 
2H), 6.65 (d, J = 8.0 Hz, 2H), 6.51 (d, J = 4.1 Hz, 2H), 3.57 (s, 4H), 2.42 (s, 3H). 13C 
NMR (75 MHz, CDCl3) δ 156.08, 144.88, 144.48, 140.88, 135.85, 131.34, 131.08, 
130.95, 130.70, 130.40, 129.13, 121.06, 119.19, 118.50, 116.18, 21.51.11B NMR (96 
MHz, CDCl3) δ 0.89 (t, JB-F = 30.6 Hz). 19F NMR (282 MHz, CDCl3) δ -138.25 (q, JF-B 
= 30.6 Hz). IR (neat): υmax/cm-1: 3781, 3036, 2925, 2840, 2393, 2249, 1544, 1424, 1264, 
1149, 1118, 992, 798. HRMS-ES Calcd for C28H24 
11B19F2N4
 + Na+: 465.2062, found: 
465.2061. 
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2-Acetylpyrrole 2.68a. 
 
 
To ZnO (0.06 g, 0.5 mmol), pyrrole (1.76 g, 1.82 mmol) and acetyl chloride (1.81 g, 1.82 
mmol) were added simultaneously and the mixture stirred for 5 min. The resulting mate-
rial was dissolved in CH2Cl2 (200 mL) and washed with saturated aqueous NaHCO3 (100 
mL). The organic layer was dried (MgSO4) and the solvent removed under reduced pres-
sure. The crude product was purified using column chromatography (CH2Cl2) to give the 
title compound 2.68a as a white solid (0.108 g, 55%), mp 89-92 ̊C (lit.11 91-92 ̊C), Rf = 
0.45 (CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 9.34 (s, 1H), 6.96 (dt, J = 1.3, 2.6 Hz, 1H), 
6.86-6.83 (m, 1H), 6.23-6.20 (m, 1H), 2.40 (s, 3H). 13C NMR (96 MHz, CDCl3) δ 188.52, 
132.16, 124.73, 116.84, 110.65, 25.46. IR (neat): υmax/cm-1: 3264, 3116, 2976, 1634. 
HRMS-ES Calcd for C6H7NO + H
+: 110.0606, found: 110.0606. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.212 
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 2-(4-Methylbenzoyl)pyrrole 2.68b. 
 
 
To ZnO (0.60 g, 7.45 mmol), pyrrole (2.0 g, 29.8 mmol) and 4-methylbenzoyl chloride 
(4.6 g, 29.8 mmol) were added simultaneously and the mixture stirred for 5 min. The 
resulting material was dissolved in CH2Cl2 (300 mL) and washed with NaHCO3 (200 
mL). The organic layer was dried (MgSO4) and the solvent was removed under reduced 
pressure. The crude product was purified using column chromatography (CH2Cl2) to give 
the title compound 2.68b as a white solid (2.94 g, 53%), mp 118-120 ̊C (lit.12 119-121 ̊C), 
Rf = 0.45 (CH2Cl2). 
1H NMR (400 MHz, CDCl3) δ 9.76 (s, 1H), 7.82 (d, J = 8.2 Hz, 2H), 
7.28 (d, J = 8.2 Hz, 2H), 7.12 (dd, J = 4.0, 2.6 Hz, 1H), 6.91 – 6.86 (m, 1H), 6.35 – 6.31 
(m, 1H), 2.43 (s, 3H). IR (neat): υmax/cm-1: 3301, 3122, 1601, 1562, 1536, 1421, 1131, 
1055, 749. HRMS-ES Calcd for C12H11NO
 + Na+: 208.0738, found: 208.0742. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.213  
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2-Ethyl-4,4-difluoro-1,3,8-trimethyl-4-bora-3a,4a-diaza-s-indacene 2.69a. 
 
 
 
2-Acetylpyrrole 2.68a (0.16 g, 1.42 mmol) was taken in dry CH2Cl2 (15 mL). 3-Ethyl-
2,4-dimethyl-1H-pyrrole (0.23 g, 1.85 mmol) and  BF3.OEt2 (0.02 g, 0.14 mmol) were 
added and the resulting solution was stirred at room temperature for 1 h. The mixture was 
then neutralized with N,N-diisopropylethylamine (1.10 g, 8.52 mmol) and treated with 
BF3.OEt2 (1.3 g, 11.36 mmol). The mixture was stirred at room temperature for 16 h and 
washed with water (150 mL). The aqueous layer was extracted with dichloromethane (2 
× 50 mL). The combined organic layers were dried (MgSO4) and the solvent was removed 
under reduced pressure. The orange crude product was purified by column 
chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 2.69a as an 
orange solid (0.24 g, 66%), mp 153-154 °C (lit.13 155-156 ̊C), Rf = 0.37 
(CH2Cl2:petroleum ether 1:1). 
1H NMR (300 MHz, CDCl3) δ 7.49 (s, 1H), 6.96 (d, J = 
3.5 Hz, 1H), 6.33 (dd, J = 3.5, 2.1 Hz, 1H), 2.50 (s, 6H), 2.35 (q, J = 7.6 Hz, 2H), 2.28 
(s, 3H), 0.99 (t, J = 7.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 160.40, 140.79, 140.38, 
136.67, 135.10, 134.09, 122.70, 114.97, 17.06, 16.64, 14.58, 14.09, 13.11.11B NMR (96 
MHz, CDCl3) δ 0.38 (t, JB-F = 31.2 Hz). 19F NMR (282 MHz, CDCl3) δ -146.33 (q, JF-B 
= 31.2 Hz). IR (neat): υmax/cm-1: 2974, 1566, 1454, 1393, 1291, 1209, 1174, 1102, 1059, 
958, 757. HRMS-ES Calcd for C14H17
11B19F2N2O3
 + H+: 263.1531, found: 263.1532. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.214 
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2-Ethyl-4,4-difluoro-1,3-dimethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-
indacene 2.69b. 
 
 
2-(4-Methylbenzoyl)pyrrole 2.68b (0.36 g, 1.92 mmol) was taken in dry CH2Cl2 (50 mL). 
3-Ethyl-2,4-dimethyl-1H-pyrrole (0.31 g, 2.50 mmol) and  BF3.OEt2 (0.02 g, 0.19 mmol) 
were added and the resulting solution was stirred at room temperature for 2 h. The mixture 
was then neutralized with N,N-diisopropylethylamine (1.50 g, 11.6 mmol) and treated 
with BF3.OEt2 (1.77 g, 15.4 mmol). The mixture was stirred at room temperature for 16 
h and washed with water (250 mL). The aqueous layer was extracted with 
dichloromethane (2 × 80 mL). The combined organic layers were dried (MgSO4) and the 
solvent was removed under reduced pressure. The green crude product was purified by 
column chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 2.69b 
as an orange solid (0.35 g, 55%), mp 146-147 °C, Rf = 0.45 (CH2Cl2:petroleum ether 1:1). 
1H NMR (300 MHz, CDCl3) δ 7.54 (s, 1H), 7.22 (d, J = 8.3 Hz, 2H), 7.15 (d, J = 8.3 Hz, 
2H), 6.31 – 6.22 (m, 2H), 2.54 (s, 3H), 2.38 (s, 3H), 2.28 (q, J = 7.6 Hz, 2H), 1.41 (s, 
3H), 0.95 (t, J = 7.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 142.37, 142.15, 139.26, 
137.14, 135.70, 134.70, 131.41, 129.04, 128.79, 128.79, 125.89, 118.05, 115.21, 21.45, 
17.14, 14.29, 13.27, 12.56. 11B NMR (96 MHz, CDCl3) δ 0.53 (t, JB-F = 31.2 Hz). 19F 
NMR (282 MHz, CDCl3) δ -145.77 (q, JF-B = 31.2 Hz). IR (neat): υmax/cm-1: 3032, 2964, 
2927, 2872, 1717, 1545, 1455, 1388, 1291, 1150, 1074, 980, 744. 
  
  Chapter 6                                                                                    Experimental section 
 
 
237 
 
6-Ethyl-4,4-difluoro-2-iodo-5,7,8-trimethyl-4-bora-3a,4a-diaza-s-indacene 2.70a. 
 
 
2-Ethyl-4,4-difluoro-1,3,8-trimethyl-4-bora-3a,4a-diaza-s-indacene 2.69a (0.14 g, 0.52 
mmol) was taken in dry CH2Cl2 (10 mL). N-Iodosuccinimide (0.15 g, 0.68 mmol) was 
added to the mixture and stirred for 16 h. The solvent was then removed under reduced 
pressure. The brown crude product was purified by column chromatography 
(CH2Cl2:petroleum ether 1:2) to give the title compound 2.70a as an orange solid (0.12 
g, 60%), mp 168-169 ̊C (lit.14 160.2-160.7 ̊C). Rf =0.35 (CH2Cl2:petroleum ether 1:1). 1H 
NMR (300 MHz, CDCl3) δ 7.40 (s, 1H), 6.96 (s, 1H), 2.49 (s, 3H), 2.41 (s, 3H), 2.34 (q, 
J = 7.6 Hz, 2H), 2.25 (s, 3H), 0.98 (t, J = 7.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
162.74, 142.02, 139.64, 138.91, 136.27, 135.24, 134.65, 127.55, 66.63, 17.10, 16.37, 
14.46, 14.20, 13.32. 11B NMR (96 MHz, CDCl3) δ -0.03 (t, JB-F = 30.7 Hz). 19F NMR 
(282 MHz, CDCl3) δ -146.07 (q, JF-B = 30.7 Hz). IR (neat): υmax/cm-1: 3115, 2962, 1867, 
1557. HRMS-ES Calcd for C14H16
11B19F2N2
127I + H+: 389.0498, found: 389.0512. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.122 
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6-Ethyl-4,4-difluoro-2-iodo-5,7-dimethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-
indacene 2.70b. 
 
 
2-Ethyl-4,4-difluoro-1,3-diimethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-indacene 
2.69b (0.32 g, 0.94 mmol) was taken in dry CH2Cl2 (20 mL). N-Iodosuccinimide (0.26 g, 
0.12 mmol) was added to the mixture and stirred for 16 h. The solvent was then removed 
under reduced pressure. The brown crude product was purified by column 
chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 2.70b as an 
orange solid (0.27 g, 85%); mp 214-215 ̊C. Rf =0.37 (CH2Cl2:petroleum ether 1:1). 1H 
NMR (300 MHz, CDCl3) δ 7.47 (s, 1H), 7.22 (d, J = 7.9 Hz, 2H), 7.13 (d, J = 7.9 Hz, 
2H), 6.32 (s, 1H), 2.55 (s, 3H), 2.38 (s, 3H), 2.28 (q, J = 7.6 Hz, 2H), 1.42 (s, 3H), 0.95 
(t, J = 7.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 164.42, 143.23, 140.99, 140.21, 139.65, 
136.65, 135.80, 133.93, 130.77, 130.49, 129.24, 128.68, 67.06, 21.46, 17.18, 14.16, 
13.50, 12.69. 11B NMR (96 MHz, CDCl3) δ 0.19 (t, J B-F= 30.9 Hz). 19F NMR (282 MHz, 
CDCl3) δ -145.69 (q, JF-B = 30.9 Hz). IR (neat): υmax/cm-1: 3128, 2963, 2457, 2292, 1552, 
1519, 1449, 1346, 1293, 1156, 2094, 980, 749. HRMS-ES Calcd for C20H20
11B19F2N2
127I 
+ H+: 465.0811, found: 465.0818. 
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6-Ethyl-4,4-difluoro-5,7,8-trimethyl-2-phenyl-4-bora-3a,4a-diaza-s-indacene 2.71. 
 
 
 
6-Ethyl-4,4-difluoro-2-iodo-5,7-dimethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-
indacene 2.70a (0.20 g, 0.52 mmol), phenylboronic acid (94.0 mg, 0.77 mmol), K3PO4 
(0.24 g, 1.03 mmol) and chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-
biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (LPd(XPhos)Cl) 3.54 (7.00 mg, 0.01 
mmol, 2 mol%)  were dissolved in THF (6 mL) and water (3 mL ). The mixture was 
heated under reflux for 16 h and then allowed to cool to room temperature. The solution 
was diluted with CH2Cl2 (60 mL) and washed with brine (30 mL). The organic layer was 
dried (MgSO4) and the solvent was removed under reduced pressure. The red crude 
product was purified by column chromatography (CH2Cl2:petroleum ether 1:1) to give 
the title compound 2.71 as a red solid (0.159 g, 83%), mp 202-204 ᵒC, Rf = 0.37 
(CH2Cl2:petroleum ether 1:1). 
1H NMR (300 MHz, CDCl3) δ 7.78 (s, 1H), 7.46 (d, J = 
7.2 Hz, 2H), 7.28 (d, J = 7.2 Hz, 2H), 7.19 – 7.13 (m, 1H), 7.12 (s, 1H), 2.49 (s, 3H), 2.45 
(s, 3H), 2.31 (q, J = 7.6 Hz, 2H), 2.21 (s, 3H), 0.97 (t, J = 7.6 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 160.71, 141.00, 140.14, 135.25, 134.77, 134.37, 133.97, 133.79, 130.66, 
128.80, 126.55, 125.13, 118.26, 17.05, 16.54, 14.58, 14.07, 13.16. 11B NMR (96 MHz, 
CDCl3) δ 0.33 (t, JB-F = 30.9 Hz). 19F NMR (282 MHz, CDCl3) δ -146.32 (q, JF-B = 30.9 
Hz). IR (neat): υmax/cm-1: 3038, 2968, 2933, 2871, 1572, 1450, 1422, 1364, 1305, 1169, 
1059, 1004, 970, 756. HRMS-ES Calcd for C20H21
11B19F2N2
23 + Na+: 361.1664, found: 
361.1649. 
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6-Ethyl-3-iodo-4,4-difluoro-5,7,8-trimethyl-2-phenyl-4-bora-3a,4a-diaza-s-
indacene 2.72. 
 
 
6-Ethyl-4,4-difluoro-5,7,8-trimethyl-2-phenyl-4-bora-3a,4a-diaza-s-indacene 2.71 (0.15 
g, 0.41 mmol) was taken in dry CH2Cl2 (15 mL). N-Iodosuccinimide (0.12 g, 0.54 mmol) 
was added to the mixture and stirred for 16 h. The solvent was then removed under 
reduced pressure. The brown crude product was purified by column chromatography 
(CH2Cl2) to give the title compound 2.72 as an orange solid (0.15 g, 78%), mp 190-192 ̊C. 
Rf = 0.45 (CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.47-7.44 (m, 2H), 7.37-7.26 (m, 3H), 
6.94 (s, 1H), 2.53 (s, 3H), 2.45 (s, 3H), 2.36 (q, J = 7.6 Hz, 2H), 2.27 (s, 3H), 1.01 (t, J = 
7.6 Hz, 3H). 11B NMR (96 MHz, CDCl3) δ 0.30 (t, JB-F = 31.1 Hz). 19F NMR (282 MHz, 
CDCl3) δ -143.96 (q, JF-B = 31.1 Hz). IR (neat): υmax/cm-1: 3115, 2962, 1867, 1557. 
HRMS-ES Calcd for C20H20
11B19F2N2
 + Na+: 487.0630, found: 487.0635. 
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6-Ethyl-4,4-difluoro-3-(2-hydroxyphenyl)-5,7,8-trimethyl-2-phenyl-4-bora-3a,4a-
diaza-s-indacene 2.73. 
 
 
6-Ethyl-3-iodo-4,4-difluoro-5,7,8-trimethyl-2-phenyl-4-bora-3a,4a-diaza-s-indacene 
2.72 (0.10 g, 0.21 mmol), 2-hydroxyphenylboronic acid (0.04 g, 0.32 mmol), K3PO4 (91.0 
mg, 426 μmol) and chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-
biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (LPd(XPhos)Cl) 3.54 (3.20 mg, 4.20 
μmol) were dissolved in THF (3 mL) and water (1.5 mL ). The mixture was heated under 
reflux for 16 h and then allowed to cool to room temperature. The solution was diluted 
with CH2Cl2 (20 mL) and washed with brine (10 mL). The organic layer was dried 
(MgSO4) and the solvent was removed under reduced pressure. The red crude product 
was purified by column chromatography (CH2Cl2) to give the title compound 2.73 as a 
red solid (0.032 g, 25%), mp 203-205 ᵒ C, Rf = 0.35 (CH2Cl2). 
1H NMR (300 MHz, CDCl3) 
δ 7.28 (d, J = 7.9 Hz, 1H), 7.23 – 7.18 (m, 2H), 7.14 – 7.04 (m, 5H), 6.96 (d, J = 8.2 Hz, 
1H), 6.88 (t, J = 7.5Hz, 1H), 5.43 (d, J = 8.4 Hz, 1H), 2.57 (s, 3H), 2.40 (s, 3H), 2.34 (q, 
J = 7.6 Hz, 2H), 2.30 (s, 3H), 0.97 (t, J = 7.6 Hz, 3H).13C NMR (176 MHz, CDCl3) δ 
161.53, 154.13, 142.89, 140.76, 139.28, 135.91, 134.44, 134.41, 134.05, 131.85, 131.10, 
130.76, 128.33, 127.27, 126.56, 121.22, 121.02, 120.67, 116.92, 17.09, 16.41, 14.50, 
14.13, 13.18. 11B NMR (96 MHz, CDCl3) δ 0.56 (apparent t, JB-F = 32.5 Hz). 19F NMR 
(282 MHz, CDCl3) δ -143.04 (dq, JF-F = 108.1, JF-B = 32.8 Hz), 143.96 (dq, JF-F = 108.1, 
JF-B = 32.3 Hz).  IR (neat): υmax/cm-1: 3279, 3040, 2925, 2854, 2402, 1692, 1602, 1566, 
1503, 1451, 1404, 1150, 1102, 750. HRMS-ES Calcd for C26H25
11B19F2N2O
 + Na+: 
453.1926, found: 453.1928. 
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N,N,O,F-Chelated BODIPY 2.74. 
 
 
6-Ethyl-4,4-difluoro-3-(2-hydroxyphenyl)-5,7,8-trimethyl-2-phenyl-4-bora-3a,4a-diaza-
s-indacene 2.73 (10.0 mg, 24.0 μmol) was taken in dry CH2Cl2 (1.5 mL). N,N-
diisopropylethylamine (3.6 mg, 2.8 μmol) was added and the mixture was stirred. 
BF3.OEt2 (2.7 mg, 2.4 μmol) was added. The mixture was heated under reflux for 10 min 
and then allowed to cool to room temperature. The solution was diluted with CH2Cl2 (10 
mL) and washed with NaHCO3 (15 mL). The organic layer was dried (MgSO4) and the 
solvent was removed under reduced pressure. The purple crude product was purified by 
column chromatography (ethyl acetate:petroleum ether 1:8) to give the title compound 
2.74 as a purple solid (6.0 mg, 50%), Rf = 0.35 (ethyl acetate:petroleum ether 1:8). 
1H 
NMR (500 MHz, CDCl3) δ 7.41-7.38 (m,  3H), 7.35 (t, J = 7.5 Hz, 2H), 7.32 – 7.27 (m, 
1H), 7.21 (d, J = 8.2 Hz, 1H), 7.12 (d, J = 8.2 Hz, 1H), 7.00 (s, 1H), 6.67 (t, J = 8.1 Hz, 
1H), 2.69 (s, 3H), 2.55 (s, 3H), 2.41 (q, J = 7.6 Hz, 2H), 2.33 (s, 3H), 1.02 (t, J = 7.6 Hz, 
3H). 11B NMR (160 MHz, CDCl3) δ 0.25 (d, JB-F = 49.1 Hz). 19F NMR (471 MHz, CDCl3) 
δ -143.70 (q, JF-B = 49.1 Hz). 
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2,2'-((4-Methoxyphenyl)methylene)bis(1H-pyrrole) 3.15. 
 
  
A flame dried Schlenk flask was charged with 4-methoxybenzaldehyde (2.7 mL, 22 
mmol) and pyrrole (38.2 mL, 551 mmol) and the resulting solution was stirred at room 
temperature for 25 min. Thereafter, BF3.OEt2 (0.2 mL, 2.00 mmol) was added to the 
mixture and stirred for 4 h. The solvent was removed under reduced pressure and the 
resulting material was pratitioned between CH2Cl2 (100 mL) and 0.1M NaOH (300 mL). 
The organic extract was dried (MgSO4) and the solvent was removed under reduced 
pressure. The resulting green oil was purified by column chromatography (CH2Cl2: 
petroleum ether 7:3) to to give the title compound 3.15 as a light grey solid (4.80 g, 87%), 
mp 97-98 °C (lit.15 98-99 ᵒ C), Rf = 0.4 (CH2Cl2:petroleum ether 7:3). 
1H NMR (300 MHz, 
CDCl3) δ 7.85 (s, 2H), 7.06 (d, J = 8.7 Hz, 2H), 6.78 (d, J = 8.7 Hz, 2H), 6.63-6.60 (m, 
2H), 6.10-6.07 (m, 2H), 5.84 (s, 2H), 5.36 (s, 1H), 3.72 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 158.60, 134.34, 133.02, 129.51, 117.28, 114.08, 108.47, 107.19, 55.42, 43.21. 
IR (neat): υmax/cm-1: 3341, 2922, 2853, 1610, 1511, 1461, 1252, 1176, 1032, 842, 723. 
HRMS-ES Calcd for C16H16N2O + Na
+: 275.1160, found: 275.1167. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.215 
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4,4-Difluoro- 8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.16. 
 
 
2,2'-((4-Methoxyphenyl)methylene)bis(1H-pyrrole) 3.15 (4.30 g, 17.3 mmol) was taken 
in dry CH2Cl2 (200 mL) and cooled to 0 °C. A solution of DDQ (3.92 g, 17.3 mmol) in 
CH2Cl2 (70 mL) was added to the mixture dropwise over 30 min. The mixture was then 
neutralized with N,N-diisopropylethylamine (25.7 g, 199 mmol) and treated with 
BF3.OEt2 (39.7 g, 280 mmol). The mixture was stirred at room temperature for 2 h and 
then washed with 0.1 M NaOH (150 mL) and water (100 mL). The aqueous layer was 
back extracted with CH2Cl2 (2 × 150 mL). The combined organic layers were dried 
(MgSO4) and the solvent was removed under reduced pressure. The resulting orange 
crude product was purified by column chromatography (CH2Cl2:petroleum ether 4:1) to 
give the title compound 3.16 as an orange solid (4.00 g, 78%), mp 135-136 °C (lit.16 mp 
137-138 °C). Rf = 0.6 (CH2Cl2:petroleum ether 4:1).
1H NMR (400 MHz, CDCl3) δ 7.91 
(s, 2H), 7.53 (d, J = 8.8 Hz, 2H), 7.04 (d, J = 8.8 Hz, 2H), 6.96 (d, J = 4.2 Hz, 2H), 6.54 
(d, J = 5.5 Hz, 2H), 3.90 (s, 3H).13C NMR (101 MHz, CDCl3) δ 162.17, 147.51, 143.49, 
134.92, 132.52, 131.45, 126.40, 118.38, 114.15, 55.63.11B NMR (128 MHz, CDCl3) δ -
0.67 (t, JB-F = 29.0 Hz).
19F NMR (376 MHz, CDCl3) δ -145.00 (q, JF-B = 29.0 Hz). IR 
(neat): υmax/cm-1: 3017, 2841, 1601, 1574, 1537, 1473, 1384, 1256, 1220, 1112, 1065, 
977, 844, 779. HRMS-ES Calcd for C16H13BN2OF2 + Na
+: 321.0987, found: 321.0975. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.216 
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4,4-Difluoro-2-iodo-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 and 
4,4-difluoro-2,6-diiodo-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.18. 
 
 
4,4-Difluoro-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.16 (0.20 g, 0.67 
mmol) was taken in dry CH2Cl2-MeOH (1:1, 48 mL). A solution of ICl (0.11 g, 0.67 
mmol) in MeOH (5 mL) was added to the mixture dropwise. The mixture was stirred at 
room temperature for 2 h. The solvent was then removed under reduced pressure and the 
crude product was dissolved in CH2Cl2 (50 mL) and washed with H2O (2 × 100 mL). The 
organic layer was dried (MgSO4) and the solvent was removed under reduced pressure. 
The resulting red crude product was purified by column chromatography (CH2Cl2: 
petroleum ether 1:1) to give: First eluted, the 2, 6-diiodide 3.18 as a pink solid (0.06 g, 
15%), mp 246–248 °C. Rf = 0.4 (CH2Cl2:petroleum ether 1: 1). 1H NMR (400 MHz, 
CDCl3) δ 7.85 (s, 2H), 7.52 (d, J = 8.5 Hz, 2H), 7.13 (s, 2H), 7.06 (d, J = 8.5 Hz, 2H), 
3.91 (s, 3H).13C NMR (101 MHz, CDCl3) δ 162.86, 147.74, 145.96, 137.50, 135.93, 
132.64, 125.62, 114.57, 72.07, 55.75. 11B NMR (128 MHz, CDCl3) δ −1.27 (t, JB-F = 28.0 
Hz). 19F NMR (376 MHz, CDCl3) δ −144.63 (q, JF-B = 28.0 Hz). IR (neat): υmax/cm-1: 
3113, 2930, 1725, 1596, 1566, 1528, 1466, 1342, 1246, 1074, 984, 896, 707. HRMS-ES 
Calcd for C16H11BN2OF2I2 + Na
+: 572.8920, found: 572.8920. Second eluted, the 
monoiodide 3.17 as a red solid (0.185 g, 65%), mp 206–208 °C. Rf = 0.3 (CH2Cl2: 
petroleum ether 1: 1). 1H NMR (400 MHz, CDCl3) δ 7.96 (s, 1H), 7.81 (s, 1H), 7.52 (d, 
J = 8.8 Hz, 2H), 7.05 (d, J = 8.8 Hz, 4H), 6.59 (d, J = 4.3 Hz, 1H), 3.91 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 162.51, 146.73, 146.11, 145.22, 135.99, 135.78, 135.08, 133.00, 
132.57, 125.95, 119.46, 114.36, 70.73, 55.69. 19F NMR (376 MHz, CDCl3) δ -144.72 (q, 
JF-B = 28.0 Hz). 
11B NMR (128 MHz, CDCl3) δ -1.26 (t, JB-F = 28.0 Hz). IR (neat): 
υmax/cm-1: 3109, 2849, 1721, 1603, 1573, 1532, 1470, 1400, 1349, 1250, 1062, 982, 706. 
HRMS-ES Calcd for C16H12BN2OF2I + Na
+: 446.9953, found: 446.9961. 
2-Bromo-4,4-difluoro-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.23. 
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4,4-Difluoro-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.16 (0.30 g, 1.01 
mmol) was taken in dry CH2Cl2/MeCN (1:1, 50 mL). A solution of NBS (0.25 g, 1.20 
mmol) in CH2Cl2 (10 mL) was added to the mixture dropwise. The mixture was stirred at 
room temperature for 90 min and then the solvent was removed under reduced pressure. 
The crude product was dissolved in CH2Cl2 (60 mL) and washed with H2O (3 x 100 mL). 
The organic layer was dried (MgSO4) and the solvent was removed under reduced 
pressure. The resulting orange crude product was purified by column chromatography 
(CH2Cl2:petroleum ether 1:1) to give the title compound 3.23 as an orange solid (0.28 g, 
73%), mp 246-248 °C. Rf = 0.5 (CH2Cl2:petroleum ether 1:1). 
1H NMR (400 MHz, 
CDCl3) δ 7.96 (s, 1H), 7.75 (s, 1H), 7.51 (d, J = 8.5 Hz, 2H), 7.04 (d, J = 8.7 Hz, 3H), 
6.91 (s, 1H), 6.59 (d, J = 4.3 Hz, 1H), 3.90 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 162.55, 
147.30, 145.45, 141.46, 135.24, 134.22, 133.05, 132.58, 130.20, 125.87, 119.41, 114.38, 
105.77, 55.70. 11B NMR (128 MHz, CDCl3) δ -0.96 (t, JB-F = 28.1 Hz). 19F NMR (376 
MHz, CDCl3) δ -144.91 (q, JF-B = 28.1 Hz). IR (neat): υmax/cm-1: 3227, 1603, 1573, 1536, 
1474, 1400, 1356, 1246, 1060, 981. HRMS-ES Calcd for C16H12BN2OF2Br + Na
+: 
398.0128, found: 398.0136.  
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.56 
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General procedure for copper catalysed amination 
 
4,4-Difluoro-2-iodo-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 
0.26 mmol), the amine (0.47 mmol), CuI (2.20 mg, 0.01 mmol, 5 mol%) Cs2CO3 (0.15 g, 
0.47 mmol), and 1, 10-phenanthroline (8.50 mg, 0.05 mmol, 20 mol%) were taken in a 
flame-dried Schlenk tube and flushed with N2 several times. Dry DMF (0.8 mL) was then 
added and the mixture was stirred at 80 °C for 24 h. The mixture was dissolved in ethyl 
acetate (30 mL) and washed with water (2 × 100 mL). The organic layer was dried 
(MgSO4) and the solvent was removed under reduced pressure. The crude product was 
purified by column chromatography. In all cases the 3-amino-6-iodo by-product 3.22 
eluted from the column first and the 3-amino compound 3.19 second. 
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4,4-Difluoro-3-(hexylamino)-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 
3.19a. 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with hexylamine (0.05 g, 0.47 mmol). The crude product was purified by column 
chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 3.19a as a dark 
yellow solid (0.06 g, 60%), mp 202–204 °C; 1H NMR (400 MHz, CDCl3) δ 7.45–7.37 
(m, 3H), 6.97 (dd, J = 6.7, 4.7 Hz, 2H), 6.94 (s, 1H), 6.44 (d, J = 3.5 Hz, 1H), 6.33 (dd, J 
= 3.6, 2.4 Hz, 1H), 6.23 (s, 1H), 6.16 (d, J = 5.0 Hz, 1H), 3.86 (s, 3H), 3.38 (dd, J = 13.5, 
6.8 Hz, 2H), 1.75–1.62 (m, 2H), 1.45–1.35 (m, 2H), 1.34–1.25 (m, 4H), 0.89 (dd, J = 9.0, 
4.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 161.67, 160.49, 136.12, 133.40, 132.80, 
132.75, 131.75, 130.84, 127.15, 119.78, 113.74, 113.39, 110.06, 55.47, 44.82, 31.44, 
30.18, 26.32, 22.59, 14.08. 11B NMR (128 MHz, CDCl3) δ −0.01 (t, JB-F = 33.5 Hz). 19F 
NMR (376 MHz, CDCl3) δ −149.24 (q, JF-B = 33.5 Hz). IR (neat): υmax/cm-1: 3413, 3127, 
2923, 1606, 1524, 1471, 1397, 1372, 1243, 1178, 1021, 977, 759. HRMS-ES Calcd for 
C22H26BN3OF2 + Na
+: 419.2071, found: 419.2060. 
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4,4-Difluoro-3-(hexylamino)-6-iodo-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-
indacene 3.22a. 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with hexylamine (0.05 g, 0.47 mmol). The crude product was purified by column 
chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 3.22a as a dark 
yellow solid (6.00 mg, 5%), 1H NMR (400 MHz, CDCl3) δ 7.42–7.34 (m, 3H), 7.01–6.93 
(m, 3H), 6.47 (s, 1H), 6.31 (s, 1H), 6.23 (d, J = 5.0 Hz, 1H), 3.40 (q, J = 6.8 Hz, 2H), 
1.68 (p, J = 7.3 Hz, 2H), 1.43–1.28 (m, 6H), 0.93–0.86 (m, 3H).13C NMR (101 MHz, 
CDCl3) δ 162.04, 160.65, 136.78, 134.61, 134.21, 133.74, 131.67, 131.05, 126.57, 
124.84, 113.92, 111.30, 65.08, 55.51, 44.97, 31.41, 30.19, 26.30, 22.57, 14.07. HRMS-
ES Calcd for C22H25BN3OF2 + Na
+: 546.1001, found: 546.1005. 
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4,4-Difluoro-8-(4-methoxyphenyl)-3-((4-methylphenyl)amino)-4-bora-3a,4a-diaza-
s-indacene 3.19b.  
 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with p-toluidine (0.05 g, 0.47 mmol). The crude product was purified by column 
chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 3.19b as an 
orange solid (0.08 g, 84%), mp 186–188 °C; 1H NMR (300 MHz, CDCl3) δ 7.86 (s, 1H), 
7.43 (s, 1H), 7.39 (d, J = 8.7 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 7.09 (d, J = 8.5 Hz, 2H), 
6.92 (d, J = 8.8 Hz, 2H), 6.89 (s, 1H), 6.47 (d, J = 3.3 Hz, 1H), 6.35–6.30 (m, 1H), 6.28 
(d, J = 4.9 Hz, 1H), 3.81 (s, 3H), 2.30 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.74, 
158.94, 136.20, 135.72, 135.01, 134.70, 133.13, 132.91, 132.17, 131.83, 130.38, 126.96, 
122.89, 121.24, 113.97, 113.85, 111.16, 55.50, 21.08. IR (neat): υmax/cm-1: 3368, 2914, 
2839, 1606,1580,1523,1489, 1397, 1293, 1241, 1175, 1032, 973, 787. 19F NMR (376 
MHz, CDCl3) δ −148.37 (q, JF-B = 33.0 Hz). 11B NMR (128 MHz, CDCl3) δ 0.06 (t, JB-F 
=33.0 Hz). HRMS-ES Calcd for C23H20BN3OF2 + H
+: 404.1742, found: 404.1740. 
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4,4-Difluoro-6-iodo-8-(4-methoxyphenyl)-3-((4-methylphenyl)amino)-4-bora-3a,4a-
diaza-s-indacene 3.22b.  
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with p-toluidine (0.05 g, 0.47 mmol). The crude product was purified by column 
chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 3.22b as a 
purple solid (7.00 mg, 5%), 1H NMR (400 MHz, CDCl3) δ 7.99 (s, 1H), 7.42 (d, J = 3.8 
Hz, 2H), 7.40 (s, 1H), 7.22 (d, J = 8.1 Hz, 2H), 7.15 (d, J = 8.2 Hz, 2H), 6.99 (s, 1H), 
6.98 (d, J = 8.4 Hz, 2H), 6.56 (s, 1H), 6.37 (d, J = 4.9 Hz, 1H), 3.87 (s, 3H), 3.79 (s, 1H), 
2.37 (s, 3H).13C NMR (101 MHz, CDCl3) δ 160.88, 159.64, 136.79, 136.39, 135.70, 
134.56, 134.26, 133.53, 132.88, 131.73, 130.44, 126.43, 126.06, 123.28, 114.00, 112.47, 
65.60, 55.52, 21.10. IR (neat): υmax/cm-1: 3374, 2934, 1712, 1604, 1519, 1477, 1251, 
1032, 733. HRMS-ES Calcd for C23H19BN3OF2I + Na
+: 551.0568, found: 551.0565. 
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4,4-Difluoro-8-(4-methoxyphenyl)-3-(N-benzamido)-4-bora-3a,4a-diaza-s-indacene 
3.19c. 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with benzamide (0.06 g, 0.47 mmol). The crude product was purified by column 
chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 3.19c as an 
orange solid (15.0 mg, 15%); 1H NMR (400 MHz, CDCl3) δ 9.61 (s, 1H), 7.97 (d, J = 7.8 
Hz, 2H), 7.67 (s, 1H), 7.63 (d, J = 7.5 Hz, 1H), 7.56 (d, J = 7.0 Hz, 2H), 7.51 (d, J = 8.4 
Hz, 2H), 7.39 (d, J = 4.7 Hz, 1H), 7.09 (d, J = 4.7 Hz, 1H), 7.03 (d, J = 8.4 Hz, 2H), 6.79 
(d, J = 3.8 Hz, 1H), 6.53–6.40 (m, 1H), 3.90 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
164.04, 161.68, 152.47, 142.51, 137.46, 135.05, 133.70, 133.35, 132.55, 132.22, 131.26, 
129.28, 127.61, 127.01, 126.29, 116.29, 114.09, 113.34, 55.60. 11B NMR (128 MHz, 
CDCl3) δ −0.15 (t, JB-F = 33.1 Hz). 19F NMR (376 MHz, CDCl3) δ −146.81 (q, JF-B = 33.1 
Hz). IR (neat): υmax/cm-1: 3402, 2919, 1692, 1588, 1503, 1444, 1348, 1287, 1250, 1176, 
1057, 1033 977, 699. HRMS-ES Calcd for C23H18BN3O2F2 + Na
+: 440.1358, found: 
440.1360. 
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3-(Benzylamino)-4,4-difluoro-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 
3.19d. 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with benzylamine (0.05 g, 0.47 mmol). The crude product was purified by column 
chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 3.19d as an 
orange solid (61.0 mg, 61%), mp 132–134 °C; 1H NMR (400 MHz, CDCl3) δ 7.44 (s, 
1H), 7.42 (d, J = 8.7 Hz, 2H), 7.40–7.36 (m, 1H), 7.34 (d, J = 6.6 Hz, 2H), 7.33–7.28 (m, 
2H), 6.97 (d, J = 8.5 Hz, 2H), 6.92 (d, J = 4.9 Hz, 1H), 6.64 (s, 1H), 6.48 (d, J = 3.6 Hz, 
1H), 6.34 (dd, J = 3.5, 2.5 Hz, 1H), 6.11 (d, J = 4.9 Hz, 1H), 4.60 (d, J = 6.3 Hz, 2H), 
3.86 (s, 3H).13C NMR (101 MHz, CDCl3) δ 161.71, 160.60, 136.81, 136.14, 133.85, 
133.28, 132.85, 131.78, 131.51, 129.15, 128.16, 127.02, 126.93, 120.55, 113.78, 113.68, 
110.04, 55.48, 48.22. 11B NMR (128 MHz, CDCl3) δ 0.02 (t, JB-F = 33.5 Hz). 19F NMR 
(376 MHz, CDCl3) δ −148.95 (q, JF-B = 33.5 Hz). IR (neat): υmax/cm-1: 3360, 2970, 1705, 
1619, 1466, 1379, 1160, 1128, 951, 816. HRMS-ES Calcd for C23H20BN3OF2 + Na
+: 
426.1565, found: 426.1584. 
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4,4-Difluoro-8-(4-methoxyphenyl)-3-((2-(thiophen-2-yl)ethyl)amino)-4-bora- 3a,4a-
diaza-s-indacene 3.19e. 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with 2-thiopheneethylamine (0.06 g, 0.47 mmol). The crude product was purified 
by column chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 
3.19e as an orange solid (65.0 mg, 65%), mp 119–120 °C; 1H NMR (400 MHz, CDCl3) 
δ 7.41 (dd, J = 9.0, 2.4 Hz, 3H), 7.18 (dd, J = 5.1, 1.3 Hz, 1H), 6.96 (t, J = 7.1 Hz, 3H), 
6.91 (dd, J = 2.9, 2.2 Hz, 2H), 6.46 (d, J = 3.5 Hz, 1H), 6.36 (s, 1H), 6.33 (dd, J = 3.7, 
2.3 Hz, 1H), 6.06 (d, J = 5.0 Hz, 1H), 3.86 (s, 3H), 3.65 (q, J = 6.6 Hz, 2H), 3.18 (t, J = 
6.7 Hz, 2H).13C NMR (101 MHz, CDCl3) δ 161.45, 160.55, 139.31, 136.06, 133.32, 
132.79, 131.78, 131.21, 127.53, 127.04, 126.43, 124.69, 120.20, 113.77, 113.58, 109.73, 
55.50, 46.23, 30.84. 11B NMR (128 MHz, CDCl3) δ −0.04 (t, JB-F = 33.2 Hz), 19F NMR 
(376 MHz, CDCl3) δ −148.47 (q, JF-B = 33.2 Hz). IR (neat): υmax/cm-1: 3361, 2923, 178, 
1606, 1401, 1293, 1257, 1025, 792. HRMS-ES Calcd for C22H20BN3OF2S + H
+: 
424.1466, found: 424.1456. 
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3-(Cyclohexylamino)-4,4-difluoro-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-
indacene 3.19f. 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with cyclohexylamine (0.05 g, 0.47 mmol). The crude product was purified by 
column chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 3.19f 
as an orange solid (73.0 mg, 78%), mp 130–131 °C; 1H NMR (400 MHz, CDCl3) δ 7.40 
(d, J = 8.4 Hz, 2H), 6.96 (d, J = 8.6 Hz, 2H), 6.93 (d, J = 5.0 Hz, 1H), 6.43 (d, J = 3.3 Hz, 
1H), 6.32 (dd, J = 3.6, 2.4 Hz, 1H), 6.19 (s, 1H), 6.16 (d, J = 5.0 Hz, 1H), 3.86 (s, 2H), 
3.43 (d, J = 8.8 Hz, 1H), 2.02 (d, J = 10.2 Hz, 2H), 1.81 (d, J = 13.3 Hz, 2H), 1.63 (d, J 
= 16.3 Hz, 1H), 1.53–1.14 (m, 4H).13C NMR (101 MHz, CDCl3) δ 160.76, 160.45, 
136.09, 133.34, 132.78, 132.47, 131.73, 130.67, 127.19, 119.56, 113.74, 113.29, 110.49, 
55.47, 53.79, 33.62, 25.21, 24.53. 11B NMR (128 MHz, CDCl3) δ −0.01 (t, JB-F = 30.0 
Hz). 19F NMR (376 MHz, CDCl3) δ −149.24 (q, JF-B = 30.0 Hz). IR (neat): υmax/cm-1: 
2931, 2858, 1718, 1604, 1511, 1293, 1253, 1175, 1062, 1027, 839, 795. HRMS-ES Calcd 
for C22H24BN3OF2 + Na
+: 418.1878, found: 418.1879. 
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3-(Cyclohexylamino)-4,4-difluoro-6-iodo-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-
s-indacene 3.22f.  
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with cyclohexylamine (0.05 g, 0.47 mmol). The crude product was purified by 
column chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 3.22f 
as a yellow solid (5.00 mg, 4%), 1H NMR (400 MHz, CDCl3) δ7.35 (s, 1H), 7.37 (d, J = 
8.8 Hz, 2H), 6.96 (d, J = 7.8 Hz, 2H), 6.97 (s, 1H), 6.46 (s, 1H), 6.23 (s, 2H), 3.86 (s, 
3H), 3.52–3.38 (m, 1H), 2.08–1.98 (m, 2H), 1.86–1.75 (m, 2H), 1.65 (d, J = 12.8 Hz, 
1H), 1.50–1.21 (m, 5H). 13C NMR (101 MHz, CDCl3) δ 161.11, 160.61, 136.72, 134.45, 
134.21, 133.70, 131.66, 130.77, 126.62, 124.63, 113.91, 111.71, 65.00, 55.51, 54.04, 
33.64, 25.14, 24.53. IR (neat): υmax/cm-1: 3373, 2916, 1608, 1574, 1519, 1480, 1392, 
1252, 1101. HRMS-ES Calcd for C22H23BN3OF2I + Na
+: 544.0845, found: 544.0850. 
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4,4-Difluoro-8-(4-methoxyphenyl)-3-(morpholino)-4-bora-3a,4a-diaza-s-indacene 
3.19g. 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with morpholine (0.04 g, 0.47 mmol). The crude product was purified by column 
chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 3.19g as an 
orange solid (76.0 mg, 85%), mp 214–215 °C; 1H NMR (400 MHz, CDCl3) δ 7.45 (s, 
1H), 7.40 (d, J = 8.6 Hz, 2H), 6.97 (d, J = 8.6 Hz, 2H), 6.92 (d, J = 5.1 Hz, 1H), 6.42 (d, 
J = 3.3 Hz, 1H), 6.37–6.33 (m, 1H), 6.20 (d, J = 5.1 Hz, 1H), 3.93 (d, J = 5.1 Hz, 4H), 
3.88 (d, J = 5.1 Hz, 4H), 3.87 (s, 3H).13C NMR (101 MHz, CDCl3) δ 162.07, 160.50, 
135.83, 135.11, 133.61, 132.07, 131.87, 131.75, 127.37, 119.51, 113.91, 113.72, 112.44, 
66.87, 55.49, 50.56. 11B NMR (128 MHz, CDCl3) δ 0.14 (t, JB-F = 33.5 Hz), 19F NMR 
(376 MHz, CDCl3) δ −135.24 (q, JF-B = 33.5 Hz).IR (neat): υmax/cm-1: 3361, 2923, 2852, 
2360, 1590, 1536, 1512, 1408, 1287, 1244, 1178, 1019, 902, 760. HRMS-ES Calcd for 
C20H20BN3O2F2 + Na
+: 405.1551, found: 405.1551. 
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4,4-Difluoro-8-(4-methoxyphenyl)-3-(pyrrolidin-1-yl)-4-bora-3a,4a-diaza-s-
indacene 3.19h. 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with pyrrolidine (0.03 g, 0.47 mmol). The crude product was purified by column 
chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 3.19h as a 
yellow solid (75.0 mg, 87%), mp 171–173 °C; 1H NMR (400 MHz, CDCl3) δ 7.46–7.42 
(m, 1H), 7.39 (d, J = 8.7 Hz, 2H), 6.96 (d, J = 8.8 Hz, 2H), 6.90 (d, J = 5.1 Hz, 1H), 6.35 
(d, J = 3.1 Hz, 1H), 6.34–6.32 (m, 1H), 6.15 (d, J = 5.1 Hz, 1H), 3.94 (br, s, 4H), 3.86 (s, 
3H), 2.11–2.00 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 160.27, 160.17, 135.53, 135.37, 
132.02, 131.83, 130.89, 129.96, 127.76, 117.46, 114.35, 113.60, 113.09, 55.46, 51.35, 
25.68. 11B NMR (128 MHz, CDCl3) δ 0.01 (t, JB-F = 31.0 Hz). 19F NMR (376 MHz, 
CDCl3) δ −128.23 (q, JF-B = 31.0 Hz). IR (neat): υmax/cm-1: 3360, 2923, 1577, 1510, 1395, 
2350, 1251, 1094, 1028, 908, 778. HRMS-ES Calcd for C20H20BN3OF2 + Na
+: 490.1565, 
found: 490.1546. 
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4,4-Difluoro-3-(pyrrolidin-1-yl)-6-iodo-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-
indacene 3.22h.  
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with pyrrolidine (0.03 g, 0.47 mmol). The crude product was purified by column 
chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 3.22h as a dark 
orange solid (5.00 mg, 4%); 1H NMR (400 MHz, CDCl3) δ 7.39 (s, 1H), 7.36 (d, J = 8.6 
Hz, 2H), 6.96 (d, J = 8.7 Hz, 2H), 6.92 (d, J = 5.2 Hz, 1H), 6.39 (s, 1H), 6.21 (d, J = 5.1 
Hz, 1H), 4.04 (s, 4H), 3.86 (s, 3H), 2.07 (t, J = 6.7 Hz, 4H). 13C NMR (101 MHz, CDCl3) 
δ 160.49, 160.33, 135.85, 133.82, 133.52, 132.53, 131.75, 129.11, 127.17, 122.68, 
115.55, 113.77, 64.87, 55.50, 52.13, 25.75. IR (neat): υmax/cm-1: 2988, 2359, 1794, 1694, 
1599, 1513, 1392, 1248, 1027, 779. HRMS-ES Calcd for C20H19BN3OF2I + Na
+: 
516.0532, found: 516.0531. 
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4,4-Difluoro-8-(4-methoxyphenyl)-3-((2-methylphenyl)amino)-4-bora-3a,4a-diaza-
s-indacene 3.19i. 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with o-toluidine (0.05 g, 0.47 mmol). The crude product was purified by column 
chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 3.19i as an 
orange solid (57.0 mg, 60%), mp 227–229 °C; 1H NMR (400 MHz, CDCl3) δ 7.50 (s, 
1H), 7.45 (t, J = 7.7 Hz, 2H), 7.40 (d, J = 8.5 Hz, 2H), 7.35 (d, J = 7.7 Hz, 1H), 7.30 (d, 
J = 7.3 Hz, 2H), 6.95 (d, J = 8.5 Hz, 2H), 6.72 (d, J = 5.1 Hz, 1H), 6.41 (d, J = 3.4 Hz, 
1H), 6.39–6.34 (m, 1H), 5.62 (d, J = 5.1 Hz, 1H), 3.96 (s, 2H), 3.85 (s, 2H). 13C NMR 
(101 MHz, CDCl3) δ 163.14, 160.34, 146.93, 135.59, 134.17, 132.93, 132.04, 131.82, 
131.17, 130.20, 128.10, 127.57, 126.72, 118.74, 116.18, 113.65, 113.57, 55.45, 43.11. 
11B NMR (128 MHz, CDCl3) δ 0.04 (t, JB-F = 33.0 Hz). 19F NMR (376 MHz, CDCl3) δ 
−148.10 (q, JF-B = 33.0 Hz). IR (neat): υmax/cm-1: 3378, 2925, 1620, 1578, 1489, 1398, 
1258, 1085, 1021, 786. HRMS-ES Calcd for C23H20BN3OF2 + Na
+: 426.1565, found: 
426.1577. 
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4,4-Difluoro-8-(4-methoxyphenyl)-3-((4-methoxyphenyl)amino)-4-bora-3a,4a-
diaza-s-indacene 3.19j 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with p-anisidine (0.06 g, 0.47 mmol). The crude product was purified by column 
chromatography (CH2Cl2:petroleum ether 9:1) to give the title compound 3.19j as an 
orange solid (77.0 mg, 78%), mp 245–247 °C; 1H NMR (400 MHz, CDCl3) δ 7.84 (s, 
1H), 7.49–7.46 (m, 1H), 7.44 (d, J = 8.6 Hz, 2H), 7.21 (d, J = 8.9 Hz, 2H), 6.98 (d, J = 
8.7 Hz, 2H), 6.95–6.90 (m, 3H), 6.52 (d, J = 3.6 Hz, 1H), 6.36 (dd, J = 3.7, 2.3 Hz, 1H), 
6.23 (d, J = 4.9 Hz, 1H), 3.87 (s, 3H), 3.85–3.80 (m, 3H). The compound was 
insufficiently soluble to determine 13C NMR. 19F NMR (376 MHz, CDCl3) δ −148.45 (q, 
JF-B = 32.5 Hz). 
11B NMR (128 MHz, CDCl3) δ 0.07 (t, JB-F = 32.5 Hz). IR (neat): υmax/cm-
1: 3368, 2914, 1580, 1293, 1241. HRMS-ES Calcd for C23H20BN3O2F2 + Na
+: 442.1514, 
found: 442.1499. 
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6-Iodo-4,4-difluoro-8-(4-methoxyphenyl)-3-((4-methoxyphenyl)amino)-4-bora-
3a,4a-diaza-s-indacene 3.22j 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with p-anisidine (0.06 g, 0.47 mmol). The crude product was purified by column 
chromatography (CH2Cl2:petroleum ether 9:1) to give the title compound 3.22j as an 
orange solid (8.00 mg, 6%), 1H NMR (400 MHz, CDCl3) δ 7.91 (s, 1H), 7.42 (s, 1H), 
7.41 (d, J = 8.9 Hz, 2H), 7.21 (d, J = 6.9 Hz, 2H), 6.98 (d, J = 6.5 Hz, 2H), 6.96 (s, 1H), 
6.93 (d, J = 6.9 Hz, 2H), 6.55 (s, 1H), 6.27 (d, J = 4.9 Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H). 
The compound was insufficiently soluble to determine 13C NMR. IR (neat): υmax/cm-1: 
3342, 3119, 2929, 1725, 1613, 1512, 1480, 1390, 1249, 1102. HRMS-ES Calcd for 
C23H19BN3OF2I + Na
+: 568.0481, found: 568.0489. 
  
  Chapter 6                                                                                    Experimental section 
 
 
263 
 
3-((4-Chlorophenyl)amino)-4,4-difluoro-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-
s-indacene 3.19k. 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with 4-chloroaniline (0.06 g, 0.47 mmol). The crude product was purified by 
column chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 3.19k 
as a dark yellow solid (66.0 g, 66%), mp 178–180 °C; 1H NMR (400 MHz, CDCl3) δ 7.89 
(s, 1H), 7.51 (s, 1H), 7.45 (d, J = 8.7 Hz, 2H), 7.37 (d, J = 8.7 Hz, 2H), 7.20 (d, J = 8.7 
Hz, 2H), 7.02–6.96 (m, 3H), 6.58 (d, J = 3.7 Hz, 1H), 6.39 (dd, J = 3.7, 2.4 Hz, 1H), 6.34 
(d, J = 4.9 Hz, 1H), 3.88 (s, 3H).13C NMR (101 MHz, CDCl3) δ 160.90, 157.99, 136.36, 
136.13, 135.74, 133.16, 132.97, 132.82, 131.86, 131.34, 129.95, 126.76, 123.72, 122.37, 
114.42, 113.89, 110.26, 55.52. 11B NMR (128 MHz, CDCl3) δ −0.01 (t, JB-F = 33.0 Hz). 
19F NMR (376 MHz, CDCl3) δ −148.10 (q, JF-B = 33.0 Hz). IR (neat): υmax/cm-1: 3348, 
2926, 2860, 1726, 1578, 1519, 1476, 1385, 1292, 1251, 1180, 1096 971, 784. HRMS-ES 
Calcd for C22H17BN3OF2Cl + Na
+: 446.1019, found: 446.1019. 
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3-((4-Chlorophenyl)amino)-4,4-difluoro-6-iodo-8-(4-methoxyphenyl)-4-bora-3a,4a-
diaza-s-indacene 3.22k. 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with 4-chloroaniline (0.06 g, 0.47 mmol). The crude product was purified by 
column chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 3.22k 
as a pink solid (13.0 mg, 13%); 1H NMR (400 MHz, CDCl3) δ 7.94 (s, 1H), 7.44 (d, J = 
14.0 Hz, 2H), 7.39 (d, J = 9.0 Hz, 3H), 7.21 (d, J = 8.6 Hz, 2H), 7.01 (d, J = 5.2 Hz, 1H), 
6.99 (d, J = 8.7 Hz, 2H), 6.61 (s, 1H), 6.38 (d, J = 5.0 Hz, 1H), 3.88 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 161.35, 156.52, 141.60, 138.11, 136.69, 136.47, 134.33, 133.96, 
132.60, 131.81, 128.85, 125.88, 121.11, 118.24, 114.10, 110.82, 108.49, 66.93, 55.51. IR 
(neat): υmax/cm-1: 3376, 2970, 1581, 1524, 1397, 1250, 1113, 1028, 785. HRMS-ES Calcd 
for C22H16BN3OF2ICl + Na
+: 571.9985, found: 571.9990. 
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3-((4-Cyanophenyl)amino)-4,4-difluoro-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-
indacene 3.19l. 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with 4-cyanoaniline (0.06 g, 0.47 mmol). The crude product was purified by 
column chromatography (CH2Cl2:petroleum ether 9:1) to give the title compound 3.19l 
as a pink solid (75.0 mg, 77%), mp 204–207 °C; 1H NMR (400 MHz, CDCl3) δ 8.06 (s, 
1H), 7.68 (d, J = 8.8 Hz, 2H), 7.61–7.55 (m, 1H), 7.47 (d, J = 8.8 Hz, 2H), 7.31 (d, J = 
8.8 Hz, 2H), 7.02 (dd, J = 10.7, 6.8 Hz, 3H), 6.67 (d, J = 4.6 Hz, 1H), 6.50 (d, J = 4.8 Hz, 
1H), 6.43 (dd, J = 3.9, 2.3 Hz, 1H), 3.89 (s, 3H).13C NMR (101 MHz, CDCl3) δ 161.26, 
155.54, 142.19, 138.61, 135.53, 135.12, 133.99, 133.21, 132.27, 131.97, 126.45,124.45, 
120.55, 118.55, 115.33, 114.01, 109.54, 107.74, 55.56. 11B NMR (128 MHz, CDCl3) δ 
−0.09 (t, JB-F = 32.0 Hz). 19F NMR (282 MHz, CDCl3) δ −147.61 (q, JF-B = 32.0 Hz). IR 
(neat): υmax/cm-1: 3383, 3072, 2224, 1599, 1560, 1524, 1476, 1396, 1251, 1175, 1113, 
1024, 936, 780. HRMS-ES Calcd for C23H17BN4OF2 + Na
+: 437.1361, found: 437.1367. 
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3-((4-Cyanophenyl)amino)-4,4-difluoro-6-iodo-8-(4-methoxyphenyl)-4-bora-3a,4a-
diaza-s-indacene 3.22l. 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with 4-cyanoaniline (0.06 g, 0.47 mmol). The crude product was purified by 
column chromatography (CH2Cl2:petroleum ether 9:1) to give the title compound 3.22l 
as a pink solid (19.0 mg, 15%); 1H NMR (300 MHz, CDCl3) δ 8.06 (s, 1H), 7.64 (d, J = 
8.6 Hz, 2H), 7.46 (s, 1H), 7.38 (d, J = 8.7 Hz, 2H), 7.27 (d, J = 8.7 Hz, 2H), 7.02 (d, J = 
4.9 Hz, 1H), 6.96 (d, J = 8.7 Hz, 2H), 6.64 (s, 1H), 6.48 (d, J = 4.9 Hz, 1H), 3.83 (s, 3H). 
IR (neat): υmax/cm-1: 3366, 2995, 2227, 1597, 1566, 1474, 1394, 1253, 1101, 720. HRMS-
ES Calcd for C23H16BN4OF2I + Na
+: 563.0328, found: 563.0323. 
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4,4-Difluoro-8-(4-methoxyphenyl)-3-(pyridin-2-ylamino)-4-bora-3a,4a-diaza-s-
indacene 3.19m. 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with 2-aminopyridine (0.04 g, 0.47 mmol). The crude product was purified by 
column chromatography (CH2Cl2:petroleum ether 7:3) to give the title compound 3.19m 
as a pink solid (55.0 mg, 60%), mp 213–215 °C; 1H NMR (400 MHz, CDCl3) δ 8.40–
8.34 (m, 2H), 7.71–7.63 (m, 1H), 7.54 (s, 1H), 7.52 (d, J = 4.9 Hz, 1H), 7.48 (d, J = 8.4 
Hz, 2H), 7.04 (d, J = 4.9 Hz, 1H), 7.02 (d, J = 3.5 Hz, 1H), 7.00 (s, 2H), 6.95 (d, J = 8.9 
Hz, 1H), 6.60 (d, J = 3.6 Hz, 1H), 6.39 (dd, J = 3.5, 2.3 Hz, 1H), 3.89 (s, 3H).13C NMR 
(101 MHz, CDCl3) δ 189.77, 160.98, 155.85, 151.33, 148.49, 138.37, 137.20, 135.35, 
133.61, 133.11, 132.11, 131.98, 126.85, 122.93, 118.88, 114.51, 113.89, 113.03, 55.52. 
11B NMR (128 MHz, CDCl3) δ 0.01 (t, JB-F = 33.2 Hz).19F NMR (376 MHz, CDCl3) δ 
−147.12– (t, JF-B = 33.2 Hz). IR (neat): υmax/cm-1: 3385, 3029, 2356, 1629, 1603,1562, 
1496, 1393, 1340, 1297, 1247, 1097, 1028, 972, 769. HRMS-ES Calcd for C21H17BN4OF2 
+ H+: 391.1542, found: 391.1549. 
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4,4-Difluoro-6-iodo-8-(4-methoxyphenyl)-3-(pyridin-2-ylamino)-4-bora-3a,4a-
diaza-s-indacene 3.22m. 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with 2-aminopyridine (0.04 g, 0.47 mmol). The crude product was purified by 
column chromatography (CH2Cl2:petroleum ether 7:3) to give the title compound 3.22m 
as a pink solid (17.0 mg, 14%); 1H NMR (400 MHz, CDCl3) δ 8.40 (s, 1H), 8.39–8.34 
(m, 1H), 7.69 (td, J = 7.8, 1.9 Hz, 1H), 7.59 (d, J = 5.0 Hz, 1H), 7.47 (d, J = 1.1 Hz, 1H), 
7.44 (d, J = 8.8 Hz, 2H), 7.07 (d, J = 5.1 Hz, 1H), 7.05–7.02 (m, 1H), 7.00 (d, J = 8.8 Hz, 
2H), 6.96 (d, J = 8.2 Hz, 1H), 6.66–6.60 (m, 1H), 3.88 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 161.14, 156.70, 150.97, 148.57, 138.51, 136.88, 136.16, 135.34, 134.38, 
132.49, 131.91, 127.54, 126.31, 119.36, 115.96, 114.06, 113.29, 66.24, 55.57. IR (neat): 
υmax/cm-1: 3384, 2997, 1629, 1604, 1563, 1496, 1393, 1248, 1029, 972, 769. HRMS-ES 
Calcd for C21H16BN4OF2I + Na
+: 539.0328, found: 539.0326. 
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4,4-Difluoro-8-(4-methoxyphenyl)-3-(methyl(phenyl)amino)-4-bora-3a,4a-diaza-s-
indacene 3.19n. 
 
 
According to the general procedure for copper catalysed amination, 4,4-difluoro-2-iodo-
8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 (0.10 g, 0.26 mmol) was 
reacted with n-methylaniline (0.05 g, 0.47 mmol). The crude product was purified by 
column chromatography (CH2Cl2:petroleum ether 1:1) to give the title compound 3.19n 
as an orange solid (38.0 mg, 40%), mp 220–221 °C; 1H NMR (400 MHz, CDCl3) δ 7.50 
(s, 1H), 7.45 (t, J = 7.7 Hz, 1H), 7.40 (d, J = 8.5 Hz, 1H), 7.36 (t, J = 7.4 Hz, 1H), 7.30 
(d, J = 7.3 Hz, 1H), 6.95 (d, J = 8.5 Hz, 1H), 6.72 (d, J = 5.1 Hz, 1H), 6.52–6.16 (m, 1H), 
5.62 (d, J = 5.1 Hz, 1H), 3.96 (s, 1H), 3.85 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 163.15, 
160.34, 146.92, 135.59, 134.17, 132.92, 132.04, 131.82, 131.16, 130.20, 128.10, 127.56, 
126.72, 118.73, 116.18, 113.65, 113.55, 55.45, 43.11. 11B NMR (128 MHz, CDCl3) δ 
0.17 (t, JB-F = 32.5 Hz). 
19F NMR (376 MHz, CDCl3) δ −129.68 (q, JF-B = 32.5 Hz). IR 
(neat): υmax/cm-1: 2962, 2919, 1681, 1603, 1513, 1298, 1258, 1020, 932, 794. HRMS-ES 
Calcd for C23H20BN3OF2 + Na
+: 425.1602, found: 425.1598. 
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6-Deuterio-4,4-difluoro-2-iodo-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 
3.39 and 2,6-dideuterio-4,4-difluoro-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-
indacene 3.42. 
 
 
4,4-Difluoro-2,6-diiodo-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.18 (0.38 
g, 0.69 mmol) was dissolved in CH2Cl2 (31 mL). Et3N (0.09 mL, 0.69 mmol), K2CO3 
(0.31 g, 2.25 mmol) and 10% Pd/C (0.38 g) were added. The mixture was stirred under 
nitrogen for 15 min and the nitrogen line was replaced with a deuterium-filled balloon. 
The mixture was stirred at room temperature for 4 h and then filtered through Celite, 
washing with CH2Cl2. The solvent was removed under reduced pressure and the orange 
crude product was purified by column chromatography eluting with CH2Cl2:petroleum 
ether (1:1) to give, first eluted: the 6-deuterio-2-iodo-BODIPY 3.39 as an orange solid 
(0.18 g, 60%); mp 214–215 °C; 1H NMR (300 MHz, CDCl3) δ 7.90 (s, 1H), 7.75 (s, 1H), 
7.46 (d, J = 8.7 Hz, 2H), 7.05–6.93 (m, 4H), 3.85 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 162.45, 146.66, 146.03, 145.07, 135.90, 135.72, 135.01, 132.81, 132.49, 125.88, 
119.19, 114.29, 70.65, 55.61. 19F NMR (282 MHz, CDCl3) δ −144.96 (q, JF-B = 28.5 Hz). 
11B NMR (96 MHz, CDCl3) δ 0.45 (t, JB-F = 28.5 Hz). HRMS-ES Calcd for 
C16H11
2HBN2F2IO + Na
+: 448.0115, found: 448.0112. 
Second eluted: 2,6-dideuterio-4,4-difluoro-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-
s-indacene 3.42. 
as an orange solid (0.04 g, 17%) mp 133–135 °C.1H NMR (300 MHz, CDCl3) δ 7.84 (s, 
2H), 7.46 (d, J = 8.8 Hz, 2H), 6.96 (d, J = 8.8 Hz, 2H), 6.89 (s, 2H), 3.83 (s, 3H). 13C 
NMR (75 MHz, CDCl3) δ 162.11, 147.44, 143.31, 134.82, 132.44, 131.27, 126.30, 
118.45, 118.12, 117.77, 114.08, 55.55. 11B NMR (96 MHz, CDCl3) δ 0.31 (t, JB-F =29.0 
Hz). 19F NMR (282 MHz, CDCl3) δ -145.02 (q, JF-B = 29.0 Hz). HRMS-ES Calcd for 
C16H11
2H2BN2F2O + Na
+: 323.1112, found: 323.1110. 
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6-Deuterio-4,4-difluoro-8-(4-methoxyphenyl)-3-(pyrrolidin-1-yl)-4-bora-3a,4a-
diaza-s-indacene 3.43 and 2-deuterio-4,4-difluoro-8-(4-methoxyphenyl)-3-
(pyrrolidin-1-yl)-4-bora-3a,4a-diaza-s-indacene 3.44. 
 
 
Following the General Procedure for copper catalyzed amination, 6-deuterio-4,4-
difluoro-2-iodo-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.39 (0.11 g, 0.25 
mmol) was reacted with pyrrolidine (0.04 g, 0.49 mmol). Purification by column 
chromatography eluting with CH2Cl2:petroleum ether (1:1) gave a 70: 30 mixture of the 
6-deuterio and 2 deuterio-BODIPYs 3.43 and 3.44 respectively as an orange solid (0.08 
g, 88%). For the mixture: 1H NMR (500 MHz, CDCl3) δ 7.48 (br, s, 1H), 7.41 (d, J = 8.7 
Hz, 2H), 6.99 (d, J = 8.7 Hz, 2H), 6.93–6.88 (m, 1H), 6.48–6.25 (m, 1H), 6.16 (d, J = 5.1 
Hz, 1H), 3.94 (br, s, 4H), 3.89 (s, 3H), 2.08–2.05 (m, 4H). 11B NMR (96 MHz, CDCl3) δ 
1.00 (t, JB-F = 32.5 Hz). 
19F NMR (282 MHz, CDCl3) δ -128.25 (q, JF-B = 32.5 Hz). 
HRMS-ES Calcd for C20H19
2HBN3F2O + Na
+: 391.1628, found: 391.1623. For the major 
product 3.43: 13C NMR (126 MHz, CDCl3) δ 160.22 (C3), 160.13 (C4′), 135.46 (C8a), 
135.24 (C1), 131.94 (C7a), 131.75 (C2′, C6′), 130.74 (C8), 129.74 (C5), 127.68 (C1′), 
117.23 (C7), 114.35 (C2), 113.55 (C3′, C5′), 112.97 (C6), 55.37 (OMe), 51.26, 25.58. 
For the minor product 3.44: 13C NMR (126 MHz, CDCl3) δ 160.17 (C3), 160.13 (C4′), 
135.46 (C8a), 135.12 (C1), 131.94 (C7a), 131.75 (C2′, C6′), 130.74 (C8), 129.82 (C5), 
127.68 (C1′), 117.23 (C7), 114.35 (C2), 113.55 (C3′, C5′), 112.97 (C6), 55.37(OMe), 
51.26, 25.58. 
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4,4-Difluoro-1,3-dimethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-indacene 3.34. 
 
 
 
2-(4-Methylbenzoyl)pyrrole 2.64b (0.21 g, 1.14 mmol) was taken in dry CH2Cl2 (50 mL). 
2,4-dimethyl-1H-pyrrole (0.14 g, 1.48 mmol) and  BF3.OEt2 (0.01 g, 0.11 mmol) were 
added and the resulting solution was stirred at room temperature for 3 h. The mixture was 
then neutralized with N,N-diisopropylethylamine (0.88 g, 6.86 mmol) and treated with 
BF3.OEt2 (1.05 g, 9.16 mmol). The mixture was stirred at room temperature for 16 h and 
washed with water (150 mL). The aqueous layer was extracted with dichloromethane (2 
× 50 mL). The combined organic layers were dried (MgSO4) and the solvent was removed 
under pressure. The green crude product was purified by column chromatography 
(CH2Cl2:petroleum ether 1:1) to give the title compound 3.34 as an orange solid (0.30 g, 
84%), mp 146-147 °C, Rf = 0.42 (CH2Cl2:petroleum ether 1:1). 
1H NMR (300 MHz, 
CDCl3) δ 7.59 (s, 1H), 7.21 (d, J = 8.1 Hz, 2H), 7.15 (d, J = 8.1 Hz, 2H), 6.40 – 6.25 (m, 
2H), 6.05 (s, 1H), 2.54 (s, 3H), 2.37 (s, 3H), 1.49 (s, 3H).13C NMR (101 MHz, CDCl3) δ 
161.84, 147.11, 143.87, 139.55, 138.53, 134.93, 133.67, 131.06, 129.18, 128.77, 127.12, 
123.20, 116.02, 21.51, 17.14, 15.26. 11B NMR (96 MHz, CDCl3) δ 0.54 (t, JB-F = 31.1 
Hz). 19F NMR (282 MHz, CDCl3) δ -145.95 (q, JF-B = 31.1 Hz). IR (neat): υmax/cm-1: 
3116, 2963, 1544, 1455, 1390, 1141, 978, 771. HRMS-ES Calcd for C18H17
11B19F2N2 + 
H+: 311.1531, found: 311.1539. 
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4,4-Difluoro-2-iodo-1,3-dimethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-
indacene 3.36 and 4,4-difluoro-6-iodo-1,3-dimethyl-8-(4-methylphenyl)-4-bora-
3a,4a-diaza-s-indacene 3.35. 
 
 
4,4-Difluoro-1,3-dimethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-indacene 3.34 (0.17 
g, 0.55 mmol) was taken in dry CH2Cl2 (10 mL). N-Iodosuccinimide (0.12 g, 0.16 mmol) 
was added to the mixture and stirred for 16 h. The solvent was then removed under 
reduced pressure. The brown crude product was purified by column chromatography 
(CH2Cl2:petroleum ether 1:1) to give, first eluted: the 4,4-difluoro-6-iodo-1,3-dimethyl-
8-(4-methylphenyl)-3a,4a-diaza-s-indacene 3.35 as an orange solid (34.0 mg, 13%). 1H 
NMR (400 MHz, CDCl3) δ 7.58 (s, 1H), 7.25 (d, J = 7.8 Hz, 2H), 7.19 (d, J = 7.8 Hz, 
2H), 6.46 (s, 1H), 6.17 (s, 1H), 2.61 (s, 3H), 2.44 (s, 3H), 1.58 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 160.85, 148.54, 141.49, 140.33, 139.97, 135.99, 131.68, 130.46, 129.37, 
129.06, 128.66, 124.18, 86.94, 21.55, 17.79, 15.39. 
Second eluted: 4,4-difluoro-2-iodo-1,3-dimethyl-8-(4-methylphenyl)-4-bora-3a,4a-
diaza-s-indacene 3.36. 
As an orange solid (0.18 g, 74%), mp 199-200 °C. 1H NMR (300 MHz, CDCl3) δ 7.67 (s, 
1H), 7.23 (d, J = 7.9 Hz, 2H), 7.15 (d, J = 7.9 Hz, 2H), 6.45 (d, J = 3.8 Hz, 1H), 6.34 (dd, 
J = 4.0, 2.0 Hz, 1H), 2.63 (s, 3H), 2.39 (s, 3H), 1.50 (s, 3H). 13C NMR (101 MHz, CDCl3) 
δ 160.89, 147.84, 144.18, 140.36, 140.01, 135.01, 133.08, 131.08, 129.33, 129.08, 
128.83, 117.06, 86.96, 21.59, 17.82, 16.48. 11B NMR (128 MHz, CDCl3) δ -0.51 (t, JB-F 
= 30.4 Hz).19F NMR (376 MHz, CDCl3) δ -145.55 (q, JF-B = 30.4 Hz). HRMS-ES Calcd 
for C18H15
11BN2
19F2
127I + Na+: 584.9284, found: 584.9285. 
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(3,5-Dimethyl-1H-pyrrol-2-yl)(p-tolyl)methanone 3.47. 
 
 
 
2,4-Dimethylpyrrole (0.92 g, 9.71 mmol) was dissolved in THF (20 mL). Methyl 
magnesium chloride solution 3.0 M in THF (3.6 mL, 10.8 mmol) was added dropwise to 
the reaction. The reaction mixture was then heated at reflux for 1 hour, cooled to room 
temperature and added via cannula to a solution of 4-methylbenzoyl chloride (1.93 g, 12.5 
mmol) in THF (10 mL) and the reaction mixture was stirred at room temperature for 24 
hours. The mixture was dissolved in CH2Cl2 (30 mL). The reaction mixture was then 
washed with water (2 x 60 mL) and the combined aqueous layers were back extracted 
with CH2Cl2 (60 mL). The combined organic layers were dried (MgSO4) filtered and the 
solvent removed under reduced pressure. The resulting orange crude product was purified 
by column chromatography (CH2Cl2) to give the title compound 3.47 as a sand coloured 
solid (0.83 g, 40%), mp 155-157 °C (lit.18 158-159 ̊C), Rf = 0.3 (CH2Cl2 ). 1H NMR (400 
MHz, CDCl3) δ 9.00 (s, 1H), 7.54 (d, J = 7.9 Hz, 2H), 7.24 (d, J = 7.9 Hz, 2H), 5.85 (s, 
1H), 2.41 (s, 3H), 2.28 (s, 3H), 1.96 (s, 3H).13C NMR (101 MHz, CDCl3) δ 185.82, 
141.47, 137.30, 135.13, 130.26, 128.99, 128.51, 127.93, 112.90, 21.67, 14.14, 13.26. IR 
(neat): υmax/cm-1:  3279, 2920, 2862, 1929, 1694, 1589, 1563, 1487, 1429, 1282, 929, 762. 
HRMS-ES Calcd for C14H15NO + H
+: 214.1232, found: 214.1233. 
The spectroscopic data obtained for this compound were consistent with those reported 
in the literature.51 
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(3,5-Dimethyl-1H-pyrrol-2-yl)(p-tolyl)methanone 3.47. 
 
Zinc oxide (0.30 g, 3.72 mmol) was taken in a flame-dried Schlenk tube. 2,4-Dimethyl 
pyrrole (1.00 g, 14.9 mmol) and p-toluoyl chloride (2.30 g, 14.9 mmol) were then added 
and the mixture was stirred at room temperature for 5 minutes. The solid crude was 
dissolved in CH2Cl2 (60 mL) and washed with an aqueous solution of sodium bicarbonate 
(100 mL × 2). The aqueous layer was back extracted with CH2Cl2 (2 × 30 mL). The 
combined organic layers were dried (MgSO4) and the solvent was removed under 
pressure. The resulting orange crude product was purified by column chromatography 
(CH2Cl2) to give the title compound 3.47 as a sand coloured solid (1.75 g, 55%). 
The spectroscopic data obtained for this compound were identical with those reported 
above. 
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(4-Iodo-3,5-dimethyl-1H-pyrrol-2-yl)(p-tolyl)methanone 3.48. 
 
 
 (3,5-Dimethyl-1H-pyrrol-2-yl)(p-tolyl)methanone 3.47 (0.52g, 2.45 mmol) was taken in 
dry CH2Cl2 (12 mL). N-Iodosuccinimide (0.55 g, 2.45 mmol) in CH2Cl2 (12 mL) was 
added over 10 minutes and the resulting solution was stirred at room temperature for 2 h. 
The crude product mixture was washed with water (100 mL). The aqueous layer was back 
extracted with CH2Cl2 (2 × 30 mL). The combined organic layers were dried (MgSO4) 
and the solvent was removed under reduced pressure. The resulting brown crude product 
was purified by column chromatography (CH2Cl2) to give the title compound 3.48 as a 
white solid (0.81 g, 98%), mp 169-170 °C.  Rf = 0.37 (CH2Cl2). 
1H NMR (400 MHz, 
CDCl3) δ 10.07 (s, 1H), 7.55 (d, J = 8.0 Hz, 2H), 7.24 (d, J = 8.0 Hz, 2H), 2.41 (s, 3H), 
2.32 (s, 3H), 1.92 (s, 3H). 13C NMR (101 MHz, CDCl3) δ185.73, 142.21, 137.37, 136.60, 
131.77, 129.09, 128.89, 128.23, 73.97, 21.73, 16.42, 14.52. IR (neat): υmax/cm-1:  3240, 
3035, 2945, 2918, 2853, 2567, 1592, 1549, 1511, 1588, 1421, 1382, 1284, 1049, 938, 
756. HRMS-ES Calcd for C14H14NO
127I + H+: 340.0198, found: 340.0259. 
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2-Ethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-
indacene 3.49. 
 
 
 (3,5-Dimethyl-1H-pyrrol-2-yl)(p-tolyl)methanone 3.47 (2.11 g, 9.88 mmol) was taken in 
dry CH2Cl2 (60 mL). 3-Ethyl-2,4-dimethyl-1H-pyrrole (1.73 mL, 12.8 mmol) and  
BF3.OEt2 (1.20 mL, 12.0 mmol) were added and the resulting solution was stirred at room 
temperature for 2 h. The mixture was then neutralized with N,N-diisopropylethylamine 
(7.66 g, 59.3 mmol) and treated with BF3.OEt2 (9.10 g, 79.1 mmol) and then the mixture 
was stirred at room temperature for 4 h. The crude mixture was washed with water (200 
mL). The aqueous layer was back extracted with CH2Cl2 (2 × 100 mL). The combined 
organic layers were dried (MgSO4) and the solvent was removed under reduced pressure. 
The resulting orange crude product was purified by column chromatography 
(CH2Cl2:petroleum ether 1:3) to give the title compound 3.49 as an orange solid (3.13 g, 
86%), mp 141-142 °C.  Rf = 0.3 (CH2Cl2:petroleum ether 1:3). 
1H NMR (300 MHz, 
CDCl3) δ 7.19 (d, J = 7.9 Hz, 2H), 7.05 (d, J = 7.9 Hz, 2H), 5.85 (s, 1H), 2.46 (s, 3H), 
2.45 (s, 3H), 2.35 (s, 3H), 2.22 (q, J = 7.5 Hz, 2H), 1.29 (s, 3H), 1.24 (s, 3H), 0.90 (t, J = 
7.5 Hz, 3H). 13C NMR (75 MHz, CDCl3)  δ 155.16, 153.64, 141.98, 141.33, 139.41, 
138.70, 133.34, 132.33, 131.43, 131.14, 129.75, 127.91, 120.46, 21.45, 17.09, 14.59, 
14.48, 14.41, 12.62, 11.82. 11B NMR (96 MHz, CDCl3) δ 0.77 (t, JB-F = 33.1 Hz). 19F 
NMR (282 MHz, CDCl3) δ -146.02 (q, JF-B =33.1 Hz). IR (neat): υmax/cm-1: 2966, 1713, 
1539, 1516, 1310, 1191, 1053, 974, 754. HRMS-ES Calcd for C22H25N 2
11 BF2 + H
+: 
367.2157, found: 367.2162.  
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6-Ethyl-4,4-difluoro-2-iodo-1,3,5,7-tetramethyl-8-(4-methylphenyl)-4-bora-3a,4a-
diaza-s-indacene 3.50. 
 
 
2-Ethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-
indacene 3.49 (2.16 g, 5.92 mmol) was taken in dry CH2Cl2 (35 mL). N-Iodosuccinimide 
(1.39 g, 5.92 mmol) in CH2Cl2 (40 mL) was added to the mixture dropwise. The mixture 
was stirred at room temperature for 4 h. The crude product mixture was washed with H2O 
(3 x 100 mL). The aqueous layer was back extracted with CH2Cl2 (2 × 30 mL). The 
combined organic layers were dried (MgSO4) and the solvent was removed under reduced 
pressure. The resulting orange crude product was purified by column chromatography 
(CH2Cl2:petroleum ether 1:1) to give the title compound 3.50 as an orange solid (2.35 g, 
80%), mp 220-221 ᵒC.  Rf = 0.5 (CH2Cl2:petroleum ether 1:1). 1H NMR (300 MHz, 
CDCl3) δ 7.22 (d, J = 7.9 Hz, 2H), 7.05 (d, J = 7.9 Hz, 2H), 2.54 (s, 3H), 2.48 (s, 3H), 
2.37 (s, 3H), 2.24 (q, J = 7.5 Hz, 2H), 1.30 (s, 3H), 1.25 (s, 3H), 0.92 (t, J = 7.5 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 157.80, 152.75, 141.92, 141.03, 140.98, 139.06, 134.52, 
132.14, 131.92, 130.68, 129.91, 127.85, 83.38, 21.49, 17.13, 16.64, 15.69, 14.43, 12.87, 
12.04. 11B NMR (96 MHz, CDCl3) δ 0.68 (t, JB-F = 32.8 Hz). 19F NMR (282 MHz, CDCl3) 
δ -145.74 (q, JF-B =32.8 Hz). IR (neat): υmax/cm-1: 2966, 2931, 1532, 1401, 1310, 1179, 
1070, 976, 754. HRMS-ES Calcd for C22H24N2
11BF2
127I + H+: 493.1124, found: 
493.1131.  
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2-Ethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-
indacene 3.49 and 2-ethyl-4,4-difluoro-2-iodo-1,3,5,7-tetramethyl-8-(4-
methylphenyl)-4-bora-3a,4a-diaza-s-indacene 3.50. 
 
 
 
 (4-Iodo-3,5-dimethyl-1H-pyrrol-2-yl)(p-tolyl)methanone 3.48 ( 0.06 g, 0.17 mmol) was 
taken in dry CH2Cl2 (20 mL). 3-Ethyl-2,4-dimethyl-1H-pyrrole (0.27 g, 0.22 mmol) and  
BF3.OEt2 (2.0 mg, 0.02 mmol) were added and the resulting solution was stirred at room 
temperature for 2 h. The mixture was then neutralized with N,N-diisopropylethylamine 
(0.12 g, 1.03 mmol) and treated with BF3.OEt2 (0.16 g, 1.37 mmol) and then the mixture 
was stirred at room temperature for 4 h. The crude product mixture was washed with 
water (100 mL). The aqueous layer was back extracted with CH2Cl2 (2 × 100 mL). The 
combined organic layers were dried (MgSO4) and the solvent was removed under reduced 
pressure. The resulting orange crude product was purified by column chromatography 
(CH2Cl2:petroleum ether 1:3) to give: First eluted BODIPY 3.49 as an orange solid (0.02 
g, 30%). Second eluted 2-iodoBODIPY 3.50 as an orange solid (0.04 g, 50%). 
The spectroscopic data obtained for these compounds were identical with those reported 
above. 
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General procedure for palladium catalyzed amination 
 
2-Ethyl-4,4-difluoro-2-iodo-1,3,5,7-tetramethyl-8-(4-methylphenyl)-4-bora-3a,4a-
diaza-s-indacene 3.50 (0.10 g, 0.20 mmol), the amine (1.01 mmol), di((2-(2'-amino-1,1'-
biphenyl))palladium(II) methanesulfonate dimer 3.54 (1.87 mg, 2.50 μmol, 1.25 mol%) 
Sphos (2.30 mg, 5.50 μmol, 2.75 mol %), and Cs2CO3 (0.11 g, 0.35 mmol) were taken in 
a flame-dried Schlenk tube and flushed with N2 several times. Dry 1,4-dioxane (2 mL) 
was then added and the mixture was stirred at 95 °C for 16 h. The mixture was dissolved 
in ethyl acetate (30 mL) and washed with water (2 × 100 mL). The organic layer was 
dried (MgSO4) and the solvent was removed under reduced pressure. The crude product 
was purified by column chromatography (ethyl acetate:petroleum ether 1:7). 
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6-Ethyl-4,4-difluoro-2-((4-methoxyphenyl)amino)-8-(4-methylphenyl)-1,3,5,7-
tetramethyl-4-bora-3a,4a-diaza-s-indacene 3.51. 
 
 
According to the general procedure for palladium catalysed amination, 2-ethyl-4,4-
difluoro-2-iodo-1,3,5,7-tetramethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-indacene 
3.50 (0.10 g, 0.20 mmol) was reacted with p-anisidine (0.12 g, 1.01 mmol). The crude 
product was purified by column chromatography (ethyl acetate:petroleum ether 1:7) to 
give the title compound 3.51 as a dark purple solid (0.09 g, 92%), mp 240-241 ̊C.  Rf = 
0.25 (ethyl acetate:petroleum ether 1:7). 1H NMR (300 MHz, CDCl3) δ 7.20 (d, J = 7.9 
Hz, 2H), 7.08 (d, J = 7.9 Hz, 2H), 6.65 (d, J = 8.9 Hz, 2H), 6.40 (d, J = 8.9 Hz, 2H), 3.65 
(s, 3H), 2.48 (s, 3H), 2.35 (s, 3H), 2.34 (s, 3H), 2.24 (q, J = 7.5 Hz, 2H), 1.26 (s, 3H), 
1.15 (s, 3H), 0.92 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 155.50, 152.52, 
151.71, 141.13, 140.86, 139.59, 138.84, 136.73, 133.31, 132.44, 131.75, 131.56, 129.84, 
129.30, 128.03, 114.89, 114.31, 55.83, 21.53, 17.15, 14.67, 12.72, 11.95, 11.19. 11B NMR 
(96 MHz, CDCl3) δ 0.78 (t, JB-F = 32.2 Hz); 19F NMR (282 MHz, CDCl3) δ -145.93 (q, 
JF-B =32.2 Hz). IR (neat): υmax/cm-1:  3399, 2962, 2927, 2360, 1541, 1508, 1477, 1184, 
1005, 798. HRMS-ES Calcd for C29H32N3
11BF2 O + H
+: 488.2686, found: 488.2685.  
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2-((4-Chlorophenyl)amino)-6-ethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(4-
methylphenyl)-4-bora-3a,4a-diaza-s-indacene 3.55. 
 
 
According to the general procedure for palladium catalysed amination, 2-ethyl-4,4-
difluoro-2-iodo-1,3,5,7-tetramethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-indacene 
3.50 (0.10 g, 0.20 mmol) was reacted with 4-chloroaniline (0.13 g, 1.01 mmol). The crude 
product was purified by column chromatography (ethyl acetate:petroleum ether 1:7) to 
give the title compound 3.55 as a dark purple solid (0.09 g, 85%), mp 270-271 ̊C.  Rf = 
0.37 (ethyl acetate:petroleum ether 1:7).1H NMR (300 MHz, CDCl3) δ 7.21 (d, J = 7.9 
Hz, 2H), 7.07 (d, J = 7.9 Hz, 2H), 7.00 (d, J = 8.6 Hz, 2H), 6.37 (d, J = 8.6 Hz, 2H), 4.77 
(s, 1H), 2.49 (s, 3H), 2.35 (s, 3H), 2.32 (s, 3H), 2.25 (q, J = 7.6 Hz, 2H), 1.27 (s, 3H), 
1.13 (s, 3H), 0.92 (t, J = 7.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 156.51, 150.89, 
145.55, 141.34, 140.12, 138.88, 137.01, 133.70, 132.20, 131.82, 130.03, 129.82, 129.10, 
127.87, 124.83, 122.55, 114.17, 21.47, 17.08, 14.55, 12.74, 12.76, 11.94, 11.09. 11B NMR 
(96 MHz, CDCl3) δ 0.69 (t, JB-F = 33.0 Hz). 19F NMR (282 MHz, CDCl3) δ -146.05 (q, 
JF-B = 33.0 Hz). IR (neat): υmax/cm-1: 3357, 2962, 2923, 2360, 1661, 1597, 1539, 1490, 
1259, 1074, 1009, 796. HRMS-ES Calcd for C28H29N3
11 B19F2
35Cl + Na+: 514.2009, 
found: 514.2012.  
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2-((4-Cyanophenyl)amino)-6-ethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(4-
methylphenyl)-4-bora-3a,4a-diaza-s-indacene 3.56. 
 
According to the general procedure for palladium catalysed amination, 2-ethyl-4,4-
difluoro-2-iodo-1,3,5,7-tetramethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-indacene 
3.50 (0.10 g, 0.20 mmol) was reacted with 4-cyanoaniline (0.12 g, 1.01 mmol). The crude 
product was purified by column chromatography (ethyl acetate:petroleum ether 1:7) to 
give the title compound 3.56 as a dark red solid (0.05 g, 51%), mp 282-286 ̊C.  Rf = 0.25 
(ethyl acetate:petroleum ether 1:7).1H NMR (300 MHz, CDCl3) δ 7.32 (d, J = 8.6 Hz, 
2H), 7.22 (d, J = 7.9 Hz, 2H), 7.07 (d, J = 7.9 Hz, 2H), 6.45 (d, J = 8.6 Hz, 2H), 5.25 (s, 
1H), 2.50 (s, 3H), 2.36 (s, 3H), 2.31 (s, 3H), 2.29 – 2.18 (m, 2H), 1.28 (s, 3H), 1.12 (s, 
3H), 0.93 (t, J = 7.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 157.91, 150.61, 149.58, 
141.59, 140.82, 139.05, 136.71, 134.29, 133.79, 132.25, 132.00, 129.89, 128.79, 127.94, 
127.80, 120.16, 112.90, 99.97, 21.45, 17.08, 14.45, 12.84, 11.99, 11.64, 11.03. 11B NMR 
(96 MHz, CDCl3) δ 0.67 (t, JB-F = 32.5 Hz).19F NMR (282 MHz, CDCl3) δ -145.91 (q, 
JF-B = 32.5 Hz). IR (neat): υmax/cm-1: 3386, 2964, 2928, 2212, 1668, 1606, 1537, 1515, 
1314, 1261, 1200, 1074, 1005, 800. HRMS-ES Calcd for C29H29N4
11B19F2 + Na
+: 
505.2351, found: 505.2355.  
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6-Ethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(4-methylphenyl)-2-((2-methylphenyl)-
amino)-4-bora-3a,4a-diaza-s-indacene 3.57. 
 
According to the general procedure for palladium catalysed amination, 2-ethyl-4,4-
difluoro-2-iodo-1,3,5,7-tetramethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-indacene 
3.50 (0.10 g, 0.20 mmol) was reacted with o-toluidine (0.11 g, 1.01 mmol). The crude 
product was purified by column chromatography (ethyl acetate:petroleum ether 1:7) to 
give the title compound 3.57 as a dark purple solid (0.09 g, 90%), mp 201-202 ̊C. Rf = 
0.37 (ethyl acetate:petroleum ether 1:7).1H NMR (300 MHz, CDCl3) δ 7.20 (d, J = 7.9 
Hz, 2H), 7.09 (d, J = 7.9 Hz, 2H), 6.98 (d, J = 7.3 Hz, 1H), 6.96 – 6.89 (m, 1H), 6.59 (td, 
J = 7.4, 1.1 Hz, 1H), 6.24 (dd, J = 8.0, 0.9 Hz, 1H), 4.54 (s, 1H), 2.49 (s, 3H), 2.35 (s, 
3H), 2.33 (s, 3H), 2.25 (q, J = 7.6 Hz, 2H), 2.17 (s, 3H), 1.27 (s, 3H), 1.14 (s, 3H), 0.92 
(t, J = 7.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 155.70, 151.54, 144.76, 141.18, 139.69, 
138.79, 137.01, 133.36, 132.34, 131.56, 130.94, 130.25, 129.78, 129.23, 127.94, 127.07, 
121.52, 117.85, 111.59, 21.47, 17.52, 17.09, 14.60, 12.68, 11.90, 11.82, 11.11. 11B NMR 
(96 MHz, CDCl3) δ 0.74 (t, JB-F = 32.5 Hz). 19F NMR (282 MHz, CDCl3) δ -146.13 (q, 
JF-B = 32.5 Hz). IR (neat): υmax/cm-1:  3410, 2962, 2972, 2868, 1535, 1475, 1323, 1303, 
1179, 1054, 977, 750.  HRMS-ES Calcd for C29H32N3
11 B19F2 + Na
+: 494.2555, found: 
494.2561. 
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6-Ethyl-4,4-difluoro-2-(hexylamino)-1,3,5,7-tetramethyl-8-(4-methylphenyl)-4-
bora-3a,4a-diaza-s-indacene 3.58. 
 
According to the general procedure for palladium catalysed amination, 2-ethyl-4,4-
difluoro-2-iodo-1,3,5,7-tetramethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-indacene 
3.50 (0.10 g, 0.20 mmol) was reacted with hexylamine  (0.10 g, 1.01 mmol). The crude 
product was purified by column chromatography (ethyl acetate:petroleum ether 1:7) to 
give the title compound 3.58 as a dark purple solid (0.03 g, 31%), mp 200-201 ̊C. Rf = 
0.49 (ethyl acetate:petroleum ether 1:7). 1H NMR (300 MHz, CDCl3) δ 7.19 (d, J = 8.0 
Hz, 2H), 7.06 (d, J = 8.0 Hz, 2H), 2.81 (t, J = 7.4 Hz, 2H), 2.50 (s, 3H), 2.46 (s, 3H), 2.37 
(s, 3H), 2.26-2.18 (m, 2H), 1.24-1.20 (m, 8H), 1.19-1.15 (m, 6H), 0.91 (t, J = 7.6 Hz, 
3H), 0.82 – 0.76 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 152.81, 149.75, 140.03, 139.56, 
138.53, 137.95, 132.70, 132.12, 130.76, 129.78, 129.61, 128.56, 128.17, 50.02, 31.69, 
30.80, 26.71, 22.62, 21.44, 17.06, 14.67, 14.04, 12.41, 12.09, 11.72, 10.85. 11B NMR (96 
MHz, CDCl3) δ 0.70 (t, JB-F = 32.5 Hz). 19F NMR (282 MHz, CDCl3) δ -146.13 (q, JF-B 
= 32.5 Hz). IR (neat): υmax/cm-1: 3290, 2962, 2359, 1544, 1411, 1260, 1017, 797. HRMS-
ES Calcd for C28H38N3
11B19F2 + H
+: 466.3205, found: 466.3205. 
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6-Ethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(4-methylphenyl)-2-(2-
nitrophenyl)amino)-4-bora-3a,4a-diaza-s-indacene 4.8. 
 
According to the general procedure for palladium catalysed amination, 2-ethyl-4,4-
difluoro-2-iodo-1,3,5,7-tetramethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-indacene 
3.50 (0.10 g, 0.20 mmol) was reacted with 2-nitroaniline (0.14 g, 1.01 mmol).The crude 
product was purified by column chromatography (ethyl acetate:petroleum ether 1:9) to 
give the title compound 4.8 as a dark red solid (0.08 g, 67%), mp 220-222 ̊C. Rf = 0.25 
(ethyl acetate:petroleum ether 1:9). 1H NMR (300 MHz, CDCl3) δ 8.72 (s, 1H), 8.10 (dd, 
J = 8.6, 1.5 Hz, 1H), 7.31 – 7.25 (m, 1H), 7.22 (d, J = 8.0 Hz, 2H), 7.09 (d, J = 8.0 Hz, 
2H), 6.63 (ddd, J = 8.4, 7.0, 1.2 Hz, 1H), 6.55 (dd, J = 8.6, 1.1 Hz, 1H), 2.51 (s, 3H), 2.36 
(s, 3H), 2.34 (s, 3H), 2.26 (q, J = 7.6 Hz, 2H), 1.29 (s, 3H), 1.14 (s, 3H), 0.94 (t, J = 7.6 
Hz, 3H). 13C NMR (176 MHz, CDCl3) δ 158.17, 149.08, 144.97, 141.65, 140.93, 139.07, 
136.36, 136.10, 134.39, 132.32, 132.34, 131.97, 129.91, 128.90, 127.80, 127.13, 126.55, 
116.75, 115.74, 21.46, 17.09, 14.46, 12.88, 12.02, 11.68, 11.02.11B NMR (96 MHz, 
CDCl3) δ 0.71 (t, JB-F = 32.6 Hz).19F NMR (282 MHz, CDCl3) δ -146.06 (q, JF-B = 32.6 
Hz). IR (neat): υmax/cm-1: 3439, 3362, 2920, 1910, 1642, 1595, 1527, 1503, 1313, 1257, 
1089, 938, 734. HRMS-ES Calcd for C28H29N4
11BF2O2 + Na
+: 525.2249, found: 
525.2256. 
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1-(1,3,2-Benzodioxaborol-2-yl)-2-[(Z)-(3,5-dimethyl-2H-pyrrol-2-ylidene)(4-
iodophenyl)methyl]-3,5-dimethyl-1H-pyrrole 4.2. 
 
 
According to the general procedure for palladium catalysed amination, 2-ethyl-4,4-
difluoro-2-iodo-1,3,5,7-tetramethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-indacene 
3.50 (0.10 g, 0.20 mmol) was reacted with 2-aminophenol (0.11 g, 1.01 mmol).The crude 
product was purified by column chromatography (CH2Cl2:petroleum ether 1:1) to give 
the title compound 4.2 as a dark purple solid (0.04 g, 64%), mp 190-191 ̊C.  Rf = 0.35 
(CH2Cl2:petroleum ether 1:1).
 1H NMR (300 MHz, CDCl3) δ 7.23 (d, J = 7.5 Hz, 2H), 
7.09-7.03 (m, 2H), 6.64 (d, J = 7.5 Hz, 2H), 6.54 – 6.46 (m, 1H), 6.43 (d, J = 8.6 Hz, 1H), 
2.38 (s, 3H), 2.18 (q, J = 7.5 Hz, 2H), 2.10 (s, 3H), 2.03 (s, 3H), 1.31 (s, 3H), 1.24 (s, 
3H), 0.86 (t, J = 7.5 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 160.28, 154.99, 151.38, 
142.16, 141.75, 140.79, 140.53, 138.94, 134.99, 132.71, 132.31, 131.22, 129.98, 129.83, 
128.15, 127.81, 119.59, 115.77, 108.56, 106.15, 85.08, 21.48, 17.15, 16.99, 16.00, 14.44, 
12.86, 12.16.11B NMR (96 MHz, CDCl3) δ 5.31 (s). IR (neat): υmax/cm-1:  3472, 3030, 
2921, 2851, 1741, 1544, 1467, 1295, 1176, 1151, 978, 722. HRMS-ES Calcd for 
C28H29N3
11BO127I + H+: 562.1527, found: 562.1532.  
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6-Ethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(4-methylphenyl)-2-(2-aminophenyl)-
amino)-4-bora-3a,4a-diaza-s-indacene 4.9. 
 
6-Ethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(4-methylphenyl)-2-((2-nitrophenyl)amino)-
4-bora-3a,4a-diaza-s-indacene 4.8 (0.05 g, 0.10 mmol) was dissolved in CH2Cl2 (1 mL) 
and MeOH ( 3 mL). 10% Pd/C (0.05 g) was added. The mixture was stirred under nitrogen 
for 15 min and the nitrogen line was replaced with a hydrogen-filled balloon. The mixture 
was stirred at room temperature for 2 h and then filtered through Celite, washing with 
CH2Cl2. The solvent was removed under reduced pressure. The crude product was 
purified by column chromatography (CH2Cl2) to give the title compound 4.9 as a dark 
purple solid (0.05 g, 95%), mp 215-218 ̊C. Rf = 0.25 (CH2Cl2). 1H NMR (300 MHz, 
CDCl3) δ 8.72 (s, 1H), 8.10 (dd, J = 8.6, 1.5 Hz, 1H), 7.31 – 7.25 (m, 1H), 7.22 (d, J = 
8.0 Hz, 2H), 7.09 (d, J = 8.0 Hz, 2H), 6.63 (ddd, J = 8.4, 7.0, 1.2 Hz, 1H), 6.55 (dd, J = 
8.6, 1.1 Hz, 1H), 2.51 (s, 3H), 2.36 (s, 3H), 2.34 (s, 3H), 2.26 (q, J = 7.6 Hz, 2H), 1.29 
(s, 3H), 1.14 (s, 3H), 0.94 (t, J = 7.6 Hz, 3H). 13C NMR (176 MHz, CDCl3) δ 157.90, 
150.61, 149.57, 141.58, 140.82, 139.05, 136.72, 134.29, 133.79, 132.24, 131.99, 129.90, 
128.78, 127.92, 127.79, 120.19, 112.90, 99.92, 21.46, 17.08, 14.47, 12.85, 12.00, 11.65, 
11.04. 11B NMR (96 MHz, CDCl3) δ 0.77 (t, JB-F = 32.4 Hz). 19F NMR (282 MHz, CDCl3) 
δ -146.00 (q, JF-B = 32.4 Hz). IR (neat): υmax/cm-1: 3440, 3362, 2921, 2360, 1642, 1595, 
1527, 1503, 1413, 1312, 1257, 1090, 733. HRMS-ES Calcd for C28H31N4
11BF2 + H
+: 
473.2688, found: 473.2690. 
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2-(2-Benzimidazolinon-l-yl)-6-ethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(4-
methylphenyl)-4-bora-3a,4a-diaza-s-indacene 4.18.  
 
6-Ethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(4-methylphenyl)-2-((2-
aminophenyl)amino)-4-bora-3a,4a-diaza-s-indacene 4.9 (0.02 g, 0.09 mmol) was 
dissolved in dry CH2Cl2 (10 mL). Triethylamine (0.09 g, 0.71 mmol) and triphosgene 
(8.70 mg, 0.29 mmol) in CH2Cl2 (1 mL) were added. The mixture was stirred at room 
temperature for 10 min. The solvent was removed under reduced pressure and the crude 
product was purified by column chromatography (CH2Cl2:ethyl acetate 10:1) to give the 
title compound 4.18 as an orange solid (0.04 g, 98%), mp 205-206 ̊C. Rf = 0.25 
(CH2Cl2:ethyl acetate 10:1). 
1H NMR (300 MHz, CDCl3) δ 10.37 (s, 1H), 7.21 (d, J = 8.6 
Hz, 2H), 7.12 (d, J = 8.6 Hz, 2H), 7.07 – 7.04 (m, 1H), 7.02-6.90 (m, 2H), 6.64 (d, J = 
7.0 Hz, 1H), 2.53 (s, 3H), 2.34 (s, 6H), 2.27 (q, J = 7.5 Hz, 2H), 1.30 (s, 3H), 1.13 (s, 
3H), 0.95 (t, J = 7.5 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 158.98, 155.23, 148.65, 
142.04, 141.26, 139.05, 136.73, 134.71, 132.67, 131.89, 131.01, 129.92, 129.80, 128.90, 
128.17, 128.00, 127.73, 122.69, 122.12, 121.55, 109.99, 108.91, 21.44, 17.11, 14.40, 
12.97, 12.07, 11.87, 11.24. 11B NMR (96 MHz, CDCl3) δ 0.78 (t, JB-F = 32.0 Hz). 19F 
NMR (282 MHz, CDCl3) δ -145.24 (dq, JF-F = 107.0, JF-B = 32.0 Hz), -146.10 (dq, JF-F = 
107.0, JF-B = 32.0 Hz). IR (neat): υmax/cm-1: 3440, 3362, 3233, 2917, 2274, 2119, 1707, 
1641, 1594, 1569, 1531, 1503, 1387, 1257, 1089, 820, 734. HRMS-ES Calcd for 
C29H29N4
10 B19F2 + Na
+: 520.2336, found: 520.2337. 
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2-(2-((2-Hydroxybenzylidene)amino)phenylamino)-6-ethyl-4,4-difluoro-1,3,5,7-
tetramethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-indacene 4.26.   
 
6-Ethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(4-methylphenyl)-2-((2-
aminophenyl)amino)-4-bora-3a,4a-diaza-s-indacene 4.9 (0.03 g, 0.06 mmol) was 
dissolved in EtOH (2 mL). Salicylaldehyde (6.45 µL, 0.06 mmol) and a drop of AcOH 
were added. The mixture was stirred under reflux for 19 h. The solvent was removed 
under reduced pressure and the crude product was purified by column chromatography 
(CH2Cl2:petroleum ether 2:3) to give the title compound 4.26 as red solid (0.03 g, 72%). 
Rf = 0.25 (CH2Cl2:petroleum ether 2:3). 
1H NMR (300 MHz, CDCl3) δ 12.87 (s, 1H), 
8.59 (s, 1H), 7.35 (dd, J = 7.8, 1.8 Hz, 1H), 7.33 – 7.26 (m, 1H), 7.20 (d, J = 8.0 Hz, 2H), 
7.09 (d, J = 8.0 Hz, 2H), 7.04 – 6.96 (m, 2H), 6.94 (dd, J = 9.0, 1.1 Hz, 1H), 6.91 – 6.85 
(m, 1H), 6.67 (td, J = 7.6, 1.3 Hz, 1H), 6.36 (dd, J = 8.1, 1.1 Hz, 1H), 2.49 (s, 3H), 2.36 
(s, 3H), 2.35 (s, 3H), 2.25 (q, J = 7.5 Hz, 2H), 1.27 (s, 3H), 1.17 (s, 3H), 0.92 (t, J = 7.5 
Hz, 4H). 11B NMR (96 MHz, CDCl3) δ 0.77 (t, JB-F = 31.5 Hz). 19F NMR (282 MHz, 
CDCl3) δ -145.99 (q, JF-B = 31.5 Hz). The compound was observed to undergo slow 
oxidation in solution. 
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6-Ethyl-2-(2-(2-hydroxyphenyl)-1H-benzimidazol-l-yl)-4,4-difluoro-1,3,5,7-
tetramethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-indacene 4.27. 
 
2-(2-((2-Hydroxybenzylidene)amino)phenylamino)-6-ethyl-4,4-difluoro-1,3,5,7-
tetramethyl-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-indacene 4.26 (0.03 g, 0.05 mmol) 
was dissolved in CHCl3 (2 mL). The mixture was left under air for 16 h. The solvent was 
removed under reduced pressure.The crude product was purified by column 
chromatography (petroleum ether:diethyl ether 4:1) to give the title compound 4.27 as a 
pink solid (0.02 g, 79%). Rf = 0.25 (petroleum ether:diethyl ether 4:1). 
1H NMR (300 
MHz, CDCl3) δ 13.80 (s, 1H), 7.70 (d, J = 7.2 Hz, 1H), 7.27 (dd, J = 7.3, 1.2 Hz, 1H), 
7.24 – 7.16 (m, 6H), 7.16 – 7.08 (m, 2H), 7.02 (dd, J = 8.7, 1.2 Hz, 1H), 6.99 – 6.94 (m, 
1H), 2.57 (s, 3H), 2.32 (s, 3H), 2.32 – 2.24 (m, 2H), 2.17 (s, 3H), 1.34 (s, 3H), 1.00 – 0.91 
(m, 6H).13C NMR (176 MHz, CDCl3) δ 160.87, 159.68, 151.21, 146.53, 142.26, 139.89, 
139.36, 135.80, 135.58, 134.70, 133.39, 131.63, 131.50, 129.99, 128.78, 127.70, 125.85, 
125.38, 123.84, 123.46, 118.67, 118.04, 112.77, 110.42, 21.43, 17.10, 14.39, 13.13, 
12.20, 11.43, 10.78.11B NMR (96 MHz, CDCl3) δ 0.79 (t, JB-F = 32.3 Hz). 19F NMR (282 
MHz, CDCl3) δ -145.95-145.55 (m). IR (neat): υmax/cm-1: 3360, 2925, 2854, 1738, 1563, 
1485, 1324, 1255, 1194, 1081, 754. HRMS-ES Calcd for C35H33N4
10B19F2 O +
 H+: 
575.2794, found: 575.2800. 
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6-Ethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(4-methylphenyl)-2-(2-(pyrid-2-
ylmethylamino)phenylamino)-4-bora-3a,4a-diaza-s-indacene 4.32 and 6-ethyl-4,4-
difluoro-1,3,5,7-tetramethyl-8-(4-methylphenyl)-2-((2-(di(pyrid-2-yl 
methyl)amino)phenylamino)-4-bora-3a,4a-diaza-s-indacene 4.31. 
 
6-Ethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(4-methylphenyl)-2-((2-
aminophenyl)amino)-4-bora-3a,4a-diaza-s-indacene 4.9 (0.02 g, 0.05 mmol) was 
dissolved in dry acetonitrile (5 mL). 2-Chloromethyl pyridine hydrochloride (0.02g, 0.14 
mmol) and K2HPO4 (0.04 g, 0.23 mmol) were added. The mixture was stirred under reflux 
for 48 h. The solvent was removed under reduced pressure and the crude product was 
purified by column chromatography (CH2Cl2:petroleum ether 1:1) to give, first eluted: 
the BODIPY 4.32 as a purple solid (4.5 mg, 17%). 1H NMR (300 MHz, CDCl3) δ 8.55 
(d, J = 6.8 Hz, 1H), 7.72 (td, J = 7.7, 1.6 Hz, 1H), 7.37 (d, J = 7.9 Hz, 1H), 7.25 (d, J = 
6.9 Hz, 1H), 7.22 (d, J = 7.8 Hz, 2H), 7.09 (d, J = 7.8 Hz, 2H), 6.70 – 6.54 (m, 3H), 6.35 
(d, J = 7.6 Hz, 1H), 5.27 (s, 1H), 5.01 (s, 1H), 4.49 (s, 2H), 2.48 (s, 3H), 2.35 (s, 3H), 
2.33 (s, 3H), 2.25 (q, J = 7.6 Hz, 2H), 1.27 (s, 3H), 1.18 (s, 3H), 0.92 (t, J = 7.6 Hz, 3H). 
11B NMR (96 MHz, CDCl3) δ 0.89  (t, JB-F = 30.2 Hz). 19F NMR (282 MHz, CDCl3) δ -
145.64 (q, JF-B = 30.2 Hz). HRMS-ES Calcd for C34H36N5
10B19F2 +
 H+: 564.3110, found: 
564.3107. 
Second eluted: BODIPY 4.31 as a purple solid (0.02 g, 69%); mp ˃300 °C. 1H NMR (700 
MHz, CDCl3) δ 8.39 (d, J = 4.2 Hz, 2H), 7.86 (s, 1H), 7.39 (t, J = 7.6 Hz, 2H), 7.21 (d, J 
= 7.9 Hz, 2H), 7.16 (d, J = 7.8 Hz, 2H), 7.12 (d, J = 7.9 Hz, 2H), 7.05 (d, J = 8.9 Hz, 1H), 
7.01 – 6.96 (m, 2H), 6.78 (t, J = 7.7 Hz, 1H), 6.48 (t, J = 7.6 Hz, 1H), 6.24 (d, J = 9.2 Hz, 
1H), 4.23 (s, 4H), 2.49 (s, 3H), 2.36 (s, 3H), 2.35 (s, 3H), 2.26 (q, J = 7.6 Hz, 2H), 1.27 
(s, 3H), 1.17 (s, 3H), 0.93 (t, J = 7.6 Hz, 3H). 13C NMR (176 MHz, CDCl3) δ 158.82, 
154.66, 152.17, 148.97, 142.27, 140.82, 139.09, 138.67, 136.57, 136.29, 135.87, 132.93, 
132.54, 131.90, 131.29, 129.71, 129.61, 128.07, 124.99, 122.95, 122.09, 121.68, 116.55, 
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111.63, 59.39, 21.44, 17.09, 14.62, 12.60, 12.10, 11.84, 11.45. 11B NMR (96 MHz, 
CDCl3) δ 0.75  (t, JB-F = 32.2 Hz). 19F NMR (282 MHz, CDCl3) δ -146.19 (q, JF-B = 32.2 
Hz). IR (neat): υmax/cm-1: 3221, 2924, 2853, 2408, 2284, 1662, 1591, 1537, 1477, 1307, 
1185, 1073, 1003, 979, 753. HRMS-ES Calcd for C40H41N6
10B19F2 +
 H+: 655.3532, 
found: 655.3539. 
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8. Appendix  
 
X-ray Crystallography Data 
2,6-Dibromo-4,4-difluoro-1,3,5,7-tetramethyl-8-phenyl-4-bora-3a,4a-diaza-s-
indacene 2.5. 
 
Table 1:  Crystal data and structure refinement for jgk130001. 
 
Identification code  jgk130001 
Chemical formula (moiety) C19H17BBr2F2N2 
Chemical formula (total) C19H17BBr2F2N2 
Formula weight  481.98 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  monoclinic, P121/n1 
Unit cell parameters a = 11.3763(5) Å  = 90° 
 b = 12.7627(6) Å  = 93.540(4)° 
 c = 12.9122(6) Å  = 90° 
Cell volume 1871.17(15) Å3 
Z 4 
Calculated density  1.711 g/cm3 
Absorption coefficient  4.356 mm1 
F(000) 952 
Crystal colour and size red, 0.32  0.20  0.20 mm3 
Reflections for cell refinement 3775 ( range 2.9 to 28.6°) 
Data collection method Oxford Diffraction Gemini A Ultra 
diffractometer 
 thick-slice  scans 
 range for data collection 2.9 to 28.6° 
Index ranges h 13 to 13, k 16 to 15, l 14 to 17 
Completeness to  = 26.0° 98.3 %  
Reflections collected 10273 
Independent reflections 4000 (Rint = 0.0307) 
Reflections with F2>2 3288 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.3362 and 0.4762 
Structure solution direct methods 
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Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0287, 0.9874 
Data / restraints / parameters 4000 / 0 / 235 
Final R indices [F2>2] R1 = 0.0320, wR2 = 0.0658 
R indices (all data) R1 = 0.0458, wR2 = 0.0710 
Goodness-of-fit on F2 1.039 
Extinction coefficient 0.0021(3) 
Largest and mean shift/su 0.066 and 0.001 
Largest diff. peak and hole 0.42 and 0.39 e Å3 
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3,5-Dibromo-4,4-difluoro-8-(4-methylphenyl)-4-bora-3a,4a-diaza-s-indacene 2.56a. 
 
 
Table 2:  Crystal data and structure refinement for jgk13. 
 
Identification code  jgk130003 
Chemical formula (moiety) C32H22B2Br4F4N4 
Chemical formula (total) C32H22B2Br4F4N4 
Formula weight  879.80 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  monoclinic, P121/n1 
Unit cell parameters a = 8.5621(6) Å  = 90° 
 b = 13.1412(12) Å  = 103.398(7)° 
 c = 14.6887(9) Å  = 90° 
Cell volume 1607.7(2) Å3 
Z 2 
Calculated density  1.817 g/cm3 
Absorption coefficient  5.060 mm1 
F(000) 856 
Crystal colour and size  , 0.30  0.30  0.20 mm3 
Reflections for cell refinement 2467 ( range 3.6 to 27.7°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.1 to 28.4° 
Index ranges h 11 to 11, k 17 to 12, l 19 to 14 
Completeness to  = 26.0° 97.6 %  
Reflections collected 8715 
Independent reflections 3387 (Rint = 0.0487) 
Reflections with F2>2 2608 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.3121 and 0.4310 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0446, 3.5410 
Data / restraints / parameters 3387 / 0 / 205 
Final R indices [F2>2] R1 = 0.0471, wR2 = 0.1003 
R indices (all data) R1 = 0.0703, wR2 = 0.1145 
Goodness-of-fit on F2 1.042 
Extinction coefficient 0.0006(4) 
                                                                                                                          Appendix 
 
 
311 
 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 1.00 and 1.01 e Å3  
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B,O-Chelated BODIPY 2.49a. 
 
Table 3:  Crystal data and structure refinement for jgk120002. 
 
Identification code  jgk120002 
Chemical formula (moiety) C28H19BN2O2 
Chemical formula (total) C28H19BN2O2 
Formula weight  426.26 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  triclinic, P1 
Unit cell parameters a = 7.9022(4) Å  = 97.135(5)° 
 b = 9.4541(6) Å  = 98.674(5)° 
 c = 14.7968(9) Å  = 105.621(5)° 
Cell volume 1036.54(11) Å3 
Z 2 
Calculated density  1.366 g/cm3 
Absorption coefficient  0.086 mm1 
F(000) 444 
Crystal colour and size red, 0.40  0.40  0.40 mm3 
Reflections for cell refinement 3419 ( range 3.2 to 28.6°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.2 to 28.6° 
Index ranges h 10 to 10, k 12 to 12, l 17 to 19 
Completeness to  = 25.0° 99.7 %  
Reflections collected 9030 
Independent reflections 4338 (Rint = 0.0227) 
Reflections with F2>2 3561 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.9665 and 0.9665 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0443, 0.3677 
Data / restraints / parameters 4338 / 0 / 300 
Final R indices [F2>2] R1 = 0.0415, wR2 = 0.0956 
R indices (all data) R1 = 0.0539, wR2 = 0.1051 
Goodness-of-fit on F2 1.024 
Extinction coefficient 0.0154(19) 
                                                                                                                          Appendix 
 
 
313 
 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole 0.30 and 0.23 e Å3 
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6-Ethyl-4,4-difluoro-5,7,8-trimethyl-2-phenyl-4-bora-3a,4a-diaza-s-indacene 2.70. 
 
Table 4: Crystal data and structure refinement for jgk150001_fa.  
 
Identification code  jgk150001_fa  
Empirical formula  C20H21BN2F2  
Formula weight  338.20  
Temperature/K  150.0(2)  
Crystal system  triclinic  
Space group  P-1  
a/Å  9.2603(4)  
b/Å  9.7317(4)  
c/Å  11.2359(4)  
α/°  64.664(4)  
β/°  77.921(3)  
γ/°  65.199(4)  
Volume/Å3  830.23(7)  
Z  2  
ρcalcg/cm3  1.353  
μ/mm-1  0.094  
F(000)  356.0  
Crystal size/mm3  0.4 × 0.18 × 0.13  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  6.182 to 58.602  
Index ranges  -12 ≤ h ≤ 12, -12 ≤ k ≤ 13, -14 ≤ l ≤ 14  
Reflections collected  26770  
Independent reflections  3974 [Rint = 0.0389, Rsigma = 0.0278]  
Data/restraints/parameters  3974/0/230  
Goodness-of-fit on F2  1.018  
Final R indexes [I>=2σ (I)]  R1 = 0.0439, wR2 = 0.1003  
Final R indexes [all data]  R1 = 0.0603, wR2 = 0.1102  
Largest diff. peak/hole / e Å-3  0.27/-0.22  
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4,4-Difluoro-2-iodo-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.17 
 
Table 5:  Crystal data and structure refinement for jgk140005. 
 
Identification code  jgk140005 
Chemical formula (moiety) C16H12BF2IN2O 
Chemical formula (total) C16H12BF2IN2O 
Formula weight  423.99 
Temperature  100(2) K 
Radiation, wavelength  synchrotron, 0.6889 Å 
Crystal system, space group  tetragonal, P42bc 
Unit cell parameters a = 21.804(5) Å  = 90° 
 b = 21.804(5) Å  = 90° 
 c = 6.3692(16) Å  = 90° 
Cell volume 3028.0(16) Å3 
Z 8 
Calculated density  1.860 g/cm3 
Absorption coefficient  1.912 mm1 
F(000) 1648 
Crystal colour and size red, 0.070  0.010  0.010 mm3 
Reflections for cell refinement 7297 ( range 2.6 to 25.5°) 
Data collection method Rigaku Saturn 724+ on kappa diffractometer 
 wide-frame  scans 
 range for data collection 2.0 to 25.5° 
Index ranges h 27 to 24, k 26 to 27, l 7 to 7 
Completeness to  = 24.4° 99.1 %  
Reflections collected 25424 
Independent reflections 3065 (Rint = 0.0749) 
Reflections with F2>2 2704 
Absorption correction multi-scan 
Min. and max. transmission 0.883 and 0.980 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0301, 2.2802 
Data / restraints / parameters 3065 / 1 / 209 
Final R indices [F2>2] R1 = 0.0303, wR2 = 0.0671 
R indices (all data) R1 = 0.0385, wR2 = 0.0693 
Goodness-of-fit on F2 1.042 
Absolute structure parameter 0.047(17) 
Largest and mean shift/su 0.001 and 0.000 
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Largest diff. peak and hole 1.08 and 0.46 e Å3 
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4,4-difluoro-2,6-diiodo-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 3.18. 
 
Table 6: Crystal data and structure refinement for jgk140006_4_fa. 
  
Identification code  jgk140006_4_fa  
Empirical formula  C16H11BN2OF2I2  
Formula weight  549.88  
Temperature/K  150.01(10)  
Crystal system  orthorhombic  
Space group  Pnn2  
a/Å  20.3020(6)  
b/Å  11.2056(3)  
c/Å  7.5174(4)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  1710.17(11)  
Z  4  
ρcalcmg/mm3  2.136  
m/mm-1  3.703  
F(000)  1032.0  
Crystal size/mm3  0.2 × 0.15 × 0.04  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection  5.778 to 58.974°  
Index ranges  -27 ≤ h ≤ 25, -14 ≤ k ≤ 15, -9 ≤ l ≤ 10  
Reflections collected  54090  
Independent reflections  4339 [Rint = 0.0602, Rsigma = 0.0316]  
Data/restraints/parameters  4339/1/219  
Goodness-of-fit on F2  1.109  
Final R indexes [I>=2σ (I)]  R1 = 0.0431, wR2 = 0.0888  
Final R indexes [all data]  R1 = 0.0560, wR2 = 0.0941  
Largest diff. peak/hole / e Å-3  1.05/-1.16  
Flack parameter 0.37(6) 
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4,4-Difluoro-3-(hexylamino)-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene 
3.19a. 
 
Table 7: Crystal data and structure refinement for jgk140003.  
 
Identification code  jgk140003  
Empirical formula  C22H26BN3OF2  
Formula weight  397.27  
Temperature/K  150.00(10)  
Crystal system  triclinic  
Space group  P-1  
a/Å  9.8145(8)  
b/Å  10.0842(6)  
c/Å  11.3461(7)  
α/°  97.195(5)  
β/°  91.225(6)  
γ/°  113.239(7)  
Volume/Å3  1020.62(13)  
Z  2  
ρcalcmg/mm3  1.293  
m/mm-1  0.092  
F(000)  420.0  
Crystal size/mm3  0.29 × 0.21 × 0.11  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection  5.932 to 57.848°  
Index ranges  -12 ≤ h ≤ 12, -13 ≤ k ≤ 13, -15 ≤ l ≤ 15  
Reflections collected  16496  
Independent reflections  4654 [Rint = 0.0489, Rsigma = 0.0536]  
Data/restraints/parameters  4654/45/284  
Goodness-of-fit on F2  1.033  
                                                                                                                          Appendix 
 
 
319 
 
Final R indexes [I>=2σ (I)]  R1 = 0.0504, wR2 = 0.0951  
Final R indexes [all data]  R1 = 0.0902, wR2 = 0.1157  
Largest diff. peak/hole / e Å-3  0.22/-0.22  
 
  
                                                                                                                          Appendix 
 
 
320 
 
4,4-Difluoro-3-(hexylamino)-6-iodo-8-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-
indacene 3.22a. 
 
Table 8: Crystal data and structure refinement for jgk140009_fa.  
 
Identification code  jgk140009_fa  
Empirical formula  C22H25BN3OF2I  
Formula weight  523.16  
Temperature/K  150.01(10)  
Crystal system  monoclinic  
Space group  P21  
a/Å  15.3219(4)  
b/Å  17.3301(4)  
c/Å  17.5462(5)  
α/°  90  
β/°  110.858(3)  
γ/°  90  
Volume/Å3  4353.7(2)  
Z  8  
ρcalcg/cm3  1.596  
μ/mm-1  1.507  
F(000)  2096.0  
Crystal size/mm3  0.31 × 0.17 × 0.13  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.598 to 59.16  
Index ranges  -20 ≤ h ≤ 20, -23 ≤ k ≤ 24, -23 ≤ l ≤ 24  
Reflections collected  141938  
Independent reflections  21418 [Rint = 0.0493, Rsigma = 0.0376]  
Data/restraints/parameters  21418/973/1090  
Goodness-of-fit on F2  1.057  
Final R indexes [I>=2σ (I)]  R1 = 0.0323, wR2 = 0.0602  
Final R indexes [all data]  R1 = 0.0483, wR2 = 0.0674  
Largest diff. peak/hole / e Å-3  0.90/-0.61  
Flack parameter 0.328(11) 
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4,4-Difluoro-8-(4-methoxyphenyl)-3-(pyrrolidin-1-yl)-4-bora-3a,4a-diaza-s-
indacene 3.19h. 
 
Table 9: Crystal data and structure refinement for jgk140002.  
 
Identification code  jgk140002  
Empirical formula  C20H20BN3OF2  
Formula weight  367.20  
Temperature/K  150.01(10)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  7.8835(5)  
b/Å  13.6664(9)  
c/Å  15.8072(8)  
α/°  90  
β/°  92.063(5)  
γ/°  90  
Volume/Å3  1701.96(17)  
Z  4  
ρcalcmg/mm3  1.433  
m/mm-1  0.104  
F(000)  768.0  
Crystal size/mm3  0.2 × 0.18 × 0.11  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection  5.958 to 57.724°  
Index ranges  -10 ≤ h ≤ 10, -17 ≤ k ≤ 14, -20 ≤ l ≤ 20  
Reflections collected  14534  
Independent reflections  3900 [Rint = 0.0432, Rsigma = 0.0440]  
Data/restraints/parameters  3900/0/245  
Goodness-of-fit on F2  1.030  
Final R indexes [I>=2σ (I)]  R1 = 0.0458, wR2 = 0.0908  
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Final R indexes [all data]  R1 = 0.0711, wR2 = 0.1037  
Largest diff. peak/hole / e Å-3  0.26/-0.22  
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6-Ethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(4-methylphenyl)-2-((2-methylphenyl)-
amino)-4-bora-3a,4a-diaza-s-indacene 3.57. 
 
Table 10: Crystal data and structure refinement for jgk150008.  
Identification code  jgk150008  
Empirical formula  C29H32BN3F2  
Formula weight  471.38  
Temperature/K  150.0(2)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  20.3605(3)  
b/Å  11.6571(3)  
c/Å  21.6409(8)  
α/°  90  
β/°  90.325(3)  
γ/°  90  
Volume/Å3  5136.2(2)  
Z  8  
ρcalcg/cm3  1.219  
μ/mm-1  0.652  
F(000)  2000.0  
Crystal size/mm3  0.4 × 0.19 × 0.12  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  8.172 to 133.924  
Index ranges  -24 ≤ h ≤ 17, -12 ≤ k ≤ 13, -25 ≤ l ≤ 24  
Reflections collected  37518  
Independent reflections  9089 [Rint = 0.0362, Rsigma = 0.0283]  
Data/restraints/parameters  9089/0/651  
Goodness-of-fit on F2  1.015  
Final R indexes [I>=2σ (I)]  R1 = 0.0384, wR2 = 0.0947  
Final R indexes [all data]  R1 = 0.0520, wR2 = 0.1043  
                                                                                                                          Appendix 
 
 
325 
 
Largest diff. peak/hole / e Å-3  0.28/-0.18  
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1-(1,3,2-Benzodioxaborol-2-yl)-2-[(Z)-(3,5-dimethyl-2H-pyrrol-2-ylidene)(4-
iodophenyl)methyl]-3,5-dimethyl-1H-pyrrole 4.2. 
 
Table 11: Crystal data and structure refinement for jgk150002_fa.  
 
Identification code  jgk150002_fa  
Empirical formula  C28H29BIN3O  
Formula weight  561.25  
Temperature/K  150.0(2)  
Crystal system  triclinic  
Space group  P-1  
a/Å  8.1161(4)  
b/Å  12.8348(6)  
c/Å  13.4466(7)  
α/°  65.729(5)  
β/°  86.864(4)  
γ/°  81.110(4)  
Volume/Å3  1261.50(12)  
Z  2  
ρcalcg/cm3  1.478  
μ/mm-1  10.163  
F(000)  568.0  
Crystal size/mm3  0.31 × 0.11 × 0.04  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  7.212 to 133.87  
Index ranges  -9 ≤ h ≤ 9, -15 ≤ k ≤ 14, -16 ≤ l ≤ 15  
Reflections collected  17841  
Independent reflections  4464 [Rint = 0.0529, Rsigma = 0.0378]  
Data/restraints/parameters  4464/90/415  
Goodness-of-fit on F2  1.209  
Final R indexes [I>=2σ (I)]  R1 = 0.0492, wR2 = 0.1154  
Final R indexes [all data]  R1 = 0.0531, wR2 = 0.1171  
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Largest diff. peak/hole / e Å-3  0.77/-0.79  
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UV/Vis Spectra 
Compound 3.19b (THF at room temperature) 
 
Compound 3.19c (THF at room temperature) 
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Compound3.19d (THF at room temperature) 
 
Compound 3.19e (THF at room temperature) 
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Compound 3.19f (THF at room temperature) 
 
Compound 3,19g (THF at room temperature) 
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Compound 3.19h (THF at room temperature) 
 
Compound 3.19j (THF at room temperature) 
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Compound 3.19m (THF at room temperature) 
 
Compound 3.19n (THF at room temperature) 
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